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Abstract 
The aim of this thesis is to further demonstrate the electrochemical detection of nitric 
oxide (NO) and hydrogen peroxide (H2O2) in-vitro, to advance the previously 
demonstrated detection of brain NO and to demonstrate the novel in-vivo detection of 
H2O2 using a paired catalase-based biosensor.  
We have recently successfully demonstrated the real-time detection of brain NO using a 
previously characterised Nafion®-modified platinum (Pt) electrochemical sensor. 
Additionally, the preliminary in-vitro development of a paired catalase based Pt sensor 
for the purpose of H2O2 detection in the physiological environment has previously been 
reported by our research group.  
A validation of the previously reported in-vitro characteristics of the NO sensor with the 
inclusion of novel post in-vivo stability attributes is presented in this thesis (see Chapter 
6). Also, the suitable functionality of the NO sensor in the neuronal environment as has 
been published recently is supported in Chapter 6.  
A verification of the previously reported in-vitro attributes of the paired catalase based 
H2O2 sensor is shown in Chapter 4. Additionally, advancements to the initial in-vitro 
characterisation of the paired H2O2 sensor are described in Chapter 4. The previously 
unreported real-time detection of brain H2O2 in freely-moving animals is presented in 
Chapter 5.  
The main focus of this thesis is the detection of NO and H2O2 as oxidative/nitrosative 
stress markers in neurological disease and dysfunction. As such the role of 
oxidative/nitrosative stress in Parkinson’s disease (PD) and autism spectrum disorders 
(ASDs) is investigated in this thesis. The novel detection of NO in a propionic acid 
(PPA) induced animal model of ASDs is presented in Chapter 7. The electrochemical 
detection of NO and the preliminary dual detection of NO and H2O2 in a paraquat (PQ) 
mediated model of PD is presented in Chapter 8. The specific focus of these 
investigations is to elucidate the role of oxidative/nitrosative stress in the etiology and 
pathophysiology of PD and ASDs. 
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1.1 Neurotransmission 
The reciprocal interplay between the external environment and the processes which 
determine brain function are principally governed by electrical and chemical pathways 
inherent to the neuronal environment. These endogenous pathways map the intricate 
processes which determine behaviour, emotion, memory and thought itself. 
The primary cell types present in the brain are nerve cells and glial cells. The brain 
consists of billions of nerve cells or neurons which can interact with other neurons via 
thousands of connections. Neurons are essentially the basic functioning unit of the brain 
and glial cells provide metabolic support and insulation. Axons and dendrites extend 
from the neuron into projections which facilitate the transmission of signals in the brain. 
 
Fig 1.1 Neuronal signal transmission. (https://sitn.hms.harvard.edu/sitnflash_wp/wp-
content/uploads/2011/01/Chemical_synapse_schema.jpg).  
The resting state of a neuron is maintained by a transmembrane concentration gradient 
of ions. Neuronal activation is triggered by a stimulus which leads to a change in resting 
membrane potential due to ionic influxes (Na+, K+) which results in the propagation of 
an electrical action potential. This action potential stimulates the release of 
neurotransmitters (NTs) into the synapse which is the cleft between nerve terminals and 
the dendrites of other neurons.  
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The release of NTs facilitates the communication between the pre and post synaptic cell 
via various receptors which leads to excitatory or inhibitory processes. NTs and their 
metabolites may then overflow from the synapse into the extracellular fluid (ECF). 
These processes may take place in the brain over sub-second time scales which leads to 
reflex reactions and additionally extended processes involved in the formation of 
memories which last decades. The concentration of NTs and their metabolites in the 
ECF is regulated by their release rate into the cerebrospinal fluid or transmission across 
the blood brain barrier (BBB).  
1.2 Neurochemical analysis 
Understanding the mechanisms underlying the function of the central nervous system 
(CNS) is of paramount importance in modern day science. A variety of techniques have 
been developed in recent years which facilitate the analysis of brain function. These 
include non-invasive techniques such as functional magnetic resonance imaging (fMRI) 
(Matthews et al., 2006), positron emission tomography (PET) (Shibasaki, 2008) and 
electrophysiological techniques include electroencephalography (EEG) (Kenemans & 
Kahkonen, 2011).  
Invasive techniques are also available such as microdialysis (MD) (Lonnroth et al., 
1987; Fillenz, 2005) and in-vivo voltammetry (IVV); including amperometric and 
voltammetric techniques (Lowry et al., 2006; Borland & Michael, 2007). Together they 
provide improved spatial and temporal resolution and in the case of IVV the real-time 
detection of chemical changes in the ECF. In addition to animal studies the application 
of MD in the clinical environment has also been shown to enable the detection of target 
species in the human brain (Ungerstedt & Rostami, 2004). The detection of target 
intercellular chemical messengers (neuromediators) in the brain may provide an insight 
into the processes behind numerous neurodegenerative diseases and disorders in 
addition to normal cognitive function. Many neurodegenerative conditions are not fully 
understood and the application of these techniques may yield previously undetermined 
information required to develop novel therapeutic strategies.  
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The implantation of electrochemical sensors into the brain allows the detection of 
chemical changes in the ECF. Monitoring neuromediators by IVV in the ECF is 
complicated by the nature of endogenous factors. A variety of NTs in the ECF are not 
electroactive, many species oxidise at similar potentials and the brain is a complex 
environment which consists of lipids and proteins which may interfere with the response 
of the implanted sensor. Since the pioneering work conducted by Clark et al. (Clark et 
al., 1958) and Adams et al. (Kissinger et al., 1973; Adams, 1990), which led to the 
development of IVV; various advancements have been made to the technique to 
overcome these inherent technical obstacles.  
Various strategies have been employed in order to improve the sensitivity, selectivity 
and stability of implanted electrochemical sensors. The inclusion of a biological 
recognition unit, typically an enzyme into the construction of the sensor facilitates the 
detection of non-electroactive species (Hu et al., 1994; Lowry et al., 1994; Garguilo & 
Michael, 1996; Ryan et al., 1997). The application of a suitable potential and the 
modification of the electrode surface with various permselective membranes has also led 
to an improvement in the selectivity and stability of the IVV technique (McAteer & 
O'Neill, 1996; Lowry et al., 1998a; Brown et al., 2009).  
As discussed by Lowry et al. IVV may be used in conjunction with processes that lead 
to a change in concentration of NTs in the ECF including depolarisation of the nerve 
terminal (Lowry et al., 2006). This may be achieved via electrical stimulation, 
behavioural activation and the application of substances which are known to lead to this 
process such as K+ and glutamate which activate receptors linked to Na+ channels. 
Additionally, pharmacological manipulations may be utilised such as inhibition of 
neurotransmitter (NT) synthesis (e.g. α-methyl-p-tyrosine), displacement of NT from 
the nerve terminal (e.g. amphetamine), inhibition of NT metabolising enzymes (e.g. 
pargyline) and substances which block NT uptake (e.g. cocaine). Together these 
processes lead to a change in NT concentration in the ECF which may be detected by 
the implanted electrochemical sensor (Lowry et al., 2006). 
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The main focus of this thesis is to establish the detection of hydrogen peroxide (H2O2) 
and nitric oxide (NO) in the in-vitro environment and to demonstrate the detection of 
these species in the ECF of the brain.  
Glutamate and dopamine are amongst others, examples of the most important NTs 
present in the brain. Glutamate has been implicated in processes such as learning and 
memory (Lamprecht & LeDoux, 2004). Dopamine is responsible for vital neurological 
processes such as reward and motivation (Wise, 2004). Additionally a dysfunction in 
glutamatergic and dopaminergic pathways has been implicated in a variety of 
neurodegenerative diseases and disorders such as schizophrenia (Goff & Coyle, 2001) 
and Parkinson’s disease (Lotharius & Brundin, 2002). A number of chemical 
messengers have been shown to modulate glutamatergic and dopaminergic pathways 
including NO (see Section 1.4) (Fejgin et al., 2009; Palsson et al., 2009) and H2O2 (see 
Section 1.3)
 
(Avshalumov et al., 2003; Bao et al., 2009).   
1.3 Hydrogen peroxide (H2O2) 
H2O2 has in recent years been indicated to act as a neuromodulator (Rice, 2011) and as a 
signalling molecule (Stone & Yang, 2006). Specifically the synaptic release of 
dopamine (DA) has been shown to be regulated by H2O2 (Rice, 2011). The effect of 
exogenously applied and endogenously altered H2O2 via various inhibitors/inducers on 
the evoked production of DA in ex-vivo brain slices has been examined
 
(Avshalumov et 
al., 2003; Bao et al., 2009). Rice et al. have demonstrated that endogenous H2O2 
modulates DA release by activation of K+ sensitive adenosine triphosphate (ATP) 
channels in ex-vivo striatal and substantia nigra neurons (Rice, 2011).  
H2O2 is neutral and membrane permeable and it is also a relatively stable molecule 
which makes it highly suitable as a diffusible signalling molecule (Maier & Chan, 2002; 
Rice, 2011).The primary source of H2O2 in the brain is mitochondrial respiration. H2O2 
is produced through the catalytic action of superoxide dismutase (SOD) and additionally 
by the considerably slower process of spontaneous dismutation (see Section 2.10.2). 
H2O2 production in the brain is a tightly regulated process as when present at high 
concentrations H2O2 can initiate neurotoxic events (Barnham et al., 2004). The main 
 Chapter 1: Introduction 
5 
 
source of H2O2 regulation is enzymatic removal by catalase and glutathione peroxidase 
(GPx). A detailed description of the regulation of H2O2 production in the brain is 
described in Section 2.10.1. H2O2 is an electroactive species and it can be detected at 
+700 mV vs. SCE by oxidation at platinum (Pt) surfaces. H2O2 is oxidised at a diffusion 
controlled rate which yields a current response that is linear and directly proportional to 
the concentration of H2O2 (Lowry et al., 1994; O'Brien et al., 2007). 
At present a limited amount of analytical techniques exist to enable the detection of 
H2O2 in the physiological environment. To date microdialysis (MD) is the main method 
of H2O2 detection in-vivo (Lei et al., 1997, 1998; Chen et al., 2012). However, MD 
suffers from poor temporal and spatial resolution and other significant drawbacks as 
discussed in Section 2.9. Electrochemical methods are highly advantageous relative to 
the MD technique as they provide long-term real-time measurements of neurochemical 
species of interest. The detection of H2O2 has previously been reported in the 
anaesthetised animal (Kulagina & Michael, 2003). However, the sensor described in this 
publication requires a mediator and an additional method to remove interference from 
AA; which is not necessary with the dual H2O2 sensor presented in this thesis.  
Research previously conducted by O’Brien et al. has demonstrated a highly sensitive 
and selective dual catalase-based sensor for the detection of H2O2 in the in-vitro 
environment (O'Brien et al., 2007). The novel electrochemical detection of H2O2 in the 
freely-moving animal is presented in this thesis.  
H2O2 is implicated in a variety of normal cellular functions and also in the 
pathophysiology of certain disease states (Andersen, 2004; Barnham et al., 2004; Rhee, 
2006; Rice, 2011). A dysfunction in H2O2/reactive oxygen species (ROS) regulation, 
which subsequently leads to the overproduction of H2O2/ROS, has been implicated in a 
number of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease 
(Valko et al., 2007; Melo et al., 2011). Enzymatically produced H2O2 by 
electrochemical biosensors is used to measure non-electroactive substrates such as 
glucose (Lowry et al., 1998b), choline (Garguilo & Michael, 1996) and glutamate (Hu et 
al., 1994; Lowry et al., 1998c)  in the brain. 
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H2O2 is implicated in a number of neurochemical processes and electrochemical 
detection methods, therefore the real-time detection of H2O2 in-vivo would provide a 
significant contribution to the field of neurochemistry.  
1.4 Nitric oxide (NO) 
The physiological role of nitric oxide (NO) as the endothelium derived relaxing factor 
(EDRF) was discovered in the late 1980’s (Ignarro et al., 1987). This research 
demonstrated the involvement of NO in the process of vasodilation and regulation of 
blood pressure and since then much interest has developed around the role of NO in the 
body. 
NO is a radical species generated in the physiological environment from three main NO 
synthase enzymes (NOS). These consist of inducible NOS (iNOS), endothelial NOS 
(eNOS) and neuronal NOS (nNOS) (Kiechle & Malinski, 1993; Bruckdorfer, 2005; 
Guix et al., 2005). The type of NO produced is dependent on the source of NOS in the 
body. NO is produced from its precursor L-arginine, in the presence of numerous co-
factors including NOS, BH4 (tetrahydrobiopterin), FMN (flavin mononucleotide), FAD 
(flavin adenine dinucleotide), haem iron and Ca2+/calmodulin as shown in Equation 1.1. 
L  Arginine  2NADPH  O  L  citrulline  NO  2NADP 
(1.1) 
L-Arginine reacts with the co-substrates molecular oxygen (O2) and nicotine adenine 
dinucleotide phosphate (NADPH); which provides the electrons necessary for the 
reaction to proceed. The nitrogen of NO is derived from the guanidine nitrogen atoms of 
L-arginine and the oxygen from O2. This reaction produces NO and L-citrulline in 
equimolar quantities. L-citrulline can then be converted back to L-arginine as part of the 
normal nitrogen metabolism of the body (Alderton et al., 2001; Bruckdorfer, 2005).  
NOS contains an oxygenase domain for binding of L-arginine, haem and BH4 and a 
reductase domain facilitates FAD, FMN redox carriers and NADPH electron transfer. 
Both domains are linked through a binding site for calmodulin. The production of NO 
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from the constitutive forms of NOS (eNOS and nNOS) is Ca2+ dependent. The inducible 
form of NO produced from iNOS is released from macrophages and is produced in a 
Ca2+ independent manner. Following binding with calmodulin NO is produced from the 
catalytic oxidation of L-arginine to citrulline which requires O2 and NADPH as co-
factors (Alderton et al., 2001; Bruckdorfer, 2005). 
 
Fig 1.1 Production of NO by NOS (http://www.biochemj.org/bj/357/0593/bj3570593a01.jpg). 
The global function of NO in the physiological environment has been studied in diverse 
processes such as the immune response (Bogdan et al., 2000), anti-microbial activity 
(Fang, 2004) and penile erection (Mas et al., 2002). Of the three isoforms of NOS, 
nNOS is present in the most abundance in the brain. Neuronal NO has been implicated 
in vital neurological processes including sleep and appetite regulation (Williams et al., 
2002; Cavas & Navarro, 2006) synaptic plasticity, neurotransmission and learning and 
memory (Wass et al., 2006a; Wass et al., 2006b; Nugent et al., 2007). Therefore the 
detection of NO in the CNS provides an insight into a variety of vital neurological 
functions.  
The majority of NO analytical techniques rely on indirect detection methods, by 
measuring nitrite and other markers of NO production using spectroscopic methods 
(Hetrick & Schoenfisch, 2009). The poor sensitivity of these techniques are not suitable 
for the detection of NO in-vivo, due to the estimated short half-life (< 10s) and relatively 
low concentration of NO in the biological environment (Wink & Mitchell, 1998; Kelm, 
1999). The selectivity of these spectroscopic methods also suffer due to interference 
from nitrite and nitrate from sources other than NO (Finnerty et al., 2012a). 
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Electrochemical techniques provide the required temporal and spatial resolution which 
is necessary to detect NO in the physiological environment to enable long-term in-vivo 
NO recordings. 
The electrochemical reduction of NO has previously been demonstrated (Meulemans, 
1993; Maskus et al., 1996; Liu et al., 2003), as O2 reduces at a similar potential to NO 
this technique is not suitable for in-vivo monitoring of NO. The electro-oxidation of NO 
is the most suitable monitoring technique and various modified electrode materials have 
been used been used for this purpose. They are predominantly carbon fibre (Friedemann 
et al., 1996; Park et al., 1998; Heinzen & Pollack, 2002), glassy carbon (Pallini et al., 
1998), and Pt electrodes (Park et al., 2010; Park et al., 2012).  
Our research group has successfully demonstrated a highly sensitive, selective and 
stable NO sensor for the purpose of in-vivo NO monitoring (Brown & Lowry, 2003; 
Brown et al., 2009). The previously described NO sensor exhibits the required 
operational characteristics i.e. a highly suitable response time and detection limit to 
enable the detection of NO in the physiological environment (Brown et al., 2009). 
Furthermore the application of this NO sensor in-vivo for the continuous real-time 
detection of NO in the brain has previously been shown (Finnerty et al., 2012a; Finnerty 
et al., 2012b). 
1.5 Oxidative stress in neurodegenerative diseases/dysfunctions 
H2O2 is an example of an oxidative stress marker and the free radical species NO is an 
example of a nitrosative stress marker. H2O2 and NO both exert beneficial and harmful 
effects in the neuronal environment (Calabrese et al., 2007; Rice, 2011). The 
uncontrolled elevation of H2O2 and NO levels in the brain leads to the further production 
of other ROS and reactive nitrogen species (RNS) and consequently the development of 
oxidative/nitrosative stress (see section 2.10). The level of ROS/RNS in the brain is 
controlled by a protective highly robust antioxidant network. The processes which lead 
to the production of ROS/RNS and the mechanism of action of the opposing antioxidant 
network which serves to maintain redox homeostasis in the brain is described in detail in 
Section 2.10. The role of oxidative/nitrosative stress in a range of neurodegenerative 
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diseases and dysfunctions such as Alzheimer’s disease, amyotrophic lateral sclerosis 
(ALS) and Friedrich’s ataxia (FD)  has been extensively reviewed elsewhere (Barnham 
et al., 2004; Melo et al., 2011; Ramalingam & Kim, 2012). Section 1.6 and 1.7 will 
focus specifically on the role of oxidative/nitrosative stress in autism spectrum disorders 
(ASDs) and Parkinson’s disease (PD) as studied in Chapter 7 and 8 respectively. 
1.6 Autism spectrum disorders (ASDs) 
ASDs consist of complex related neurodevelopmental disorders which are defined by a 
varying degree of social impairment, difficulties with communication, repetitive 
behaviours and restricted interests (Rapin & Tuchman, 2008). ASDs are relatively 
common in that they occur in 1 in 88 children in the United States alone as determined 
by the U.S centre for disease control (CDC). Much focus is given to the negative aspects 
of ASDs as symptoms may be extremely debilitating in certain individuals depending on 
the severity of the condition. However, little attention is given to the positive attributes 
seen in certain cases of ASDs such as an enhanced memory, heightened ability in areas 
such as mathematics or the arts and a superior ability to concentrate (Walsh et al., 2011).  
Currently the relationship between the brain and the behavioural traits which are 
characteristic of ASDs are not fully understood. Research has indicated that ASDs have 
a strong genetic basis however inherited factors do not entirely explain the etiology of 
the condition (Folstein & Rosen-Sheidley, 2001). A variety of environmental agents 
have been indicated in the development of autism such as prenatal exposure to infection 
(Meyer et al., 2011), ethanol and valproic acid (Arndt et al., 2005).  
A wide range of evidence has indicated that oxidative/nitrosative stress is implicated in 
the pathophysiology of ASDs. Increased levels of oxidative/nitrosative stress markers 
have been found in ASDs post mortem brain tissue preparations. Specifically the level 
of glutathione (GSH) one of the key antioxidant substances in the brain is reduced in 
ASDs individuals (Rose et al., 2012). This research group indicated that the balance 
between GSH and its oxidised form GSSG is disrupted in ASDs individuals; which is 
one of the major indications of the presence of oxidative stress (see Section 2.10.1). 
Additionally, Rose et al. found an abnormally high level of 3-nitrotyrosine (3-NT) and 
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superoxide O· in ASDs brain tissue preparations. 3-NT is derived from NO through 
its production of the highly toxic secondary RNS peroxynitrite ONOO and O·which 
is the primary source of H2O2 production in the brain (Winterbourn, 2008; Rose et al., 
2012). Chauhan et al. have also reported a decreased level of GSH in post mortem 
autistic brain preparations in comparison to controls (Chauhan et al., 2012).  
A decrease in the catalytic function of catalase one of the primary sources of H2O2 
removal in the brain and an elevated level of xanthine oxidase, which is a major source 
of superoxide O· production have been found in the blood of individuals with ASDs 
(Zoroglu et al., 2004). Additionally, haematological studies conducted by Yorbik et al. 
and Sogut et al. have demonstrated a decreased level of antioxidant enzyme activity 
(Yorbik et al., 2002) and an increased level of NO respectively in individuals with 
ASDs (Sogut et al., 2003). 
This combined research indicates that oxidative/nitrosative stress is highly implicated in 
the pathophysiology of ASDs. However, these techniques rely on the indirect detection 
of oxidative/nitrosative stress markers, i.e. nitrate/nitrite and the activity of ROS 
removal enzymes (aconitase) (Chauhan & Chauhan, 2006; Rose et al., 2012). 
Additionally conflicting results have been reported by Yorbik et al. and Sogut et al., 
between the levels of superoxide dismutase (SOD) activity in ASDs erythrocytes. 
Specifically Yorbik et al. reported a decreased level of SOD activity and Sogut et al. 
demonstrated unchanged SOD enzymatic function (Yorbik et al., 2002; Sogut et al., 
2003). This may reflect a variation in the sensitivity of the chosen analytical technique. 
Also, the limited availability of post mortem ASDs brain tissue preparations restricts the 
application of these techniques.  
The exact mechanism of possible NO production in ASDs remains to be elucidated. The 
role of iNOS in the expression of NO has been demonstrated in neurodegenerative 
disease states such as Parkinson’s and Alzheimer’s disease (Calabrese et al., 2007). 
Additionally, the expression of iNOS has been implicated in the development of autism 
(Chauhan & Chauhan, 2006). Neuropathological investigations of post mortem autistic 
brain preparations have indicated the presence of activated microglia and astrocytes 
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(Vargas et al., 2005). Cytokines produced by this process lead to an inflammatory 
process which is known to activate iNOS and hence elicit an increase in NO (Guix et al., 
2005).  
The specific mechanism of oxidative/nitrosative stress development in individuals with 
ASDs has yet to be elucidated. It has been postulated that the development of ASDs is 
multifactorial and is influenced by genetic, environmental and immunological factors in 
addition to oxidative/nitrosative stress (Chauhan & Chauhan, 2006). The direct 
electrochemical detection of H2O2/NO in an animal model of ASDs would provide a 
major insight into the role of ROS/RNS in the etiology ASDs. The electrochemical 
detection of NO in an animal model of autism is demonstrated in Chapter 7 of this 
thesis.  
Currently the core symptoms of ASDs are ameliorated with behavioural and educational 
interventions. The medical treatment of ASDs is directed towards cases of severe 
impairment by debilitating restricted and repetitive traits seen in certain ASDs cases. 
Resperidone and aripiprazole which are antipsychotic medications may be useful in 
certain cases where severe ASDs negative behavioural characteristics manifest 
(McPheeters et al., 2011). However, these medical treatments may exhibit serious side 
effects which facilitate the need for novel ASDs therapeutic strategies.  
1.7 Parkinson’s disease (PD) 
Parkinson’s disease (PD) is a severe progressive neurodegenerative movement disorder. 
PD affects approximately 1 in 100 people over the age of 65 in the USA alone. PD is 
clinically characterised by a resting tremor, rigidity, bradykinesia (slowness of voluntary 
movement), postural imbalance and gait abnormalities. Non-motor symptoms also 
present in PD such as neuropsychiatric symptoms and sleep abnormalities. The 
pathological hallmark of PD is dopamine (DA) cell degeneration in an area of the 
midbrain known as the substantia nigra pars compacta (SNc) leading to a loss of striatal 
DA. The presence of intracytoplasmic inclusions known as ‘Lewy bodies’ that are 
composed of α-synuclein and parkin is characteristic of PD (Olanow & Tatton, 1999; 
Lotharius & Brundin, 2002; Schapira & Jenner, 2011). One hypothesised normal 
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physiological role of the protein α-synuclein is in the intracellular storage of DA within 
the presynaptic terminal (Lotharius & Brundin, 2002). Additionally, α-synuclein has 
been postulated to play a role in synaptic plasticity (Maguire-Zeiss et al., 2005). 
There are various familial forms of PD which have been linked to genetic mutations in 
specific proteins including α-synuclein and parkin (Olanow & Tatton, 1999; Lotharius 
& Brundin, 2002; Schapira & Jenner, 2011) which tend to affect relatively younger 
individuals. Parkin has been postulated to function as an intermediate in the ubiquitin 
pathway, controlling levels of other proteins such as α-synuclein or itself by regulated 
degradation (Gu et al.). However, familial forms of PD are relatively uncommon and 
count for less than 10 % of all PD cases (Maguire-Zeiss et al., 2005). 
Sporadic idiopathic forms of PD which are relatively more common and have been 
linked to certain environmental factors including exposure to pesticides, herbicides and 
toxins (Olanow & Tatton, 1999; Schapira & Jenner, 2011). The toxic effect of MPTP 
(1,2,3,6,-methyl-phenyl-tetrahydropyridine); a by-product in the synthesis of the anolog 
of the narcotic drug meperidine, was accidentally discovered following its distribution in 
‘synthetic heroin’ in certain parts of California in the 1980’s and following a botched 
meperidine analog synthesis attempt by a college student in the late 1970’s (Davis et al., 
1979). The compound was injected intravenously by these individuals who subsequently 
developed severe irreversible parkinsonism (Langston et al., 1983). The role of various 
toxins including rotenone, paraquat (PQ) and MPTP in the development of PD has 
previously been examined and utilised to study PD in animal models (Beal, 2001; 
McCormack et al., 2005; McCormack et al., 2006). In addition to environmental toxins 
other risk factors contribute to the development of PD including advancing age and head 
trauma (Tanner et al., 2011; Wirdefeldt et al., 2011). 
The contribution of oxidative stress to the loss of dopaminergic neurons predominantly 
in the SNc which is a pathological outcome of PD is possibly as a result of DA 
metabolism related oxidative stress (Lotharius & Brundin, 2002; Andersen, 2004; 
Chinta & Andersen, 2008). Equation 1.2 to 1.6 demonstrates the enzymatic and 
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chemical metabolism of DA in the neuronal environment (Olanow & Tatton, 1999; 
Lotharius & Brundin, 2002). 
DA  O  HO  !"# DOPAC  NH%  HO 
(1.2) 
DA  O  SQ•  O·  2H 
(1.3) 
DA  O·  2H   SQ•  HO 
(1.4) 
HO  2GSH  GSSG  2HO 
(1.5) 
HO  Fe •OHOH  Fe% 
(1.6) 
DA may be metabolised enzymatically by MAO (monoamine oxidase) into DOPAC (3, 
4-dihydroxyphenylacetic acid) and may auto-oxidise to form H2O2 as shown in 
Equations 1.2 to 1.4. The metabolism of DA leads to the production of other toxic 
species such as O·, DA-quinone species SQ• and hydroxy radicals (•OH). A 
deficiency in the normal enzymatic/non-enzymatic function of the antioxidant network 
leads to the uncontrolled production of these species which leads to oxidative/nitrosative 
stress (see Section 2.10).  
Neuropathological investigations of post mortem PD brain preparations have indicated 
the presence of activated microglia (Jenner, 2003). This process is known to activate 
iNOS and lead to the production of NO (Guix et al., 2005). In a pro-oxidant 
environment NO can interact directly with O·and lead to the formation of the main 
secondary highly toxic RNS; ONOO (see Section 2.10.3).  
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This imbalance between ROS/RNS control and production may be accelerated due to 
exposure to environmental toxins, advancing age or an underlying genetic malfunction 
(Lotharius & Brundin, 2002; Chinta & Andersen, 2008; Wirdefeldt et al., 2011). The 
uncontrolled production of ROS or other reactive intermediates, (e.g. RNS) leads to 
damage to cell structures, DNA, lipids and proteins (Valko et al., 2007).  
DA dependent oxidative stress has been postulated to lead to the loss of dopaminergic 
neurons in the SNc (Olanow & Tatton, 1999; Lotharius & Brundin, 2002). A deficiency 
in the catalytic function of SOD, the main source of O·removal (see Section 2.10.1) 
has been demonstrated in nigral tissues of PD patients which would support this 
hypothesis  (Chinta & Andersen, 2008).  
Post mortem findings have indicated an increased level of ‘free iron’ (see Section 
2.10.2) and a decreased level of glutathione (GSH) in PD (Olanow & Tatton, 1999; 
Lotharius & Brundin, 2002; Chinta & Andersen, 2008). Additionally, iron related 
oxidative stress has been postulated to promote α-synuclein accumulation (Chinta & 
Andersen, 2008). These contributing factors directly demonstrate that oxidative stress is 
implicitly linked to the development of PD. Degeneration of dopaminergic neurons due 
to oxidative stress may lead to a vicious cycle of further ROS/RNS production primarily 
from DA oxidation and the consequential further loss of DA nerve cells.  
Much contention arises around the role of oxidative stress in the process of 
neurodegeneration particularly in the case of PD (Jenner, 2003; Andersen, 2004; 
Schapira & Jenner, 2011). Much debate has arisen over whether oxidative stress is the 
causative factor in the development of PD or whether it is as a result of a cascade of 
events initiated by some other influence.  
Schapira et al. and Jenner et al. amongst others have questioned the role of oxidative 
stress in PD due specifically to DA metabolism (Olanow & Tatton, 1999; Jenner, 2003; 
Schapira & Jenner, 2011). As previously stated SNc dopaminergic neurons are affected 
in PD whereas other DA containing neurons may be spared e.g. DA cells in the ventral 
tegmental area (VTA). Additionally, non dopaminergic neurons also die in PD (Schapira 
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& Jenner, 2011) which necessitates a discussion on the role of DA related oxidative 
stress in the pathology of PD.  
The regional difference in neurodegeneration of dopaminergic cells in PD may be 
explained by a difference in the level of function of the antioxidant network. For 
example the normal level of activity of catalase and GPx is higher in the VTA and 
nucleus accumbens (NA) in comparison to the SNc (Hung & Lee, 1998). This may 
explain why certain dopaminergic cells are spared in the progression of PD whereas 
others are not.  
Chen et al. and Rice et al. have demonstrated that endogenous H2O2 regulates the 
production of somatodendritic release of DA in ex-vivo brain slices (Chen et al., 2002; 
Rice, 2011). This research demonstrates that endogenous H2O2 suppresses the release of 
DA in the SNc and striatum but has no effect on DA release in the VTA (Chen et al., 
2002). These findings reflect a lower production of modulatory endogenous H2O2 in the 
VTA or stronger regulation of its production (Chen et al., 2002). Therefore, impairment 
in the neuromodulatory role of endogenous H2O2 such as that caused by DA metabolism 
related oxidative stress in PD, may exert a higher effect in the SNc in comparison to the 
VTA. This may account for the destruction of dopaminergic cells in some regions which 
is not as detrimental elsewhere in PD.   
Neurodegeneration of non-dopaminergic cells is also a consequence of PD (Obeso et al., 
2010; Schapira & Jenner, 2011). Braak’s staging hypothesis indicates that ‘Lewy body’ 
formation progresses once initiated in a stepwise manner throughout PD, this may 
explain the loss of non-dopaminergic cells in PD (Braak et al., 2004). It has been 
postulated that oxidative stress may lead to the accumulation of α-synuclein which is the 
main component of ‘Lewy bodies’ (Maguire-Zeiss et al., 2005). Theoretically this 
suggests that oxidative stress may trigger the accumulation and regional distribution of 
‘Lewy body’ formation in PD. However, current pathological outcomes of PD are 
routinely assessed by post mortem techniques. This process does not facilitate the 
analysis of PD progression over time, which leads to a difficulty in the assessment as to 
what exact mechanisms contribute to the initiation of PD and propagate the progression 
of the disease.  
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The general consensus of the etiology of PD is of a multifactorial disorder influenced by 
genetics, environmental factors (including various toxins), advancing age and oxidative 
stress (Olanow & Tatton, 1999; Lotharius & Brundin, 2002; Schapira & Jenner, 2011). 
Various animal models of PD exist (Beal, 2001), it may be possible to determine the 
role of oxidative stress as a cause or a consequence of PD through the use of 
electrochemical methods in conjunction with an animal model of PD. The real-time 
detection of NO/H2O2 in an animal model of PD may facilitate a further understanding 
of PD progression and etiology. Therefore this strategy may facilitate new therapeutic 
advances. The detection of NO and the preliminary detection of H2O2 in an animal 
model of PD is presented in Chapter 8.  
1.9 Mitochondrial dysfunction (MTdys) in PD and ASDs 
Mitochondria are the site of many vital biochemical pathways which maintain normal 
cellular function (Calabrese et al., 2001). Mitochondria produce energy in the form of 
ATP via the process of oxidative phosphorylation. Mitochondria play a central role in 
the process of cell survival and cell death via apoptosis and necrosis. Inherited or 
acquired mitochondrial DNA (mtDNA) mutations impair the function of the electron 
transport chain (ETC). Dysfunction of mitochondrial energy metabolism leads to 
reduced ATP production, disruption in Ca2+ homeostasis, and generates ROS/RNS such 
as O·, H2O2, •OH  and ONOO (Lin & Beal, 2006).   
Due to the high energy demand of the brain the impact of mitochondrial impairment is 
particularly significant in the neuronal environment. Mitochondrial dysfunction 
(MTdys) and the subsequent unregulated production of ROS/RNS has long been 
implicated in neurodegenerative diseases such as multiple sclerosis (MS), amyotrophic 
lateral sclerosis (ALS) and Alzheimer’s disease (Lin & Beal, 2006). This section will 
focus on the role of MTdys in the pathophysiology of PD and ASDs.  
The part played by mitochondria in the etiology of PD was discovered by the role of 
MPTP a by-product of ‘synthetic heroin’ synthesis, in the development of severe 
parkinsonism (Langston et al., 1983). The metabolite of MPTP, MPP+ inhibits Complex 
I of the mitochondrial ETC (Abou-Sleiman et al., 2006; Lin & Beal, 2006). Genetic 
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mutations or polymorphisms in mtDNA in several genes including α-synuclein and 
parkin have also been linked to the pathophysiology of PD (Lin & Beal, 2006). Complex 
I inhibition by MPP+ can directly result in increased oxidative stress particularly through 
the production of O· . This process leads to the further generation of secondary 
RNS/ROS and subsequent deleterious processes which can damage DNA, lipids and 
proteins (Lin & Beal, 2006; Valko et al., 2007; Melo et al., 2011) (see Section 2.10.2).  
The herbicide paraquat (PQ) is an environmental toxin which has previously been linked 
to the development PD (Tanner et al., 2011). A detailed description of the properties of 
PQ and the mechanism of action of this herbicide in the physiological environment is 
provided for in Chapter 8 of this thesis.  
Briefly PQ may be reduced to form a PQ monocation free radical (PQ•+) in the neuronal 
environment by cellular diaphorases, which are enzymes that transfer electrons from 
NADPH to small molecules such as PQ. PQ•+ is rapidly re-oxidised in the presence of 
molecular oxygen which generates O· and initiates the processes which lead to 
oxidative/nitrosative stress (see Section 2.10). Under normal physiological conditions 
Complex I of the mitochondrial ETC accepts electrons from NADH. However when PQ 
is present PQ preferentially accepts these electrons and leads to Complex I inhibition 
and subsequently MTdys (Dinis-Oliveira et al., 2006; Mohammadi-Bardbori & Ghazi-
Khansari, 2008). The characteristics of PQ, MPP+ and rotenone as Complex I inhibitors 
and oxidative stressors have enabled the successful replication of certain aspects of the 
pathophysiology of PD in animal models (Beal, 2001; McCormack et al., 2005; 
McCormack et al., 2006).  
MTdys leads to an insufficient supply of ATP. ATP is necessary for the normal 
physiological function of various cellular processes including sequestering DA into 
synaptic vesicles by the vesicular monoamine transporter (VMAT2) (Andersen, 2004). 
Therefore insufficient ATP may lead to increased cytoplasmic DA and subsequently DA 
metabolism related oxidative stress (Lotharius & Brundin, 2002; Andersen, 2004).  
SNc DA neurons are rich in glutamate receptors, a lack of ATP due to MTdys leads to 
the glutamate mediated activation of N-methyl-D-aspartate (NMDA) receptors which 
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results in an influx of Ca2+ and leads to depolarisation of the cell (Olanow & Tatton, 
1999). The constitutive forms of NOS (eNOS and nNOS) are activated by Ca2+ followed 
by binding with calmodulin which leads directly to the production of NO (Alderton et 
al., 2001; Saulskaya & Fofonova, 2006).    
Classical mitochondrial disease occurs in a subset of ASDs due to genetic abnormalities 
and a subsequent deficiency in mitochondrial respiration (Frye & Rossignol, 2011). 
MTdys has also been implicated in the pathophysiology of ASDs and is not directly 
related to mitochondrial disease. Several biochemical, pathological and neuroimaging 
studies have suggested that MTdys is implicated in certain cases of ASDs (Chauhan & 
Chauhan, 2006; Palmieri & Persico, 2010). Specifically, diminished levels of ATP have 
been indicated in the brain of ASDs individuals by PET and NMR imaging (Lombard, 
1998). An elevated level of lactate and pyruvate has also been demonstrated in 
biological ASDs samples (Haas, 2010). A disruption to oxidative phosphorylation 
would lead to increased levels of lactate/pyruvate in the periphery and suggest that 
MTdys plays a role in the development of ASDs. Chauhan et al. have demonstrated that 
the protein levels of various mitochondrial ETC complexes were decreased in different 
brain regions of children with autism. This study was determined by western blot 
analysis of post mortem ASDs brain tissue samples which were compared against age 
matched controls (Chauhan et al., 2011).  
Although a variety of evidence indicates that MTdys is related to the etiology of ASDs it 
has been postulated by several research groups not to be a primary initiating event in the 
disorder (Palmieri & Persico, 2010).  It has been hypothesised that MTdys seen in ASDs 
individuals is a secondary event due to oxidative stress possibly initiated by 
environmental agents (Frye & Rossignol, 2011). A variety of environmental agents may 
contribute to the process of MTdys in ASDs such as prenatal exposure to infection 
(Meyer et al., 2011), ethanol and valproic acid (Arndt et al., 2005).  
Gastrointestinal (GI) disturbances are commonly associated with ASDs, specifically due 
to an abnormal composition of gut bacteria in ASDs individuals (Parracho et al., 2005; 
de Theije et al., 2011). Propionic acid (PPA) is produced by oppurtunistic enteric 
bacteria such as clostridial species in the gut and elevated levels of these bacteria have 
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been found in ASDs individuals (Finegold et al., 2002). PPA may lead to MTdys by the 
direct inhibition of oxidative phosphorylation (MacFabe et al., 2007). Additionally, 
MacFabe et al. have demonstrated that PPA may be used in rats to mimic the 
behavioural changes and neuroinflammatory responses which are associated with autism 
spectrum disorders (ASDs) (MacFabe et al., 2008; Shultz et al., 2009).  
It is known that MTdys leads to oxidative/nitrosative stress and the consequential 
production of ROS and RNS which subsequently leads to a vicious cycle of further 
MTdys and antioxidant impairment (Lin & Beal, 2006).  
Neuropathological investigations of PPA treated rat brain tissue and post mortem 
autistic brain preparations have indicated the presence of activated microglia and 
astrocytes which are indicative of an inflammatory response (Vargas et al., 2005; 
MacFabe et al., 2011). As previously stated cytokines produced by this process are 
known to activate iNOS and hence elicit an increase in NO (Guix et al., 2005). In a pro-
oxidant environment NO can interact directly with O·  and lead to the formation of the 
main secondary highly toxic RNS; ONOO (see Section 2.10.3). This process may be 
accelerated in response to an inflammatory insult where O·and NO specifically 
produced by iNOS, are produced and lead to MTdys (Calabrese et al., 2007). 
The detection of oxidative/nitrosative stress markers in an animal model of ASDs may 
contribute to a more complete understanding of the processes which lead to the 
development of ASDs. This information may yield new strategies to treat and alleviate 
ASDs symptoms. The detection of NO in a PPA induced animal model of ASDs is 
presented in Chapter 7 of this thesis.  
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1.10 Current therapeutic strategies for PD  
The primary treatment for the motor symptoms which are characteristic of PD is the DA 
replacement therapy drug Levodopa (Schapira, 2008; Lipski et al., 2011). Levodopa/L-
dopa is orally administered and absorbed in the intestine where it is distributed in the 
blood and subsequently crosses the BBB. L-dopa is metabolised in the dopaminergic 
cells of the SNc where it is then converted by decarboxylation to DA by aromatic L-
amino acid decarboxylase (Schapira, 2008; Lipski et al., 2011).  
L-dopa is highly efficient in the initial treatment of PD by the direct replacement of 
insufficient DA. However, the long-term administration of L-dopa results in the 
appearance of motor complications such as dyskinesias and motor fluctuations due to 
the effect of the drug ‘wearing off’ (Kieburtz, 2008; Schapira, 2008; Lipski et al., 2011). 
Additionally, serious side effects such as nausea and vomiting are associated with L-
dopa treatment (Schapira, 2008). The ‘wearing off’ effect of L-dopa administration may 
be ameliorated by the joint or pre-administration of DA agonists which result in a more 
consistent release of DA or in conjunction with other methods which reduce L-dopa 
peripheral metabolism and improve absorption e.g. carbidopa (Schapira et al., 2009).   
The role of other potential therapeutic options in the treatment of PD have been 
suggested including antioxidants and vitamins, metal chelators and antiglutamatergic 
agents (Barnham et al., 2004; Melo et al., 2011).  However, clinical trials have not 
supported a beneficial effect of antioxidant (Vitamin E) treatment of PD (Barnham et 
al., 2004). The production of ROS in PD activates glutamate-mediated excitotoxicity; 
NMDA receptor antagonists which may prevent this process have been used in the 
treatment of PD and some clinical efficiency has been observed (Melo et al., 2011). The 
potential benefit of metal chelators in the prevention of iron mediated oxidative stress in 
neurodegenerative disease has also been investigated (Barnham et al., 2004; Melo et al., 
2011). However, the primary treatment of PD remains to be the ‘gold standard’ therapy 
of L-dopa administration (Schapira et al., 2009).    
Some evidence has been presented that treatment with L-dopa may have a propensity to 
induce DA metabolism related oxidative stress (Schapira et al., 2009; Lipski et al., 
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2011). The negative aspects of L-dopa treatment are highly dependent on the L-dopa 
dose concentration and length of administration.  In-vitro studies have demonstrated that 
L-dopa is toxic in cell cultures via the process of oxidative stress (Lipski et al., 2011). 
However, clinical trials in humans and studies conducted with animals, including 
rodents and primates, have failed to conclusively reveal a toxic effect following the 
administration of L-dopa (Fahn et al., 2004; Schapira, 2008; Schapira et al., 2009; 
Lipski et al., 2011). The general consensus is that L-dopa is not capable of stopping the 
progression of dopaminergic cell loss in the SNc but can only slow the rate of PD 
progression (Fahn et al., 2004; Lipski et al., 2011). This fact necessitates the further 
development of novel PD therapeutic strategies. 
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1.11 Conclusion 
This thesis demonstrates the further in-vitro development of a paired catalase-based 
H2O2 sensor and the utilisation of this sensor design to detect changes in H2O2 in the 
physiological environment. The verification of previous in-vitro and in-vivo 
characterisations of a Nafion®-modified Platinum disc (Ptd) (5 pre-coats, 2 applications) 
NO sensor is presented in this thesis. The detection of NO/H2O2 in animal models of 
neurodegenerative disease and dysfunction is also presented.  
The present chapter outlines the concept of neuronal transmission, details of the role of 
H2O2 and NO in normal physiological function and dysfunction are also given. The 
theoretical aspects which form the fundamental basis of experimental studies conducted 
in this thesis are described in Chapter 2. The materials and methods utilised throughout 
the course of this body of work are described in detail in Chapter 3. 
The sensitivity, selectivity and stability of the paired H2O2 sensor in the in-vitro 
environment is demonstrated in Chapter 4. The novel in-vivo characterisation of the dual 
H2O2 sensor in the anaesthetised animal and the previously unreported electrochemical 
detection of H2O2 in the freely-moving animal is presented in Chapter 5. Verification of 
the detection of NO in-vitro and in the physiological environment and novel stability 
characteristics of the NO sensor are presented in Chapter 6. Details of the original 
electrochemical detection of NO in an animal model of autism and Parkinson’s disease 
are presented in Chapter 7 and 8 respectively. Additionally, the preliminary detection of 
H2O2 in conjunction with NO in a parkinsonian animal model is reported in Chapter 8. 
Finally Chapter 9 concludes the thesis and outlines the main experimental outcomes.   
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2.1 Introduction 
This thesis describes the electrochemical detection of hydrogen peroxide (H2O2) and 
nitric oxide (NO) in-vitro and in the brain of freely moving-animals. The main aim of 
this chapter is to explain the fundamental electrochemical principles and techniques 
utilised in this thesis in order to detect H2O2 and NO in the in-vitro and in-vivo 
environment.  
A description of the electrochemical cell set-up utilised for the attainment of in-vitro 
data is given in Section 3.7. Additionally the protocol for implantation of the working 
electrodes for the attainment of in-vivo H2O2 and NO data is outlined in Section 3.10. 
Both strategies rely on the same basic electrochemical principles. In each case the 
electrochemical circuit consists of a reference electrode, an auxiliary electrode and a 
specified number of working electrodes. 
The electrochemical changes being investigated take place at the working electrode. The 
reference electrode has a fixed potential against which the potential of the working 
electrodes in the cell can be measured. The final electrode is the auxiliary or counter 
which functions as a source or sink for electrons and completes the electrical circuit.  
Many electroanalytical techniques are available, however Constant Potential 
Amperometry (CPA) was utilised without exception in this thesis (see Section 2.4). 
CPA provides the appropriate time resolution necessary in-vivo to detect species such as 
H2O2 and NO which are expected to have a relatively short lifetime in tissue (Wink & 
Mitchell, 1998; Kelm, 1999; Maier & Chan, 2002; Rice, 2011). An extensive 
description of the basic electrochemical principles outlined in this chapter have 
previously been described by Bard and Faulkner (Bard & Faulkner, 2001). 
The process of oxidation and reduction at the electrode surface is described in Section 
2.2. The three processes which contribute to mass transport of the analyte to the 
electrode surface including diffusion, convection and migration are outlined in Section 
2.3. CPA is discussed in detail in Section 2.4, the oxidation mechanisms of H2O2, NO 
and ascorbic acid (AA) are also presented in Section 2.4.  
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The structure of the permselective membranes used in the design of the sensors 
described in this thesis including Nafion® and PPD are shown in Section 2.5 and 2.6 
respectively.  
A detailed description of the function of the catalase enzyme utilised in this research 
project is provided in Section 2.7. Additionally the derivation of the paired catalase-
based H2O2 sensor response is mathematically presented in section 2.8. An overview of 
the main principles of microdialysis (MD) and retrodialysis (RD) is given in Section 2.9. 
A detailed description of the development of oxidative and nitrosative stress is provided 
in Section 2.10.  
2.2 Oxidation/Reduction 
CPA involves the application of a fixed potential between the working and reference 
electrode which causes oxidation or reduction of the target species. The equation for 
oxidation/reduction of a species is given in Equation 2.1. O and R represent the oxidised 
and reduced forms and n refers to the number of electrons.  
-  ./ 0 1 
(2.1)    
When a potential is applied oxidation or reduction processes occur at the active surface 
of an electrode and a resulting faradaic current flows. As the variation in potential gives 
rise to the transfer of electrons that are governed by Faraday’s law (Equation 2.3) they 
are termed faradaic processes.  
As shown in Figure 2.1 at equilibrium (Eeq), i.e. no negative (-ve) or positive (+ve) 
potential is applied consequently no oxidation/reduction processes occur. The fermi 
level (Ef) or highest energy level of the metal based working electrode is equal in energy 
to the highest occupied molecular orbital (HOMO) of the solution species.  
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Figure 2.1 The system at equilibrium. 
Upon the application of a potential (Eapp) which is more positive than Eeq the Ef of the 
metal decreases. It is now energetically more favourable for electrons to move from the 
HOMO level of the solution species to the lower lying Ef of the metal. This process 
results in an oxidation reaction and a corresponding oxidation current (Figure 2.2). A 
reduction reaction occurs where a negative potential is applied relative to Eeq and 
electrons move from the increased Ef of the metal to the LUMO level of the solution 
species. 
 
 
 
  
 
 
 
Figure 2.2 An oxidation reaction. 
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Additionally a capacitance current (charging/background current) arises following the 
application of a potential which is due to opposing charges between the electrode and 
target medium. However this charging current is not due to the presence of the analyte 
and is excluded from the experimental data presented in this thesis. The two main 
contributing processes to the reaction (Equation 2.1) are mass transport of the analyte to 
the electrode surface and electron transfer.  
Long-term in-vivo electrochemistry (L.I.V.E) involves the chronic detection of changes 
in concentration of a particular analyte in the biological environment. For the evaluation 
of the concentration of a given analyte the Nernst equation is used (Equation 2.2). With 
the consideration that electron transfer is relatively fast as is the case with 
microelectrodes (Forster, 1994).The Nernst equation describes the variation of electrode 
potential for each electrochemical reaction with the concentrations of oxidised [O] and 
reduced species [R] under conditions of equilibrium at the electrode surface. Diffusion is 
an important contributing factor and is discussed in Section 2.2.1.  
234 5 26 5 17.8 ln
9-:
91: 
(2.2) 
Where E* is the standard electrode potential. R is the gas constant, T is the temperature, 
F is the Faraday constant (96, 485 C mol-1) and n is the number of electrons.  
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2.3 Mass transport  
Mass transport of the analyte to the electrode surface and the rate of electron transfer 
determines how the reaction proceeds. The experimentally measured current (I) is a 
direct indication of the rate of the electrochemical reaction and is given by Faraday’s 
law. 
; 5 .8<= 
(2.3) 
Where (I) indicates the current, n refers to the number of moles, F is the Faraday 
constant, A is the area of the electrode (m2) and J is the flux of ions (mol m-2 s-1). 
Three processes control the movement of charged species to the electrode surface and 
these are diffusion, convection and migration.  
2.3.1 Diffusion 
Assuming that the electron transfer is very rapid as is the case with microelectrodes 
(Forster, 1994) the measured current is directly related to diffusion of the target species 
to the electrode surface. Diffusion is defined as the movement of molecules from an area 
of high concentration to an area of low concentration across a concentration gradient as 
described by Fick’s first law (Equation 2.4).  
=> 5 ?> @A@B 
(2.4) 
Where Jb is the flux of species b, ?> is the proportionality factor between flux and 
concentration gradient known as the diffusion coefficient and CDCE is the concentration 
gradient in direction x. The negative sign is present as the flux of species b tends to 
cancel the concentration gradient. Fick’s first law describes the flux (Jb) as being 
directly proportional to the concentration gradient.  
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Concentration changes over time of the electroactive species of interest (b) near to the 
electrode surface due to the movement described in Figure 2.3 may be determined using 
Fick’s second law (Equation 2.5). 
 
     
 
 
 
Figure 2.3 One dimensional diffusion opposing a concentration gradient. In relation to movement of 
a position (x) within an element of width (dx) 
@9F:
@G 5 ?
@A
@B 
(2.5) 
Assuming that the concentration gradient is constant (no change in [b] with t), as is the 
case with microelectrodes due to the small dimensions of the electrode and the minimal 
removal of the analyte from the surrounding solution. A steady-state current response is 
obtained. No change in concentration is observed with respect to time according to 
Fick’s second law due to the absence of a change in concentration gradient.  
For planar electrodes where the geometry permits uniform access to the bulk solution. 
The variation in current with time may be calculated from Fick’s second law which 
results in the Cottrell equation (Equation 2.6). Therefore for a disc electrode the steady-
state current in the limiting region is given by Equation 2.6.  
; 5 .8<= 5 .8<?H ⁄ AJKGH ⁄  
(2.6) 
dx 
J (x, t) J (x+dx, t) 
x x+dx 
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(I) represents the measured current, n is the number of electrons, F is the Faraday 
constant, A is the surface area, D being the diffusion coefficient, where J is the flux and 
AJ represents the concentration of the electroactive species in the bulk solution.  
A Laplace operator L is substituted into Equation 2.4 to determine the flux for any 
geometry of electrode. As shown in Equation 2.7.  
= 5 ?LA 
(2.7) 
Fick’s second law for any geometry is given by Equation 2.8. 
@A
@G 5 ?LA 
(2.8) 
The laplacian operator for cylinder electrodes is given by Equation 2.8.1 
@
@M  N
1
MP N
@
@MP 
(2.8.1) 
If initial conditions pertaining to t = 0 and two boundary conditions relating to spatial 
coordinates are obeyed. From Fick’s first law the flux can be directly related to current 
density, QR ; as follows. 
=> 0, G 5  U.8< 5 ?> V
@A> B, GWB XEYZ 
(2.9) 
Where J relates to flux, i is the current, n is the number of transferred electrons, F is the 
Faraday constant and A relates to the active surface area of the electrode.  
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2.3.2 Convection 
Convection relates to movement of species due to an applied external force as with the 
process of stirring. With in-vitro experiments aliquots of substrate were introduced into 
the electrochemical cell via brief agitation of the bulk solution with a magnetic stirrer. 
The contribution of convection to the process of mass transport is negated as rapidly 
achieved steady-state currents in the quiescent environment were utilised in the analysis 
of all calibration data. 
2.3.3 Migration 
Migration is the movement of charged species due to the presence of an electric field. 
The electric field is limited to small distances away from the electrode surface. 
Migration process are eliminated with microelectrodes from the process of mass 
transport due the large amount of an inert electrolyte utilised i.e. phosphate buffer saline 
(PBS) (see Section 3.3.2.1). Additionally, the background electrolyte (PBS) reduces the 
resistance of the solution and prevents ohmic potential drop otherwise termed IR drop as 
given by Ohm’s law (Equation 2.10).  
[ 5 ;1 
(2.10) 
2.4 Constant Potential Amperometry (CPA) 
All data presented in this thesis was recorded using CPA. CPA involves the application 
of a fixed potential and the continuous detection of a corresponding current change. 
Consumption of the analyte by the microelectrode is rapid and produces a current which 
is limited by mass transport. With CPA diffusion to the electrode surface is assumed to 
be the only form of mass transport which results in a steady-state diffusion limited 
currentU\\.  
U\\ 5 .8<]?M  
(2.11) 
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Where n refers to the number of electrons, F is the Faraday constant, A refers to the 
surface area, C relates to concentration, D is the diffusion coefficient and r is the radius. 
The resulting current is directly proportional to the diffusion coefficient and the 
concentration of the target substrate.  
Practically the steady-state current is also dependent on aspects such as the insulation 
thickness of the electrode (Dayton et al., 1980) and as a result a geometric factor (G) is 
incorporated into Equation 2.11.  
U\\ 5 ^.8<]?M  
(2.12) 
2.4.1 Hydrogen peroxide (H2O2) 
Platinum (Pt) electrodes are commonly used for the oxidation of H2O2. Pt is widely used 
in first generation biosensors for the detection of enzymatically produced H2O2 (Lowry 
et al., 2006). At +700 mV vs. SCE H2O2 is oxidised on the surface of Pt at a diffusion 
controlled rate which results in a current response which is linear and directly 
proportional to the concentration of the target species (Lowry et al., 1994; O'Brien et al., 
2007). The oxidation of H2O2 is known to be a two-electron process as outlined below in 
Equation 2.13 This process is similar to the oxidation of H2O2 at palladium electrodes 
where the formation of an oxide at the surface of the electrode is an essential step in the 
process of H2O2 oxidation (Hall et al., 1998) as seen in Equations 2.14 and 2.15.  
_-  -  2_  2/ 
(2.13) 
`G-_  _-  `G  2_-  - 
(2.14) 
`G  2_-  `G-_  2_  2/ 
(2.15) 
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2.4.2 Nitric oxide (NO) 
Nitric oxide (NO) can be electrochemically detected at the surface of Pt via a three-
electron oxidation mechanism.  
a-  a-  / 
(2.16) 
a-  -_  _a- 
(2.17) 
_a-  _-  a-%  2/  3_ 
(2.18) 
In this thesis a Nafion®-modified Pt
 
disc electrode was constructed as previously 
described in detail by Brown et al. (Brown et al., 2009) for the detection of NO. Briefly 
Nafion®, a negatively charged species, is thermally annealed onto the Pt surface of the 
electrode to facilitate interference rejection. Additionally an increase in NO sensitivity 
occurs following the Nafion® modification procedure (Brown et al., 2009). The 
oxidation of NO at bare Pt surfaces involves the presence of adsorbed intermediates. As 
described by Brown et al. the presence of Nafion® in the modified NO sensor design 
eliminates these absorbed species by stabilising the production of NO+ (Equation 2.16) 
Thereby preventing the processes described in Equation 2.17 and 2.18. The oxidation of 
NO at the Nafion® modified active surface  may be described in terms of Equation 2.16.  
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2.4.3 Ascorbic acid (AA) 
AA is an electroactive substance with an E1/2 of between -100 and +400 mV vs. SCE 
(Lowry et al., 2006). The mechanism for oxidation of AA is represented below in Figure 
2.4. AA is oxidised and in the process it loses two electrons and two hydrogen ions. The 
reaction is a 2e- process whereby L-dehydroascorbic acid is formed, this is then hydrated 
and exists in equilibrium with its hydrated form. L-dehydroascorbic is readily 
hydrolysed to form L-2-3-diketogulonic acid which is not electroactive.  
 
Figure 2.4 Reaction scheme for the oxidation of ascorbic acid. 
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2.5 Electropolymerisation of o-Phenylenediamine (o-PD) 
o-Phenylenediamine (o-PD) (1, 2-diaminobenzene) may be electropolymerised onto the 
surface of a Pt electrode to form an insulating poly-o-phenylenediamine (PPD) polymer. 
The use of PPD in sensor design has previously been demonstrated by Lowry et al. 
amongst other research groups (Sasso et al., 1990; Lowry & O'Neill, 1992; Lowry et al., 
1994; Lowry et al., 1998a; Rothwell et al., 2010).  
 
Figure 2.4 Structure of the monomer (o-PD). 
The purpose of the PPD layer is to act as a permselective membrane which permits 
access of small molecules such as H2O2 to the Pt surface and prevents the access of 
relatively larger molecules such as AA. The formation of PPD as a conducting polymer 
has previously been demonstrated (Malitesta et al., 1990). In this thesis PPD was 
electropolymerised onto the surface of the Pt electrode in a neutral electrolyte (PBS) 
which facilitates the formation of an insulating polymer. This process results in the 
formation of a thin layer (10-30 nM) of PPD on the active surface of the electrode 
(O'Neill et al., 2008). The PPD modified sensor maximises H2O2 sensitivity and 
effectively eliminates the detection of AA. This aspect is important in relation to the 
selectivity of the catalase-based paired H2O2 sensor design described in this thesis (see 
Section 4.3.3 and 4.5.3).  
The exact structure of the non-conducting PPD structure has yet to be determined. As 
discussed by Losito et al. two possible structures exist (Losito et al., 2001). These 
proposed structures consist of a ‘ladder’ (phenazine-like) structure presented in Figure 
2.4(A) where the amino groups (NH2) are condensed within the benzene ring adjacent to 
each other along the polymer chain. The other proposed PPD formation consists of an 
‘open-ring’ formation (1, 4 substituted benzenoid-quinoid structure) as shown in Figure 
2.4(B). Losito et al. have shown that increased NH2 content is found when PPD is 
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formed at a more neutral pH (Losito et al., 2003). This finding indicates that the ‘open-
ring’ structure is formed under the polymerisation conditions outlined in this thesis (see 
Section 3.5.1). 
(A) 
(B) 
Figure 2.5 Proposed PPD polymer structures. (A) ‘ladder’ formation and (B) ‘open-ring’ structure 
2.6 Nafion® 
 
Figure 2.4 The structure of Nafion®. 
Nafion® (Section 3.3.1.1) is a polyflourinated polyacid which consists of a hydrophobic 
fluorocarbon scaffold permeated with clusters of hydrophilic ionic sulfonic acid groups 
(SO3-). Nafion® is commonly used in sensor design due to the cation exchange 
properties of this polyacid (Mercado & Moussy, 1998; Park et al., 1998; Mas et al., 
2002). Additionally, our research group has previously demonstrated a highly sensitive 
and selective NO sensor design which incorporates a Nafion® layer (Brown & Lowry, 
2003; Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 2012b). The negatively 
charged Nafion® membrane repels anions such as AA and enables the stabilisation of 
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NO+ which is formed upon the oxidation of NO as discussed in Section 2.4.2. 
Additionally the anionic rejection characteristics of Nafion® facilitate the selective 
detection of other cationic and neutral species such as H2O2 against interference species 
such as AA in sensor design (O'Brien et al., 2007).  
2.7 Catalase 
Catalase is one of the primary antioxidant enzymes present in the brain (Rice, 2011). 
The primary function of this enzyme is the catalytic removal of potentially harmful 
H2O2 by the conversion of H2O2 into inert substances i.e. water and oxygen (Equation 
2.19).  
2HO c 2HO  O 
(2.19) 
The catalase enzyme found in humans has a teterameric structure with a heme group at 
the central active site (Kirkman & Gaetani, 2007). The catalytic dismutation of H2O2 by 
the heme-containing enzyme is outlined in Equation 2.20 and 2.21. The overall process 
occurs by a two stage mechanism. In the initial step (Equation 2.20) H2O2 oxidises the 
heme-containing enzyme to form a porphyrin (Por) cationic radical. 
Enz Por  Feggg  HO  Cpx I Por·  Fegk 5 O  HO 
(2.20) 
In the second step of the H2O2 dismutation mechanism (Equation 2.21) an additional 
molecule of H2O2 will reduce Complex I (CPx I) to regenerate the resting state of the 
catalase enzyme (Enz) and produce water and oxygen.  
Cpx I Por·  Fegk 5 O  HO   Enz Por  Feggg  HO  O 
(2.21) 
These combined processes (Equation 2.20 and 2.21) lead to the conversion of H2O2 into 
water and oxygen (Equation 2.19). 
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2.8 Paired catalase-based H2O2 biosensor 
The paired H2O2 sensor utilised in this thesis was fabricated and modified by a process 
previously described by O’Brien et al. (O'Brien et al., 2007). Additionally, a detailed 
description of the fabrication process is given in Chapter 3 Section 3.4.3.  
Briefly, the paired H2O2 sensor utilised in this thesis consists of a pair of Pt cylinder 
electrodes both modified with the permselective membranes Nafion® (Section 2.6) and 
PPD (Section 2.5). One of these electrodes was further modified with catalase (Section 
2.7). This process yielded two amperometric electrodes one with catalase adhered (Cat) 
and the other without (Blank). Two sensors are produced by this process; one capable of 
detecting H2O2 [Ptc/Nafion®/PPD (Blank)] and a paired sensor capable of removing 
H2O2 [Ptc/Nafion®/PPD/Cat-Ga (Cat)].  
The H2O2 sensitivity of the paired biosensor design was derived by subtracting the Cat 
sensor current response from that recorded at the Blank sensor. A detailed description of 
the overall subtracted response of the paired H2O2 sensor has previously been described 
by O’Brien et al. (O'Brien et al., 2007). For the purpose of clarity a synopsis of the 
previously described subtracted response of the paired H2O2 sensor is given in this 
section.  
When implanted in the physiological environment the current measured at the Blank 
sensor (IBlank) and Cat sensor (ICat) will arise from interference species IINTb and IINTc 
respectively in addition to H2O2 (IHP).  
;lmnop 5 ;qrs>  ;tu 
(2.22) 
;vnw 5 ;qrsD  ]tu;tu 
(2.23) 
Equation 2.22 represents the current response of the Blank sensor in-vivo. Equation 2.23 
demonstrates overall current response of the Cat sensor implanted in the physiological 
environment. CHP represents the fraction of H2O2 not degraded by the catalase-based 
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sensor (Cat). The value of CHP is effectively eliminated from the equation as ~98 % of 
the H2O2 signal is removed by the Cat sensor (see Section 4.7). Provided the value of 
IINTb and IINTc are essentially the same the overall response of the paired catalase-based 
H2O2 sensor (∆I is determined by subtracting the current response of the Cat sensor 
from the Blank sensor. The matched interference rejection characteristics of the Blank 
and Cat sensor are demonstrated in Section 4.8. The overall H2O2 response of the paired 
sensor is described as follows.  
∆; 5 ;lmnop  ;vnw 5 1  ]tu;tu 
(2.24) 
As discussed the interference rejection properties of the Cat (IINTc) and Blank (IINTb) 
sensor are matched (see Section 4.8).  
If ;qrs> z ;qrsD {.W ;qrsD 5 ]qrs;qrs> 
(2.25) 
Where CINT represents the proportionality factor between (IINTc) and (IINTb). 
| ∆; 5 1  ];a7;;a7F  1  ]_`;_`  
(2.26) 
The value of CINT is effectively unity and also the value of CHP is effectively zero. 
|  ∆; 5 ;;a7F  ;_` 
(2.27) 
The value of IINTb is very low as shown by the response of the Blank sensor to the 
addition of AA in-vitro (see Section 4.5.4). Additionally, the impact of the value of IINTb 
diminishes relative to large response of IHP. Therefore, the overall response of the paired 
catalase-based H2O2 sensor in-vivo is simply yielded by subtraction of the Cat sensor 
response from that of the Blank sensor ;lmnop  ;vnw. 
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2.9 Microdialysis 
Microdialysis (MD) is a technique which may be used to sample low molecular weight 
substances in the physiological environment. The use of the MD sampling technique for 
the collection of small molecules present in the extracellular fluid (ECF) of the brain has 
previously been extensively reviewed (Lonnroth & Smith, 1990; Peters et al., 2000; 
Tisdall & Smith, 2006).  
A small probe is implanted into the brain which consists of a hollow fibre dialysis 
membrane. A liquid is perfused through this probe (perfusate) and low molecular weight 
substances are recovered from the outlet fluid (dialysate) by the process of diffusion. 
The perfusate normally used is artificial cerebrospinal fluid (aCSF) (see Section 
3.3.2.2).  
The MD technique functions by the diffusion of a higher concentration of analyte in the 
surrounding tissue across a concentration gradient towards the lower concentration 
present within the microdialysis probe. Subsequently, the dialysate may be analysed by 
various methods including high performance liquid chromatography (HPLC) (Perry et 
al., 2009). The primary disadvantage of this technique is the time lag associated with the 
collection of the dialysate (O'Neill & Lowry, 2000).  
In this thesis the dialysate was not collected for the purpose of analysis. The paired H2O2 
sensor was glued to the microdialysis probe and the entire construct was implanted into 
the brain (see Chapter 5). In this way real-time electrochemical data from the implanted 
sensor was facilitated following the perfusion of substances of interest (see Chapter 5). 
The local administration of substances to the brain in this manner has previously been 
demonstrated and is termed retrodialysis (RD) (Huynh et al., 2007).  
Additionally, the ECF concentration of the target substrate may be estimated by the RD 
method. The perfusion of substrate, which has a higher concentration to that present in 
the surrounding tissue, will result in an increase in the recorded current at the implanted 
sensor.  Correspondingly the perfusion of a lower substrate concentration in relation to 
the ECF will result in a decrease in the current recorded by the sensor. The perfusion of 
various concentrations of substrate will yield a calibration curve from the implanted 
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sensor. The basal concentration of substrate in the ECF may be determined from this 
calibration curve as previously shown (Miele & Fillenz, 1996; Lowry et al., 1998b). 
This method is a modification of the zero net flux technique as previously demonstrated 
by Lonnroth et al.(Lonnroth et al., 1987).   
However, the determination of the ECF concentration of the target analyte in this 
manner has significant drawbacks. The implanted sensor may disturb the natural 
processes taking place in the surrounding brain tissue. For example the absolute basal 
concentration of dopamine determined by microdialysis has been much debated due to 
uptake mechanisms present in-situ and a proposed trauma layer induced by implantation 
of the probe itself (Bungay et al., 2003).  
Additionally, the delivery of the target substrate to the electrochemical sensor implanted 
in the brain may be restricted by recovery issues associated with the MD/RD technique. 
The recovery ratio of a substance using the MD technique is defined as the 
concentration in the dialysate expressed as a percentage of the concentration present in 
the interstitial fluid. Ideally the recovery ratio should be 100 % however under maximal 
conditions where a slow flow rate and relatively long MD membrane are utilised the 
recovery ratio has been estimated to be only 70 % (Ungerstedt & Rostami, 2004). 
Therefore with the RD technique not all of the substrate added to the perfusate will 
reach the tissue surrounding the implanted sensor. Thus this inherent recovery issue may 
result in a lower than expected recorded response by the implanted sensor.   
2.10 Oxidative and nitrosative stress 
Reactive oxygen species (ROS) such as H2O2 and reactive nitrogen species (RNS) such 
as NO exert both beneficial and harmful effects in the neuronal environment (Calabrese 
et al., 2007; Rice, 2011). An extensive antioxidant network tightly regulates the 
production of ROS and RNS in the brain and exists to maintain normal redox 
homeostasis (Simonian & Coyle, 1996; Valko et al., 2007). A disruption to this robust 
network leads to the over production of ROS (e.g. H2O2) and RNS (e.g. NO) which 
leads to the development of oxidative/nitrosative stress and consequently a disruption to 
normal cell function. Oxidative/nitrosative stress has been linked to a variety of 
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neurodegenerative diseases and dysfunctions such as Parkinson’s disease, Alzheimer’s 
disease and more recently autism spectrum disorders (ASDs) (Barnham et al., 2004; 
Chauhan & Chauhan, 2006). This section will outline the main antioxidant defence 
processes and mechanisms which lead to ROS/RNS production in the brain. 
2.10.1 Antioxidants 
As previously stated a variety of defence mechanisms exist to control the excess 
production of ROS/RNS and hence maintain redox homeostasis in the brain. These 
consist of various enzymatic and non-enzymatic sources. The primary enzymes 
responsible for the maintenance of redox balance are catalase (Cat) superoxide 
dismutase (SOD) and glutathione peroxidase (GPx). The mechanism of action of the 
catalase enzyme in the removal of potentially harmful H2O2 is presented in Section 2.7. 
The metalloenzyme SOD catalyses the disproportionation of superoxide (O·) into 
H2O2 and O2 (Liochev & Fridovich, 2000). The dismutation i.e. oxidation and reduction 
of O·, due to the variable oxidation state of the metallic centre of the enzyme occurs 
by a two-step mechanism and is outlined below in Equation 2.28 and 2.29.   
Enz  Cugg  O· } Enz  Cug  O 
(2.28) 
Enz  Cug  O·  2H } Enz  Cugg  HO 
(2.29) 
The selenoprotien i.e. selenium containing enzyme GPx is one of the primary enzymes 
responsible for the regulation of H2O2/ROS levels in the brain (Dringen et al., 2005). 
The presence of glutathione (GSH) is a necessary requirement in the catalytic reduction 
of H2O2 by GPx. The catalytic removal of H2O2 by GPx occurs by a multi-step 
mechanism which involves the recycling of GSH from its oxidised form glutathione 
disulfide (GSSG) (Dringen, 2000; Prabhakar et al., 2005).  
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Enz  SeH  HO  Enz  SeOH  HO 
(2.30) 
Enz  SeOH  GSH  Enz  Se  SG  HO 
(2.31) 
Enz  Se  SG  GSH  Enz  SeH  GSSG 
(2.32) 
GSSG is converted back to GSH by the glutathione reductase enzyme (GR). The GR 
enzyme transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) 
to GSSH which produces GSH. The entire mechanism of GPx mediated H2O2 removal 
results in the production of water and is dependent on the cyclic conversion between 
GSH and GSSH (Valko et al., 2007). The contributing processes of catalytic removal of 
H2O2 by Cat, SOD and GPx are summarised below in Figure 2.5.  
 
Figure 2.5 Enzymatic antioxidant processes. 
A variety of non-enzymatic sources of antioxidants also exist in the neuronal 
environment including ascorbate (vitamin C), α-tocopherol (vitamin E) and GSH which 
collectively contribute to maintain redox homeostasis (Rice, 2000; Valko et al., 2007; 
Winterbourn, 2008). The basic mechanism of action of ascorbate as an antioxidant relies 
Hydrogen peroxide (H2O2)
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on its ability to donate electrons to directly scavenge ROS/RNS such as O· or 
peroxynitrite ONOO (Rice, 2000). The oxidation of ascorbate in this manner 
produces dehydroascorbate (Section 2.4.3) and this radical intermediate may be reduced 
to reform ascorbate by GSH (Rice, 2000). Vitamin E carries out its antioxidant effects in 
a similar manner to vitamin C (Winterbourn, 2008). Additionally the oxidised form of 
Vitamin E can be reduced and replenished by Vitamin C and GSH (Valko et al., 2007). 
A disruption to the normal physiological function of these various enzymatic and non- 
enzymatic antioxidant sources leads to the over production of ROS and RNS and hence 
the development of oxidative/nitrosative stress (Barnham et al., 2004). 
2.10.2 Reactive oxygen species (ROS) 
The primary ROS; O· is produced within the mitochondria of a cell. Molecular oxygen 
O is routinely reduced to form water by the mitochondrial electron transport chain 
(ETC) which produces energy in the form of ATP. Molecular oxygen has a unique 
electronic configuration in that it consists of two unpaired electrons and exists 
essentially as two free radicals. The addition of one electron to O will result in the 
formation of O· . During the mitochondrial energy transduction process a small 
number of electrons may ‘leak’ to molecular oxygen and form O·as shown in 
Equation 2.33. Due to the high energy demand of the brain this process is particularly 
relevant in the neuronal environment. Additional sources of O· production exist 
including the action of NADPH oxidases (NOXs) and xanthine oxidase (Maier & Chan, 
2002).  
O  e  O·  
(2.33) 
O·  is readily scavenged by the antioxidant network in the physiological environment 
which leads to the production of secondary ROS such as H2O2. H2O2 is a relatively 
stable ROS and is primarily produced by the action of the catalytic enzyme SOD as 
discussed in Section 2.10.1. Additionally, H2O2 may form spontaneously by dismutation 
although this process is considerably slower (Equation 2.34). Detailed descriptions of 
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the various normal physiological functions of H2O2 are outlined in Chapter 1. However, 
this section will outline the production of excess H2O2 amongst other ROS in a pro-
oxidant environment.   
O·  O·  2H  HO  O 
(2.34) 
The highly reactive ROS hydroxyl radical (•OH) can be formed from the interaction 
between H2O2 and transition metal ions. The process of •OH formation occurs via the 
Fenton reaction which relies on the presence of free catalytic iron (Valko et al., 2007). 
This process commonly occurs in-vitro however in the physiological environment iron 
is bound and sequestered as ferritin (Jomova & Valko, 2011). In a pro-oxidant neuronal 
environment the presence of O·results in the release of iron from sequestered sources, 
thereby leading to the production of •OH via the Fenton reaction (Equation 2.35) (Maier 
& Chan, 2002). O·may drive the Fenton reaction in the physiological environment due 
to the release of free iron by the action of O·itself through the Haber-Weiss reaction 
[Equation 2.36 (i) and (ii)] (Liochev & Fridovich, 1999). 
Fe%  HO  Fe  OH •OH 
(2.35) 
(i), Fe%  O·  Fe  O 
(ii), Fe  HO  Fe%  OH •OH 
(2.36) 
A schematic representation of the main sources of primary and secondary ROS 
production in the physiological environment is shown in Figure 2.6.  
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Figure 2.6 Main sources of ROS. 
Collectively the uncontrolled production of ROS leads to damage to cell structures, 
DNA, lipids and proteins (Valko et al., 2007). H2O2 is a relatively stable ROS, it is 
considerably less reactive than O·and •OH (Rice, 2011). Additionally H2O2 has a 
relatively longer half-life in-vivo (Maier & Chan, 2002). Therefore the detection of this 
stress marker (H2O2) is a highly suitable target for the purpose of monitoring oxidative 
stress in the physiological environment.  
2.10.3 Reactive nitrogen species (RNS) 
NO is a radical species generated in the physiological environment from three main NO 
synthase enzymes (NOS). The source of NOS determines the specific type of NO 
produced in the body and these consist of inducible NOS (iNOS), endothelial NOS 
(eNOS) and neuronal NOS (nNOS) (Bruckdorfer, 2005; Guix et al., 2005). A detailed 
description of the biosynthesis of NO is described in Section 1.4. Briefly NO is 
produced from L-arginine in the presence of numerous co-factors including NOS, BH4 
(tetrahydrobiopterin), FMN (flavin mononucleotide), FAD (flavin adenine dinucleotide) 
haem and calmodulin. The variety of neuroprotective physiological functions of NO 
while present at tonic levels are discussed in Section 6.1. This section primarily outlines 
the role of high levels of NO in a pro-oxidant environment.  
All three isoforms of NOS consist of a reductase and an oxygenase domain which 
facilitate the interaction with the stated co-factors for the purpose of NO biosynthesis 
(Alderton et al., 2001). A deficiency in the co-factor BH4 can lead to electron transfer 
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between NOS and molecular oxygen and result in the formation of the primary ROS 
O·. This process is referred to as ‘NOS uncoupling’ and results in the preferential 
formation of O·over NO by NOS (Kuzkaya et al., 2003). 
In a pro-oxidant environment NO can interact directly with O·and lead to the 
formation of the main secondary highly toxic RNS; ONOO (Equation 2.37). This 
process may be accelerated in response to an inflammatory insult where O·  and NO 
specifically produced by iNOS, are produced (Calabrese et al., 2007). ONOO is a 
powerful oxidising agent which may lead to the degradation of DNA and lipids 
(Ramalingam & Kim, 2012).  
a-  O·  ONOO 
(2.37) 
The interaction between NO and other ROS can lead to the production of other 
secondary RNS such as nitrogen dioxide (NO2) and dinitrogen trioxide (N2O3) which 
exert toxic effects in the body (Equation 2.38 and 2.39) (Wink & Mitchell, 1998).  
2NO  O  2NO 
(2.38) 
NO  NO  NO% 
(2.39) 
NO can also activate the constitutive and inducible forms of cyclooxygenase which are 
recruited in response to an inflammatory insult (Mollace et al., 2005). The consumption 
of cyclooxygenase leads to the release of free radicals which can lead to deleterious 
neuronal processes (Mancuso et al., 2007). Figure 2.7 outlines the main mechanisms of 
RNS production in the in-vivo environment.  
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Figure 2.7 Main sources of RNS. 
The real-time electrochemical detection of NO which is represented in this thesis may 
facilitate the analysis of nitrosative stress processes amongst other applications.   
This section outlines the main processes underlying the intricate natural balance which 
exists between the processes of ROS/RNS production and the defence mechanism of the 
robust antioxidant network in the neuronal environment. A disruption to these myriad of 
vital neuronal processes leads to redox imbalance and consequently oxidative/nitrosative 
stress. A detailed description of the role of oxidative/nitrosative stress in specific 
neurodegenerative diseases and dysfunctions is provided in Chapter 1.  
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3.1 Introduction 
This chapter details the experimental procedures involved in the in-vitro and in-vivo 
characterisation of a catalase-based hydrogen peroxide (H2O2) biosensor pair. The 
excellent sensitivity and selectivity of the H2O2 biosensor has previously been 
demonstrated in-vitro (O'Brien et al., 2007). Further investigations utilising a previously 
characterised nitric oxide (NO) sensor will also be discussed; the in-vivo application of 
this NO sensor enables real time detection of rapid fluctuations in brain NO (Brown et 
al., 2009). 
Section 3.2 will give an overview of the computer based instrumentation used in this 
research project. A detailed description of the chemicals and solutions used throughout 
the project will be given in Section 3.3. Section 3.4 will describe how each sensor was 
constructed during the course of this body of work. The modifications and treatments 
made to the fabricated sensors will be presented in Sections 3.5 and 3.6 respectively. A 
detailed description of the experiments used in the in-vitro characterisation of each 
sensor is outlined in Section 3.7.  
Section 3.8 will discuss the technique of microdialysis (MD) and its application in this 
research project. The use of scanning electron microscopy (SEM) will be outlined in 
Section 3.9. The protocol followed for the application of these sensors in the in-vivo 
environment will be detailed in Section 3.10. Section 3.11 will outline the systemic 
administrations utilised throughout the in-vivo experiments.  
The in-house synthesis of NO is referred to in Section 3.12 and any additional 
equipment used during the project will be described in Section 3.13. 
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3.2 Computer based Instrumentation 
Three main components were used in the acquisition of experimental data. These three 
instruments consist of the computer, the Powerlab® and the potentiostat. The function of 
each instrument is outlined in this section. The arrangement of the in-vitro 
instrumentation is displayed in the image below. 
 
Fig 3.1: The in-vitro experimental set-up. 
3.2.1 The Computer 
A logiQ M76OTG notebook with an Intel dual core processor running at 1.8 GHz was 
used for the attainment of in-vitro data. In-vivo data was recorded using a MAC OS X 
with an Intel core 2 duo processor running at 2.4 GHz.  
 
3.2.2 The Powerlab® 
The Powerlab® is a data acquisition system comprising hardware and software to record 
and display experimental data. The Powerlab® is an interface between the computer and 
potentiostat which allows digital-analogue and analogue-digital conversion. In this 
research project an eight channel Powerlab® 8/30 from AD Instruments was utilised. 
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Fig 3.2: PowerLab® 8/30. 
3.2.3 The Potentiostat 
The potentiostat utilised was a four channel Biostat from ACM Instruments. The basic 
operating principle of the biostat is to control the potential of the working electrode at a 
constant level with respect to the reference electrode. This device allows the application 
of a fixed potential and the detection of a corresponding current change. 
 
 
Fig 3.3: ACM instruments four channel biostat. 
 
3.3 Chemicals & Solutions 
3.3.1 Chemicals 
The following is a list of all chemicals, and the relevant suppliers, used throughout this 
research project. For clarity the list is divided into in-vitro and in-vivo chemicals. 
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3.3.1.1 In-vitro chemicals 
L-ascorbic acid       Sigma Chemical Co. 
Bovine serum albumin (Fraction V)    Fluka Chemical Co. 
Catalase       Sigma Chemical Co.   
Glutaraldehyde ~25% in H2O     Sigma Chemical Co.   
Hydrogen peroxide 30% w/w ACS reagent   Sigma Chemical Co. 
Nafion®, 5% in aliphatic alcohol    Sigma Chemical Co.  
N-1-Naphthyl-ethylenediamine     Sigma Chemical Co. 
Nitric oxide gas      In-house synthesis 
Nitrogen gas       BOC Gases 
o-Phenylenediamine      Sigma Chemical Co.   
L-α-Phosphatidylethanolamine     Sigma Chemical Co.   
Potassium chloride      Sigma Chemical Co. 
Potassium hydroxide      Sigma Chemical Co. 
Pyrogallol       Hopkin and Williams 
Sodium chloride       Sigma Chemical Co. 
Sodium hydroxide      Sigma Chemical Co.  
Sodium nitrite       Sigma Chemical Co. 
Sodium phosphate      Sigma Chemical Co.   
Sulphanilamide      Sigma Chemical Co. 
Sulphuric acid       97 %, BDH 
3.3.1.2 In-vivo chemicals 
L-arginine       Sigma Chemical Co. 
Buprenorphine hydrochloride (Temgesic®)   Sigma Chemical Co.  
Calcium chloride      Sigma Chemical Co. 
Dentalon®       Hereaus Kulzer Gmbh 
Isoflurane       Abbott Diagnostics 
Magnesium chloride      Sigma Chemical Co. 
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Mercaptosuccinate       Sigma Chemical Co. 
Methyl viologen dichloride hydrate (Paraquat)  Sigma Chemical Co. 
N (G)-nitro-L-arginine methyl ester (L-NAME)  Sigma Chemical Co. 
Sodium ascorbate      Sigma Chemical Co. 
Sodium azide       Sigma Chemical Co. 
Sodium propionate      Sigma Chemical Co. 
Videne®       Ecolab Ltd. 
3.3.2 Solutions 
All solutions required were prepared on the day of the experiment unless otherwise 
stated. Each solution was made by the procedure outlined below. All solutions were 
made using doubly distilled deionised water denoted by H2O unless mentioned 
otherwise. The list is divided into in-vitro and in-vivo solutions. 
3.3.2.1 In-vitro solutions 
Ascorbic acid (AA) 
A 0.1 M stock solution of AA was prepared in H2O and used for up to 12 hours (0.176 
g/10 mL). 
 
Bovine serum albumin (BSA) 
A 10% (w/v) solution of BSA was prepared by dissolving 0.1 g in 1 mL H2O.   
 
Catalase-Glutaraldehyde (Cat-Ga(0.25%)) 
A Cat-Ga(0.25%) solution was prepared by dissolving 25 mg of catalase in 1 mL of 0.25% 
Glutaraldehyde. 
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Glutaraldehyde (Ga(0.25%)) 
A 0.25% solution of Glutaraldehyde was made up by dissolving 0.1 mL of 25% 
Glutaraldehyde in 25 mL of PBS.  
 
H2O2 
A 0.1 M solution of H2O2 was prepared by dissolving 255 µL of a 30% w/w stock 
solution in 25 mL H2O.   
 
L-α-phosphatidylethanolamine (PEA) 
A 10% (w/v) solution was prepared by dissolving 0.1 g of PEA in 1 mL H2O.   
 
Neutral Griess reagent 
A reagent consisting of 0.4 mM N-1-Naphthyl-ethylenediamine (NEDD) and 0.017 mM 
Sulfanilamide (SULF) was prepared in air saturated 100 µM PBS, pH 7.4, containing 
0.293 g SULF and 0.0104 g NEDD/100 mL. 
 
Nitric oxide (NO) 
A stock solution of NO was prepared by bubbling NO gas into H2O and its subsequent 
concentration was determined using UV spectroscopy. 
 
o-Phenylenediamine (o-PD) 
Using nitrogen (N2) saturated PBS a 300 mM stock solution was made up using (0.341 g 
/ 10 mL).  
 
Potassium hydroxide (KOH) 
A 4 N KOH stock solution was prepared in H2O (224 g/L), which was stored at room 
temperature. 
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Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 8.9 g NaCl (0.15 M), 1.76 g NaOH (0.044 M) and 6.86 
g NaH2PO4.2H2O (0.044 M) in 1 L of H2O. The pH was adjusted to 7.4.  The solution 
was then N2 saturated for a minimum of one hour and stored at 4 °C. 
 
Pyrogallol 5% alkaline 
A 5 % stock solution was prepared in 4 N KOH (5 g / 100 mL). 
 
Sodium nitrite (NaNO2) 
A saturated stock solution of NaNO2 was prepared in H2O. 
 
Sulfuric acid (H2SO4) 
A 6 M H2SO4 stock solution was prepared from a 97 % H2SO4 commercial solution. 329 
mL of H2SO4 is added carefully to H2O, made up to 1 L and stored at room temperature. 
3.3.2.2 In-vivo solutions 
Artificial cerebrospinal fluid (aCSF) 
aCSF was prepared by dissolving 8.6 g NaCl (0.15 M), 0.298 g KCl (0.004 M), 0.176 g 
CaCl2 (0.0016 M) and 0.204 g MgCl2 (0.021 M) in 1 L of H2O.  
 
Buprenorphine hydrochloride (Temgesic®) 
Temgesic® is a stock solution of 0.3 mg/mL buprenorphine hydrochloride which is 
injected in a volume of 1 mL/kg.  
 
H2O2  
For local administrations various dilutions of a 0.1 M solution of H2O2 made up in aCSF 
were prepared including 25, 50, 100, 200, 500 and 1000 µM.  
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L-arginine 
For systemic administration 300 mg/kg was dissolved in normal saline and injected in a 
volume of 1 mL.  
 
L-NAME 
For systemic administration a 30 mg/kg dose was prepared and administered in a 
volume of 1 mL of normal saline. 
 
Mercaptosuccinate 
For local administration various dilutions including, 0.1 mM and 1 mM, were made up 
in aCSF.  
 
Normal saline solution 
A 0.9% solution was prepared by dissolving 0.9 g NaCl in 100 mL H2O.   
 
Paraquat (Methyl viologen dichloride hydrate) 
Varying systemic administrations of 5, 10, 20 and 30 mg/kg were prepared in normal 
saline and injected in a volume of 2 mL/kg.  
 
Propionic acid (PPA) 
For systemic administration a stock solution of PPA was prepared by dissolving 0.5 g of 
sodium propionate in 1 mL saline which was subsequently injected at 1 mL/kg. 
 
Sodium ascorbate 
A 2g/kg dose was prepared and injected systemically in a volume of 1 mL of normal 
saline. It is preferable to use sodium ascorbate as an interferent in-vivo as AA, even with 
pH adjustment, causes significant discomfort to the animal. For local administration a  
1 mM solution was prepared in aCSF. 
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Sodium azide 
For systemic administration 20 mg/kg was prepared in normal saline and injected in a 
volume of 2 mL/kg. For local administration a 10 mM solution was prepared in aCSF. 
3.4 Working electrode preparation 
3.4.1 Disc and cylinder platinum electrodes 
Platinum (Pt) was the material utilised in the manufacture of all working electrodes 
(sensors) in this body of work. Two basic electrode types were fabricated throughout the 
course of this study, electrodes with disc and cylinder geometries were utilised during 
all investigations. Approximately 4 cm of Teflon® coated Pt/Ir (90%/10%) wire (125 µm 
bare diameter, 175 µm coated diameter (5T); Advent Research Materials, Suffolk, UK) 
was used to construct each sensor. 2 mm of Teflon® was carefully removed from one 
end of the wire. The exposed section was soldered into a gold electrical contact to 
improve rigidity and to provide a transducer that could be attached to the potentiostat 
(see section 3.2.3). The opposite end of the wire was then cut transversely with a sharp 
scalpel blade to expose a Pt disc. A schematic of the Pt disc working electrode (Ptd) is 
shown in Figure 3.4. The exposed disc surface denoted below by (E) is the active region 
of the electrode where the redox reactions occur.  
 
 
 
Fig 3.4: A schematic of a Ptd electrode: (A) Gold clip (B); Solder (C); Pt/Ir wire (D); Teflon®  
(E); exposed Pt disc surface 
 
B C D E A 
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A 1 mm cylinder Pt electrode (Ptc) was constructed in a similar manner to the Pt disc. 
Following the soldering procedure 1.5 mm of Teflon® was removed from the opposite 
end of the wire. The exposed length of wire was accurately cut back to 1 mm with the 
aid of a microscope. A schematic of a Ptc electrode is illustrated below in Figure 3.5. 
 
 
Fig 3.5: Schematic of a Ptc electrode (A) 1mm of exposed Pt/Ir wire 
 
3.4.2 Nitric oxide sensor 
A Nafion®-modified Ptd was constructed as previously described in detail by Brown et 
al. (Brown et al., 2009) for the detection of NO. A schematic of the sensor is shown 
below in Figure 3.6. Further applications of this sensor type in novel animal models will 
be discussed in Chapter 7 and 8. The modified disc surface denoted below by (A) is 
where Nafion® has been thermally annealed onto the surface of the electrode by a pre-
cast procedure as previously reported (Brown et al., 2009).  
 
 
Fig 3.6:  Schematic of an NO sensor (A): Nafion® modified active surface 
 
A 
A 
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3.4.3 H2O2 catalase-based paired biosensor 
A pair of Ptc electrodes were fabricated and modified by a process previously described 
(O'Brien et al., 2007). Nafion® was applied to both Ptc as described in Section 3.5.2 and 
o-PD was then polymerised electrochemically onto the Nafion® modified surface of each 
sensor (see Section 3.5.1). A sensor capable of detecting H2O2 was made by this process 
[Ptc/Nafion®/PPD (Blank)]. A paired sensor which was modified with catalase was then 
constructed (see Section 3.5.3). Catalase is an enzyme which degrades H2O2 into water 
and oxygen.
 
Application of catalase resulted in a paired sensor capable of removing the 
signal arising from H2O2 without compromising matched selectivity 
[Ptc/Nafion®/PPD/Cat-Ga (Cat)]. This process yielded two amperometric electrodes one 
with catalase adhered (Cat) and the other without (Blank). The H2O2 sensitivity of this 
biosensor design was derived by subtracting the Cat sensor current response from that 
recorded at the Blank sensor. A more detailed description of how the sensitivity of the 
catalase-based paired biosensor is obtained is described in Section 2.8 (Theory). 
 
3.5 Electrode modifications 
Electropolymerisation of o-PD onto the active surface of the electrode provides an 
insulating layer of poly-o-phenylenediamine (PPD). This technique has previously been 
used in biosensor design (Lowry et al., 1998). Fundamentally the function of PPD in 
this case is to provide selectivity over other electroactive species present in the 
biological milieu. PPD also provides a scaffold for the entrapment of enzymes as has 
been shown by O’Neill and colleagues (O'Neill et al., 2008). The morphology of the 
PPD polymer allows the rejection of interfering species e.g. AA, by a size exclusion 
mechanism. The application of Nafion® to the bare metal provides a further interference 
rejection layer, Nafion® is a polyflourinated ionomer permselective membrane and 
displays effective anionic rejection characteristics (Gerhardt & Hoffman, 2001). A 
detailed description of the properties of Nafion® is provided in Section 2.6 (Theory).  
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The presence of Nafion® also increases the bio-compatibility of the sensor (Borland & 
Michael, 2007).  
3.5.1 PPD-modified electrodes 
The modification of sensors with PPD has been extensively described (O'Neill et al., 
2008). Briefly, a 300 mM saturated solution of o-PD was freshly prepared as detailed in 
Section 3.3.2.1. Great care was taken to ensure N2 saturation of the monomer solution. 
The electrochemical cell was also purged with N2 and the electropolymerisation was 
carried out under N2 atmospheric conditions. The exclusion of air in this procedure was 
necessary as the monomer solution is highly susceptible to oxidation. The working 
electrodes were placed in the monomer solution and a potential of +700 mV vs. SCE 
was applied to the electrodes for a duration of 30 minutes. The electrodes were removed 
and allowed to dry for a minimum of 1 hour and stored in the refrigerator at 4 ◦C when 
not in use. 
3.5.2 Nafion® dip-absorption modification 
Nafion® was applied to the surface of the electrode by a dip absorption method unless 
otherwise stated. The electrode was placed in the stock Nafion® solution described in 
3.3.1.1 for ca. 0.5s. The electrode was then removed and allowed to dry for 5 minutes in 
a vertical position with the active surface of the electrode facing down. This process was 
repeated a further four times and the electrodes were allowed to dry following 
modification for a minimum of three hours. This procedure was carried out at room 
temperature. The electrodes were stored in the refrigerator at 4◦C when not in use. 
3.5.3 Catalase modification 
A Cat-Ga(0.25%) solution as described in 3.3.2.1 was prepared. The Blank sensor was 
placed in the catalase solution for an initial period of five minutes and the electrodes 
were subsequently allowed to air dry for five minutes. Following this drying period a 
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further four dips of ca. 0.5s duration were carried out with five minutes of air drying in 
between each immersion. The catalase solution was kept over ice during the 
modification to maintain the enzyme. This process produced the catalase-based sensor 
Ptc/Nafion®/PPD/Cat-Ga (Cat).  
 
3.6 Electrode treatments 
Various parameters were explored to determine the bio-compatibility and stability of the 
H2O2 biosensor. The effect of proteins and lipids similar to those found in the brain’s 
extracellular environment was examined. The purpose of these experiments is to mimic 
the type of conditions encountered by the working electrode in the in-vivo environment 
and to examine the effect of these substances on the sensitivity and the selectivity of the 
paired biosensor. The modified electrodes (sensors) were exposed to bovine serum 
albumin (BSA), L-α-phosphatidylethanolamine (PEA) and a homogenised sample of ex-
vivo brain tissue (BT). The procedure for each examination is detailed below. 
3.6.1 BSA treated sensors 
A complete selectivity characterisation has previously been undertaken by O’Brien et al. 
(O'Brien et al., 2007), however it is necessary to test the sensor for selectivity against 
AA as it is the most abundantly present interferent in the brain. The sensors were 
initially tested to determine sensitivity towards H2O2 and selectivity against AA.  Once 
these parameters were established the sensors were submerged in a fresh solution of 
BSA (see Section 3.3.2.1). The working electrodes remained in solution in the 
refrigerator at 4 ◦C for the required time and were intermittently tested. To mimic the 
constant exposure of the sensor to the biological medium the sensors were immersed in 
BSA, removed and re-calibrated according to the times specified. Following re-
calibration the same sensors were re-immersed in BSA for further testing.  
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3.6.2 PEA treated sensors 
These sensors were treated with PEA (see Section 3.3.2.1) in the same manner as 
described in Section 3.6.1.  
3.6.3 BT treated sensors 
A sample of homogenised ex-vivo brain tissue (BT) was obtained. The working 
electrodes were carefully inserted into the tissue to ensure direct contact as would occur 
when implanted in the brain. Concomitantly the protocol outlined in Section 3.6.1 was 
adhered to. 
3.6.4 Long-term sensor stability investigations 
The same protocol was followed as that with the treated sensors, however these sensors 
were stored in the refrigerator at 4 ◦C in the absence of any solutions between specified 
time periods and intermittently tested.  
3.6.5 Post-implanted sensors 
Following implantation of the working electrodes into the brain over extended periods 
they were removed and re-calibrated. The purpose of these experiments was a further 
verification of the long term stability of the sensor in the brain. The stability of the NO 
sensor has been established in this manner (Finnerty et al., 2012). 
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3.7 Electrochemical experiments 
 
Fig 3.7: Schematic of an electrochemical cell (A) Gas inlet (B); Teflon® cap (C); Auxiliary electrode 
(D); SCE (E); Working electrodes (sensors) (F); Magnetic stirrer 
 
3.7.1 Electrochemical cell set-up 
All in-vitro experiments were carried out at room temperature (ca. 25°C). The diagram 
above demonstrates a typical three electrode set-up. The electrochemical cell consists of 
a reference electrode, an auxiliary electrode and four working electrodes. The 
electrochemical changes being investigated take place at the working electrode. The 
reference electrode has a fixed potential against which the potential of the working 
electrodes in the cell can be measured. The final electrode is the auxiliary which 
functions as a source or sink for electrons and completes the electrical circuit. All 
experiments were performed in PBS (see section 3.3.2.1). The reference electrode used 
in these experiments was a saturated calomel electrode (SCE). The auxiliary electrode 
can consist of any conducting metal wire and in our case was a bare silver wire. The cell 
was covered with a Teflon® cap which allows placement of all electrodes, an inlet for 
A 
B 
C 
E 
D 
F 
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gas and an injection port. The gas supply which may be N2, air or O2 provides a cloud of 
gas over the solution and is used to control the atmosphere surrounding the PBS, and 
may be used to saturate the PBS. A glass container holds the solution in which a 
magnetic stirrer was placed for agitation of the bulk solution. The in-vivo set-up utilises 
a similar methodology and will be discussed in detail in Section 3.10. 
3.7.2 Experimental techniques 
Throughout this body of work the primary experimental technique utilised was Constant 
Potential Amperometry (CPA). CPA is an example of a potentiostatic measurement. 
CPA involves the application of a continuous fixed potential and the corresponding 
detection of faradaic current changes arising from electroactive target species. This 
experimental technique allows for the real-time detection of a wide range of 
electroactive analytes. This technique is not selective however as a range of 
electroactive species aside from the target analyte may also be detected. The applied 
voltage will detect all species with oxidation/reduction potentials within the same range 
as the target species and contribute to the overall faradaic current. Due to the non-
selective nature of CPA it is imperative to design a sensor which will exclude 
interference from other electroactive species. All electrodes were calibrated using CPA 
at the appropriate potential prior to implantation. All in-vivo measurements were 
determined using CPA.  
3.7.3 AA calibrations 
20 mL of PBS was N2 saturated for approximately 30 minutes prior to all calibrations. 
The atmosphere surrounding the PBS was purged with N2 during the calibration. A 
potential of +700 mV vs. SCE was applied to the working electrodes. A capacitance 
current was immediately observed upon application of the potential. The magnitude of 
this response is entirely dependent upon the surface characteristics of the individual 
sensor. The capacitance current was allowed to dissipate prior to commencement of 
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calibrations and the time required for this procedure varied between sensors. In general 
the more complex sensor designs require a longer time to achieve a stable baseline and 
were allowed to settle overnight. Aliquots of AA were introduced into the cell by means 
of an injection port. Brief agitation of the bulk solution for approximately 3 seconds was 
achieved via a magnetic stirrer. Once a steady-state response was achieved a subsequent 
injection of AA was made. The concentration range examined was as follows: 
 
0, 200, 400, 600, 800 and 1000 µM 
3.7.4 NO calibrations 
NO calibrations were carried out in a similar manner to the AA calibrations. In order to 
detect NO a potential of +900 mV vs. SCE was applied to the working electrodes. The 
concentrations of NO introduced into the cell are outlined below: 
 
0, 0.2, 0.4, 0.6, 0.8 and 1 µM 
 
As the in-vitro characterisation of the NO sensor has previously been established 
(Brown et al., 2009), the predominant interference species present in the brain AA was 
used to establish the selectivity of the NO sensor.  
3.7.5 H2O2 calibrations 
The H2O2 calibrations were performed utilising air-saturated PBS. A potential of +700 
mV vs. SCE was applied to the working electrodes. H2O2 was injected into the cell over 
the concentration range specified below. As the interference rejection characteristics of 
the H2O2 paired sensor were previously reported (O'Brien et al., 2007) a subsequent AA 
calibration was sufficient to determine the selectivity properties of the sensor.  
 
0, 1, 2, 5, 10, 20, 50, 100, 150, 250, 350, 550 µM 
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3.7.6 Data recording and analysis 
All electrochemical experiments carried out used Chart 5 (Windows Version 5.2) and 
LabChart 6 (AD Instruments Ltd, Gladstone Road, Castle Hill, NSW 2154, Australia). 
Analysis of all experimental data was preformed using Graphpad Prism version 4.02 
(GraphPad Software Inc., California U.S.A). 
3.8 Microdialysis  
Microdialysis (MD) is a sampling technique whereby small molecules present in the 
extracellular fluid in the brain can be recovered by perfusion of a liquid through a semi-
permeable dialysis membrane. The perfusate typically used is aCSF and molecules are 
recovered in the dialysate by the process of diffusion. The technique functions by the 
diffusion of a higher concentration of analyte in the surrounding tissue across a 
concentration gradient towards the lower concentration present within the microdialysis 
probe. The technique can also allow the introduction of substances into the brain which 
cannot be administered systemically because they can not cross the blood brain barrier 
(BBB). The dialysate may be analysed by various methods including high performance 
liquid chromatography (HPLC) (Perry et al., 2009) which provides a highly selective 
analytical tool. The main disadvantage of MD is the time lag associated with the 
diffusion of the analyte across the membrane and through the system (O'Neill & Lowry, 
2000). Electrochemical techniques yield an advantage over MD however in that they 
provide real-time localised recordings of electroactive species (Lowry et al., 2006). 
Electrochemical sensors are also much smaller than microdialysis probes which causes 
minimal damage to the surrounding tissue (Khan & Michael, 2003). It is also possible to 
combine sensor technology and MD to ascertain that the designed sensor will 
correspond to changes in the target analyte as discussed in Section 2.9 (Theory). 
 Chapter 3: Experimental 
82 
 
 
 
3.9 Scanning electron microscopy (SEM) 
This technique involves the direction of a focused beam of electrons with energy 
between 0-30 kV across the surface of a sample. Approximately 1 cm of the active 
surface end of the sensor was mounted onto an aluminium stub using a carbon dag 
which restricts the movement of the sample. The sample is then sputtered with a thin 
layer of gold (20 – 30 nm thickness).The gold layer functions by preventing an electrical 
charge build up which may be caused by the scanning process. The scanning electron 
microscope used was a 14 Hitachi S-3200N Variable Pressure SEM and electron beams 
of 15 kV were utilised. The SEM technique provides a detailed image of the active 
surface of the sensor.  
3.10 In-vivo experiments 
This section will outline in detail the materials and methods required for the 
implantation of electrochemical sensors constructed in this body of work into the brain 
of male Wistar rats. All experiments conducted on animals were performed under 
license (B100/2205) in accordance with the European Communities Regulations 2002 
(Irish Statutory Instrument 566/2002 and U.K. Animals (Scientific procedures) Act 
1986).  
3.10.1 Subjects 
Male Wistar rats (Charles River UK Ltd., Manston Rd., Margate, Kent CT9 4LT UK)  
weighing between 200 and 300 g were group housed in a temperature-controlled (17-
23°C), humidity-controlled and light-controlled (12 hr light/12 hr dark) environment 
with access to food and water ad libitum prior to surgery. 
3.10.2 Surgical protocol 
Prior to surgical procedures all equipment and surfaces were thoroughly sterilised. All 
experiments were conducted in an aseptic manner to minimise any possible infection 
arising. Anaesthesia was achieved by using the volatile anaesthetic (Isoflurane). The 
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subject is placed in an induction chamber for 3-4 min, removed and the scalp is then 
shaved. The animal is subsequently returned to the induction chamber for a further 2-3 
min. The animal is then placed in the stereotaxic frame (Kopf) where a nose piece 
facilitates the administration of Isoflurane during the surgery. Once anaesthesia is 
established the head is carefully positioned in the nose piece and the head of the subject 
is levelled between bregma and lambda. Anaesthesia is constantly maintained by the use 
of a vapouriser (Univentor). The level of anaesthetic provided to the subject is outlined 
below. 
 
Anaesthetic Chamber 
(Air) 
Chamber 
(Isoflurane) 
Nose piece 
(Air) 
Nose piece 
(Isoflurane) 
Isoflurane 700 - 800 4 % 400 – 500 1.5 – 3 % 
 
Table 3.1: The level of anaesthetic and air provided to the subject during surgery. 
 
The surface of the scalp is sterilised with an iodine solution (Videne®). A small incision 
of approximately 1.5 cm is made to the scalp along the anterior-posterior plane. The 
scalp is held open using clamps exposing an increased surface area of the skull. 
Underlying muscle and tissue are removed to allow the positive identification of 
bregma, which is the point where the sagittal and coronal sutures of the skull meet. 
Bregma is the reference point upon which the coordinates of various brain regions are 
established according to the published stereotaxic atlas (Paxinos & Watson, 1998) The 
specific regions examined in this project are outlined below. 
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Brain region (A–P) (M–L) (D–V) 
Striatum + 1.0 mm ± 2.5 mm - 5.0 mm 
Prefrontal  
Cortex + 3.2 mm ± 0.8 mm - 4.2 mm 
Nucleus 
Accumbens + 1.85 mm ± 1.3 mm - 6.8 mm 
Dorsal 
Hippocampus -3.6 mm ± 3 mm - 4.0 mm 
 
Table 3.2: Stereotaxic coordinates for electrode implantation in stated brain regions. 
Anterior–posterior (A-P) and medial-lateral (M-L) coordinates are obtained using 
bregma as the zero point of reference and dorsal-ventral (D-V) coordinates with respect 
to the dura. The dura is the outermost layer surrounding the brain. Small burr holes are 
made in the skull to allow the placement of anchor screws. Once the support screws are 
in place a hole is drilled for the working electrodes and the reference electrode. Two or 
four working electrodes may be implanted depending on the purpose of the experiment. 
Once all electrodes are implanted the electrodes are cemented (Dentalon®) at the point 
of insertion into the skull to ensure no further movement takes place. The gold clips of 
the electrodes are then placed within a plastic support, a Teflon® pedestal (Plastics One 
Inc.), and cemented into the pedestal while ensuring that no cement enters the cavity of 
the gold clips. Images of the Teflon® pedestal are displayed below in figure 3.8. 
 
 
Fig 3.8: Images of Teflon® pedestal (A) Lower surface (B); Upper surface 
A B 
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This provides a method of connection between the gold clips and potentiostat through a 
six-pinned cable post surgery. All electrodes are then manipulated to position them close 
to the surface of the skull with the plastic support positioned centrally and vertically. 
The entire construct with the exception of the upper surface and sides of the pedestal 
may then be cemented, eliminating the possibility of damage inflicted by the subject 
post surgery and avoiding exposure to moisture. The surgical clamps are removed and 
the skin surrounding the cement is sutured. The animal is removed from the stereotaxic 
frame and placed in an incubator (27 °C) for 2-4 hours until fully recovered. Post-
operative analgesia was provided in the form of a subcutaneous injection (1 mL/kg, s.c.) 
of Temgesic® (Section 3.3.1.2) which was administered after recovery from surgery. 
The subject is then closely monitored and left to recover for a minimum of 24 hours 
before any experiments take place. The recovery time of each subject will vary and is 
also dependent on the volume and length of exposure to the anaesthetic. The animal is 
monitored regularly post-operatively and if necessary the required procedure was 
followed to ensure the subject was comfortable and free from pain. 
 
3.10.3 In-vivo reference and auxiliary electrode 
 
 
Fig 3.9: Images of (A) auxiliary electrode and (B); reference electrode 
A B 
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The images above show the constructed reference and auxiliary electrodes utilised for 
in-vivo experiments. Both were made from 4-5 cm lengths of Teflon® coated silver wire 
(200 µm bare diameter, 270 µm coated diameter (8T), Advent Research Materials, 
Suffolk, UK). Approximately 3 mm of Teflon® was removed from one end of the wire 
and soldered into a gold electrical contact. The exposed section of wire was glued to 
provide the flexibility required to manipulate the sensors during the surgery. At the 
opposite end of the wire ca. 3.5 mm of Teflon® was removed. To construct a reference 
electrode the bare wire was twisted in a manner which would allow it to rest on the skull 
of the subject to control the position of the wire ventrally as can be seen in Figure 3.9. 
The auxiliary electrode was constructed in a similar manner, however the exposed 
section of silver wire was soldered to a surgical screw. The auxiliary electrode is 
attached to a surgical screw to provide a larger surface area and to minimise the 
invasiveness of the surgical procedure by utilising a pre-existing implant. The reference 
was implanted into the cortex as has been reported previously (Fillenz & O'Neill, 1986). 
The potential of the reference utilised in-vivo is comparable to that seen by the SCE 
used in in-vitro experiments (O'Neill & Lowry, 2000). 
3.11 In-vivo injections 
 
3.11.1 Intraperitoneal injection (i.p.) 
This injection is given into the lower left or right quadrant of the abdomen of the 
subject. This position is chosen as there are no vital organs present in this area. The 
injection is given at a 45° angle with the subject positioned on its back in an upright 
position (Wolfensohn, 2003). 
3.11.2 Subcutaneous injection (s.c.) 
The drug is injected into the scruff of the neck, the skin is gathered using the thumb and 
first two fingers of the hand and lifted away from the body. The injection is made under 
the skin parallel to the body to avoid the tissue beneath (Wolfensohn, 2003). 
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3.12 NO Synthesis and UV Spectroscopy 
NO was synthesised in-house using a very reliable and relatively inexpensive method 
which has previously been described (Brown et al., 2005).  
3.13 Additional equipment 
3.13.1 Anaesthesia system 
The set-up consisted of a vaporiser for induction which was a Univentor 400 anaesthesia 
unit. The air pump in the system was a Stellar S30 and the induction chamber was a 1.4 
L Perspex box which were all obtained from Agnthos, Sweden. The entire system was 
contained within a laminar flow unit supplied by Air Science™. 
3.13.2 Electrode wire 
All platinum and silver wire was sourced from Advent Research Materials, Oxford, UK. 
3.13.3 Incubator 
Following surgery the animal was placed in a heated incubator (Thermacage MKII from 
Datesand Ltd, UK) at 27 °C until fully recovered. 
3.13.4 Microdialysis pump 
A Univentor 801 syringe pump was used for all microdialysis experiments 
3.13.5 Microdialysis probes 
All probes that were used throughout the project were BR4 brain microdialysis probes 
supplied from BAS Inc. 
3.13.6 Microscope  
The Microscopes used for all in-vitro experiments were the stereomicroscope SZ51 
from Olympus America Inc. and the SM 33-745-F from Hund® WETZLER, Germany. 
In-Vivo surgeries utilised an SZ61 microscope from Olympus. 
3.13.7 pH meter 
The pH meter used was the S20 Seveneasy™ from Mettler-Toledo, Switzerland. The 
device was used to correct the pH of solutions as required. 
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3.13.8 Sonicator 
The sonicator used was a Fisherbrand FB11002, Leicestershire, UK.  
3.13.9 Stereotaxic frame 
The stereotaxic frame (Kopf) allowed the animal to be held in the correct orientation, 
and to obtain exact coordinates in order to implant sensors into the brain region of 
interest. 
3.13.10 Vortex 
The Vortex (Reax Control from Heidolph) was used for creating homogenous solutions. 
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4.1 Introduction 
This chapter outlines the development and characterisation of a paired catalase-based 
hydrogen peroxide (H2O2) sensor in-vitro. Investigations previously carried out by 
O’Brien et al. have demonstrated a highly sensitive and selective dual catalase-based 
sensor for the detection of H2O2 in-vitro (O'Brien et al., 2007). The sensor designs 
described here are based on these investigations. The primary aim of this chapter is to 
replicate this dual sensor design to establish the sensitivity, selectivity and stability of 
the catalase-based paired sensor in-vitro. Novel selectivity and stability parameters of 
this dual sensor design are also presented here. 
To date very few reports exist of the real-time detection of H2O2 in the intact living 
brain. Fluorescent imaging has been used to visualise relative changes in H2O2 in ex-
vivo brain slices (Avshalumov et al., 2005), however absolute concentrations of H2O2 
cannot be determined using this method. Sanford et al. have studied H2O2 in brain slice 
preparations using carbon fibre microelectrodes (CFEs) (Sanford et al., 2010). Many of 
the techniques employed to detect H2O2 utilise microdialysis (MD) (Hyslop et al., 1995; 
Lei et al., 1997, 1998), however this analytical tool is restricted by the time delay 
associated with obtaining samples and by damage caused by insertion of the probe itself 
(Khan & Michael, 2003).  
An implantable biosensor for the detection of H2O2 has previously been reported, 
however this sensor relies on the presence of a polymer-based mediator and ascorbate 
oxidase to eliminate interference from ascorbic acid (AA) (Kulagina & Michael, 2003). 
The H2O2 sensor described here does not require a mediator and consists of a simple 
modified platinum surface which effectively eliminates interference from AA without 
compromising sensitivity to the target substrate (H2O2).   
The results obtained from the dual catalase-based sensor described in this chapter 
demonstrate a high H2O2 sensitivity and exhibit a low limit of detection (LOD). H2O2 
has been shown to exist as a tightly regulated diffusible messenger in the brain (Rice, 
2011), this would indicate that the presence of H2O2 in the brain may be short-lived as 
has been suggested previously (Bao et al., 2009) and hence requires a fast method of 
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detection. The response time of our H2O2 sensor will be investigated in this chapter. The 
selectivity of the dual sensor design will be clearly established. An investigation into the 
stability of the paired catalase-based sensor using proteins, lipids and brain tissue 
samples is also presented. The main focus of this chapter is to develop this paired sensor 
in-vitro in order to detect H2O2 in the in-vivo environment.  
4.2 Experimental 
The instrumentation, chemicals, solutions and software used in this section are described 
in detail in Chapter 3. The working electrodes were manufactured from Pt/Ir wire as 
outlined in Section 3.4. The various procedures utilised to modify electrodes are 
presented in Section 3.5. The sensor treatment protocol adhered to is described in 
Section 3.6. All experiments were performed using Constant Potential Amperometry 
(CPA). A potential of +700 mV vs. SCE was applied to the working electrodes for all 
H2O2 and AA calibrations (see Section 3.7).  
The data is represented as a Mean ± SEM and (n) corresponds to the number of 
electrodes used in each case. All H2O2 calibration data was linear, in each case the slope 
value was used to represent the H2O2 sensitivity which is denoted by (nA/µM) or 
(pA/µM) and an R2 value is given to express the extent of linearity for each H2O2 
calibration.  
In the case of a linear AA calibration plot the data is represented in the same manner as 
H2O2 calibrations. In order to compare non-linear AA responses an alternative analysis 
method was employed. The corresponding current expressed in nA, attributable to 400 
µM AA (I400 µM) and arising from 1000 µM AA (I1000 µM) was examined.  
Statistical analysis was carried out using paired or unpaired t-tests. One-way ANOVA 
was used to simultaneously compare results which contained more than two seperate 
groups. These tests were performed using Graphpad Prism and gave a probability value 
(P) which indicates the level of significant or non-significant difference between groups. 
P > 0.05, denotes no significant difference. The extent of significant difference is 
divided into three parameters (P < 0.05,*), (P < 0.01,**) and (P < 0.0001,***) from the 
lowest relative level of difference (*) to the highest (***).  
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4.3 Sensitivity of the H2O2 sensor in-vitro 
4.3.1 Ptc  
In this section the ability of a 1 mm platinum cylinder electrode (Ptc) to detect H2O2 in-
vitro is presented. A bare Ptc may be used to detect H2O2 in-vivo, however this type of 
sensor will detect other electroactive species present in the brain which oxidise at a 
similar potential e.g. AA. Consequently it is essential to remove the signal arising from 
such species and focus on H2O2 by modifying the surface of the sensor using 
permselective membranes (Lowry et al., 1998; Brown & Lowry, 2003). However the 
required alteration to the Ptc surface must not impair the detection of H2O2. Without 
alteration of the active surface of the electrode, the specificity of the signal arising 
exclusively from H2O2 would be masked by other species present in the biological 
environment and would furthermore be more susceptible to fouling by lipids and 
proteins (Bolger et al., 2011).  
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Figure 4.3.1: (A) The current-concentration profile of H2O2 at Ptc (n = 5). (B) A typical raw data 
trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations. CPA carried out at +700 mV vs. SCE. 
Arrows indicate the addition of aliquots of H2O2.  
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H2O2, µM Mean I, nA SEM 
0 
1 
2 
5 
10 
20 
50 
100 
150 
250 
350 
550 
0 
0.52 
1.61 
3.56 
5.99 
12.67 
26.51 
56.59 
99.86 
146.84 
200.99 
290.27 
0 
0.08 
0.27 
0.63 
0.51 
1.84 
2.63 
6.67 
8.33 
7.72 
2.12 
3.79 
 
Table 4.3.1: Data obtained from the calibration shown in Figure 4.3.1(A), n = 5. R2 = 0.9946. Data is 
represented as a Mean ± standard error of the mean (SEM). Background values subtracted. Mean 
background current = 0.57 ± 0.1 nA. 
In this section a H2O2 calibration was carried out on a Ptc electrode. The purpose of this 
experiment is to act as a control against which various modifications made to the 
electrode surface may be compared. It is clear from the data displayed above that it is 
possible to detect H2O2 at an unmodified Ptc electrode. The response is directly 
proportional to the amount of H2O2 introduced into the cell. Calibrating the Ptc over a 0 
to 550 µM H2O2 concentration range yielded a sensitivity of 0.54 ± 0.01 nA/µM, n = 5.  
 
4.3.2 Ptc /Nafion®  
Nafion® has previously been used in sensor design to improve selectivity over 
interference species without compromising sensitivity to the target substrate (Gerhardt 
& Hoffman, 2001; Brown & Lowry, 2003). Nafion® is a perfluorinated polymer which 
is a sulfonated derivative of Teflon®; ionic clusters of sulfonic acid groups present in 
Nafion® provide a negatively charged layer which is capable of repelling anionic species 
such as AA (Park et al., 1998; Brown & Lowry, 2003). The ability of Nafion® to protect 
the exposed surface and to increase the biocompatibility of the sensor has also been 
shown (Turner et al., 1991; Finnerty et al., 2012). In this instance the detection of H2O2 
by adsorption of Nafion® (Ptc/Nafion®) onto the active surface of the electrode was 
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investigated. Nafion® was applied to the surface of the electrode as discussed in Section 
3.5.2.   
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Figure 4.3.2: (A) The current-concentration profile of H2O2 at Ptc /Nafion® (n = 5). (B) A typical raw 
data trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations.  CPA carried out at +700 mV vs. SCE. 
Arrows indicate the addition of aliquots of H2O2.   
Figure 4.3.2 displays the detection of H2O2 by a Ptc sensor modified with Nafion®. 
Calibrating the Ptc/Nafion® over a 0 to 550 µM H2O2 range yielded a sensitivity of 0.76 
± 0.01 nA/µM, n = 5. 
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H2O2, µM Mean I, nA SEM 
0 
1 
2 
5 
10 
20 
50 
100 
150 
250 
350 
550 
0 
1.00 
2.06 
4.61 
8.85 
16.78 
41.77 
80.09 
121.35 
193.27 
267.84 
419.87 
0 
0.08 
0.21 
0.35 
0.45 
0.85 
2.17 
2.29 
5.25 
1.28 
3.58 
3.50 
 
Table 4.3.2: Data obtained from the calibration shown in Figure 4.3.2(A), n = 5. R2 = 0.998. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.24 ± 
0.08 nA. 
An increase in H2O2 sensitivity is observed with this sensor design however the response 
seen at the Ptc/Nafion® sensor was not significantly different (P > 0.05) to that seen at 
the unmodified Ptc. 
 
4.3.3 Ptc /PPD  
A detailed description of the function and properties of poly-o-phenylenediamine (PPD) 
is given in Section 2.5 (Theory). Briefly, selectivity for the desired analyte (H2O2) over 
other interferents such as AA can be achieved by the incorporation of permselective 
membranes such as PPD. The modification of a Ptc electrode with PPD does not hinder 
the detection of H2O2 as is illustrated in Figure 4.3.3.  
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Figure 4.3.3: (A) The current-concentration profile of H2O2 at Ptc /PPD (n = 12). (B) A typical raw 
data trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations. CPA carried out at +700 mV vs. SCE. 
Arrows indicate the addition of aliquots of H2O2.   
 
Figure 4.3.3 shows the detection of H2O2 by a Ptc sensor modified with PPD. Calibrating 
this sensor
 
over a 0 to 550 µM H2O2  range yielded a sensitivity of 0.50 ± 0.01 nA/µM, n 
= 12. The response seen at the Ptc/PPD sensor was not significantly different (P > 0.05) 
to that seen at the unmodified Ptc. The incorporation of PPD into the biosensor design 
does not significantly reduce the detection of H2O2. Lowry et al. have previously 
demonstrated that incorporation of PPD into a Pt based sensor design does not obstruct 
the detection of enzymatically generated H2O2 (Lowry et al., 1994). 
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H2O2, µM Mean I, nA SEM 
0 
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2 
5 
10 
20 
50 
100 
150 
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350 
550 
0 
1.08 
2.33 
4.74 
8.10 
14.79 
35.31 
62.43 
89.91 
143.68 
183.09 
271.75 
0 
0.10 
0.22 
0.35 
0.56 
0.88 
2.7 
4.98 
7.44 
12.42 
14.4 
22.95 
 
Table 4.3.3: Data obtained from the calibration shown in Figure 4.3.3(A), n = 12. R2 = 0.9942. Data 
is represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.71 
± 0.08 nA. 
 
4.3.4 Ptc /Nafion®/PPD  
In order to maximise the selectivity of the Blank sensor design Nafion® was utilised in 
conjunction with PPD to optimise the ability to match the rejection characteristics seen 
at the catalase-based sensor as previously shown (O'Brien et al., 2007). The ability of 
this Blank sensor to efficiently detect H2O2 must also be considered. There must be no 
impairment in the sensitivity to the target substrate. This important parameter was 
maintained and the results are shown below.  
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Figure 4.3.4: (A) The current-concentration profile of H2O2 at Ptc /Nafion®/PPD (n = 24). (B) A 
typical raw data trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations. CPA carried out at +700 
mV vs. SCE. Arrows indicate the addition of aliquots of H2O2.   
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Table 4.3.4: Data obtained from the calibration shown in Figure 4.3.4(A), n = 24. R2 = 0.9997. Data 
is represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.38 
± 0.03 nA. 
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Figure 4.3.4 shows the detection of H2O2 at a Ptc sensor modified with Nafion® and 
subsequently electropolymerised with PPD. Calibrating this modified electrode
 
over a 0 
to 550 µM H2O2 concentration range yielded a sensitivity of 0.47 ± 0.003 nA/µM and 
was linear with an R2 value of 0.9997, n = 24. The response seen at the Ptc/ 
Nafion®/PPD sensor was not significantly different (P > 0.05) to that seen at the 
unmodified Ptc. The combined incorporation of Nafion® and PPD into the biosensor 
design does not obstruct the detection of H2O2.  
 
4.3.5 Ptc /PPD/Cat-Ga  
The basis of the dual H2O2 biosensor design (see Chapter 2, Section 2.8) requires a 
second paired sensor which will successfully remove the signal attributed to H2O2. In 
order to investigate the simplest possible design achievable a polymerised electrode was 
modified with catalase (see Section 3.5.3). Catalase is an enzyme which degrades H2O2 
into water and oxygen (Simonian & Coyle, 1996). The effect of introducing the enzyme 
into the design was investigated over the concentration range of 0 to 550 µM H2O2 in-
vitro. The presence of catalase effectively eliminates the current arising from H2O2 as 
can be seen below in Figure 4.3.5.  
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Figure 4.3.5: (A) The current-concentration profile of H2O2 at Ptc /PPD/Cat-Ga (n = 4). (B) A typical 
raw data trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations. CPA carried out at +700 mV vs. 
SCE. Arrows indicate the addition of aliquots of H2O2.   
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Table 4.3.5: Data obtained from the calibration shown in Figure 4.3.5(A), n = 4. R2 = 0.9750. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.29 ± 
0.04 nA. 
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Figure 4.3.5 shows the detection of H2O2 by a Ptc electrode electropolymerised with PPD 
and subsequently modified with catalase. Calibrating this sensor
 
over a concentration 
range of 0 to 550 µM H2O2 yielded a sensitivity of 3.89 ± 0.20 pA/µM, n = 4. The 
response seen at the Ptc/PPD/Cat-Ga sensor was significantly different (P < 0.05,*) to 
that seen at the unmodified Ptc. The incorporation of catalase into the biosensor design 
removes ~99% of the signal attributed to H2O2.  
 
4.3.6 Ptc /Nafion®/PPD/Cat-Ga  
It was necessary to utilise Nafion® in the construction of the catalase-based sensor to 
improve the matched selectivity with the Blank sensor described in Section 4.3.4. 
Fluctuations in the level of AA in the extracellular fluid (ECF) under certain 
circumstances has been observed previously (Miele et al., 1994). It is paramount in the 
in-vivo environment that changes in the concentration of AA will not disrupt the paired 
detection of H2O2 achievable with the paired biosensor design (see Chapter 2, Section 
2.8). Accordingly, the addition of Nafion® must not deter the function of the catalase 
enzyme, i.e. the removal of H2O2. The results from this section show that the integration 
of Nafion® into the assembly of the catalase-based sensor does not appreciably impact 
negatively on the function of the enzyme.  
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Figure 4.3.6: (A) The current-concentration profile of H2O2 at Ptc /Nafion®/PPD/Cat-Ga (n = 24). (B) 
A typical raw data trace 0-50 µM and (C) 50-550 µM for H2O2 calibrations. CPA carried out at 
+700 mV vs. SCE. Arrows indicate the addition of aliquots of H2O2.   
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Table 4.3.6: Data obtained from the calibration shown in Figure 4.3.6(A), n = 24. R2 = 0.9989. Data 
is represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.43 
± 0.03 nA. 
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Figure 4.3.6 shows the removal of H2O2 by a Ptc sensor modified with Nafion®, 
electropolymerised with PPD and subsequently modified with catalase. Calibrating this 
sensor
 
over a concentration range of 0 to 550 µM H2O2 yielded a sensitivity of 5.64 ± 
0.06 pA/µM, n = 24. The response seen at the Ptc/Nafion®/PPD/Cat-Ga sensor was 
significantly different (P < 0.05,*) to that seen at the unmodified Ptc. The incorporation 
of catalase into the biosensor design efficiently removes the signal attributable to H2O2. 
The trace displayed in Figure 4.3.6 is appreciably closer to baseline levels throughout 
the calibration and this is an improvement to that seen with the absence of Nafion® in 
the catalase-based sensor design (Figure 4.3.5). The response seen here is not 
significantly different (P > 0.05) when compared with Ptc/PPD/Cat-Ga. The improved 
selectivity of Ptc/Nafion®/PPD/Cat-Ga over Ptc/PPD/Cat-Ga was an essential factor in 
deciding which sensor would be used as the catalase-based pair and this will be fully 
discussed in Section 4.5.  
 
4.4 H2O2 sensor sensitivity summary 
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Figure 4.4.1 Comparison of H2O2 sensitivities of modifications to Ptc discussed in Section 4.3. 
Average sensitivity represented as a slope value [(A), nA/µM] and [(B), pA/µM] mean response ± 
SEM. 
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Design 
 I,  
(nA/µM) SEM n 
Ptc 0.54 0.01 5 
Ptc/Nafion® 0.76 0.004 5 
Ptc/PPD 0.50 0.01 12 
Ptc/Nafion®/PPD 0.47 0.003 24 
 
Table 4.4.1 Comparison of H2O2 sensitivities of stated modifications to Ptc shown in Figure 4.4.1 (A) 
Data represented as a mean response ± SEM. The number of each sensor type is denoted by (n). 
Design 
 I,  
(pA/µM) SEM n 
Ptc/PPD/Cat-Ga 3.89 0.20 4 
Ptc/Nafion®/PPD/Cat-Ga 5.64 0.06 24 
 
Table 4.4.2 Comparison of H2O2 sensitivities of stated modifications to Ptc shown in Figure 4.4.1 (B) 
Data represented as a mean response ± SEM. The number of each sensor type is denoted by (n). 
In summary, various modifications were made to the bare Ptc electrode to produce a 
sensor capable of detecting H2O2 and a paired design, removing H2O2 by inclusion of the 
enzyme catalase. Each stated alteration, with the exception of catalase adsorption did not 
negatively effect H2O2 sensitivity and a one-way ANOVA analysis of variance revealed 
the successive adjustments showed no significant variation P > 0.05. The sensitivity of 
each sensor type to the target substrate has been established and summarised in Table 
4.4.1.  
The inclusion of catalase resulted in ~99% removal of the H2O2 signal in the case of the 
Ptc/PPD/Cat-Ga sensor with respect to the Ptc/PPD sensor. A ~98% removal of H2O2 
signal occurred with the Ptc/Nafion®/PPD/Cat-Ga sensor design with respect to the 
corresponding Blank sensor design (Ptc/Nafion®/PPD). Removal of H2O2 is comparable 
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with both catalase-based sensor types and is not significantly different (P > 0.05). The 
sensitivity of each catalase-based sensor type to H2O2 has been established and 
summarised in Table 4.4.2.  
In order to establish the correct pair suitable for in-vivo applications both sensor types 
i.e Blank and Cat must be capable of a matched response for AA. The next Section deals 
with the selectivity of each sensor in relation to AA, the main inteferent species present 
in the brain.  
4.5 Selectivity of the H2O2 sensor in-vitro 
4.5.1 Ptc  
This section examines the response observed at a Ptc electrode calibrated at 700 mV vs. 
SCE following addition of aliquots of AA in the concentration range of 0-1000 µM. The 
purpose of this experiment is to act as a control against which various modifications to 
the Ptc electrode may be measured.  
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Figure 4.5.1: (A) The current-concentration profile of AA
 
at Ptc (n = 6). (B) A typical raw data trace 
0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. Arrows indicate the addition 
of aliquots of AA. 
As has been shown with H2O2, AA is also detectable at +700 mV vs. SCE using a bare 
Ptc (see Figure 4.3.1). The response to AA is proportional to the concentration of AA 
added to the electrochemical cell with a calculated sensitivity of 0.88 ± 0.04 nA/µM, n = 
6. It is not possible to independently detect H2O2 in the presence of AA at the same 
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potential without further modification of the Ptc. For the purpose of in-vivo experiments 
the required H2O2 sensor must be effective at interference rejection.  
AA, µM Mean I, nA S.E.M 
0 
200 
400 
600 
800 
1000 
0 
208.39 
424.46 
581.87 
730.09 
889.32 
0 
3.63 
11.80 
25.63 
27.06 
11.61 
 
Table 4.5.1: Data obtained from the calibration shown in Figure 4.3.6(A), n = 6. R2 = 0.9933. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.86 ± 
0.09 nA. 
 
4.5.2 Ptc /Nafion®  
This section examines the effect of the incorporation of Nafion® onto the electrode 
surface in terms of the response towards AA. Nafion® is a perfluorinated polymer that 
has been used previously in sensor design to block AA interference (Park et al., 1998).  
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Figure 4.5.2: (A) The current-concentration profile of AA
 
at Ptc/Nafion® (n = 4). (B) A typical raw 
data trace 0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. Arrows indicate 
the addition of aliquots of AA. 
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AA, µM Mean I, nA S.E.M 
0 
200 
400 
600 
800 
1000 
0 
6.01 
11.42 
16.75 
22.01 
26.08 
0 
0.21 
0.40 
0.60 
0.80 
0.86 
 
Table 4.5.2: Data obtained from the calibration shown in Figure 4.3.6(A), n = 4. R2 = 0.9971. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.29 ± 
0.03 nA. 
 
Table 4.5.2 displays data representing the selectivity of this Nafion®-modified sensor 
against AA. It is clear from the tabulated data that this sensor is not sufficiently effective 
at interference rejection; the response is linear with a sensitivity of 0.03 ± 0.001 nA/µM, 
n = 4. A significant difference (P < 0.0001,***) was observed for the current 
attributable to 400 µM AA (I400 µM) and the current arising from 1000 µM AA (I1000 µM) 
with this design when compared to Ptc. However, further alterations were found 
necessary in order to facilitate effecient interference rejection. 
4.5.3 Ptc /PPD  
This section will show the benefit yielded by incorporation of PPD into the H2O2 
biosensor design. The interference rejection characteristics of the sensor need to be 
optomised and for this purpose a film of PPD was grown electrochemically on the 
surface of the electrode. This method has previously been used in biosensor design 
(Lowry et al., 1998; O'Neill et al., 2008). The effect of the presence of PPD can clearly 
be observed in the calibration data below by the presence of the distinguishing bi-phasic 
calibration curve. As can be seen below an initial peak which reaches a maximum point 
(Imax) occurs at ca. 400 µM which is followed by a plateau region and a subsequent 
return to baseline levels. The plateau region is the result of a phenomenon known as 
self-blocking where the polymer structure has become saturated with the products of AA 
oxidation (McAteer & O'Neill, 1996). Figure 4.5.3 below details the AA response 
observed with the Ptc/PPD sensor. The two main parameters utilised previously to 
analyse the AA response at PPD modified electrodes are Imax and the current observed 
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due to exposure to 1000 µM  AA (I1000 µM). However, in this chapter it was decided that 
as comparisons are made to sensors which lack PPD, and due to linear responses 
observed with some sensor types, the most comparable aspects from each sensor design 
are the current attributable to 400 µM AA (I400 µM) and the current arising from 1000 µM 
AA (I1000 µM). 
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Figure 4.5.3: (A) The current-concentration profile of AA
 
at Ptc/PPD (n = 16). (B) A typical raw 
data trace 0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. Arrows indicate 
the addition of aliquots of AA. 
 
AA, µM Mean I, nA S.E.M 
0 
200 
400 
600 
800 
1000 
0 
0.63 
0.71 
0.57 
0.41 
0.24 
0 
0.04 
0.06 
0.06 
0.06 
0.08 
 
Table 4.5.3: Data obtained from the calibration shown in Figure 4.3.4(a), n = 16. Data is represented 
as a Mean ± SEM. Background values subtracted. Mean background current = 1.02 ± 0.1nA. 
PPD efficiently blocks AA as can be seen from the characteristic non-linear response 
observed here as demonstrated previously (McAteer & O'Neill, 1996). The AA response 
of this sensor is comparable to previously published work (O'Neill et al., 2008). 
However, the utilisation of PPD in isolation as part of the paired H2O2 biosensor design 
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is not desirable. The rejection characteristics of this sensor can not be matched with the 
corresponding catalase-based sensor (see Section 4.5.5). Incorporation of a further 
interference rejection layer is necessary as described in the next Section. It is paramount 
to reduce the signal attributable to AA as much as possible in order to achieve effective 
pairing between the chosen Blank and Cat sensor without affecting sensitivity (see 
Section 2.8). The I400 µM and I1000 µM values for these sensors are 0.71 ± 0.06 nA and 0.24 
± 0.08 nA respectively. A significant difference (P < 0.0001,***) was observed between 
the I400 µM and I1000 µM values of this sensor design and the Ptc electrode (see Section 
4.5.1).  
4.5.4 Ptc /Nafion®/PPD 
The previous sections have not demonstrated desirable results for the purpose of 
matching the AA rejection characteristics of both sensors precisely i.e. Blank and Cat 
sensor. Investigations into the practical application of the use of the semi-permeable 
membrane Nafion® in conjunction with PPD were therefore carried out. These results 
compare well with previously published data (O'Brien et al., 2007). 
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Figure 4.5.4: (A) The current-concentration profile of AA
 
at Ptc/ Nafion®/PPD (n = 28). (B) A typical 
raw data trace 0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. Arrows 
indicate the addition of aliquots of AA. 
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AA, µM Mean I, nA SEM 
0 
200 
400 
600 
800 
1000 
0 
0.11 
0.16 
0.18 
0.20 
0.15 
0 
0.01 
0.02 
0.02 
0.02 
0.03 
 
Table 4.5.4: Data obtained from the calibration shown in Figure 4.3.7(A), n = 28. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.32 ± 
0.02 nA.  
The I400 µM and I1000 µM values for these sensors are 0.16 ± 0.02 nA and 0.15 ± 0.03 nA 
respectively. A non-linear response was observed which is in sharp contrast to the 
response seen with Ptc and the I400 µM and I1000 µM values of this sensor design were 
significantly different
 
(P < 0.0001,***) to Ptc. The Ptc/Nafion®/PPD sensor (Blank) was 
chosen as the most suitable candidate for the purpose of in-vivo experiments due to very 
low AA permeability characteristics and a high affinity for the target substrate (H2O2) as 
seen in Section 4.3.4 
 
4.5.5 Ptc /PPD/Cat-Ga  
The objective of this section is to determine whether exclusion of Nafion® will affect the 
selectivity of the desired Catalase-based sensor. The results below illustrate that the AA 
response of this sensor design (Ptc/PPD/Cat-Ga) is not sufficiently low enough for 
application of this type of sensor in the in-vivo environment.  
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Figure 4.5.5: (A) The current-concentration profile of AA
 
at Ptc/PPD/Cat-Ga (n = 5). (B) A typical 
raw data trace 0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. Arrows 
indicate the addition of aliquots of AA. 
 
AA, µM Mean I, nA SEM 
0 
200 
400 
600 
800 
1000 
0 
0.87 
1.54 
2.08 
2.50 
2.93 
0 
0.06 
0.14 
0.20 
0.25 
0.32 
 
Table 4.5.5: Data obtained from the calibration shown in Figure 4.3.7(A), n = 5. R2 = 0.9783. Data is 
represented as a Mean ± SEM. Background values subtracted. Mean background current = 0.33 ± 
0.07 nA.  
Despite the inclusion of PPD the characteristic self-blocking response typically seen is 
not apparent in this case. The response is linear as can be observed in Figure 4.5.5. A 
sensitivity of 3.89 ± 0.20 pA/µM, n = 5 was recorded. It is clear that this sensor design 
is not suitable for in-vivo use due to a relatively high AA response and the fact that the 
AA response shown here cannot be successfully matched to the corresponding sensor 
design which lacks catalase (Ptc/PPD) due to the linearity of the response attained here. 
As stated previously the Blank and Cat sensor designs must demonstrate matching 
selectivity parameters. 
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4.5.6 Ptc /Naf/PPD/Cat-Ga  
This section deals with the integration of a Nafion® layer into the construction of the 
catalase-based sensor. Nafion® was utilised to improve the selectivity in relation to the 
main endogenous electroactive interference species present in the brain (AA), in order to 
match AA responses between the Blank and Cat sensor. The results shown in this 
section compare well with previous demonstrations of the response towards AA of this 
sensor design (O'Brien et al., 2007). 
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Figure 4.5.6: (A) The current-concentration profile of AA at Ptc/ Nafion®/PPD/Cat-Ga (n = 28). (B) 
A typical raw data trace 0-1000 µM for AA calibrations. CPA carried out at +700 mV vs. SCE. 
Arrows indicate the addition of aliquots of AA. 
 
AA, µM Mean I, nA S.E.M 
0 
200 
400 
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800 
1000 
0 
0.08 
0.14 
0.18 
0.22 
0.22 
0 
0.01 
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0.02 
0.03 
0.03 
 
Table 4.5.6: Data obtained from the calibration shown in Figure 4.3.7(A) n = 28. Data is represented 
as a Mean ± SEM. Background values subtracted. Mean background current = 0.23 ± 0.02 nA. 
The I400 µM and I1000 µM values for these sensors are 0.14 ± 0.02 nA and 0.22 ± 0.03 nA 
respectively. The incorporation of Nafion® into the construction of this sensor 
successfully achieved a reduction in AA response with respect to Ptc/PPD/Cat-Ga with a 
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significant difference (P < 0.0001,***) observed between I400 µM and I1000 µM values. The 
sensor shown in this section (Ptc/Nafion®/PPD/Cat-Ga) was chosen as the catalase-based 
sensor (Cat) to use in in-vivo experiments due to low AA permeability, efficient removal 
of H2O2 (Section 4.3.6) and the correlation seen with the AA response when compared 
to the paired sensor lacking catalase i.e. Ptc/Nafion®/PPD (Section 4.5.4).  
4.6. H2O2 sensor selectivity summary 
The Imax and I1000 µM values are the parameters which have previously been used to 
compare selectivity characteristics of biosensor designs which incorporate PPD as 
discussed in Section 4.5.3. In this section, as comparisons are made to sensors which 
lack PPD and due to the linear responses observed with certain sensor designs; the most 
comparable aspects from each sensor design are the current attributable to 400 µM (I400 
µM) and the current arising from 1000 µM AA (I1000 µM). The analysis parameters chosen 
take into account that the ECF concentration of AA is expected to be between 100 and 
500 µM (O'Neill & Lowry, 2000) with fluctuations to higher levels in certain 
circumstances (Miele et al., 1994).  
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Figure 4.6.1 Comparison of AA responses following modifications to Ptc discussed in Section 4.5. 
Data represented as a mean response ± SEM. (A) I400 µM and (B) I1000 µM (P < 0.0001,***), where (P) 
represents the outcome of a unpaired t-test with each design when compared to the response 
recorded with Ptc. 
The addition of Nafion® to the Ptc caused a significant reduction in I400 µM (P < 0.0001, 
***) and also in I1000 µM (P < 0.0001,***). The Ptc/PPD sensor also caused a significant 
reduction in I400 µM and I1000 µM with (P < 0.0001,***) and (P < 0.0001,***) respectively 
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when compared to Ptc. A significant decrease in AA response with Ptc/Nafion®/PPD 
(Blank) was observed in relation to the bare Ptc with P < 0.0001,*** for I400 µM and P < 
0.0001,*** for I1000 µM.  
The greatest reduction in AA response of the non catalase-based sensors was the Ptc/ 
Nafion®/PPD (Blank). The I400 µM of this sensor was significantly less than Ptc/Nafion® 
(P < 0.0001, ***). A similar finding was seen with the I1000 µM response (P 
<0.0001,***). In relation to the polymerised electrode Ptc/PPD the Ptc/Nafion®/PPD 
(Blank) showed a significant improvement in AA rejection capabilities at I400 µM (P < 
0.0001,***) and a matched result with the I1000 µM response which was shown as not 
significantly different  (P > 0.05).  
The I400 µM and I1000 µM response of the Ptc/PPD design and the corresponding catalase-
based sensor Ptc/PPD/Cat-Ga did not correlate well together with significant differences 
(P < 0.0001, ***) recorded for both. A Ptc/PPD sensor combined with a Ptc/PPD/Cat-Ga 
sensor would be unsuitable for the detection of H2O2 in-vivo as matching AA rejection 
capabilities cannot be achieved. Figure 4.6.2 below shows how incorporation of Nafion® 
into the catalase-based sensor design improves AA rejection capabilities.  
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Figure 4.6.2 Comparison of AA selectivity with alterations to Ptc and subsequent modification with 
catalase as discussed in Section 4.5. Data represented as a mean response ± SEM. (A) I400 µM and           
(B) I1000 µM (P < 0.0001, ***).  
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Following incorporation of Nafion® into the sensor design Ptc/Nafion®/PPD/Cat-Ga, a 
significant difference (P < 0.0001,*** ) in AA response was observed with respect to 
the Ptc/PPD/Cat-Ga sensor construct for both I400 µM and I1000 µM. The excellent AA 
rejection characteristics achieved by the combination of Ptc/Nafion®/PPD (Blank) and 
Ptc/ Nafion®/PPD/Cat-Ga (Cat) are fully discussed in Section 4.8. 
 
Design  I, nA (1000 µM) SEM 
I, nA 
(400 µM) SEM n 
Ptc 889.32 11.61 424.46 11.8 6 
Ptc/ Nafion® 26.08 0.86 11.42 0.4 4 
Ptc/PPD 0.24 0.08 0.71 0.06 16 
Ptc/ Nafion®/PPD(Blank) 0.15 0.03 0.16 0.02 28 
Ptc/PPD/Cat-Ga 2.93 0.32 1.54 0.14 5 
Ptc/ Nafion®/PPD/Cat-Ga(Cat) 0.22 0.03 0.14 0.02 28 
 
Table 4.6.1 Comparison of AA selectivities following various modifications to Ptc discussed in 
Section 4.5. Data represented as a mean response ± SEM. The number of each sensor type is 
denoted by (n). 
 
4.7. Paired H2O2 sensor sensitivity 
The detection of H2O2 in this body of work is based on a dual paired sensor design. It is 
necessary at this point to reiterate that the subtracted current response determined by the 
paired sensor design is the target of the individual results shown in this chapter. As has 
been demonstrated in the previous Sections of this chapter Ptc/Nafion®/PPD was the 
preferred design chosen for the Blank sensor (Blank) for application in the in-vivo 
environment. The Blank design was determined on balance by the highest H2O2 
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sensitivity and the lowest AA permeability. The matched catalase-based biosensor 
[Ptc/Nafion®/PPD/Cat-Ga (Cat)] was the most appropriate candidate for application in-
vivo. The Cat sensor was identified as suitable due to very similar selectivity 
characteristics with the Blank sensor (see Section 4.8.1). This Cat sensor 
(Ptc/Nafion®/PPD/Cat-Ga) also showed a high proportion of H2O2 removal (~98%). The 
results displayed going forward are a representation of the subtracted current response 
achieved with the paired sensor design i.e. Blank-Cat. The sensitivity of the paired H2O2 
sensor is discussed in this section. 
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Figure 4.7.1: (A) The current-concentration profile of the H2O2 sensitivity of the paired sensor 
response (Blank-Cat) (n = 24). CPA carried out at +700 mV vs. SCE. (B) Comparison of the average 
sensitivity of (Blank (n = 24)), (Cat (n = 24)) and (Blank-Cat (n = 24+24)) represented as a slope 
value (nA/µM) ± SEM.  
The overall sensitivity of the dual H2O2 sensor (Blank-Cat) is represented above in 
Figure 4.7.1 (A). The sensitivity of the paired H2O2 sensor is 0.47 ± 0.003 nA/µM and is 
linear with an R2 value of 0.9996, n = 24+24. No significant diifference (P > 0.05) is 
observed between the paired sensitivity (Blank-Cat) and the H2O2 response at the Blank 
sensor as can be seen in Figure 4.7.1(B). This highly reproducible value is in agreement 
with previously published data (O'Brien et al., 2007).  
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4.7.1 Limit of detection 
The limit of detection (LOD) is the smallest concentration of analyte detectable by a 
sensor. LOD is defined as the analyte concentration which corresponds to three times 
the standard deviation of the background current and was calculated as 0.075 ± 0.006 
µM, n = 24 for the Blank sensor. The ECF concentration of H2O2 is expected to be 
between 25 and 50 µM (Hyslop et al., 1995), suggesting that in an in-vivo environment 
our Blank sensor can reliably detect low levels of H2O2. The Cat sensor removes ~98% 
of the H2O2 signal and would therefore have a minimal effect on the overall LOD of the 
paired sensor design.  
4.7.2 Response time 
The response time of a sensor is defined as the time required to change from 10% to 
90% of the maximum response. The response of the Blank sensor over time is shown 
below in Figure 4.7.2.  
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Figure 4.7.2: The average H2O2 response at the Blank sensor design (n = 6) for addition of 1 µM 
H2O2. Data shown as a percentage with 100% representative of the maximum H2O2 sensitivity, 
SEM is denoted by the dashed line. The response is plotted vs. minutes (A) and versus seconds (B). 
Arrows indicate the addition of H2O2. 
The data shown in Figure 4.7.2 represents the response of the Blank sensor over time 
following the introduction of an aliquot of H2O2 (1 µM) into the electrochemical cell. 
The solution is stirred immediately following the injection for approximately 3 seconds. 
It is clear from Figure 4.7.2 (A) an immediate increase in response occurs as H2O2 is 
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injected into the cell which reaches a peak value and subsequently exhibits a steady-
state behaviour. On closer inspection of this data as presented in Figure 4.7.2 (B) the 
maximum response of the Blank sensor is achieved within the mixing time (~3 s), which 
has been demonstrated with other polymer-based sensors (Lowry et al., 1994; Ryan et 
al., 1997). An instantaneous increase in response to H2O2 is observable with this sensor 
type. The response time of the Blank sensor is on the sub-second time scale. The 
transition from 10 % to 90 % of the maximum response occurs within < 1s. This rapid 
response time is highly suitable in order to detect H2O2 which is a highly permeable 
short-lived molecule particularly in the in-vivo environment (Bao et al., 2009). As 
previously stated the overall H2O2 response is based on a paired design (Blank-Cat). The 
Cat sensor removes ~98% of the H2O2 signal and therefore has a minimal effect on the 
response time of the dual sensor design.  
 
4.8. Paired H2O2 sensor selectivity 
AA is the primary source of electrochemical interference in the brain. However, other 
potential sources of interference are possible from various species. These species can be 
detected over the same potential range as H2O2. A complete in-vitro selectivity 
characterisation of the H2O2 sensor has been demonstrated by O’Brien et al. (O'Brien et 
al., 2007). In the work presented by O’Brien et al. the current arising from the H2O2 
paired sensor by introduction of a wide range of relevant chemical species was 
examined. The effect of introduction of uric acid (UA), serotonin (5-HT), DOPAC, 5-
HIAA, dopamine (DA), glutathione, homovanillic acid (HVA), L-tryptophan, L-cysteine 
and L-tyrosine into the electrochemical cell on the paired H2O2 sensor response was 
tested. The expected ECF concentration of each analyte was utilised in this examination. 
The results are displayed in Table 4.8.1.  
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 ECF (µM) a Paired H2O2 sensor response b n 
H2O2 25-50 0.47 ± 0.003 (nA/µM) 24 
UA 100 < 0.1 % * 4 
5-HT 0.01 < 0.1 % * 4 
DOPAC 20 < 0.1 % * 4 
5-HIAA 10 < 0.1 % * 4 
DA 0.05 < 0.1 % * 4 
Glutathione 50 < 0.1 % * 4 
HVA 20 < 0.1 % * 4 
L-Tryptophan 100 < 0.1 % * 4 
L-Cysteine 50 < 0.1 % * 4 
L-Tyrosine 100 < 0.1 % * 4 
 
Table 4.8 In-vitro responses of the paired H2O2 sensor to H2O2 and the stated potential interferents. 
a
 expected ECF concentration. b expected response at the stated ECF concentration. * Less than 0.1 
% of H2O2 sensitivity (O'Brien et al., 2007). 
The response from each interference species tested was < 0.1 % of the H2O2 sensitivity 
of the paired sensor. The paired H2O2 sensor is highly selective over the range of 
interference species tested. It is possible to definitively measure micromolar 
concentrations of H2O2 in the presence of these interference species.  
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4.8.1 Paired H2O2 sensor AA selectivity 
As the interference rejection characteristics of the H2O2 paired sensor were previously 
reported (see Section 4.8) a subsequent AA calibration was sufficient to determine the 
selectivity properties of the sensor.  
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Figure 4.8.1 : AA response of the paired sensor (Blank-Cat). The current-concentration profile of 
each sensor design (A) Blank sensor (n = 28) and Cat sensor (n = 28). The current-concentration 
profile of the paired response Blank-Cat (B) (n = 28+28). CPA carried out at +700 mV vs. SCE.   
Figure 4.8.1(A) above shows the current values recorded individually by the Blank and 
Cat sensor in response to introduction of 0-1000 µM AA. As discussed previously the 
response of the H2O2 dual sensor design is obtained by a subtraction method (Blank-
Cat). As can be seen in Figure 4.8.1.1(B) the subtracted current does not vary much 
from baseline levels, denoted by the dashed line. The current remains above basal levels, 
up to a concentration of 600 µM AA and subsequently a slight drift below baseline is 
observed. It is clear that the AA response of the dual sensor design is minimised. The 
small responses to AA are very well matched between the Blank and Cat sensor as can 
be observed in Figure 4.8.1(A). The selectivity over AA of the paired sensor is clearly 
established. The I400 µM of the Blank sensor was found to be 0.16 ± 0.02 nA (n = 28) and 
this value was not significantly different (P > 0.05) when compared to the I400 µM of the 
Cat sensor (0.14 ± 0.02 nA, n = 28). Additionally the I1000 µM AA response of the Blank 
sensor (0.15 ± 0.03 nA, n = 28) showed no significant variation (P > 0.05) from the I1000 
µM of the Cat sensor (0.22 ± 0.03 nA, n = 28). 
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In conclusion, as the selectivity characteristics of both sensor types are very well 
matched the interference from AA is successfully eliminated by the paired sensor design 
(Blank-Cat). The I400 µM of this dual sensor design is 0.02 ± 0.03 nA (n = 28+28) and the 
I1000 µM value recorded was -0.07 ± 0.04 nA (n = 28+28). 
4.8.2 H2O2 sensitivity in the presence of AA 
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Figure 4.8.2 : H2O2 sensitivity of the paired sensor in the presence of AA. (A) The current-
concentration profile (Blank-Cat, n = 2+2). CPA carried out at +700 mV vs. SCE. (B) Average 
paired sensitivity represented as a mean slope ± SEM, in normal PBS (n = 24+24) and in the 
presence of AA (n = 2+2). 
The basal concentration of AA in-vivo has been stated as ~400 µM (Miele & Fillenz, 
1996). In addition the level of AA may fluctuate in response to various stimuli including 
behavioural, electrical and pharmacological inputs as previously stated (Miele et al., 
1994). Taking this factor into account it is intuitive to examine what occurs with a 
normal H2O2 calibration when AA has been added to the electrochemical cell initially in 
order to examine conditions encountered in an in-vivo environment. An injection of AA 
(500 µM) was made prior to introduction of the target analyte (H2O2). In the presence of 
AA the H2O2 sensitivity was preserved yielding a value of 0.31 ± 0.002 nA/µM, n = 2+2 
with an R2 value of 0.9996 and this was not significantly different (P > 0.05) from a 
normal H2O2 calibration in PBS. In addition the signal observed following addition of 
AA was minimal with a maximum increase of 0.05 ± 0.04 nA, n = 2+2. This value is 
significantly different (P < 0.0001, ***) than that observed on addition of 1 µM H2O2 
(0.47 ± 0.003 nA, n = 24+24). To conclude, the pre-existing concentration of AA in the 
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cell prior to commencement of the H2O2 calibration does not significantly inhibit the 
sensitivity to the target substrate (H2O2). The sensitivity of the paired sensor was slightly 
less than that observed in PBS alone (~ 0.06% per 1 µM of H2O2). 
The interaction between AA and H2O2 in-vitro demonstrated here has been studied 
previously (Lowry & O'Neill, 1992). The reported homogeneous interference of AA has 
been shown to cause a similar decrease in H2O2 levels when AA is introduced to the cell 
prior to a H2O2 calibration in the in-vitro environment. The homogenous interference of 
AA described by Lowry et al. which is apparent in-vitro was demonstrated to be absent 
in the in-vivo environment (Lowry et al., 1994).   
4.8.3 H2O2 sensitivity in the presence of DA 
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Figure 4.8.3 : H2O2 sensitivity of the paired sensor in the presence of Dopamine (DA). (A) The 
current-concentration profile (Blank-Cat, n = 3+3). CPA carried out at +700 mV vs. SCE. (B) 
Average paired sensitivity represented as a mean slope ± SEM, in normal PBS (n = 24+24) and in 
the presence of DA (n = 3+3). 
In order to mimic physiological conditions it was deemed necessary to investigate the 
performance of the H2O2 sensor in the presence of dopamine (DA). The basal 
concentration of DA in-vivo is estimated to be between 5 and 50 nM and DA may also 
be detected at +700 mV vs. SCE. However, the absolute basal concentration of DA in-
vivo has been much debated due to uptake mechanisms present in-situ and a possible 
trauma layer induced by implantation of a microdialysis probe used to record DA levels 
(Bungay et al., 2003). A relatively high concentration of DA was chosen (500 nM) to 
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examine the selectivity of the H2O2 sensor. An injection of DA (500 nM) was added into 
the electrochemical cell prior to a H2O2 calibration. In the presence of DA the H2O2 
sensitivity was retained, yielding a value of 0.40 ± 0.004 nA/µM, n = 3+3 with an R2 
value of 0.9992 and this was not significantly different (P > 0.05) from a normal H2O2 
calibration in PBS. The response of this sensor towards DA in isolation was negligible 
(0.020 ± 0.004 nA, n = 3+3). This value is significantly different (P < 0.0001, ***) to 
that observed on addition of 1 µM H2O2 (0.47 ± 0.003 nA, n = 24+24). In conclusion, 
the presence of DA had no significant effect on the subsequent H2O2 calibration.  
4.8.4 H2O2 sensitivity in aCSF 
As recently discussed by Bolger et al. redox reactions of various electroactive species 
in-vitro may depend on the aqueous media conditions utilised to facilitate experiments 
(Bolger et al., 2011). Specifically a variation in the sensitivity of CFE’s to DA, DOPAC 
and 5-HT has been demonstrated in-vitro between different aqueous media including 
HEPES-buffered saline, PBS and artificial cerebrospinal fluid (aCSF) (Chen & Rice, 
1999). For the purpose of normal in-vitro H2O2 calibrations all experiments were 
performed in PBS (see Section 3.7.5). In order to fully investigate the media dependence 
of H2O2 oxidation at Pt surfaces, the H2O2 sensitivity of an unmodified Pt disc electrode 
(Ptd) was tested in aCSF aqueous media and compared to the H2O2 sensitivity of Ptd 
calibrated in PBS aqueous media (Figure 4.8.4).   
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Figure 4.8.4 : H2O2 sensitivity of Ptd in different aqueous media conditions. (A) The current-
concentration profile of Ptd in aCSF. CPA carried out at +700 mV vs. SCE. (B) Average H2O2 
sensitivity of Ptd represented as a mean slope ± SEM, in normal PBS (n = 4) and in aCSF (n = 4). 
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Under normal conditions in PBS aqueous media the H2O2 sensitivity of Ptd was 0.03 ± 
0.00004 nA/µM, n = 4 with an R2 value of 1.000. In aCSF aqueous media the H2O2 
sensitivity of Ptd was retained, yielding a value of 0.02 ± 0.00041 nA/µM, n = 4 with an 
R2 value of 0.9970 and this was not significantly different (P > 0.05) from a normal 
H2O2 calibration in PBS. A small drop in H2O2 sensitivity was seen in aCSF aqueous 
media however no significant difference (P > 0.05) was observed.  
For all in-vitro experiments H2O2 added to the electrochemical cell was made up in 
doubly distilled deionised water (H2O) (see Section 3.3.2.1). However for the purpose of 
in-vivo experiments; the substrate itself (H2O2) was diluted in aCSF for local 
administrations (see Chapter 5). To investigate the viability of H2O2 made up in a 
solution of aCSF, the target substrate was diluted in aCSF (see Section 3.3.2.2) and the 
H2O2 sensitivity of Ptd was tested in-vitro in a PBS aqueous environment; which was 
compared to that seen with normal substrate (H2O2) dilution conditions (H2O) (Figure 
4.8.4.1).  
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Figure 4.8.4.1 : H2O2 sensitivity of Ptd with different substrate dilution conditions. (A) The current-
concentration profile of Ptd (Substrate: H2O2 in aCSF). CPA carried out at +700 mV vs. SCE. (B) 
Average H2O2 sensitivity of Ptd represented as a mean slope ± SEM, with substrate diluted in H2O 
(n = 4) and in aCSF (n = 8). 
Under normal conditions where H2O2 is diluted in H2O and calibrated in PBS aqueous 
media the H2O2 sensitivity of Ptd was 0.03 ± 0.00004 nA/µM, n = 4 with an R2 value of 
1.000. With aCSF substrate dilution conditions the H2O2 sensitivity of Ptd was retained, 
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yielding a value of 0.03 ± 0.00015 nA/µM, n = 8 with an R2 value of 0.9997 and this 
was not significantly different (P > 0.05) from normal H2O2 calibration conditions. 
4.9 Paired H2O2 sensor stability and biocompatibility 
A long-term stability experiment (see Section 3.6.4) was conducted where the stability 
of the paired sensor over 28 days was investigated in the absence of treatment. The 
effect of repeated calibrations on the sensitivity and selectivity of the paired H2O2 sensor 
can be examined in this manner.  
The in-vitro characteristics of a sensor may not match its properties in-vivo. This factor 
is due in part to how the sensors may be altered by the various constituents of brain 
tissue and this may be reflected by variations in the sensor’s characteristics (O'Neill, 
1993). It has been demonstrated previously that when sensors are exposed to biological 
samples a drop in sensitivity occurs due to fouling of the sensor by proteins and other 
biomolecules present within the tissue (Garguilo & Michael, 1994).  
An examination into the biocompatibility of the paired H2O2 sensor was carried out. In 
order to mimic the conditions encountered by the H2O2 sensor in-vivo the effect of 
exposure to brain tissue and its components on the sensitivity and selectivity of the 
Blank and Cat sensor were investigated. A method previously demonstrated by Brown 
et al. and Bolger et al. was used to determine the in-vitro biocompatibility of the paired 
catalase-based sensor (Brown et al., 2009; Bolger et al., 2011). Each sensor (Blank and 
Cat) was exposed to samples of homogenised brain tissue (BT), protein (BSA) and lipid 
(PEA) and tested at specified durations (see Section 3.6) to examine the 
biocompatibility of the H2O2 sensor.  
The intention of these sets of experiments is to gauge the stability of the sensor prior to 
and during Long Term In-Vivo Electrochemistry (L.I.V.E) recordings. Although these 
parameters mimic the in-vivo medium it must be stated that it is not an entirely correct 
representation of the response of the sensor, when in contact with intact living brain 
tissue and only serves as a guide to performance of the paired sensor in-vivo.  
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4.10 Blank stability (long-term) 
This section investigates the stability of the Blank sensor (Ptc/Nafion®/PPD) over a four 
week period (see Section 3.6.4). The experiments outlined in this section also serve as a 
control against which the biocompatibility of the Blank sensor may be compared. The 
sensitivity of the Blank sensor was tested over a 0 to 550 µM H2O2 concentration range. 
The selectivity of the Blank sensor was also assessed over a concentration range of AA 
(0-1000 µM). These sensors were stored at 4◦C in a refrigerator when not in use; the 
sensitivity and selectivity of the sensors were intermittently tested at the times specified 
below. 
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Figure 4.10.1 H2O2 response of the Blank sensor over 28 days the number of days is represented on 
the x-axis. (A) Data represented as a mean response ± SEM (B) Data shown as a percentage with 
100% as the H2O2 sensitivity recorded on the initial day of experiments. (P < 0.05,*).  
Upon examining the data above in Figure 4.10.1 it is clear that the H2O2 sensitivity of 
the Blank sensor
 
increases over time as part of this long-term stability study with 
reference to day 0. A significant difference P < 0.05,* is observed between the first 
calibration prior to initiation of the shelf-life study and days 3, 14 and 28. No significant 
difference (P > 0.05) is observed between 0 and 7 days. A maximum increase is 
observed on day 14 which represents a 49.7 % increase. A decrease was observed 
between day 14 and 28 with a drop in sensitivity of ~3%. Although a gradual increase in 
sensitivity is observed the magnitude of the response is stymied as the shelf-life study 
proceeds. A similar sensitivity is observed between day 3 and day 7 and subsequently 
between 14 and 28 days as shown in Table 4.10.1. A larger exposed Pt surface area 
would give a higher H2O2 sensitivity value. It is possible that repeated exposure to a 
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high concentration of the substrate (H2O2) has caused deterioration in the PPD structure 
thereby increasing the exposed surface area of the sensor. However, the magnitude of 
this deterioration does not increase in a linear fashion which supports the overall 
stability of this sensor.  
Day 
Mean I, 
(nA/µM) SEM % SEM (%) P n 
0 0.30 0.003 100 0.94 n/a 4 
3 0.37 0.001 124.38 0.34 0.0352 4 
7 0.38 0.008 128.77 2.68 0.0590 4 
14 0.45 0.004 149.7 1.48 0.0283 4 
28 0.44 0.002 146.48 0.79 0.0334 4 
 
Table 4.10.1 Data obtained from the calibrations shown in Figure 4.10.1. Data represented as a 
mean response ± SEM and as a percentage change (%) ± SEM. Where (P) represents the outcome 
of a paired t-test at each time point (3, 7, 14 and 28 days) when compared to the response recorded 
with untreated sensors (day = 0). The number of sensors is denoted by (n). 
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Figure 4.10.2 AA response of the Blank sensor over 28 days. Data represented as a mean response ± 
SEM (A) I400 µM and (B) I1000 µM 
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Upon examining the data above in Figure 4.10.2 it is apparent that an increase in AA 
response is observed by the Blank sensor on progression of this stability investigation in 
comparison to day 0. The level of significant difference is shown in Table 4.10.2. The 
extent of the increase slows between day 7 and 14 (Figure 4.10.2) in relation to I400 µM 
and I1000 µM. This data implicates that a disruption in the polymerised surface has 
occurred which has created an increased Pt surface area, thereby causing an increase in 
response to AA. The cause of the stated disruption occurs due to prolonged exposure to 
H2O2 and due to the necessary repeated physical manipulation of these sensors for each 
calibration. This structural issue is negated for in-vivo experiments as all sensors are 
calibrated only once immediately prior to implantation. 
 
Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.10 0.03 0.06 0.01 4 n/a n/a 
3 1.09 0.22 0.72 0.14 4 0.0385 0.0153 
7 4.76 0.88 2.34 0.39 4 0.0086 0.0131 
14 5.84 0.39 2.94 0.25 4 < 0.0001 0.0007 
28 11.31 1.11 5.52 0.52 4 0.0018 0.0020 
 
Table 4.10.2 Data obtained from the calibrations shown in Figure 4.10.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (3, 7, 14 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
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4.11 Cat stability (long-term) 
In this section the stability of the Cat sensor (Ptc/Nafion®/PPD/Cat-Ga) was investigated 
over a four week period (see Section 3.6.4). The experiments outlined in this section 
also serve as a control against which the biocompatibility of the Cat sensor may be 
compared. The sensitivity of the Cat sensor was tested with H2O2 (0-550 µM) 
concentration range. The selectivity of the Blank sensor was assessed over a 
concentration range of AA (0-1000 µM). These sensors were stored at 4◦C in a 
refrigerator when not in use. The sensitivity and selectivity of the sensors were 
intermittently tested at the times specified below. 
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Figure 4.11.1 H2O2 response of the Cat sensor over 28 days. Data represented as a mean response ± 
SEM and (P < 0.05,*).  
The sensitivity of the Cat sensor to H2O2 is shown in Figure 4.11.1 this data shows a 
consistent pattern, a significant difference (P < 0.05,*) from day 0 is observed at all time 
points i.e. day 3, 14, 21 and 28. As the function of the catalase enzyme is to remove 
H2O2, the data in Figure 4.11.1 signifies a loss in functionality of the catalase-based 
sensor. The response observed here is typical when compared to other biosensor 
responses due to constant exposure to high levels of substrate (550 µM H2O2). The 
enzyme becomes saturated and does not retain the same function as observed initially on 
day 0 (Bolger, 2007). On further investigation it was apparent that the relative loss in 
H2O2 sensitivity was attributable to a variation in sensitivity on introduction of a higher 
concentration of H2O2 (250-550 µM). As the responses observed here are enzymatic it is 
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possible to examine and compare Cat sensor data obtained at a lower concentration of 
H2O2 i.e. (0-150 µM). No significant variation (P > 0.05) was observed at this lower 
concentration range (0-150 µM) between successive time points day 3, 14, 21 and 28 
when compared to the sensitivity recorded on day 0. It is apparent that the Cat sensor is 
stable over 28 days up to a concentration of 150 µM. As the expected ECF 
concentration of H2O2 is much lower (25-50 µM) the trend shown in Figure 4.11.1 
should not be observed in-vivo. This factor is supported by evidence provided in Chapter 
5 Section 5.11.2, where the baseline of the Cat sensor does not show significant changes 
over an extended period when implanted in-vivo. Additionally, all electrodes were 
calibrated immediately prior to in-vivo implantation which excludes long-term stability 
considerations.  
 
Day 
Mean I, 
(nA/µM) SEM P n 
0 0.01 0.0001 n/a 4 
3 0.02 0.001 0.0291 4 
14 0.06 0.001 0.0322 4 
21 0.12 0.001 0.0310 4 
28 0.20 0.003 0.0276 4 
 
Table 4.11.1 Data obtained from the calibrations shown in Figure 4.10.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (3, 14, 
21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). The 
number of sensors is denoted by (n). 
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Figure 4.11.2 AA response of the Cat sensor over 28 days. Data represented as a mean response ± 
SEM (A) I400 µM and (B) I1000 µM 
On examination of the AA response of the Cat sensor shown in Figure 4.11.2 a 
significant difference (P < 0.05,*) in AA response is observed on day 3, 14 and 21 
during this long-term stability experiment in comparison to day 0. A similar disruption 
in the modified surface as seen in Section 4.10 is evident here. As previously stated this 
structural issue is negated for in-vivo experiments as all sensors are calibrated 
immediately prior to implantation. 
Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.25 0.02 0.18 0.01 4 n/a n/a 
3 1.31 0.27 0.69 0.11 4 0.0214 0.0322 
14 8.69 1.28 5.49 0.66 4 0.0040 0.0277 
21 16.17 3.98 7.61 2.02 4 0.0342 0.0277 
28 25.20 8.81 12.51 4.4 4 0.0671 0.0658 
 
Table 4.11.2 Data obtained from the calibrations shown in Figure 4.11.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (3, 14, 21 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
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4.12 Blank biocompatibility (BSA) 
The Blank sensor (Ptc/Nafion®/PPD) was exposed to a solution of the protein BSA (see 
Section 3.6.1) and was tested over a four week period to investigate the effect of protein 
on the performance of the Blank sensor. The sensitivity to the target substrate of the 
Blank sensor was examined (0-550 µM H2O2). The selectivity of the Blank sensor was 
evaluated with AA (0-1000 µM). These sensors were stored at 4◦C in a refrigerator in a 
10% (w/v) solution of BSA (see Section 3.6.1) when not in use. The sensitivity and 
selectivity of the sensors was examined at the times specified below. 
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Figure 4.12.1 H2O2 response of the Blank sensor exposed to BSA over 28 days. (A) Data represented 
as a mean response ± SEM (B) Data shown as a percentage with 100% as the H2O2 sensitivity 
recorded on the initial day of experiments. (P < 0.05,*). 
The effect of exposure to the protein BSA on the sensitivity of the Blank sensor is 
shown in Figure 4.12.1. An increase in sensitivity is observed after 24 hours (day 1) 
which is significantly different (P < 0.05,*) from the initial calibration. No significant 
difference can be seen on day 3 and 7 with reference to day 0. Day 1, 14, 21 and 28 
show a significant variation (P < 0.05,*) from day 0. The maximum increase on addition 
of H2O2 is observed on day 14 (82.4 %) which falls to a lower level on day 28 (59.8 %). 
A relative drop in H2O2 response is observed after 14 days. The values are given in 
Table 4.12.1 and no significant difference (P > 0.05) is seen between day 21 and 28. 
BSA does affect the sensitivity of this sensor type which could be due to a disruption of 
the modified surface which would result in an increased Pt surface area. The 
concentration of BSA used here is quite high (10%) which may be more severe than the 
concentration of protein found in-vivo. In an effort to mimic the in-vivo environment 
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more closely the Blank sensor was treated with a sample of homogenised brain tissue 
(see Section 4.16). 
 
Day 
Mean I, 
(nA/µM) SEM % SEM (%) P n 
0 0.38 0.002 100 0.61 n/a 4 
1 0.50 0.003 128.92 0.69 0.0477 4 
3 0.43 0.001 110.52 0.29 0.0650 4 
7 0.61 0.055 149.55 13.58 0.3217 4 
14 0.70 0.003 182.41 0.85 0.0312 4 
21 0.55 0.004 151.10 1.08 0.0210 4 
28 0.62 0.004 159.78 1.17 0.0455 4 
 
Table 4.12.1 Data obtained from the calibrations shown in Figure 4.12.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
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Figure 4.12.2 AA response of the Blank sensor exposed to BSA over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM 
No significant difference (P > 0.05) in AA response was observed after 24hrs (1) 
exposure of the Blank sensor to a protein solution (BSA). A significant difference (P < 
0.05,*) was observed at day 3, 7, 14, 21 and 28, however the magnitude of the increase 
in AA sensitivity slows following day 3 as can be seen in Figure 4.12.2. The first level 
of significant difference is observed on day 3. The results represented here suggest that a 
loss of the integrity of the modified surface has occurred following repeated exposure to 
BSA. It is possible that the repeated calibration itself may have affected the modified 
surface of the sensor (see Section 4.10). In order to mimic the in-vivo environment more 
closely the Blank sensor was exposed to a sample of homogenised brain tissue (see 
Section 4.16). 
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Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.10         0.01 0.16 0.01 4 n/a n/a 
1 2.16 0.99 0.01 0.41 4 0.1194 0.1287 
3 20.51 2.44 9.16 1.10 4 0.0038 0.0036 
7 16.66 1.09 7.17 0.53 4 0.0009 0.0006 
14 20.68 2.05 7.58 1.20 4 0.0032 0.0021 
21 18.48 2.24 8.31 1.07 4 0.0048 0.0038 
28 16.2 2.22 7.58 1.20 4 0.0088 0.0054 
 
Table 4.12.2 Data obtained from the calibrations shown in Figure 4.12.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1, 3, 7, 14, 21 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
4.13 Cat biocompatibility (BSA) 
This section investigates the stability of the Cat sensor (Ptc/Nafion®/PPD/Cat-Ga) over a 
period of four weeks following exposure to BSA, examining the effect of protein on the 
function of the Cat sensor (see Section 3.6.1). The sensitivity of the Cat sensor was 
tested over a concentration range of H2O2 (0-550 µM). The selectivity of the Cat sensor 
was tested over a concentration range of AA (0-1000 µM). These sensors were stored at 
4◦C in a refrigerator in a 10% (w/v) solution of BSA (see Section 3.6.1). The sensitivity 
and selectivity of the sensors were tested at each time point specified below.  
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Figure 4.13.1 H2O2 response of the Cat sensor exposed to BSA over 28 days. Data represented as a 
mean response ± SEM and (P < 0.05,*).  
The data shown in Figure 4.13.1 shows a definite trend. A significant difference (P < 
0.05,*) from day 0 is observed at all time points i.e. 24 hrs day 3, 7, 14, 21 and 28. The 
ability of the Cat sensor to degrade H2O2 is impaired. The maximum loss in sensitivity 
is seen on day 14 which plateaus on day 21 and is followed by an improved response on 
day 28. The sensitivity data for each time point is displayed below in Table 4.13.1. As 
has previously been demonstrated in Section 4.11 the variation in response is more 
apparent in response to relatively high concentrations of H2O2 (250-550 µM).  At lower 
concentrations, i.e. 0-150 µM, no significant difference (P > 0.05) was observed at any 
time point (1, 3, 7, 14, 21 and 28 days) with reference to day 0. These results further 
illustrate that the loss in H2O2 sensitivity is due to saturation of the catalase enzyme by 
the substrate (H2O2) and this factor is particularly noticeable in response to high 
concentrations of H2O2 i.e. 250-550 µM.  
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Day 
Mean I, 
(nA/µM) SEM P n 
0 0.01 0.0003 n/a 4 
1 0.06 0.0011 0.0344 4 
3 0.07 0.0008 0.0357 4 
7 0.34 0.0014 0.0321 4 
14 0.37 0.0048 0.0261 4 
21 0.36 0.005 0.0243 4 
28 0.22 0.0009 0.0292 4 
 
Table 4.13.1 Data obtained from the calibrations shown in Figure 4.11.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
In order to minimise the possible saturation of the catalase enzyme, a further 
investigation was necessary to determine the stability of this sensor design in the 
presence of BSA. Ptc/Nafion®/PPD/Cat-Ga sensors were constructed and immersed in a 
solution of BSA (see Section 3.6.1) for 14 days. These sensors were then removed and 
re-tested with no intermediate tests undertaken. The expected ECF concentration of 
H2O2 is 25-50 µM which is much lower than that used in the in-vitro calibration. This 
protocol limits repeated exposure of the enzyme to the substrate and minimises 
saturation of the enzyme. The results of this experiment are displayed below in Figure 
4.13.2.  
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Figure 4.13.2 H2O2 response of the Cat sensor exposed to BSA for a constant period of 14 days. 
The sensitivity of the Cat sensor was tested over a concentration range of H2O2 (0-550 
µM). The H2O2 sensitivity of the Ptc/Nafion®/PPD/Cat-Ga sensor prior to emersion in a 
protein solution (day 0) was 8.53 ± 0.13 pA/µM, n = 4 with an R2 value of 0.9978. 
Following 14 days of exposure to BSA the sensors were removed and re-calibrated. On 
day 14 these sensors displayed a H2O2 sensitivity of 37.27 ± 0.78 pA/µM, n = 4 with an 
R2 value of 0.9957. A significant difference (P < 0.05,*) was found between day 0 and 
14. On day 14 of this stability test a loss in function of the catalase sensor was observed, 
the loss recorded here is relatively lower than that recorded at the same time-point 
shown in Table 4.13.1 (day 14). Minimising catalase saturation in this experiment has 
improved the stability of this sensor design.  This factor further supports previous 
evidence which suggests that saturation of the catalase enzyme with H2O2 is responsible 
for the apparent loss in ability to degrade H2O2 and not the treatment itself. The loss in 
sensitivity shown in Figure 4.13.2 is significant (P < 0.05,*) but not detremental to the 
function of the paired sensor design as a high proportion of function is still retained 
when compared to an untreated Blank sensor (Ptc/Nafion®/PPD). A ~92% removal in 
signal at a 550 µM concentration of H2O2 is apparent when compared in this manner.  
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Figure 4.13.3 AA response of the Cat sensor exposed to BSA over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM 
On examination of the data shown graphically above in Figure 4.13.3, a significant 
difference (P < 0.05,*) was observed in AA response on day 1 to 28 when compared to 
day 0. A similar trend was observed with I400 µM and I1000 µM values as can be seen below 
in Table 4.13.2. The results displayed here suggest a deterioration of the modified 
surface of the sensor due to exposure to BSA. In order to replicate the in-vivo 
environment more closely the Blank sensor was exposed to a sample of homogenised 
brain tissue (see Section 4.16). 
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Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.41 0.11 0.25 0.06 4 n/a n/a 
1 4.55 1.17 2.32 0.58 4 0.0394 0.0448 
3 16.33 2.47 7.57 1.08 4 0.0067 0.0081 
7 24.21 3.83 10.68 1.47 4 0.0054 0.0081 
14 31.64 5.39 14.41 2.19 4 0.0069 0.0097 
21 29.05 5.76 14.23 2.63 4 0.0122 0.0149 
28 37.45 6.38 17.03 2.74 4 0.0084 0.0101 
 
Table 4.13.2 Data obtained from the calibrations shown in Figure 4.13.3. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1, 3, 7, 14 , 21 and 28 days) when compared to the response recorded with 
untreated sensors (day = 0). The number of sensors is denoted by (n). 
 
4.14 Blank biocompatibility (PEA)  
The Blank sensor (Ptc/Nafion®/PPD) was treated with a solution of the lipid PEA (see 
Section 3.6.2) and was tested over 28 days in order to evaluate the effect of this lipid on 
the characteristics of the Blank sensor. The sensitivity to the target analyte of the Blank 
sensor was tested (0-550 µM H2O2). The selectivity of the Blank sensor was examined 
using AA (0-1000 µM). These sensors were stored at 4◦C in a refrigerator in a 10% 
(w/v) solution of PEA (see Section 3.6.2) when not in use, the sensitivity and selectivity 
of the sensors were intermittently tested at the times stated below. 
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Figure 4.14.1 H2O2 response of the Blank sensor exposed to PEA over 28 days. (A) Data represented 
as a mean response ± SEM (B) Data shown as a percentage with 100% as the H2O2 sensitivity 
recorded on the initial day of experiments. (P < 0.05,*). 
The effect of exposure to the lipid PEA on the sensitivity of the Blank sensor is shown 
in Figure 4.14.1. It is clear from the data displayed above in Figure 4.14.1 that a gradual 
decrease in H2O2 sensitivity of the Blank sensor is observed over an increased exposure 
time to the lipid (PEA). A significant difference (P < 0.05,*) from day 0 is observed at 
all time points i.e. day 1, 3, 7, 14, 21 and 28. A maximum decrease in sensitivity is seen 
on day 14 (31.8 %) which makes a gradual return towards baseline levels as can be seen 
from the data displayed in Table 4.14.1. A decrease in sensitivity is observed overall, 
however after the initial fall in H2O2 sensitivity the effect of PEA on the Blank sensor 
subsides. No significant difference (P > 0.05) was observed between day 1 and 28. This 
indicates that no significant change in sensitivity is apparent on increasing the length of 
exposure time to the lipid which validates the stability of this sensor design. 
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Day 
Mean I, 
(nA/µM) SEM % SEM (%) P n 
0 0.39 0.002 100 0.39 n/a 4 
1 0.34 0.003 87.75 0.72 0.0146 4 
3 0.31 0.002 80.14 0.51 0.0235 4 
7 0.31 0.0004 80.34 0.11 0.0275 4 
14 0.27 0.001 68.22 0.29 0.0433 4 
21 0.28 0.002 70.85 0.44 0.0308 4 
28 0.30 0.001 75.87 0.33 0.0327 4 
 
Table 4.14.1 Data obtained from the calibrations shown in Figure 4.12.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
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Figure 4.14.2 AA response of the Blank sensor exposed to PEA over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM 
Figure 4.14.2 displays the AA response of the Blank sensor when treated with PEA for a 
period of four weeks. An increase in AA response can be seen at all time points (1, 3, 7, 
14, 21 and 28) with respect to day 0 of treatment. The data shown here would suggest a 
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deterioration has occurred in the polymer surface. The current responses obtained under 
these conditions (Table 4.14.2) are not entirely detremental to the function of the Blank 
sensor. As the high H2O2 sensitivity of the Blank sensor is maintained over 28 days a 
resolution in H2O2 response over AA is still achievable under these conditions. 
 
Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.006 0.014 0.07 0.01 4 n/a n/a 
1 3.78 0.89 1.79 0.34 4 0.0137 0.0244 
3 5.49 0.74 2.54 0.25 4 0.0021 0.0049 
7 5.40 0.63 2.53 0.20 4 0.0011 0.0032 
14 5.65 0.38 2.61 0.14 4 0.0004 0.0006 
21 6.97 0.77 3.14 0.30 4 0.0020 0.0028 
28 8.25 0.58 3.65 0.21 4 0.0004 0.0007 
 
Table 4.14.2 Data obtained from the calibrations shown in Figure 4.14.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1,3, 7, 14,21 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
4.15 Cat biocompatibility (PEA) 
This section investigates the stability of the Cat sensor (Ptc/Nafion®/PPD/Cat-Ga) over a 
period of four weeks following continuous exposure to PEA, examining the effect of 
lipids on the performance of the Cat sensor (see Section 3.6.2). The sensitivity of the 
Cat sensor was tested over a concentration range of H2O2 (0-550 µM). The selectivity of 
the Cat sensor was tested over a concentration range of AA (0-1000 µM). These sensors 
were stored at 4◦C in a refrigerator in a 10% (w/v) solution of PEA (see Section 3.6.2); 
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the sensitivity and selectivity of the sensors were intermittently tested at the times 
outlined below. 
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Figure 4.15.1 H2O2 response of the Cat sensor exposed to PEA over 28 days. Data represented as a 
mean response ± SEM and (P < 0.05,*). 
A significant difference (P < 0.05,*) is observed between day 0 and the successive time 
points 3, 7, 14, 21 and 28 days. The function of the catalase enzyme i.e. to degrade H2O2 
into water and oxygen is impacted upon. The maximum loss in sensitivity is observed 
on day 28 which displays similar current responses to those observed on day 21 and day 
14 which can be seen in Table 4.15.1. As has been shown with previous 
biocompatibility tests with this catalase-based sensor in this chapter, a deterioration in 
the function of this sensor is observed following exposure to relatively high 
concentrations of H2O2 (250-550 µM). When sensitivities at lower concentrations of 
H2O2 i.e. 0-150 µM are examined no significant differences (P > 0.05) are reported at all 
time points (1, 3, 7, 14, 21 and 28 days) with reference to day 0. The stability of this 
sensor (Ptc/Nafion®/PPD/Cat-Ga) is maintained over 28 days when exposed to PEA up 
to a concentration of 150 µM H2O2. The concentration of PEA used in this experiment 
(10%) may be less than that encountered under physiological conditions.  
 
 
 
Chapter 4: In-vitro H2O2 
 
146 
 
Day 
Mean I, 
(nA/µM) SEM P n 
0 0.004 0.001 n/a 4 
1 0.03 0.0003 0.0504 4 
3 0.12 0.001 0.0407 4 
7 0.13 0.001 0.0359 4 
14 0.21 0.001 0.0349 4 
21 0.22 0.002 0.0295 4 
28 0.22 0.001 0.0309 4 
 
Table 4.15.1 Data obtained from the calibrations shown in Figure 4.13.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
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Figure 4.15.2 AA response of the Cat sensor exposed to PEA over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM. 
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Figure 4.15.2 displays the AA response of the Cat sensor when treated with PEA for 28 
days. A significant difference is observed on day 1, 3, 7, 14, 21 and 28 in comparison to 
day 0. It appears that the modified surface of the Cat sensor is disrupted. This protocol 
only replicates one aspect of the in-vivo environment and it was necessary to expose the 
Cat sensor to a more global representation of the in-vivo environment (see Section 4.17).
 
 
Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.62 0.27 0.38 0.11 4 n/a n/a 
1 7.03 0.94 3.61 0.57 4 0.0062 0.0027 
3 11.54 2.18 5.94 1.04 4 0.0122 0.0128 
7 13.33 0.47 6.41 0.18 4 < 0.0001 < 0.0001 
14 12.90 1.15 7.24 0.35 4 0.0004 0.0031 
21 12.94 1.52 6.47 0.34 4 0.0008 0.0058 
28 15.08 3.81 6.76 1.59 4 0.0284 0.0328 
 
Table 4.15.2 Data obtained from the calibrations shown in Figure 4.15.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1,3, 7, 14,21 and 28 days) when compared to the response recorded with untreated 
sensors (Day = 0). The number of sensors is denoted by (n). 
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4.16 Blank biocompatibility (BT) 
In this section the Blank sensor (Ptc/Nafion®/PPD) was exposed to a homogenised 
sample of ex-vivo brain tissue (BT) (see Section 3.6.3) and was tested over 28 days in 
order to examine the effect of exposure to BT on the sensitivity and selectivity of the 
sensor. The protocol followed here mimics the conditions encountered in a physiological 
environment more reliably than the biocompatibility tests discussed in the previous 
sections. The sensitivity of the Blank sensor was tested (0-550 µM H2O2). The 
selectivity of the Blank sensor was examined using AA (0-1000 µM). These sensors 
were stored at 4◦C in a refrigerator in BT (see Section 3.6.3) when not in use, the 
sensitivity and selectivity of the sensors were intermittently tested at the times stated 
below. 
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Figure 4.16.1 H2O2 response of the Blank sensor exposed to BT over 28 days. (A) Data represented 
as a mean response ± SEM (B) Data shown as a percentage with 100% as the H2O2 sensitivity 
recorded on the initial day of experiments. 
The effect of exposure to BT on the sensitivity of the Blank sensor can be seen in Figure 
4.16.1. On examining the data displayed in Figure 4.16.1, it is apparent that a gradual 
decrease in sensitivity of the Blank sensor is observed on increasing the duration of 
exposure to BT. The maximum drop in sensitivity can be seen on day 7 (29.2 %). As the 
experiment proceeds a return towards the initial sensitivity occurs following continuous 
BT exposure. The current values are displayed in Table 4.16.1. An initial decrease in 
sensitivity occurs until day 7, subsequently the sensitivity returns towards control levels 
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and no significant difference (P > 0.05) is observed between the sensitivity on day 28 
and that recorded after 24 hours (day 1) of contact with BT. The biocompatibility test 
shown in this section (BT) is the closest method of mimicking the conditions 
encountered by the sensor in the in-vivo environment. The in-vitro results displayed in 
this section strongly suggest that the Blank sensor will remain stable after an initial 
decrease (in-vitro, ~29.2 %). It must be stated at this point that these experiments cannot 
exactly replicate the in-vivo biological medium but serve only as an indication about the 
stability of a sensor design.  
 
Day 
Mean I, 
(nA/µM) SEM % SEM (%) P n 
0 0.30 0.001 100 0.42 n/a 4 
1 0.26 0.001 87.51 0.23 0.0289 4 
3 0.24 0.002 78.75 0.53 0.0290 4 
7 0.21 0.001 70.76 0.34 0.0313 4 
14 0.22 0.001 73.46 0.44 0.0306 4 
21 0.24 0.002 78.49 0.75 0.0384 4 
28 0.24 0.003 80.65 1.04 0.0417 4 
 
Table 4.16.1 Data obtained from the calibrations shown in Figure 4.16.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
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Figure 4.16.2 AA response of the Blank sensor exposed to BT over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM 
Figure 4.16.2 above represents the response of the Blank sensor to AA following 
exposure to BT for a period of 28 days. A decrease in AA response is observed on day 3 
and 7 of this protocol. A significant difference in AA signal was recorded on day 1, 14 
and 28 in comparison to day 0 (see Table 4.16.2). On examination of the current 
responses, a massive improvement in the biocompatibility characteristics of the Blank 
sensor is observable with respect to BSA and PEA treatments. The exposure of the 
sensor to a sample of brain tissue is a far more accurate representation of the in-vivo 
environment. The work presented in this section supports the feasability of maintaining 
the stability of this H2O2 detecting sensor during L.I.V.E experiments.  
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Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P, 
(400 µM) 
P, 
 (1000 µM) 
0 0.20 0.02 0.11 0.01 4 n/s n/s 
1 0.43 0.04 0.25 0.02 4 0.0022 0.0036 
3 0.13 0.02 0.06 0.01 4 0.0039 0.0010 
7 0.17 0.02 0.09 0.01 4 0.1589 0.0064 
14 0.54 0.09 0.31 0.06 4 0.0385 0.0236 
21 0.43 0.14 0.27 0.11 3 0.2707 0.2479 
28 0.84 0.08 0.47 0.05 4 0.0081 0.0034 
 
Table 4.16.2 Data obtained from the calibrations shown in Figure 4.16.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1,3, 7, 14,21 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
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4.17 Cat biocompatibility (BT) 
In this section the stability of the Cat sensor (Ptc/Nafion®/PPD/Cat-Ga) following 
exposure to BT is examined over a period of 28 days, to investigate the effect of a brain 
tissue sample on the function of the Cat sensor (see Section 3.6.3). The sensitivity of the 
Cat sensor was tested over a concentration range of H2O2 (0-550 µM). The selectivity of 
the Cat sensor was examined using a concentration range of AA (0-1000 µM). These 
sensors were stored at 4◦C in a refrigerator in a sample of BT (see Section 3.6.3); the 
sensitivity and selectivity of the sensors were intermittently tested at the times shown 
below. 
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Figure 4.17.1 H2O2 response of the Cat sensor exposed to BT over 28 days (0-550 µM H2O2). Data 
represented as a mean response ± SEM and (P < 0.05,*). 
A significant difference (P < 0.05,*) is observed between day 0 and the respective days 
of exposure. The ability of the catalase enzyme to remove H2O2 is compromised. The 
maximum current response on day 28 is much less than observed with previous 
biocompatibility tests (see Table 4.17.1). On further examination it was found that at a 
lower concentration of H2O2 (0-150 µM), the stability of this sensor is maintained (See 
Section 4.17.2) as has been demonstrated in the previous sections. No significant 
difference (P > 0.05) was observed between days of exposure at this lower 
concentration. 
 
Chapter 4: In-vitro H2O2 
 
153 
 
Day Mean I, nA/µM SEM P n 
0 0.002 0.0001 n/a 4 
1 0.01 0.00009 0.0374 4 
3 0.046 0.00019 0.0325 4 
7 0.056 0.00126 0.0373 4 
14 0.072 0.0015 0.0355 4 
21 0.097 0.00106 0.0294 4 
28 0.10 0.00082 0.0267 4 
 
Table 4.17.1 Data obtained from the calibrations shown in Figure 4.17.1. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
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Figure 4.17.2 H2O2 response of the Cat sensor exposed to BT over 28 days (0-150 µM H2O2). Data 
represented as a mean response ± SEM and (P < 0.05,*). 
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Day Mean I, nA/µM SEM P n 
0 0.002 0.00003 n/a 4 
1 0.009 0.00004 0.0695 4 
3 0.046 0.00032 0.0636 4 
7 0.046 0.00117 0.0531 4 
14 0.069 0.0008 0.0616 4 
21 0.098 0.00067 0.0608 4 
28 0.093 0.00134 0.0598 4 
 
Table 4.17.2 Data obtained from the calibrations shown in Figure 4.17.2. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test at each time point (1, 3, 
7, 14, 21 and 28 days) when compared to the response recorded with untreated sensors (day = 0). 
The number of sensors is denoted by (n). 
The same trend was observed here in relation to previous biocompatibility tests on the 
catalase-based sensor, the stability of this sensor was maintained at relatively lower 
concentrations (0-150 µM) as illustrated in Figure 4.17.2. This factor may be 
attributable to saturation of the catalase enzyme by the substrate at higher 
concentrations.  This evidence further demonstrates that the deterioration in the function 
of the catalase-based sensor is dependent on the repeated exposure to high levels of 
H2O2 (550 µM). In order to further investigate this possibility a separate experiment was 
undertaken. A set of Ptc/Nafion®/PPD/Cat-Ga sensors were manufactured and left in a 
sample of BT without removal for 14 days. These sensors were then removed and re-
tested with no intermediate tests undertaken. This protocol limits repeated exposure of 
the enzyme to the substrate and hence should avoid saturation of the enzyme. The 
results of this experiment are displayed below in Figure 4.17.3.  
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Figure 4.17.3 H2O2 response of the Cat sensor exposed to BT for a constant period of 14 days. 
The sensitivity of the Cat sensor was tested over a concentration range of H2O2 (0-550 
µM). The H2O2 sensitivity of the Ptc/Nafion®/PPD/Cat-Ga sensor prior to BT exposure 
(day 0) was 8.04 ± 0.38 pA/µM, n = 3 with an R2 value of 0.9786. Following 14 days of 
exposure to BT, the sensors were removed and re-calibrated. On day 14 these sensors 
gave a H2O2 sensitivity of 7.29 ± 0.19 pA/µM, n = 3 with an R2 value of 0.9929. No 
significant difference (P > 0.05) was found between day 0 and 14. The Cat sensor did 
not show a significant loss in sensitivity due to treatment with BT in this case. This 
further supports previous evidence which suggests that saturation of the catalase enzyme 
with H2O2 is responsible for the apparent loss in ability to degrade H2O2 and not the 
treatment itself. As saturation considerations are effectively eliminated in this instance it 
is clear that BT does not significantly effect the stability of the Cat sensor for up to 14 
days. 
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Figure 4.17.4 AA response of the Cat sensor exposed to BT over 28 days. Data represented as a 
mean response ± SEM (A) I400 µM and (B) I1000 µM 
Figure 4.17.4 above illustrates the response of the Cat sensor to AA following exposure 
to BT for 28 days. A similar response is obtained between day 3 and 7 in comparison to 
day 0 the current values are given in Table 4.17.4. A significant difference (P < 0.05) in 
AA rejection characteristics is seen on day 1, 14, 21 and 28 and the results are 
summarised in Table 4.17.4. On further inspection of the current responses, a massive 
improvement in AA rejection capabilities of the Cat sensor is evident here in 
comparison to that seen with BSA and PEA treatments. The treatment of the sensor with 
a sample of brain tissue is the closest representation of conditions encountered in a 
physiological environment. The results presented in this section suggest the Cat sensor 
is quite stable in the presence of brain tissue. Many of the parameters of the in-vivo 
environment cannot be replicated in-vitro, however these results support the stability of 
the Cat sensor for use in L.I.V.E experiments.  
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Day 
I, nA  
(1000 µM) SEM 
I, nA  
(400 µM) SEM n 
P 
(400 µM) 
P 
(1000 µM) 
0 0.20 0.04 0.07 0.02 4 n/a n/a 
1 1.65 0.26 0.93 0.11 3 0.0201 0.0357 
3 0.21 0.05 0.1 0.02 4 0.4315 0.8621 
7 0.24 0.02 0.13 0.01 4 0.0568 0.4013 
14 0.56 0.05 0.21 0.02 3 0.0059 0.0059 
21 1.21 0.12 0.54 0.05 3 0.0048 0.0057 
28 1.61 0.11 0.72 0.09 4 0.0067 0.0009 
 
Table 4.17.4 Data obtained from the calibrations shown in Figure 4.17.4. Data represented as a 
mean response ± SEM. Where (P) represents the outcome of a paired t-test for I400 µM and I1000 µM at 
each time point (1,3, 7, 14,21 and 28 days) when compared to the response recorded with untreated 
sensors (day = 0). The number of sensors is denoted by (n). 
4.18 Blank stability and biocompatibility summary 
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Figure 4.18.1 Comparison of H2O2 responses between long-term stability (L-T) and biocompatibility 
tests on day 28. Data represented as a percentage change. With 100% as the H2O2 sensitivity 
recorded on day 0 of each treatment. 
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The data represented in Figure 4.18.1 compares the effect of the long-term stability test 
(L-T) and the various biocompatibility tests (PEA, BSA and BT) on the sensitivity of 
the Blank sensor. The H2O2 response of the Blank sensor recorded on day 28 is shown. 
With the long-term stability test (L-T) a significant difference (P < 0.05,*) was observed 
between day 0 and day 28. The repeated calibration itself has an effect on the Blank 
sensor performance. In each biocompatibility test a significant difference (P < 0.05,*) 
was observed between day 0 and 28. The concentration of BSA used here is quite high 
(10%) which may be more severe than the concentration of protein found in-vivo. In the 
case of the PEA test no significant difference (P > 0.05) was observed between day 1 
and 28. The use of BT is the closest mimic achievable to physiological conditions and 
the response of the Blank sensor on exposure to BT is typical when compared to other 
sensor designs (Garguilo & Michael, 1994; Finnerty et al., 2012). 
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Figure 4.18.2 Comparison of AA responses between long-term stability (L-T) and biocompatibility 
tests on day 28. Data represented as a mean response ± SEM.  
Figure 4.18.2 demonstrates the I1000 µM of the Blank sensor recorded on day 28 of the 
long term stability test (L-T) and the various biocompatibility tests. A significant 
difference (P < 0.05, **) was observed between day 0 and 28 of the long-term stability 
test. It is likely that a disruption in the polymerised surface has occurred which has 
created an increased Pt surface area, thereby causing an increase in response to AA. This 
structural issue is negated for in-vivo experiments as all sensors are calibrated 
immediately prior to implantation. A significant difference was also observed between 
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day 0 and 28 with the biocompatibility tests. A large reduction in AA response was 
observed following exposure to BT. The BT biocompatibility test is the closest method 
of mimicking the conditions encountered by the sensor in the in-vivo environment.  
4.19 Cat stability and biocompatibility summary 
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Figure 4.19.1 Comparison of H2O2 responses between long-term stability (L-T) and 
biocompatibility tests on day 28. Data represented as a mean response ± SEM. 
Figure 4.19.1 demonstrates the effect of the long-term stability test (L-T) and the 
various biocompatibility tests (PEA, BSA and BT) on the function of the catalase 
enzyme. The ability of the catalase enzyme to remove H2O2 is impaired. With each 
treatment a significant difference (P < 0.05,*) was demonstrated on day 28 when 
compared to day 0. However no significant variation (P > 0.05) was observed at a lower 
concentration range of H2O2 (0-150 µM) between successive time points when 
compared to the sensitivity recorded on day 0 with each treatment. This stability of the 
Cat sensor was further supported by the fact that removal of repetitive calibrations 
improved the performance of this sensor design (see Section 4.13 and 4.17). The 
stability of the Cat sensor following exposure to BT showed an improvement over the 
other biocompatibility tests.  
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Figure 4.19.2 Comparison of AA responses between long-term stability (L-T) and biocompatibility 
tests on day 28. Data represented as a mean response ± SEM.  
Figure 4.19.2 demonstrates the I1000 µM of the Cat sensor recorded on day 28 of the long 
term stability test (L-T) and the various biocompatibility tests. No significant difference 
(P > 0.05) was observed between day 0 and 28 of the long-term stability test however an 
increase in AA response was observed. A corruption in the polymerised surface has 
occurred which has created an increased Pt surface area, which would increase the 
response to AA. This damage to the sensor does not impact upon in-vivo experiments as 
all sensors are calibrated immediately prior to implantation. A significant difference (P 
< 0.05) was observed between day 0 and 28 with the biocompatibility tests. A large 
reduction in AA response was observed following exposure to BT. The BT 
biocompatibility test is the closest method achievable to mimic physiological conditions.  
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4.20 Post in-vivo stability 
Following implantation of the paired catalase-based biosensor over an extended period, 
the sensors were removed and re-calibrated. The sensitivity towards H2O2 and 
selectivity against AA of the sensors was examined. The calibration procedures are 
outlined in Section 3.7.3 and 3.7.5 respectively. When in contact with biological 
samples a drop in sensitivity often occurs with Pt based sensors due to fouling of the 
active surface by proteins and other biomolecules (Garguilo & Michael, 1994; Finnerty 
et al., 2012). Sensor damage during ex-plantation may also negatively affect the 
characteristics of the working electrode. The purpose of these experiments is to gauge 
the stability of the sensors after contact with endogenous lipids and proteins present in 
the living brain.  
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Figure 4.20.1: (A) The current-concentration profile of H2O2 at the paired sensor following 
implantation (n = 2+2). (B) A typical raw data trace 0-50 µM and (C) 50-550 µM for H2O2 
calibrations. CPA carried out at +700 mV vs. SCE. Arrows indicate the addition of aliquots of H2O2.  
Figure 4.20.1 (A) demonstrates the average H2O2 response of the catalase-based paired 
sensor following implantation. The sensors described here were implanted over a period 
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of 16 to 20 days. These sensors were removed following cessation of in-vivo 
experiments. A drop in sensitivity of approximately 46 % was apparent following 
calibration with H2O2 (0-550 µM). This value is consistent with other reports which 
have demonstrated a 20 to 50 % loss in sensitivity of sensors following exposure to BT    
(Garguilo & Michael, 1994; Hu et al., 1994; Finnerty et al., 2012). The paired post-
implantation sensitivity obtained was 0.248 ± 0.004 nA/µM and is linear with an R2 
value of 0.9969, n = 2+2. This value is significantly different (P < 0.05,*) when 
compared to average pre-implantation sensitivity of the paired H2O2 sensor. The overall 
H2O2 response is based on a subtraction value (Blank-Cat). The 46% overall loss in 
H2O2 sensitivity is attributable to the fact that there is an increased response at the Cat 
sensor. The post-implantation sensitivity of the Cat sensor is 0.252 ± 0.003 nA/µM (n = 
2) and this response is significantly different (P < 0.05,*) when compared against pre-
implantation data of these sensors. A loss in ability of the Cat sensor to remove H2O2 is 
evident. The post-implantation sensitivity of the Blank sensor is 0.50 ± 0.01 nA/µM (n = 
2) and this response is not significantly different (P > 0.05) when compared against the 
response of these sensors prior to implantation.  
On visual inspection under a microscope and further examination using scanning 
electron microscopy (SEM) imaging of the Blank and Cat sensor, it became clear that 
the PPD layer which is part of each sensor design was corrupted. The catalase enzyme is 
adhered to the PPD structure as part of the Cat sensor design and removal of this PPD 
layer would lead to a loss in function of the Cat sensor. The body’s natural response to 
the presence of a foreign object can also inhibit the sensitivity of an implanted sensor 
(Wisniewski et al., 2000). A possible explanation of the damaged PPD structure is that 
following explantation of the sensors the PPD layer is left behind due to encapsulation 
by gliosis which occurs at the sensor-tissue interface (O'Neill & Lowry, 1995).  
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Figure 4.20.2 SEM images of sensors. (A) Ptc electrode [pre-implantation] (x 300), (B) Ptc/PPD 
electrode [pre-implantation] (x 800) and (C) Ptc/Naf/PPD sensor (x 120) [following implantation].  
 
Figure 4.20.2 shows examples of SEM images obtained of (A) an unmodified Ptc 
electrode prior to implantation, (B) a Ptc electrode modified with PPD prior to 
implantation and (C) a Ptc/Naf/PPD electrode following implantation for 10 days. The 
bare Ptc has a smooth surface and the striations on the disc surface caused by cutting the 
electrode can clearly be seen. Following modification with PPD the development of a 
grainy morphological structure can be seen on the surface of the electrode. Corruption of 
the PPD surface following ex-plantation is apparent as shown in Figure 4.20.2 (C) a 
detachment of the outer membrane from the bare Pt surface can be seen.  
The disruption of the PPD layer should lead to an increase in H2O2 sensitivity as a 
greater surface area of bare Pt should be present. The loss in H2O2 sensitivity observed 
here is mainly attributable to an increase in sensitivity at the Cat sensor. On further 
examination of the raw data trace in Figure 4.20.1 (A) and (B) an instantaneous increase 
A B 
C 
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in signal is observed following each injection of H2O2. A decline in response is observed 
following each injection and the magnitude of this decline is greater than that seen with 
in-vitro H2O2 calibration data of the sensors prior to implantation (see Figure 4.7.2). 
It is feasible that proteins and lipids present on the surface of each sensor limit the 
diffusion of H2O2 in the bulk solution to the active surface of each sensor. The process 
of stirring following addition of an aliquot of H2O2, creates forced convection of the 
analyte to the active surface of the sensor. This explains the initial increase observed in 
these post in-vivo experiments and subsequent decline. In an in-vitro H2O2 calibration an 
immediate plateau in signal is observed following injection of H2O2 (see Figure 4.7.2). 
During in-vivo experiments however the PPD structure remains intact which is proven 
by the implanted dual sensor response towards AA as demonstrated in Chapter 5. In 
order to examine the damage incurred during the process of explantation the selectivity 
of the sensors in relation to AA was examined as shown below in Figure 4.20.3.  
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Figure 4.20.3: Raw data trace 0-1000 µM for an AA calibration at the paired H2O2 sensor following 
implantation. CPA carried out at +700 mV vs. SCE. Arrows indicate the addition of aliquots of AA.  
A large AA response was obtained with these sensors following 16 days of implantation 
in the striatum of a male wistar rat (see Figure 4.20.3). This would implicate that the 
PPD structure is disrupted, leading to a larger surface area of Pt and subsequently 
increasing the AA response. The I400 µM and I1000 µM values for the sensors represented in 
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Figure 4.18.3 are 110.89 nA and 189.6 nA respectively, n=1+1. It is clear that the PPD 
layer which is an intricate part of each sensor design i.e. Blank and Cat is damaged 
during explantation. It is not possible to achieve reliable post in-vivo calibration data 
from this sensor design particularly for the duration of implantation prior to removal of 
the sensors examined here (16-20 days). The reported damage to the PPD structure 
during explantation may be caused by gliosis at the sensor-tissue interface. Extensive 
gliosis has been demonstrated in-vivo by O’Neill & Lowry following 7 days of 
implantation of a fixed cannulae (O'Neill & Lowry, 1995). It is plausible in this case that 
the process of gliosis has encapsulated the implanted paired H2O2 sensor and upon 
explantation the PPD layer is removed. 
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4.21 Conclusion 
The primary aim of this chapter was to validate the sensitivity and selectivity of the 
paired catalase-based H2O2 sensor in-vitro as demonstrated previously (O'Brien et al., 
2007). The H2O2 sensitivity of the dual sensor design was established (see Section 4.7) 
and reported as 0.47 ± 0.003 nA/µM, n = 24+24. Table 4.21.1 displays the H2O2 
response of the relevant sensor designs. 
Design H2O2 response R2 n 
Ptc/Nafion®/PPD (Blank) 0.47 ± 0.003 (nA/µM) 0.9997 24 
Ptc/Nafion®/PPD/Cat-Ga (Cat) 5.64 ± 0.06 (pA/µM) 0.9989 24 
Paired sensor response (Blank-Cat) 0.47 ± 0.003 (nA/µM) 0.9996 24+24 
 
Table 4.21.1 H2O2 sensitivity of the Blank sensor, Cat sensor and the final paired sensor design 
(Blank-Cat). 
No significant difference (P > 0.05) was observed between the H2O2 sensitivity of the 
paired design presented here and in comparison to that previously reported by O’Brien 
et al. (O'Brien et al., 2007).  
The required H2O2 sensor must exhibit a low limit of detection (LOD) and a fast 
response time in order to detect H2O2 in-vivo. The low LOD of the paired H2O2 sensor is 
demonstrated in Section 4.7.1 which was 0.075 ± 0.006 µM, n=24. The LOD of the 
paired H2O2 sensor is lower than that demonstrated by Sanford et al. who reported a 
detection limit of ~2 µM for H2O2 using CFEs (Sanford et al., 2010). Kulagina & 
Michael also demonstrated a higher LOD for H2O2 of approximately 0.3 µM using an 
amperometric microsensor (Kulagina & Michael, 2003).  
The response time of the H2O2 sensor is demonstrated in Section 4.7.2 The paired H2O2 
sensor displayed a fast response time of < 1s. This value compares well with previously 
reported in-vitro electrochemical H2O2 detection methods (Li et al., 2010; Sanford et al., 
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2010). These parameters support the feasibility of utilising the dual H2O2 sensor in the 
in-vivo environment.  
The selectivity of the paired sensor against AA, the primary intereferent species in the 
brain in relation to H2O2 detection was validated (see Section 4.8). The response of our 
H2O2 sensor to AA was minimal with an I400 µM of 0.02 ± 0.03 nA and an I1000 µM value 
of -0.07 ± 0.04 nA (n = 28+28).  
Design  I, nA  (1000 µM) 
I, nA  
(400 µM) n 
Ptc/Nafion®/PPD (Blank) 0.15 ± 0.03 0.16 ± 0.02 28 
Ptc/Nafion®/PPD/Cat-Ga (Cat) 0.22 ± 0.03 0.14 ± 0.02 28 
Paired sensor response (Blank-Cat) -0.07 ± 0.04 0.02 ± 0.03 28+28 
 
Table 4.21.2 AA response of the Blank sensor, Cat sensor and the final paired sensor design (Blank-
Cat). 
The paired H2O2 sensor is also highly selective over a range of other potential 
interference species as outlined in Section 4.8. The response to each interference species 
tested was < 0.1 % of the H2O2 sensitivity. The H2O2 sensitivity of the dual sensor is 
also maintained in the presence of AA (500 µM) and Dopamine (500 nM) as can be 
seen in Section 4.8.2 and 4.8.3 respectively, no significant difference (P > 0.05) was 
seen in each case when compared to a normal H2O2 calibration in PBS. The H2O2 
sensitivity of Ptd sensors was retained in aCSF aqueous media conditions in comparison 
to PBS aqueous conditions. Additionally substrate dilution conditions were examined, 
the H2O2 added to the electrochemical cell was diluted in aCSF as opposed to H2O and 
no significant difference (P > 0.05) in Ptd H2O2 sensitivity was observed (see Section 
4.8.4). 
The stability of the Blank and Cat sensor was examined as part of a long-term study 
over 28 days (Section 4.10 and 4.11). It was demonstrated that repeated calibrations in 
the absence of treatment had a negative effect on the sensitivity and selectivity of each 
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sensor type. However, the observed loss in function of each sensor in-vitro is eliminated 
for in-vivo experiments as all sensors are calibrated immediately prior to implantation.    
Biocompatibility characteristics were also examined following treatment with BSA, 
PEA and BT for each sensor (Blank and Cat). Variations in the sensitivity and 
selectivity of the Blank and Cat sensor design were seen in response to treatment with 
BSA and PEA and details of these experiments are provided in Sections 4.12 to 4.15. It 
was determined that the high concentration of protein (BSA) and lipid (PEA) of these 
treatments had a negative effect on the sensitivity and stability of the Cat and Blank 
sensor.  
In order to more accurately reflect conditions encountered in the in-vivo environment, an 
ex-vivo sample of brain tissue (BT) was utilised as a sensor treatment. The stability of 
the Blank and Cat sensor was relatively maintained after exposure to BT with respect to 
BSA and PEA tests (Section 4.16 and 4.17). The use of BT is the closest method 
achievable in-vitro to mimic physiological conditions. 
An examination of sensor characteristics following implantation was discussed in 
Section 4.20. It was determined that post in-vivo sensitivity and selectivity 
characteristics of the dual sensor could not be reliably obtained due to the unavoidable 
structural damage inflicted on the PPD based sensor design during explantation of these 
sensors (Section 4.20).  
The in-vitro characterisation of the paired catalase-based H2O2 sensor was verified and 
the in-vivo characterisation of this sensor design is shown in Chapter 5. 
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5.1 Introduction 
The in-vitro characterisation of the paired hydrogen peroxide (H2O2) catalase-based 
sensor has been demonstrated in the previous Chapter. This chapter outlines the 
characterisation of the dual H2O2 sensor design in the biological environment. The 
paired H2O2 sensor was implanted into the brain of Wistar rats. The effect of local and 
systemic administration of known inducers and inhibitors of H2O2 on the performance of 
the dual H2O2 sensor response is investigated in this chapter. 
A variation between an electrochemical sensor’s characteristics observed in-vitro can 
often be seen in-vivo. Commonly, a discrepancy in the characteristics of the sensor can 
be seen when utilised in the biological milieu (O'Neill, 1993). This observed variation is 
attributable to factors inherent to a complex physiological environment such as the 
brain. Brain tissue consists of lipids and proteins which may affect the properties of the 
sensor in-vivo (Garguilo & Michael, 1994). The reaction of the body to the presence of a 
foreign object can also negatively affect the properties of a sensor (Wisniewski et al., 
2000). Mass transport of the analyte to an electrochemical sensor may also be restricted 
by the brain tissue itself (Cheng et al., 1979; Dayton et al., 1983). 
Additionally, potential interferent species are present in the brain, principally ascorbic 
acid (AA) which can fluctuate under certain circumstances (Miele et al., 1994; Miele & 
Fillenz, 1996). It is therefore necessary to investigate the function of the dual H2O2 
sensor when utilised in the biological environment. Various procedures outlined in this 
chapter were used to establish sensitivity, selectivity and stability of the catalase-based 
H2O2 sensor when implanted in the brain. 
Currently few methods exist to detect H2O2 in the brain, most of these methods rely on 
the use of microdialysis (Lei et al., 1997, 1998) which suffers from poor temporal and 
spatial resolution. Electrochemical methods have an advantageous distinction in that 
they provide long-term real-time measurements of neurochemical species of interest. 
The detection of H2O2 in the anaesthetised animal has been previously reported 
(Kulagina & Michael, 2003), however the sensor described in this publication requires a 
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mediator and an additional method to remove interference from AA; which is not 
required with the dual H2O2 sensor presented in this work.  
H2O2 is a reactive oxygen species (ROS) which has recently been indicated to act as a 
neuromodulator (Rice, 2011) and as a signalling molecule (Stone & Yang, 2006). 
Synaptic dopamine release has been shown to be regulated by H2O2. Avshalumov and 
Bao have investigated the effect of exogenously applied and endogenously altered H2O2 
on the evoked production of dopamine in ex-vivo brain slices
 
(Avshalumov et al., 2003; 
Bao et al., 2009). H2O2 is neutral and membrane permeable and it is also a relatively 
stable ROS which makes it suitable as a diffusible signalling molecule (Rice, 2011).  
H2O2 is implicated in a variety of normal cellular functions and also in the 
pathophysiology of disease states (Andersen, 2004; Rhee, 2006). An over production of 
ROS/H2O2 has been implicated in neurodegenerative diseases such as Parkinson’s and 
Alzheimer’s disease (Valko et al., 2007; Melo et al., 2011). Additionally, many 
biosensors rely on the detection of enzymatically produced H2O2 to measure substrates 
such as glucose (Lowry et al., 1998b), choline (Garguilo & Michael, 1996) and 
glutamate (Hu et al., 1994) in the brain. 
As H2O2 is implicated in a number of neurochemical processes and electrochemical 
analytical techniques the real-time detection of H2O2 in-vivo would provide a major 
advancement in the field of neurochemistry.  
5.2 Experimental 
The instrumentation, chemicals, solutions and software used in this section are described 
in detail in Chapter 3. Details of the manufacture of the working electrodes are outlined 
in Section 3.4. All experiments outlined in this chapter were performed using Constant 
Potential Amperometry (CPA). A potential of +700 mV vs. Ag wire (see Section 3.10.3) 
was applied to the working electrodes for all in-vivo experiments. 
Chronic in-vivo experiments were carried out in freely-moving animals where long-term 
recordings were obtained and this protocol is discussed in Section 3.10. An alternative 
experimental procedure was utilised to obtain acute in-vivo data which is derived from 
Chapter 5: In-vivo H2O2 
 
175 
 
short-term recordings. A similar protocol to the chronic preparation is used to conduct 
an acute experiment. However acute experiments were carried out over a shorter time 
frame while the animal is under anaesthesia and held in the stereotaxic frame. The same 
protocol for implantation of the catalase-based paired H2O2 sensor was followed for 
chronic and acute in-vivo experiments. The catalase-based paired H2O2 sensor was glued 
to a microdialysis probe and the entire construct was implanted into the striatum of a 
male Wistar rat.  
The number of implanted dual catalase-based H2O2 sensors is denoted by (n) i.e. a Blank 
and a Cat sensor in the same number of animals. In the case where the number of 
administrations included in the data exceeds the number of sensors/animals the value is 
given and denoted by (adm).  
The average data is represented as a Mean ± SEM. The maximum current response was 
used to analyse the response to the addition of each perfusate and the administration of 
each physiologically relevant substance. Reported in-vivo H2O2 concentration changes 
are based on the average in-vitro pre-implantation calibration data.  
Statistical analysis was carried out using paired or unpaired t-tests. One-way ANOVA 
was used to simultaneously compare results which contained more than two seperate 
groups. These tests were performed using Graphpad Prism and gave a probability value 
(P) which indicates the level of significant or non-significant difference between groups. 
P > 0.05, denotes no significant difference. The extent of significant difference is 
divided into three parameters (P < 0.05,*), (P < 0.01,**) and (P < 0.0001,***) from the 
lowest relative level of difference (*) to the highest (***). 
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5.3 Local and systemic control experiments (freely-moving) 
The data displayed in this section was obtained from freely-moving male Wistar rats. 
This section outlines the control experiments conducted in freely-moving animals. The 
effect of the local perfusion of artificial cerebrospinal fluid (aCSF) and the systemic 
administration of saline on the H2O2 sensor response is described here. The effect of the 
local administration of H2O2 and the addition of substances of interest to the perfusate 
on the paired H2O2 sensor response may be compared against the local addition of aCSF 
(Section 5.3.1). The effect of systemic administration of various physiologically relevant 
substances on the paired H2O2 sensor response may be compared against that observed 
upon systemic administration of saline (Section 5.3.2).  
5.3.1 Local aCSF Administration 
As a control experiment aCSF was perfused through the microdialysis (MD) probe. A 
typical example of the outcome of this perfusion on the paired catalase-based H2O2 
sensor response is shown below in Figure 5.3.1. 
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Figure 5.3.1 A typical example of an aCSF perfusion detected by the paired H2O2 sensor implanted 
in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the perfusion. 
An immediate decrease in H2O2 signal is apparent upon commencement of the aCSF 
perfusion. A decrease of -361.6 ± 161.7 pA (n = 3) was observed which corresponds to a 
concentration change of -775.2 ± 346.6 nM H2O2 (n = 3). The aCSF perfusion decreased 
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the H2O2 sensor response to 58.5 ± 6.2 % (n = 3) of basal levels following 13.3 ± 0.2 
mins (n = 3) from the start of each perfusion. A return to a baseline level is apparent 
after 70.2 ± 5.5 mins (n = 3). No significant difference (P > 0.05) was observed between 
the pre-perfusion baseline 823.3 ± 297.3 pA (n = 3) and the post-perfusion baseline 
790.7 ± 283.2 pA (n = 3). The decrease observed here is due to diffusion of H2O2 
through the microdialysis membrane and into the dialysate thus reducing the 
concentration of H2O2 surrounding the sensor. On cessation of the perfusion H2O2 
diffuses back in the extracellular fluid (ECF) towards the implanted sensor and hence an 
increase in H2O2 signal is observed. The response recorded here was used as a control 
against which various perfusions which were carried out in freely-moving animals were 
compared in this chapter. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
aCSF 
-361.6 ± 
161.7 
58.5 ± 
6.2 
-775.2 ± 
346.6 
13.3 ± 
0.2 
70.2 ± 
5.5 
823.3 ± 
297.3 
790.7 ± 
283.2 
 
Table 5.3.1: Summary of results obtained on perfusion of aCSF. Data obtained from 3 paired H2O2 
sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.3.1.1 A typical example of an aCSF perfusion detected by (A) Blank sensor and (B) Cat 
sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the perfusion. 
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An immediate decrease in response by the Blank (A) and Cat (B) sensor is apparent 
upon perfusion of aCSF as can be seen in Figure 5.3.1.1 A decrease in current was 
observed at the Blank sensor of -467.4 ± 163.1 pA (n = 3) and a decrease was also 
observed at the Cat sensor of -105.3 ± 18.1 pA (n = 3).The aCSF perfusion causes a 
decrease in current response detected by the Blank sensor to 66.7 ± 3.8 % (n = 3) of 
basal levels following 13.3 ± 0.2 mins (n = 3) from the start of each perfusion. Similarly 
a decrease in response was detected by the Cat sensor (84.6 ± 2.8 %, n = 3). A return to 
a baseline level is apparent subsequently which was complete on both sensor types after 
70.2 ± 5.5 mins (n = 3). No significant difference (P > 0.05) was observed between the 
pre-perfusion baseline and the post-perfusion baseline of the Cat and Blank sensor. 
Additionally, no significant difference (P > 0.05) was seen between the maximum 
current response of the Cat and Blank sensor. 
aCSF 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -467.4 ± 
163.1 66.7 ± 3.8 13.3 ± 0.2 70.2 ± 5.5 
1341.3 ± 
323.5 
1272.4 ± 
317.3 
Cat -105.3 ± 
18.1 84.6 ± 2.8 - - 
518 ±  
35.7 
481.5 ± 
37.9 
 
Table 5.3.1.1: Summary of results obtained on perfusion of aCSF. Data obtained from 3 paired 
H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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5.3.2 Systemic (s.c.) Saline Administration 
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Figure 5.3.2 A typical example of a 2 mL/kg s.c. injection of saline detected by the paired H2O2 
sensor implanted in the striatum of a freely-moving Wistar rat. The arrow indicates the point of 
administration. Inset: Initial 60 sec of response. 
As a control experiment saline (Section 3.3.3.2) was administered subcutaneously (s.c.) 
(Section 3.11.2) and the effect on the H2O2 signal was measured. Immediately following 
the injection a brief fluctuation in H2O2 response is observed which is due to the 
physical manipulation of the subject. A small increase was observed (155.3 ± 123.9 pA, 
n = 3) following 7.9 ± 0.9 mins (n = 3) and a return to a steady baseline was recorded 
after 12.7 ± 0.4 mins (n = 3). The purpose of the experiments shown in this section is to 
demonstrate the response observed which is attributed to the injection itself. The 
administration of various substances in this manner (s.c.) may be compared against the 
saline response. It is clear that a transient fluctuation in H2O2 signal is observed 
following injection of saline and quickly returns to a baseline level. The immediate brief 
response due to the injection is demonstrated by the inset graph in Figure 5.3.2. No 
significant difference (P > 0.05) was observable between the pre and post-injection 
baseline levels No lasting effect on the H2O2 response can be seen following saline 
administration.  
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Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
Saline 
155.3 ± 
123.9 
1.0 ±  
4.4 
69.3 ± 
55.3 
7.9 ±  
0.9 
12.7 ± 
0.4 
842.6 ± 
749.9 
1390.2 ± 
699.9 
 
Table 5.3.2: Summary of results obtained on injection of saline. Data obtained from 3 paired H2O2 
sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.3.2.1 A typical example of a 2 ml/kg s.c. injection of saline detected by (A) Blank sensor 
and (B) Cat sensor; implanted in the striatum of a Wistar rat. The arrow indicates the point of 
administration. 
A brief fluctuation in response by the Blank (A) and Cat (B) sensor is apparent 
immediately following the injection of saline as can be seen in Figure 5.3.2. A small 
increase in current was observed at the Blank sensor of 79.4 ± 68.1 pA (n = 3) and a 
similar change was observed at the Cat sensor of 10.1 ± 21.7 pA (n = 3). No significant 
difference (P > 0.05) was observed between the pre-injection baseline and the post-
injection baseline of the Cat and Blank sensor. Additionally, no significant difference (P 
> 0.05) was seen between the maximum current response of the Cat and Blank sensor. 
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Saline 
Current 
change 
(pA) 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
Blank 79.4 ± 
68.1 3.0 ± 2.2 7.9 ± 0.9 12.7 ± 0.4 
2176.6 ± 
595.2 
2240.6 ± 
636.6 
Cat 10.1 ± 
21.7 2.2 ± 3.0 - - 
818.2 ± 
137.7 
850.4 ± 
130.7 
 
Table 5.3.2.1: Summary of results obtained on injection of saline. Data obtained from 3 paired H2O2 
sensors implanted in the striatum of 3 Wistar rats. 
 
5.4 Local H2O2 Administration (freely-moving) 
This section demonstrates the response of the paired H2O2 sensor to the local perfusion 
of various concentrations of H2O2 in freely-moving animals. The experimental condition 
utilised here is otherwise termed as a chronic preparation. The animal is allowed to 
recover from anaesthetic (Section 3.10) prior to commencement of experiments in order 
to enable long-term recording of the analyte of interest. Various concentrations of H2O2 
were added to the perfusate in order to examine the response of the H2O2 sensor in the 
in-vivo environment (Section 3.3.2.2). The vehicle used for perfusion of each 
concentration of substrate was aCSF. The response of the dual sensor to each dilution of 
H2O2 was compared against aCSF as shown in Figure 5.3.1. The method utilised to 
deliver the target substrate to the implanted paired H2O2 sensor is termed retrodialysis 
(RD) as discussed in Section 2.9.  
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5.4.1 25 µM H2O2 
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Figure 5.4.1: A typical example of a 25 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
An immediate decrease was observed on perfusion of 25 µM H2O2 (Figure 5.3.1). A 
decrease of -311.6 ± 172.6 pA (n = 2) was recorded which corresponds to a 
concentration change of -668.0 ± 370.0 nM H2O2 (n = 2). The presence of 25 µM H2O2 
in the perfusate caused a reduction in the paired sensor response to 66.2 ± 5.0 % (n = 2) 
of baseline levels which was observed after 13.4 ± 0.7 mins (n = 2). A subsequent return 
to a baseline level was observed which occured 66.1 ± 3.1 mins (n = 2) following the 
start of the perfusion. The percentage change recorded here is quite similar to that 
observed on perfusion with aCSF (Figure 5.3.1) and was not significantly different P > 
0.05. No significant difference (P > 0.05) was observed between the baseline current 
pre-perfusion 866 ± 382.2 pA (n = 2) and the new post-perfusion basal level 816.7 ± 
339.2 pA (n = 2). 
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
25 µM 
H2O2 
-311.6 ± 
172.6 
66.2 ± 
5.0 
-668.0 ± 
370.0 
13.4 ± 
0.7 
66.1 ± 
3.1 
866 ± 
382.2 
816.7 ± 
339.2 
 
Table 5.4.1: Summary of results obtained on perfusion of 25 µM H2O2. Data obtained from 2 paired 
H2O2 sensors implanted in the striatum of 2 Wistar rats. 
0 10 20 30 40 50 60 70 80
20
40
60
80
100
120
Time, min
%
, 
H
2O
2
0 10 20 30 40 50 60 70 80
20
40
60
80
100
120
140
Time, min
%
, 
H
2O
2
A B
 
Figure 5.4.1.1: A typical example of a 25 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the 
perfusion. 
An immediate decrease in response by the Blank (A) and Cat (B) sensor can be seen  
following perfusion of 25 µM H2O2 (Figure 5.4.1.1). A decrease in current was observed 
at the Blank sensor of -414.0 ± 158.7 pA (n = 2) and a similar decrease was observed at 
the Cat sensor of -102.4 ± 13.9 pA (n = 2). No significant difference (P > 0.05) was 
observed between the pre-perfusion baseline and the post-perfusion baseline of the Cat 
and Blank sensor. Additionally, no significant difference (P > 0.05) was seen between 
the maximum current response of the Cat and Blank sensor. 
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25 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -414.0 ± 
158.7 71.7 ± 3.9 13.4 ± 0.7 66.1 ± 3.1 
1412.8 ± 
364.9 
1332.2 ± 
352.4 
Cat -102.4 ± 
13.9 81.3 ± 1.9 - - 
546.9 ± 
17.4 
515.6 ± 
13.0 
 
Table 5.3.1.1: Summary of results obtained on perfusion of 25 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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Figure 5.4.2: A typical example of a 100 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
A decrease was observed following the perfusion of 100 µM H2O2 to 71.8 ± 5.3 % (n = 
2) of basal levels as can be seen in Figure 5.4.2. A recorded decrease of -243.0 ± 146.8 
pA (n = 2) which corresponds to a concentration change of -520.8 ± 314.6 nM H2O2 (n 
= 2) was observed. The magnitude of this decrease is not as pronounced as that seen 
with perfusion of aCSF however no significant difference was observed (P > 0.05). The 
maximum change observed here occurred 10.9 ± 1.1 mins (n = 2) following the start of 
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the perfusion and returned to a baseline level 45.5 ± 3.0 mins (n = 2) subsequently. No 
significant difference (P > 0.05) was observed between pre-perfusion and post-perfusion 
baseline levels. A summary of this data is provided in Table 5.4.2. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
100 µM 
H2O2 
-243.0 ± 
146.8 
71.8 ± 
5.3 
-520.8 ± 
314.6 
10.9 ± 
1.1 
45.5 ± 
3.0 
791.5 ± 
372.4 
756.7 ± 
281.6 
 
Table 5.4.2: Summary of results obtained on perfusion of 100 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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Figure 5.4.2.1: A typical example of a 100 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the 
perfusion. 
Figure 5.4.2.1 demonstrates the response of the Blank (A) and Cat (B) sensor following 
perfusion of 100 µM H2O2. A clear decrease in current was observed at the Blank sensor 
of -414.0 ± 158.7 pA (n = 2) and similarly a decrease was observed at the Cat sensor of 
-102.4 ± 13.9 pA (n = 2). No significant difference (P > 0.05) was observed between the 
pre-perfusion baseline and the post-perfusion baseline of the Cat and Blank sensor. 
Additionally, no significant difference (P > 0.05) was observed between the maximum 
current response of the Cat and Blank sensor. 
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100 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -330.5 ± 
120.8 75.0 ± 2.2 10.9 ± 1.1 45.5 ± 3.0 
1291.8 ± 
371.1 
756.7 ± 
281.6 
Cat -88.3 ± 
26.6 82.4 ± 5.3 - - 
500.2 ± 
1.0 
503.5 ± 
47.7 
 
Table 5.4.2.1: Summary of results obtained on perfusion of 100 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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Figure 5.4.3: A typical example of a 200 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
As can be seen in Figure 5.4.3 a relatively small decrease in the paired sensor response 
was observed following perfusion of 200 µM H2O2 to 86.9 ± 8.2 % (n = 3, 4adm). The 
percentage change observed here is significantly less (P < 0.05,*) than the change 
observed in the control experiment with the perfusion of aCSF (Figure 5.3.1). A 
decrease of -179.7 ± 91.5 pA (n = 3, 4adm) was observed which corresponds to a 
concentration change of -385.1 ± 196.1 nM H2O2 (n = 3, 4adm). The maximum change 
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recorded in this instance was seen 11.8 ± 0.7 mins (n = 3, 4adm) from the start of the 
perfusion and returned 59.1 ± 4.2 mins (n = 3, 4adm) after the initiation of the perfusion. 
No significant difference (P > 0.05) was observed between pre-perfusion (1589.3 ± 
428.2 pA, n = 3, 4adm) and post-perfusion H2O2 levels (1389.7 ± 302.4 pA, n = 3, 
4adm).  
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
200 µM 
H2O2 
-179.7 ± 
91.5 
86.9 ± 
8.2 
-385.1 ± 
196.1 
11.8 ± 
0.7 
59.1 ± 
4.2 
1589.3 ± 
428.2 
1389.7 ± 
302.4 
 
Table 5.4.3: Summary of results obtained on perfusion of 200 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. The average data includes 4 
administrations. 
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Figure 5.4.3.1: A typical example of a 200 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the 
perfusion. 
Figure 5.4.3.1 demonstrates the response of the Blank (A) and Cat (B) sensor following 
the addition of a higer concentration of H2O2 to the perfusate (200 µM). A clear decrease 
in current was observed at the Blank sensor of -237.5 ± 94.1 pA (n = 3, 4ad) and a 
decrease was also observed at the Cat sensor (-57.9 ± 28.0 pA, n = 3, 4ad). No 
significant difference (P > 0.05) was observed between the pre-perfusion baseline and 
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the post-perfusion baseline of the Cat and Blank sensor. Additionally, no significant 
difference (P > 0.05) was observed between the maximum current response of the Cat 
and Blank sensor. 
200 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -237.5 ± 
94.1 87.3 ± 6.2 11.8 ± 0.7 59.1 ± 4.2 
2045.0 ± 
381.0 
1853.3 ± 
261.0 
Cat -57.9 ± 
28.0 89.2 ± 3.7 - - 
455.7 ± 
77.9 
463.6 ± 
75.0 
 
Table 5.4.3.1: Summary of results obtained on perfusion of 200 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. The average data includes 4 
administrations. 
5.4.4 500 µM H2O2 
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Figure 5.4.4: A typical example of a 500 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
As can be seen in Figure 5.4.4 a minor decrease in the paired catalase-based sensor 
response was observed on perfusion of 500 µM H2O2 to 91.8 ± 2.6 % (n = 2, 3ad). A 
current decrease of -127.8 ± 35.0 pA (n = 2, 3ad) was recorded and this value 
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corresponds to a concentration change of -274.0 ± 75.0 nM H2O2 (n = 2, 3ad). The 
maximum change in signal was observed 12.2 ± 0.7 mins (n = 2, 3ad) following 
commencement of the perfusion and returned to a steady baseline 70.5 ± 2.7 mins (n = 
2, 3ad) after the perfusion. The change in H2O2 signal observed here was significantly 
different (P < 0.01,**) from that observed on perfusion of aCSF. No significant 
difference (P > 0.05) was observed between pre-perfusion (1834.9 ± 765.3 pA, n = 2, 
3ad) and post-perfusion H2O2 levels (1748.3 ± 697.1 pA, n = 2, 3ad). 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change 
(nM)  
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
500 µM 
H2O2 
-127.8 ± 
35.0 
91.8 ± 
2.6 
-274.0 ± 
75.0 
12.2 ± 
0.7 
70.5 ± 
2.7 
1834.9 ± 
765.3 
1748.3 ± 
697.1 
 
Table 5.4.4: Summary of results obtained on perfusion of 500 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. The average data includes 3 
administrations. 
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Figure 5.4.4.1: A typical example of a 500 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the 
perfusion. 
The response of the Blank (A) and Cat (B) sensor following perfusion of 500 µM H2O2 
is demonstrated in Figure 5.4.4.1. A relatively small decrease in current was recorded by 
the Blank sensor of -166.7 ± 36.3 pA (n = 2, 3ad) and a minor deviation from baseline 
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level was recorded by the Cat sensor (-39.1 ± 71.5 pA, n = 2, 3ad). No significant 
difference (P > 0.05) was observed between the pre-perfusion baseline and the post-
perfusion baseline of the Cat and Blank sensor. Additionally, no significant difference 
(P > 0.05) was observed between the maximum current response of the Cat and Blank 
sensor. 
500 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -166.7 ± 
36.3 91.2 ± 2.9 12.2 ± 0.7 70.5 ± 2.7 
2322.8 ± 
653.8 
2261.3 ± 
641.0 
Cat -39.1 ± 
71.5 
102.6 ± 
16.9 - - 
488.0 ± 
179.3 
513.1 ± 
125.3 
 
Table 5.4.4.1: Summary of results obtained on perfusion 500 µM H2O2. Data obtained from 2 paired 
H2O2 sensors implanted in the striatum of 2 Wistar rats. The average data includes 3 
administrations. 
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Figure 5.4.5: A typical example of a 1000 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
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As seen in Figure 5.4.4 a slight change in the paired sensor response was observed on 
perfusion of 1000 µM H2O2 (Figure 5.4.5) which on further inspection was found to be 
not significantly different (P > 0.05) from pre-perfusion baseline levels. A decrease of 
17.6 ± 88.3 pA (n = 2) was recorded which corresponds to a concentration change of 
37.7 ± 189.3 nM H2O2 (n = 2). The magnitude of this decrease was 98.3 ± 5.3 % (n = 2) 
of baseline levels. The change in H2O2 signal observed here was significantly different 
(P < 0.01,**) from that observed on perfusion of aCSF. No significant difference (P > 
0.05) was observed between the pre-perfusion (929.7 ± 73.85 pA, n = 2) and post-
perfusion baseline levels (919.3 ± 46.0 pA, n = 2).  
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
1000 µM 
H2O2 
17.6 ± 
88.3 
98.3 ± 
5.3 
37.7 ± 
189.3 
11.8 ± 
0.1 
53.0 ± 
11.9 
929.7 ± 
73.9 
919.3 ± 
46.0 
 
Table 5.4.5: Summary of results obtained on perfusion of 1000 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats.  
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Figure 5.4.5.1: A typical example of a 1000 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a Wistar rat. The arrows indicate the duration of the 
perfusion. 
Figure 5.4.3.1 demonstrates the response of the Blank (A) and Cat (B) sensor following 
the addition of a higer concentration of H2O2 to the perfusate (1000 µM). A small 
deviation in response was recorded by the Blank sensor of -31.5 ± 60.7 pA (n = 2) and a 
minor deviation from baseline was recorded by the Cat sensor -49.1 ± 27.6 pA, n = 2). 
No significant difference (P > 0.05) was observed between the pre-perfusion baseline 
and the post-perfusion baseline of the Cat and Blank sensor. Additionally, no significant 
difference (P > 0.05) was observed between the maximum current response of the Cat 
and Blank sensor. 
1000 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -31.5 ± 
60.7 97.2 ± 3.6 11.8 ± 0.1 
53.0 ± 
11.9 
2586.4 ± 
1128.8 
2541.1 ± 
1179.8 
Cat -49.1 ± 
27.6 92.6 ± 2.7 - - 
605.7 ± 
151.6 
549.8 ± 
153.8 
 
Table 5.4.5.1: Summary of results obtained on perfusion of 1000 µM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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5.5 Local H2O2 administration summary (freely-moving) 
This section provides a summary of the data presented in Section 5.4. The maximum 
change recorded due to the local administration of H2O2 by the paired H2O2 sensor 
(Blank-Cat), the Blank sensor and the Cat sensor is compared against the corresponding 
aCSF response.  
5.5.1 Paired H2O2 sensor summary (freely-moving) 
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Figure 5.5.1: Paired H2O2 sensor response following perfusions as discussed in Section 5.4. Data 
shown as an average percentage change, with 100 % as the pre-perfusion H2O2 baseline signal.  
The effect of the local administration of H2O2 on the maximum response of the paired 
H2O2 sensor (Blank-Cat) is demonstrated in Figure 5.5.1. It is clear from the data 
illustrated above in Figure 5.5.1 and that shown in Table 5.5.1 that the local 
administration of H2O2 does not cause an obvious increase in the paired catalase-based 
H2O2 sensor response. The effect of the local administration of aCSF can be used as a 
control against which the perfusion of each concentration of H2O2 can be measured. No 
significant difference (P > 0.05) was observed following administration of 25 µM and 
100 µM H2O2 when compared to the addition aCSF to the perfusate. A significant 
difference (P < 0.01,**) was observed following perfusion of 200, 500 and 1000 µM 
H2O2 when compared to the response seen with aCSF (Section 5.3.1).  
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When compared to the perfusion of aCSF the addition of H2O2 to the perfusate reduces 
the deviation below basal levels in a concentration dependent manner. As the 
concentration of H2O2 in the perfusate increases with each experiment the H2O2 signal 
remains appreciably closer to baseline levels in each case. The H2O2 sensor is 
responding to a change in exogenously applied H2O2. A definitive trend is observed here 
and the lack of an increase by the H2O2 sensor may be due to the effect of an inherent 
mechanism of the in-vivo environment.  
A network of antioxidant mechanisms regulate the level of H2O2/ROS in the brain 
which consist of the peroxidase enzymes, primarily catalase and glutathione peroxidase 
(Rice, 2011). Homeostasis of the level of ROS and peroxidase activity must be 
maintained to prevent oxidative damage (Simonian & Coyle, 1996; Valko et al., 2007). 
It is possible that the effect of the local addition of H2O2 on the catalase-based H2O2 
sensor is dampened by this network of control mechanisms. The ECF concentration of 
H2O2 has been estimated to be between 25-50 µM (Hyslop et al., 1995). However it is 
possible that the local addition of H2O2 of concentrations higher than that estimated to 
be present in the ECF can be controlled by the antioxidant network. The data presented 
here would indicate that the robust antioxidant network can tolerate the presence of a 
high concentration of H2O2.  
A one-way ANOVA analysis of variance revealed no significant difference (P > 0.05) in 
the maximum response time of each perfusion and similarly in the subsequent time 
required to return to baseline levels following each perfusion with (P > 0.05). No 
significant difference (P > 0.05) was observed for the pre-perfusion and post-perfusion 
baseline level for each change in concentration of H2O2 added to the perfusate which 
was determined by a one-way ANOVA analysis of variance.  
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-361.6 ± 
161.7 
58.5 ± 
6.2 
-775.2 
± 346.6 
13.3 ± 
0.2 
70.2 ± 
5.5 
823.3 ± 
297.3 
790.7 ± 
283.2 3 n/a 
25 µM 
H2O2 
-311.6 ± 
172.6 
66.2 ± 
5.0  
-668.0 
± 370.0 
13.4 ± 
0.7 
66.1 ± 
3.1 
866 ± 
382.2 
816.7 ± 
339.2 2 0.4436 
100 µM 
H2O2 
-243.0 ± 
146.8 
71.8 ± 
5.3 
-520.8 
± 314.6 
10.9 ± 
1.1 
45.5 ± 
3.0 
791.5 ± 
372.4 
756.7 ± 
281.6 2 0.2311 
200 µM 
H2O2 
-179.7 ± 
91.5 
86.9 ± 
8.2 
-385.1 
± 196.1 
11.8 ± 
0.7 
59.1 ± 
4.2 
1589.3 ± 
428.2 
1389.7 ± 
302.4 4 0.0494 
500 µM 
H2O2 
-127.8 ± 
35.0 
91.8 ± 
2.6 
-274.0 
± 75.0 
12.2 ± 
0.7 
70.5 ± 
2.7 
1834.9 ± 
765.3 
1748.3 ± 
697.1 2 0.0075 
1000 µM 
H2O2 
17.6 ± 
88.3 
98.3 ± 
5.3 
37.7 ± 
189.3 
11.8 ± 
0.1 
53.0 ± 
11.9 
929.7 ± 
73.9 
919.3 ± 
46.0 2 0.0015 
 
Table 5.5.1: Summary of paired H2O2 sensor results obtained following perfusions in freely-moving 
animals as discussed in Section 5.4. 
5.5.2 Blank sensor summary (freely-moving) 
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Figure 5.5.2: Blank sensor response following perfusions as discussed in Section 5.4. Data shown as 
an average percentage change, with 100 % as the pre-perfusion baseline signal.  
The effect of the local administration of H2O2 on the maximum response of the Blank 
sensor is demonstrated in Figure 5.5.2. It is apparent that the addition of H2O2 to the 
perfusate does not induce a clear increase in the Blank sensor response above basal 
levels as denoted by the dashed line in Figure 5.5.2. The effect of the local 
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administration of aCSF may be compared against the perfusion of each concentration of 
H2O2. No significant difference (P > 0.05) in response was observed following 
administration of 25 µM, 100 µM and 200 µM H2O2 when compared to the addition of 
aCSF to the perfusate. A significant difference (P < 0.05) was observed following 
perfusion of 500 and 1000 µM H2O2 when compared to the response seen with aCSF 
(Section 5.3.1).  
No significant difference (P > 0.05) was observed between the maximum response of 
the Blank sensor, following the local administration of aCSF and the various 
concentrations of H2O2 when compared to the paired H2O2 sensor response (Section 
5.5.1). This finding means that the contribution to the overall signal by the Cat sensor is 
negligible due to the efficency of H2O2 removal by the catalase-modified electrode 
which is demonstrated in the next Section (5.5.3).  
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-467.4 ± 
163.1 66.7 ± 3.8 13.3 ± 0.2 
70.2 ± 
5.5 
1341.3 ± 
323.5 
1272.4 ± 
317.3 3 n/a 
25 µM 
H2O2 
-414.0 ± 
158.7 71.7 ± 3.9 13.4 ± 0.7 
66.1 ± 
3.1 
1412.8 ± 
364.9 
1332.2 ± 
352.4 2 0.4414 
100 µM 
H2O2 
-330.5 ± 
120.8 75.0 ± 2.2 10.9 ± 1.1 
45.5 ± 
3.0 
1291.8 ± 
371.1 
756.7 ± 
281.6 2 0.2013 
200 µM 
H2O2 
-237.5 ± 
94.1 87.3 ± 6.2 11.8 ± 0.7 
59.1 ± 
4.2 
2045.0 ± 
381.0 
1853.3 ± 
261.0 4 0.0503 
500 µM 
H2O2 
-166.7 ± 
36.3 91.2 ± 2.9 12.2 ± 0.7 
70.5 ± 
2.7 
2322.8 ± 
653.8 
2261.3 ± 
641.0 2 0.0067 
1000 µM 
H2O2 
-31.5 ± 
60.7 97.2 ± 3.6 11.8 ± 0.1 
53.0 ± 
11.9 
2586.4 ± 
1128.8 
2541.1 ± 
1179.8 2 0.0117 
 
Table 5.5.2: Summary of Blank sensor results obtained following perfusions in freely-moving 
animals as discussed in Section 5.4. 
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5.5.3 Cat sensor summary (freely-moving) 
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5.5.3: Cat sensor response following perfusions as discussed in Section 5.4. Data shown as an 
average percentage change, with 100 % as the pre-perfusion baseline signal.  
The effect of the local administration of H2O2 on the maximum response of the Cat 
sensor is demonstrated in Figure 5.5.3. A consistent pattern is evident following the 
addition of H2O2 to the perfusate. No significant difference (P > 0.05) in response was 
observed following administration of each concentration of H2O2 (25-1000 µM) when 
compared to the addition of aCSF to the perfusate. The Cat sensor effectively eliminates 
a contribution to the overall response by removing the signal attributable to H2O2. As 
can be seen in Figure 5.5.2 the Cat sensor response remains below baseline levels 
(dashed line) following each perfusion. A clear increase in the Cat sensor response 
above baseline levels would indicate a disruption in the function of the catalase-based 
sensor.  
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-105.3 ± 
18.1 84.6 ± 2.8 13.3 ± 0.2 
70.2 ± 
5.5 
518 ±  
35.7 
481.5 ± 
37.9 3 n/a 
25 µM 
H2O2 
-102.4 ± 
13.9 81.3 ± 1.9 13.4 ± 0.7 
66.1 ± 
3.1 
546.9 ± 
17.4 
515.6 ± 
13.0 2 0.4524 
100 µM 
H2O2 
-88.3 ± 
26.6 82.4 ± 5.3 10.9 ± 1.1 
45.5 ± 
3.0 
500.2 ± 
1.0 
503.5 ± 
47.7 2 0.6954 
200 µM 
H2O2 
-57.9 ± 
28.0 89.2 ± 3.7 11.8 ± 0.7 
59.1 ± 
4.2 
455.7 ± 
77.9 
463.6 ± 
75.0 4 0.4015 
500 µM 
H2O2 
-39.1 ± 
71.5 
102.6 ±   
16.9 12.2 ± 0.7 
70.5 ± 
2.7 
488.0 ± 
179.3 
513.1 ± 
125.3 2 0.3529 
1000 µM 
H2O2 
-49.1 ± 
27.6 92.6 ± 2.7 11.8 ± 0.1 
53.0 ± 
11.9 
605.7 ± 
151.6 
549.8 ± 
153.8 2 0.1474 
 
Table 5.5.3: Summary of Cat sensor results obtained following perfusions in freely-moving animals 
as discussed in Section 5.4. 
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0 5 10 15 20 25 30 35
70
80
90
100
110
120
130
Time, min
%
, 
H
2O
2
 
Figure 5.6.1: A typical example of a 10 mM SA perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
Catalase is one of the primary peroxidase enzymes present in the brain (Cohen, 1994; 
Dringen et al., 2005), the function of this enzyme is to convert potentially harmful H2O2 
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into water and oxygen. Sodium azide (SA) inhibits the function of catalase in the brain 
(Zimatkin et al., 2006). As catalase is an enzyme which degrades H2O2; impairment in 
the activity of catalase in the brain should lead to an increase in H2O2 levels. A current 
increase of 219.8 ± 108.7 pA (n = 1, 2ad) was recorded which corresponds to a 
concentration change of 471.1 ± 232.9 nM H2O2 (n = 1, 2ad). An elevated H2O2 
response
 
was observed following perfusion of SA of 118.4 ± 0.8 % (n = 1, 2ad). This 
value was significantly different (P < 0.01,**) from perfusion of aCSF. No significant 
difference (P > 0.05) was observed between the pre-perfusion (1170.8 ± 541.5 pA, n = 
1, 2ad) and post-perfusion baseline levels (1182.3 ± 547.5 pA, n = 1, 2ad) in this case. 
The maximum change in signal was observed 1.3 ± 0.2 mins (n = 1, 2ad) following 
perfusion of this concentration of SA
 
(10 mM) and returned to a steady baseline 25.5 ± 
1.7 mins (n = 1, 2ad) post perfusion. Additionally no significant difference (P > 0.05) 
was observed between the baseline and maximum current response of the catalase-based 
sensor (Cat) following perfusion of SA. Therefore the local administration of SA does 
not increase the Cat sensor response.  
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
SA 219.8 ± 
108.7 
118.4 ± 
0.8 
471.1 ± 
232.9 
1.3 ±  
0.2 
25.5 ± 
1.7 
1170.8 ± 
541.5 
1182.3 ± 
547.5 
 
Table 5.6.1: Summary of results obtained on perfusion of sodium azide (10 mM). Data obtained 
from 1 paired H2O2 sensor implanted in the striatum of 1 Wistar rat. The average data includes 2 
administrations. 
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5.6.1 Systemic SA administration 
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Figure 5.6.1: A 20mg/kg s.c. injection of SA detected by the paired H2O2 sensor implanted in the 
striatum of a freely-moving Wistar rat. The arrow indicates the point of administration. Inset: 
Initial 30 min of response.  
As previously stated sodium azide (SA) inhibits the function of catalase in the brain 
(Zimatkin et al., 2006; Jamal et al., 2007). A disruption in the function of the catalase 
enzyme should lead to an elevation in the level of H2O2. An increase in H2O2 signal was 
observed following injection of sodium azide (SA) the maximum current increase 
recorded was 0.3 nA which corresponds to a change of 5.7% which occurred after 49 
mins following the injection and returned to a steady baseline after 193 mins. The data 
represented in Figure 5.6.1 is preliminary, however, it does suggest that an increased 
production in H2O2 occurs following the systemic introduction of SA. Following on 
from this work the effect of this systemic administration on the local administration of 
H2O2 was investigated (Section 5.6.2). 
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5.6.2 The effect of systemic SA administration on the local administration of H2O2 
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Figure 5.6.2: A typical example of a 1 mM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat following pre-administration with sodium 
azide (SA). The arrows indicate the duration of the perfusion. 
This section investigates the effect of systemic pre-administration of SA (20 mg/kg) on 
the local administration of H2O2. SA was injected approximately 30 mins prior to 
perfusion of H2O2. The addition of 500 µM and 1 mM H2O2 to the perfusate following 
pre-administration with SA was examined. As previously stated (Section 5.6.1) SA 
inhibits the function of catalase and inhibition of this peroxidase enzyme should increase 
H2O2 levels. The local perfusion of 500 µM H2O2 following pre-administration of SA 
was investigated which resulted in a reduction in H2O2 levels to 94.6 ± 2.3 %, n = 2 of 
baseline. The control value for local administration of 500 µM (Section 5.4.4) resulted 
in a minor decrease to 91.8 ± 2.6 % (n = 2, 3ad) of basal H2O2 levels. The effect of pre-
treatment with SA on the perfusion of 500 µM H2O2 was not significant (P > 0.05), 
however the magnitude of the maximum decrease recorded was reduced. In order to 
further investigate the effect of pre-administration with SA further a higher 
concentration of H2O2 was added to perfusate (1 mM) following pre-treatment with SA.  
The recorded change following perfusion of 1mM H2O2 following pre-treatment (SA) is 
shown in Figure 5.6.2. A clear increase above basal levels of H2O2 (100 %) can be seen 
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which is markedly different to that seen with the control experiment (Section 5.4.5). An 
increase of 0.2 nA (109.3%) was observed due to this perfusion (1 mM H2O2). This 
preliminary experiment suggests pre-administration with SA appears to have a negative 
effect on the robust peroxidase enzyme catalase.  
Other mechanisms exist to maintain redox homeostasis in the brain such as the 
peroxidase enzyme glutathione peroxidase (GPx) (Dringen et al., 2005). Previous work 
has demonstrated that catalase and GPx play a dual role in the prevention of H2O2 
mediated toxicity in brain preperations (Avshalumov et al., 2004; Baud et al., 2004). It 
is likey that although the function of catalase can be challenged by the inhibitor SA, the 
overall mechanisms which prevent oxidative stress indued by ROS/H2O2  may not be 
completely compromised. The next Section (5.7) investigates the effect of GPx 
inhibition on endogenous levels of H2O2 in the brain.  
5.7 Local mercaptosuccinate (MCS) administration  
The aim of this section is to investigate the effect of local perfusion of 
mercaptosuccinate (MCS) on the H2O2 sensor response when implanted in the freely-
moving animal. MCS is a glutathione peroxidase (GPx) inhibitor (Dringen et al., 1998; 
Avshalumov et al., 2003; Avshalumov et al., 2005). GPx is the primary enzyme 
responsible for regulation of neuronal ROS/H2O2 levels. The local perfusion of MCS 
should disrupt H2O2 removal and hence lead to an increase in H2O2 levels in the brain. 
The preliminary data shown in this section is a dose response study from one animal. 0.1 
mM and 1 mM MCS were added to the perfusate and the H2O2 response was measured 
by the dual H2O2 sensor.  
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Figure 5.7.1: An example of a 1 mM MCS perfusion detected by the paired H2O2 sensor implanted 
in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the perfusion. 
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Figure 5.7.2: Preliminary dose response comparison of MCS perfusion on H2O2 response implanted 
in the striatum of a freely-moving Wistar rat. Data represented as a percentage increase above 
baseline. 
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
0.1 mM 212.6 115.8 455.7 10.9 24.7 1344.3 1339.5 
1 mM 449.9 124.6 964.4 6.2 23.5 1830.8 1724.3 
 
Table 5.7.1: Summary of results obtained on perfusion of MCS. Data obtained from 1 
paired H2O2 sensor implanted in the striatum of 1 Wistar rat.  
Preliminary findings indicate that the local administration of MCS in a dose dependent 
manner produces a dose related increase in H2O2 as is summarised in Table 5.7.1. Future 
work may involve the similtaneous inhibition of catalase and GPx using SA and MCS 
respectively in order to supress the anti-oxidant network and increase the endogenous 
level of H2O2 in the brain.  
5.8 Local ascorbic acid (AA) administration 
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Figure 5.8.1: A typical example of a 1 mM AA perfusion detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
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Ascorbic acid  is the primary interference species in the brain, with an estimated 
concentration of between 100 and 500 µM in the ECF (Lowry et al., 1996). It is 
necessary to test the selectivity of the H2O2 sensor against this potential interferent. In 
order to determine whether the presence of AA would interfere with the detection of 
H2O2 in the brain 1 mM AA was added to the perfusate and locally introduced. A 
maximum current increase of 245.3 ± 38.4 pA (n = 2) which corresponds to 117.9 ± 7.8 
% (n = 2) was recorded by the H2O2 sensor following perfusion of 1 mM AA. The 
response was slow to achieve a maximum response (10.3 ± 3.3 mins, n = 2) and no 
significant difference (P > 0.05) was observed between pre-perfusion (1780.6 ± 966.6 
pA) and post-perfusion baseline levels (1828.4 ± 1105.5 pA).  
Carbon paste electrodes (CPEs) have been previously utilised to demonstrate changes in 
ECF ascorbate (Lowry et al., 1996; Miele & Fillenz, 1996; Lowry et al., 1998a). Miele 
et al. demonstrated a sharp immediate increase in current detected by the CPE upon 
local administration of ascorbate which was attenuated for the duration of the perfusion 
(Miele & Fillenz, 1996). In this instance a comparitively slower and minimal current 
change was observed (Figure 5.8.1) it is probable that the PPD layer which is part of the 
H2O2 sensor design slows the access of AA to the active surface of the sensor and 
effectively eliminates intereference as seen previously (Lowry et al., 1998b; O'Neill et 
al., 2008). The expected rapid fluctuation of H2O2 in-vivo (Rice, 2011) should exclude 
contributions to the signal by slow fluctuations in basal concentrations of AA which are 
expected to be much lower than the concentration added to the perfusate here (1 mM) 
(Miele et al., 1994; Miele & Fillenz, 1996). 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
AA 245.3 ± 38.4 
117.9 ± 
7.8 
10.3 ±   
3.3 
29.8 ±   
2.0 
1780.6 ± 
966.6 
1828.4 ± 
1105.5 
 
Table 5.6.1: Summary of results obtained on perfusion of AA. Data obtained from 2 paired H2O2 
sensors implanted in the striatum of 2 Wistar rats.  
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5.8.1 Systemic AA administration 
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Figure 5.8.1.1: An intraperitoneal injection (i.p) of AA (2 g/kg) detected by the paired H2O2 sensor 
implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the duration of the 
perfusion. 
In this section the selectivity of the H2O2 sensor against systemically introduced 
ascorbate (2 g/kg, s.c.) was investigated which has previously been demonstrated with 
PPD based sensors (Lowry et al., 1998a). Sodium ascorbate was the preferred choice as 
an interference test in-vivo as AA, even with pH adjustment, causes significant 
discomfort to the animal. An immediate decrease in H2O2 signal was observed following 
the injection. The maximum decrease recorded was 170.0 pA in this case which 
corresponds to a current change of -95.0 %. As previously stated the overall response of 
the H2O2 sensor design is based on a subtraction value i.e. Blank-Cat. The recorded 
decrease here is seen due to an increase in signal detected by the Cat sensor of 30.8 % 
however the response at the Blank sensor remained steady with a maximum increase of 
7.1 % (see Figure 5.8.1.2).  
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Figure 5.8.1.2: An intraperitoneal injection (i.p) of AA (2 g/kg) detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of a freely-moving Wistar rat. The arrows indicate the 
duration of the perfusion. 
From in-vitro calibration data it is feasible that the current at the Cat sensor attributable 
to the presence of a high concentration of AA (1000 µM) may be slightly higher than 
that recorded at the Blank sensor. The in-vitro AA response of the paired sensor is low 
however and no significant difference is observed between the Blank and Cat sensor 
(Section 4.8). No distinct increase in the Blank sensor response was observed following 
this systemic administration of ascorbate. The baseline current values of the Blank 
sensor are higher than the Cat sensor in-vivo (Section 5.11), therefore the response 
towards basal concentrations of AA of the paired sensor does not have a negative effect 
on the sensitivity of the paired design. It must be stated that the work presented in this 
section is preliminary and further examination of the response to systemically 
introduced ascorbate needs to be carried out.  
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Figure 5.8.1.3: A bivariate scattergram of changes in the Blank and Cat sensor currents following 
the systemic administration of AA.  
Figure 5.8.1.3 illustrates a correlation analysis of the changes in current recorded by the 
Blank and Cat sensor following the systemic administration of AA (2 g/kg, s.c.). There 
is a high correlation between both sensor designs with a calculated correlation 
coefficient of 0.8314 (p < 0.0001). 
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5.9 Local H2O2 administration (acute preparation) 
This section demonstrates the response of the paired H2O2 sensor to the local perfusion 
of various concentrations of H2O2 in the “Acute” preparation. An acute preparation is 
where the recording takes place while the animal is still under anaesthetic and held in 
the stereotaxic frame. Additionally the acute preparation facilitates the perfusion of high 
concentrations of H2O2 (10 and 100 mM) which would likely not be tolerated in the 
freely-moving animal.   
5.9.1 aCSF 
As a control experiment aCSF was perfused through the microdialysis probe. A typical 
example of the outcome of this perfusion on the paired catalase-based H2O2 sensor 
response is shown below in Figure 5.9.1. 
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Figure 5.9.1: A typical example of an aCSF perfusion detected by the paired H2O2 sensor implanted 
in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the perfusion. 
Figure 5.9.1 represents the paired H2O2 sensor response following aCSF perfusion in the 
anaesthetised animal. The average paired current response following aCSF perfusion 
demonstrated a decrease in current (-76.7 ± 24.6 pA, n = 2) which corresponds to a 
concentration change of -164.4 ± 52.7 nM H2O2 (n = 2). In the anaesthetised animal the 
pre-perfusion baseline of the Cat and Blank sensor are not significantly different (P > 
0.05) (Table 5.9.1.1). This observation contrasts greatly to the baseline current values 
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for the Cat and Blank sensor seen in the freely-moving animal. The Blank sensor 
baseline is consistently much higher than the Cat sensor in the freely-moving animal 
(see Section 5.5.2 and 5.5.3). Additionally the maximum current response obtained by 
both sensors (Blank and Cat) following perfusion of aCSF in the anaesthetised animal 
was not significantly different (P > 0.05). Therefore difficulty arises in representing the 
overall paired response (Blank-Cat). The individual response of the Cat and Blank 
sensor following perfusion of aCSF is shown in Figure 5.9.1.1. The discrepancy in the 
baseline level of the paired H2O2 sensor between the freely-moving and the acute 
preparation is fully discussed in Section 5.12.  
The aCSF perfusion decreased the paired H2O2 sensor response to -105.7 ± 52.9 % (n = 
2) of basal levels following 13.2 ± 0.3 mins (n = 2) from the start of each perfusion. A 
return to a baseline level is apparent after 20.7 ± 0.6 mins (n = 2). No significant 
difference (P > 0.05) was observed between the pre-perfusion and post-perfusion 
basline levels. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
aCSF -76.7 ± 
24.6 
-105.7 ± 
52.9 
-164.4 ± 
52.7 
13.2 ± 
0.3 
20.7 ± 
0.6 
117.2 ± 
97.3 
39.0 ± 
47.6 
 
Table 5.9.1: Summary of results obtained on perfusion of aCSF. Data obtained from 2 paired H2O2 
sensors implanted in the striatum of 2 Wistar rats. 
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Figure 5.9.1.1: A typical example of an aCSF perfusion detected by (A) Blank sensor and (B) Cat 
sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration 
of the perfusion. 
An immediate decrease in response by the Cat (A) and Blank (B) sensor is apparent on 
commencement of the aCSF perfusion. The aCSF perfusion decreased the current of the 
Blank sensor to 69.4 ± 4.4 % (n = 2) of basal levels after 13.2 ± 0.3 mins (n = 2) from 
the start of each perfusion. Similarly a decrease was detected by the Cat sensor (80.6 ± 
8.1 %, n = 2). A return to a baseline level occured on both sensor designs after 20.7 ± 
0.6 mins (n = 2). No significant difference (P > 0.05) was observed between the pre-
perfusion baseline and the post-perfusion baseline of the Cat and Blank sensors. 
Additionally no significant difference P > 0.05 was observed between the maximum 
current response of the Blank and Cat sensor following perfusion with aCSF.  
The decrease observed here by both sensor designs is due to diffusion of H2O2 through 
the microdialysis membrane and into the dialysate thus reducing the concentration of 
H2O2 surrounding the sensor. On cessation of the perfusion H2O2 diffuses back towards 
the implanted sensors and hence an increase in H2O2 signal is observed.  
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aCSF 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -142.1 ± 
54.6 69.4 ± 4.4 13.2 ± 0.3 20.7 ± 0.6 
447.7 ± 
114.1 
305.6 ± 
59.5 
Cat -65.4 ± 
30.0 80.6 ± 8.1 - - 
330.6 ± 
16.9 
277.6 ± 
6.3 
 
Table 5.9.1.1: Summary of results obtained on perfusion of aCSF. Data obtained from 2 paired 
H2O2 sensors implanted in the striatum of 2 Wistar rats. 
As can be seen in Figure 5.9.1.1 a decrease is observed in the Cat and Blank sensor 
response following perfusion of aCSF. However the overall subtracted response is 
masked by the proximity of the baseline levels of the Cat and Blank sensor prior to 
perfusion of the analyte. The overall H2O2 response is based on a subtraction value 
(Blank–Cat). Due to the similarity of the initial baselines of the Cat and Blank sensor the 
decrease in current response detected individually by both sensor designs is not clearly 
represented by an overall paired response. The maximum current response obtained by 
both sensors following perfusion of aCSF is quite similar. Hence, a difficulty arises 
when the overall maximum change in H2O2 response is represented by subtraction. This 
finding was fully investigated and the outcome is discussed in Section 5.12.  
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5.9.2 50 µM H2O2 
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Figure 5.9.2: A typical example of a 50 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
The response of the paired H2O2 sensor following perfusion of 50 µM H2O2 is shown in 
Figure 5.9.2. The signal remains close to baseline levels for the duration of the 
perfusion. As mentioned previously (Section 5.9.1) with the concentration used in this 
case, the pre-perfusion baseline and the maximum current response of the Cat and Blank 
sensor are not significantly different (P > 0.05). The individual response of the Cat and 
Blank sensor following perfusion of 50 µM H2O2 is shown in Figure 5.9.3.1. 
A slight deviation from baseline levels following the perfusion of 50 µM H2O2 (55.7 ± 
63.6 pA, n = 3) was apparent. No significant difference (P > 0.05) was observed 
between the baseline current pre-perfusion -28.8 ± 64.8 pA (n = 3) and the new post-
perfusion basal level -18.2 ± 48.1 pA (n = 3). 
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
50 µM 
H2O2 
55.7 ± 
63.6 
87.9 ± 
17.8 
119.5 ± 
136.4 
11.3 ± 
2.0 
20.6 ± 
1.5 
-28.8 ± 
64.8 
-18.2 ± 
48.1 
 
Table 5.9.2: Summary of results obtained on perfusion of 50 µM H2O2. Data obtained from 3 paired 
H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.9.2.1: A typical example of a 50 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
The concentration of H2O2 in the perfusate was increased to 50 µM H2O2 and a decrease 
in response by the Cat (A) and Blank (B) sensor was recorded. This perfusion decreased 
the Blank sensor current response to 93.3 ± 3.0 % (n = 3) of basal levels following 11.3 
± 2.0 mins (n = 3) from the start of each perfusion. A similar decrease was detected by 
the Cat sensor (92.5 ± 1.8 %, n = 3). A return to the pre-perfusion baseline level can be 
seen following the end of the perfusion which was complete on both sensor designs after 
20.6 ± 1.5 mins (n = 3). No significant difference (P > 0.05) was observed between the 
pre-perfusion baseline and the post-perfusion baseline of the Cat and Blank sensor. 
Additionally, no significant difference (P > 0.05) was determined between the Cat and 
Blank sensor maxium current response. 
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50 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -21.5 ± 
10.9 93.3 ± 3.0 11.3 ± 2.0 20.6 ± 1.5 
300.4 ± 
22.7 
278.9 ± 
11.9 
Cat -26.0 ± 
9.3 92.5 ± 1.8 - - 
329.2 ± 
55.2 
301.0 ± 
42.4 
 
Table 5.9.2.1: Summary of results obtained on perfusion of 50 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
The pre-perfusion baseline level prior to administration and the maximum current 
change recorded by both sensors (Bank and Cat) following perfusion of 50 µM are not 
significantly different (P > 0.05). Therefore it is difficult to represent the overall 
maximum change in H2O2 response by subtraction. This factor is discussed in Section 
5.12.  
 
5.9.3 100 µM H2O2 
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Figure 5.9.3: A typical example of a 100 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
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An immediate increase in response (93.3 ± 42.4 pA, n = 3) was observed due to the 
perfusion of 100 µM H2O2 which corresponds to a 142.9 ± 11.5 %, n = 3 change from 
baseline. A continuous increase in response is apparent on progression of the perfusion. 
Once the perfusion is stopped as indicated by the arrows in Figure 5.9.3, an immediate 
decrease in response can be seen. The maximum change observed occurred after 8.6 ± 
2.0 mins (n = 3) following the start of the perfusion and returned to a baseline level 21.2 
± 1.4 mins (n = 3) subsequently. No significant difference (P > 0.05) was observed 
between pre-perfusion and post-perfusion baseline levels. A summary of the data is 
provided below in Table 5.9.4. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
100 µM 
H2O2 
93.3 ± 
42.4 
142.9 ± 
11.5 
200.1 ± 
91.0 8.6 ± 2.0 
21.2 ± 
1.4 
-192.4 ± 
48.2 
-116.3 ± 
25.2 
 
Table 5.9.3.1: Summary of results obtained on perfusion of 100 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
A greater discrepancy in the maximum current response could be seen between the Cat 
and Blank sensor following addition of 100 µM H2O2 and higher concentrations to the 
perfusate. The Blank sensor responded to an increased concentration of H2O2 added to 
the perfusate (Figure 5.9.3.1). 
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Figure 5.9.3.1: A typical example of a 100 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
An overall increase in response was detected by the paired H2O2 sensor due to the 
addition of 100 µM H2O2 to the perfusate.  This perfusion decreased the response of the 
Blank sensor (A) to 89.2 ± 7.2 % (n = 3) of basal levels after 8.6 ± 2.0 mins (n = 3) from 
the start of each perfusion. A greater decrease was detected by the Cat sensor (B) (83.1 
± 9.5 %, n = 3). No significant difference (P > 0.05) was observed between the pre-
perfusion baseline and the post-perfusion baselines of the Cat and Blank sensors.  
100 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -67.4 ± 
52.7 89.2 ± 7.2 8.6 ± 2.0 21.2 ± 1.4 
509.6 ± 
99.1 
420.2 ± 
41.8 
Cat -144.2 ± 
101.2 83.1 ± 9.5 - - 
632.8 ± 
199.8 
474.3 ± 
109.8 
 
Table 5.9.3.1: Summary of results obtained on perfusion of 50 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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5.9.4 200 µM H2O2 
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Figure 5.9.4: A typical example of a 200 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
The concentration of H2O2 in the perfusate was increased to 200 µM. An increase in 
current response was recorded (47.9 ± 10 pA, n = 4, 5adm) due to the perfusion. The 
maximum change observed here occurred 5.0 ± 0.4 mins (n = 4, 5adm) following the 
start of the perfusion and returned to a baseline level 19.7 ± 1.1 mins (n = 4, 5adm) 
subsequently. No significant difference (P > 0.05) was observed between pre-perfusion 
and post-perfusion baseline levels. A summary of the data is provided below in Table 
5.9.4. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
200 µM 
H2O2 
47.9 ± 
10.0 
135.9 ± 
7.6 
102.6 ± 
21.5 5.0 ± 0.4 
19.7 ± 
1.1 
19.7 ± 
1.1 
-72.7 ± 
52.8 
 
Table 5.9.4: Summary of results obtained on perfusion of 200 µM H2O2. Data obtained from 4 
paired H2O2 sensors implanted in the striatum of 4 Wistar rats. The average data includes 5 
administrations. 
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Figure 5.9.4.1 A typical example of a 200 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
The Blank sensor (A) response remained close to baseline levels following the perfusion 
of 200 µM H2O2, a maximum current response of (-15.1 ± 31.2 pA, n = 4, 5adm) was 
recorded by the Blank sensor which corresponds to a 97.6 ± 9.3 %, n = 4, 5adm change. 
A decrease in current response was detected by the Cat sensor (-63.0 ± 22.3 pA, n = 4, 
5adm). Due to the proximity of the pre-perfusion baseline of both sensor designs (Table 
5.9.5.1) an overall maximum increase was detected by the paired H2O2 sensor following 
addition of 200 µM H2O2 to the perfusate. No significant difference (P > 0.05) was 
observed between the pre-perfusion baseline and the post-perfusion baselines of the Cat 
and Blank sensors.  
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200 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -15.1 ± 
31.2 97.6 ± 9.3 5.0 ±  0.4 19.7 ± 1.1 
370.9 ± 
31.5 
353.0 ± 
22.2 
Cat -63.0 ± 
22.3 85.3 ± 6.5 - - 
472.4 ± 
64.4 
444.6 ± 
57.9 
 
Table 5.9.4.1: Summary of results obtained on perfusion of 200 µM H2O2. Data obtained from 4 
paired H2O2 sensors implanted in the striatum of 4 Wistar rats. The average data includes 5 
administrations. 
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Figure 5.9.5: A typical example of a 500 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
The concentration of H2O2 in the perfusate was increased to 500 µM. An immediate 
increase in response (161.3 ± 17.6 %, n = 3) was observed due to the perfusion of 500 
µM H2O2. There was an immediate increase in H2O2 response and a subsequent return to 
baseline levels as shown in Figure 5.9.5. The maximum change observed here occurred 
9.9 ± 0.8 mins (n = 3) following the start of the perfusion and returned to a baseline 
level 20.3 ± 1.4 mins (n = 3) subsequently. No significant difference (P > 0.05) was 
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observed between pre-perfusion and post-perfusion baseline levels. A summary of the 
data is provided below in Table 5.9.5. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
500 µM 
H2O2 
72.1 ± 
25.3 
161.3 ± 
17.6 
154.5 ± 
54.2 
9.9 ±  
0.8 
20.3 ± 
1.4 
-115.4 ± 
37.4 
-43.3 ± 
28.0 
 
Table 5.9.5: Summary of results obtained on perfusion of 500 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.9.5.1: A typical example of a 500 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
Following the perfusion of 500 µM H2O2 the Blank sensor (A) response remained close 
to baseline levels, a maximum current response of (-25.0 ± 17.0 pA, n = 3) was recorded 
by the Blank sensor which corresponds to a 93.3 ± 4.6 %, n = 3 change. A deviation 
from baseline in current response was detected by the Cat sensor of -24.7 ± 48.7 pA, n = 
3. As observed with the 200 µM perfusion, due to the proximity of the pre-perfusion 
baseline of both sensor designs (Table 5.9.5.1) an overall maximum increase was 
detected by the paired H2O2 sensor following addition of 500 µM H2O2 to the perfusate. 
No significant difference (P > 0.05) was observed between the pre-perfusion baseline 
and the post-perfusion baselines of the Cat and Blank sensors.  
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500 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank -25.0 ± 17.0 93.3 ± 4.6 9.9 ±  0.8 20.3 ± 1.4 
382.1 ± 
8.9 
351.2 ± 
10.9 
Cat -24.7 ± 48.7 
98.6 ± 
13.8 - - 
422.5 ± 
84.9 
383.5 ± 
90.1 
 
Table 5.9.5.1: Summary of results obtained on perfusion of 500 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
5.9.6 1000 µM H2O2 
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Figure 5.9.6: A typical example of a 1000 µM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
In this case a relatively high concentration of H2O2 was added to the perfusate (1000 
µM). An immediate increase in response was observed due to the perfusion (162.7 ± 
12.0 %, n = 3). There was a sharp immediate increase in H2O2 response and a 
subsequent return to baseline levels as shown in Figure 5.9.7. The change observed here 
was not significantly different (P > 0.05) from that seen on introduction of 500 µM 
H2O2 (Figure 5.9.5). However a plateau region is not evident in this case when compared 
to Figure 5.9.5. The increase in response outlasts the duration of the perfusion. It is 
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possible that this concentration of H2O2 (1000 µM) has more of a detremental effect on 
mechanisms which exist in-vivo to remove exogenously appplied H2O2. The maximum 
change detected here occurred 5.4 ± 1.8 mins (n = 3) following the start of the perfusion 
and returned to a baseline level 18.6 ± 0.9 mins (n = 3) subsequently. No significant 
difference (P > 0.05) was found between pre-perfusion and post-perfusion baseline 
levels. A summary of the data is provided below in Table 5.9.6. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
1000 µM 
H2O2 
56.5 ± 
14.7 
162.7 ± 
12.0 
121.1 ± 
31.5 5.4 ± 1.8 
18.6 ± 
0.9 
-48.3 ± 
76.2 
-41.0 ± 
75.7 
 
Table 5.9.6: Summary of results obtained on perfusion of 1000 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.9.6.1: A typical example of a 1000 µM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
An average increase was detected by the Blank sensor (A) following the perfusion of 
1000 µM H2O2, a maximum current response of (26.9 ± 37.9 pA, n = 3) was recorded by 
the Blank sensor which corresponds to a (110.7 ± 13.9 %, n = 3) change. A decrease in 
current response was detected by the Cat sensor (-29.6 ± 33.4, n = 3) which corresponds 
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to (97.6 ± 10.7 %, n = 3) . An overall increase was detected by the paired H2O2 sensor 
following addition of 1000 µM H2O2 to the perfusate. No significant difference (P > 
0.05) was observed between the pre-perfusion baseline and the post-perfusion baselines 
of the Cat and Blank sensors.  
1000 µM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank 26.9 ± 
37.9 
110.7 ± 
13.9 5.4 ± 1.8 18.6 ± 0.9 
327.6 ± 
31.3 
325.4 ± 
24.9 
Cat -29.6 ± 
33.4 
97.6 ± 
10.7 - - 
375.9 ± 
106.0 
366.5 ± 
100.5 
 
Table 5.9.6.1: Summary of results obtained on perfusion of 1000 µM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
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Figure 5.9.7: A typical example of a 10 mM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
A high concentration of H2O2 (10 mM) was introduced to the perfusate. An immediate 
increase in response (1696.2 ± 80.0 pA, n = 2) was observed due to the perfusion which 
reached a distinct maximum increase
 
of 932.7 ± 157.8 % (n = 2) above basal levels. The 
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maximum change detected here occurred 10.6 ± 1.4 mins (n = 2) following the start of 
the perfusion and returned to a baseline level 16.6 ± 2.1 mins (n = 2) following the 
perfusion. No significant difference (P > 0.05) was found between pre-perfusion and 
post-perfusion baseline levels. A summary of the data is provided  in Table 5.9.7. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
10 mM  
H2O2 
1696.2 ± 
80.0 
932.7 ± 
157.8 
3636.0 ± 
171.5 
10.6 ± 
1.4 
16.6 ± 
2.1 
-58.9 ± 
60.0 
-58.9 ± 
59.4 
 
Table 5.9.7: Summary of results obtained on perfusion of 10 mM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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Table 5.9.7.1: A typical example of a 10 mM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
Following the perfusion of 10 mM H2O2 a clear increase in response of (1374.4 ± 39.3 
pA, n = 2) was detected by the Blank sensor (A), which corresponds to a percentage 
change of (626.5 ± 53.6 %, n = 3). A  slight deviation from baseline levels was detected 
by the Cat sensor (0.7 ± 1.3 pA, n = 3) which corresponds to (100.3 ± 0.4 %, n = 3) . An 
overall increase was detected by the paired H2O2 sensor following addition of 10 mM 
H2O2 to the perfusate. No significant difference (P > 0.05) was observed between the 
pre-perfusion baseline and the post-perfusion baselines of the Cat and Blank sensors. 
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Additionally a significant difference (P < 0.05,*) was determined between the Cat and 
Blank sensor maxium current response. 
10 mM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank 1374.4 ± 39.3 
626.5 ± 
53.6 10.6 ± 1.4 16.6 ± 2.1 
263.0 ± 
19.3 
260.9 ± 
16.4 
Cat 0.7 ± 1.3 100.3 ± 0.4 - - 
321.9 ± 
40.7 
319.8 ± 
42.9 
 
Table 5.9.7.1: Summary of results obtained on perfusion of 10 mM H2O2. Data obtained from 2 
paired H2O2 sensors implanted in the striatum of 2 Wistar rats. 
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Figure 5.9.8: A typical example of a 100 mM H2O2 perfusion detected by the paired H2O2 sensor 
implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the duration of the 
perfusion. 
Figure 5.9.8 demonstrates the typical response recorded following the perfusion of 100 
mM H2O2. An immediate increase in response (2725.1 ± 1011.5 pA, n = 3) was seen 
following the perfusion. There was an instantaneous increase in H2O2 response followed 
by a plateau region and a subsequent return to baseline levels as shown in Figure 5.9.8. 
The highest concentration of H2O2 used in these sets of experiments (100 mM) exerts 
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the highest overall effect on H2O2 detection by the paired H2O2 sensor in the acute 
preperation. The maximum change in signal detected here occurred 3.7 ± 0.7 mins (n = 
3) following the start of the perfusion and returned to a baseline level 15.5 ± 2.8 mins (n 
= 3) following the perfusion. No significant difference (P > 0.05) was found between 
pre-perfusion and post-perfusion baseline levels of the paired H2O2 sensor. A summary 
of the data is provided in Table 5.9.8. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
100 mM  
H2O2 
2725.1 ± 
1011.5 1078 ± 
408.4 
5841.6 ± 
2168.3 3.7 ± 0.7 
15.5 ± 
2.8 
-309.3 ± 
115.5 
5841.6 ± 
2168.3 
 
Table 5.9.8: Summary of results obtained on perfusion of 100 mM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats.  
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Table 5.9.8.1: A typical example of a 100 mM H2O2 perfusion detected by (A) Blank sensor and (B) 
Cat sensor; implanted in the striatum of an anaesthetised Wistar rat. The arrows indicate the 
duration of the perfusion. 
An immediate increase in response of (3280.1 ± 1100.6 pA, n = 3) was detected by the 
Blank sensor (A) following the perfusion of 100 mM H2O2, which corresponds to a 
percentage change of (16055 ± 8930.6 %, n = 3). A  slight deviation from baseline 
levels was detected by the Cat sensor (0.7 ± 1.3 pA, n = 3) which corresponds to (100.3 
± 0.4 %, n = 3). An overall increase was detected by the paired H2O2 sensor following 
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addition of 100 mM H2O2 to the perfusate. No significant difference (P > 0.05) was 
observed between the pre-perfusion baseline and the post-perfusion baselines of the Cat 
and Blank sensors.  
100 mM 
H2O2 
Current 
change 
(pA) 
Baseline 
Change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Blank 3280.1 ± 
1100.6 
16055 ± 
8930.6 3.7 ± 0.7 15.5 ± 2.8 
126.5 ± 
105.6 
137.5 ± 
119.2 
Cat 555 ± 
291.5 
258.4 ± 
95.8 - - 
352.4 ± 
79.1 
2499.2 ± 
998.4 
 
Table 5.9.8.1: Summary of results obtained on perfusion of 100 mM H2O2. Data obtained from 3 
paired H2O2 sensors implanted in the striatum of 3 Wistar rats. 
5.10 Local H2O2 administration summary (acute preparation) 
This section provides a summary of the data presented in Section 5.9. The maximum 
change recorded due to the local administration of H2O2 by the paired H2O2 sensor 
(Blank-Cat), the Blank sensor and the Cat sensor is compared against the corresponding 
aCSF response.  
5.10.1 Paired H2O2 sensor summary (acute) 
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Figure 5.10.1: Paired H2O2 sensor response following perfusions as discussed in Section 5.9. Data 
shown as an average percentage change, with 100 % as the pre-perfusion H2O2 baseline signal. 
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-76.7 ± 
24.6 
-105.7 ± 
52.9 
-164.4 
± 52.7 
13.2 ± 
0.3 
20.7 ± 
0.6 
117.2 ± 
97.3 
39.0 ± 
47.6 2 n/a 
50 µM 
H2O2 
55.7 ± 
63.6 
87.9 ± 
17.8 
119.5 ± 
136.4 
11.3 ± 
2.0 
20.6 ± 
1.5 
-28.8 ± 
64.8 
-18.2 ± 
48.1 3 0.0240 
100 µM 
H2O2 
93.3 ± 
42.4 
142.9 ± 
11.5 
200.1 ± 
91.0 
8.6 ±   
2.0 
21.2 ± 
1.4 
-192.4 ± 
48.2 
-116.3 ± 
25.2 3 0.0097 
200 µM 
H2O2 
47.9 ± 
10.0 
135.9 ± 
7.6 
102.6 ± 
21.5 
5.0 ±   
0.4 
19.7 ± 
1.1 19.7 ± 1.1 
-72.7 ± 
52.8 4 0.0005 
500 µM 
H2O2 
72.1 ± 
25.3 
161.3 ± 
17.6 
154.5 ± 
54.2 
9.9 ±    
0.8 
20.3 ± 
1.4 
-115.4 ± 
37.4 
-43.3 ± 
28.0 3 0.0099 
1000 µM 
H2O2 
56.5 ± 
14.7 
162.7 ± 
12.0 
121.1 ± 
31.5 
5.4 ±   
1.8 
18.6 ± 
0.9 
-48.3 ± 
76.2 
-41.0 ± 
75.7 3 0.0080 
10 mM 
H2O2 
1696.2 ± 
80.0 
932.7 ± 
157.8 
3636.0 
± 171.5 
10.6 ± 
1.4 
16.6 ± 
2.1 
-58.9 ± 
60.0 
-58.9 ± 
59.4 2 0.0247 
100 mM 
H2O2 
2725.1 ± 
1011.5 
1078 ± 
408.4 
5841.6 
± 
2168.3 
3.7 ±   
0.7 
15.5 ± 
2.8 
-309.3 ± 
115.5 
5841.6 ± 
2168.3 3 0.1111 
 
Table 5.10.1: Summary of paired H2O2 sensor results obtained following perfusions in anaesthetised 
animals as discussed in Section 5.9. 
Figure 5.10.1 and Table 5.10.1 summarises the paired H2O2 sensor data discussed in 
Section 5.9. The effect of the local administration of aCSF can be used as a control 
against which the perfusion of each concentration of H2O2 can be measured. A 
significant difference (P < 0.05,*) was observed between the local aCSF and 50 µM 
perfusion of H2O2. A significant difference (P < 0.05) was observed on perfusion of a 
higher concentration range of H2O2 which was observed at each incremental stage from 
100 µM to 10 mM H2O2 when compared to the response observed with aCSF (Section 
5.9.1) and the details of these statistical tests are presented in Table 5.10.1. At each 
intermediate increase in the concentration of H2O2, a proportional increase in H2O2 
response was detected by the dual catalase-based H2O2 sensor. No significant difference 
(P > 0.05) was observed between the 100 mM perfusion and the local administration of 
aCSF, however a clear increase above baseline levels of H2O2 is apparent.  
A one-way ANOVA analysis of variance revealed a significant difference (P < 0.01,**) 
between the maximum response time of each perfusion. The time required to reach a 
maximum response generally decreased as the concentration of H2O2 added to the 
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perfusate increased. The time required to return to baseline levels following each 
perfusion was not significantly different (P > 0.05) as determined by one-way ANOVA. 
A significant difference (P < 0.01,***) for the pre-perfusion and post-perfusion baseline 
level for each change in concentration of H2O2 added to the perfusate was observed as 
determined by a one-way ANOVA analysis of variance. The difference observed with 
pre and post-perfusion baseline levels between different H2O2 concentrations locally 
introduced, is due to the proximity of the Blank and Cat sensor baseline response in the 
anaesthetised animal which is further discussed in Section 5.12.  
A contrasting H2O2 response was observed here in comparison to that observed in the 
freely-moving animal data. A clear increase above baseline levels of H2O2 was detected 
by the dual H2O2 sensor at each stage from a concentration of 100 µM to 100 mM H2O2 
in the acute experimental set-up. The disparity in the results between the acute and 
freely-moving animal data may be due to the constant use of anaesthetic in the acute 
procedure. Anaesthesia has been shown to cause an alteration of various mechanisms 
and levels of neurotransmitters in the central nervous system (CNS) which has been 
exstensively reviewed by O’Neill et al. (O'Neill et al., 1998). A limited amount of in in-
vivo data is available on the effect of volatile anesthetics such as Isoflurane on 
elecroactive species such as H2O2 in the brain.  
Generally anaesthesia causes systemic CNS depression and hence a decrease in neuronal 
activity (Mueller et al., 2011). It is possible that the network of antioxidant mechanisms 
which regulate the level of H2O2/ROS in the brain cannot function normally due to the 
effect of anaesthesia. In which case exogenously applied H2O2 may not be effeciently 
removed and therefore an increase in H2O2 levels in the ECF surrounding the implanted 
paired sensor occurs and a corresponding increase in current due to the presence of H2O2 
is detected by the sensor.  
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5.10.2 Blank sensor summary (acute) 
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Figure 5.10.2: Blank sensor response following perfusions as discussed in Section 5.9. Data shown as 
an average percentage change, with 100 % as the pre-perfusion baseline signal. 
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-142.1 ± 
54.6 69.4 ± 4.4 13.2 ± 0.3 
20.7 ± 
0.6 
447.7 ± 
114.1 305.6 ± 59.5 2 n/a 
50 µM 
H2O2 
-21.5 ± 
10.9 93.3 ± 3.0 11.3 ± 2.0 
20.6 ± 
1.5 300.4 ± 22.7 278.9 ± 11.9 3 0.0177 
100 µM 
H2O2 
-67.4 ± 
52.7 89.2 ± 7.2 8.6 ± 2.0 
21.2 ± 
1.4 509.6 ± 99.1 420.2 ± 41.8 3 0.1369 
200 µM 
H2O2 
-15.1 ± 
31.2 97.6 ± 9.3 5.0 ±  0.4 
19.7 ± 
1.1 370.9 ± 31.5 353.0 ± 22.2 4 0.1339 
500 µM 
H2O2 
-25.0 ± 
17.0 93.3 ± 4.6 9.9 ±  0.8 
20.3 ± 
1.4 382.1 ± 8.9 351.2 ± 10.9 3 0.1339 
1000 µM 
H2O2 
26.9 ± 
37.9 
110.7 ± 
13.9 5.4 ± 1.8 
18.6 ± 
0.9 327.6 ± 31.3 325.4 ± 24.9 3 0.1075 
10 mM 
H2O2 
1374.4 ± 
39.3 
626.5 ± 
53.6 10.6 ± 1.4 
16.6 ± 
2.1 263.0 ± 19.3 260.9 ± 16.4 2 0.0092 
100 mM 
H2O2 
3280.1 ± 
1100.6 
16055 ± 
8930.6 3.7 ± 0.7 
15.5 ± 
2.8 
126.5 ± 
105.6 
137.5 ± 
119.2 3 0.2597 
 
Table 5.10.2: Summary of Blank sensor results obtained following perfusions in anaesthetised 
animals as discussed in Section 5.9. 
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Figure 5.10.2 and Table 5.10.2 summarises the Blank sensor data discussed in Section 
5.9. At relatively lower concentrations of H2O2 added to the perfusate (50-1000 µM 
H2O2) the Blank sensor response remains close to baseline levels. However a significant 
difference (P < 0.05,*) was observed following perfusion of 50 and 500 µM H2O2 when 
compared to the response observed following aCSF perfusion (Section 5.9.1). In relation 
to the freely-moving animal data a higher response was detected by the Blank sensor in 
the acute preperation on perfusion of these concentrations of H2O2 (50-1000 µM H2O2). 
Following perfusion of 100 mM H2O2 in the anaesthetised animal no significant 
difference (P > 0.05) in the Blank sensor response was seen in comparison to the effect 
of aCSF administration however a clear increase above baseline levels can be seen 
(Figure 5.10.2).   
5.10.3 Cat sensor summary (acute) 
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Figure 5.10.3: Cat sensor response following perfusions as discussed in Section 5.9. Data shown as 
an average percentage change, with 100 % as the pre-perfusion baseline signal.  
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Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
n P 
aCSF 
-65.4 ± 
30.0 80.6 ± 8.1 13.2 ± 0.3 
20.7 ± 
0.6 
330.6 ± 
16.9 
277.6 ± 
6.3 2 n/a 
50 µM 
H2O2 
-26.0 ± 9.3 92.5 ± 1.8 11.3 ± 2.0 20.6 ± 1.5 
329.2 ± 
55.2 
301.0 ± 
42.4 3 0.1633 
100 µM 
H2O2 
-144.2 ± 
101.2 83.1 ± 9.5 8.6 ± 2.0 
21.2 ± 
1.4 
632.8 ± 
199.8 
474.3 ± 
109.8 3 0.8690 
200 µM 
H2O2 
-63.0 ± 
22.3 85.3 ± 6.5 5.0 ±  0.4 
19.7 ± 
1.1 
472.4 ± 
64.4 
444.6 ± 
57.9 4 0.7059 
500 µM 
H2O2 
-24.7 ± 
48.7 
98.6 ± 
13.8 9.9 ±  0.8 
20.3 ± 
1.4 
422.5 ± 
84.9 
383.5 ± 
90.1 3 0.4095 
1000 µM 
H2O2 
-29.6 ± 
33.4 
97.6 ± 
10.7 5.4 ± 1.8 
18.6 ± 
0.9 
375.9 ± 
106.0 
366.5 ± 
100.5 3 0.3402 
10 mM 
H2O2 
0.7 ± 1.3 100.3 ± 0.4 10.6 ± 1.4 
16.6 ± 
2.1 
321.9 ± 
40.7 
319.8 ± 
42.9 2 0.1361 
100 mM 
H2O2 
555 ± 
291.5 
258.4 ± 
95.8 3.7 ± 0.7 
15.5 ± 
2.8 
352.4 ± 
79.1 
2499.2 ± 
998.4 3 0.2466 
 
Table 5.10.3: Summary of Cat sensor results obtained following perfusions in anaesthetised animals 
as discussed in Section 5.9. 
Figure 5.10.3 and Table 5.10.3 summarises the Cat sensor data discussed in Section 5.9. 
When compared to the corresponding aCSF perfusion no significant difference (P > 
0.05) in the Cat sensor response was seen following each perfusion of H2O2 (50 µM-100 
mM) in the anaesthetised animal. Although no significant difference (P > 0.05) was 
observed between the 100 mM H2O2 perfusion and the addition of aCSF to the perfusate 
a clear increase above baseline levels can be seen (Figure 5.10.3). The observed increase 
above baseline levels due the local addition of the highest concentration of H2O2 used in 
these experiments (100 mM) causes saturation of the catalase enzyme which is part of 
the Cat sensor design. Therefore an increased response occurs due to the local addition 
of a comparatively high concentration of H2O2. However it is clear from Figure 5.10.3 
and Table 5.10.3 that the Cat sensor effectively eliminates a contribution to the overall 
response by removing the signal attributable to H2O2 up to a concentration of 10 mM 
H2O2. The Cat sensor data obtained in the acute set-up compares well with that observed 
in the freely-moving animal experiments. In both scenarios no significant difference (P 
> 0.05) can be seen following each concentration of H2O2 locally introduced in 
comparison to the corresponding aCSF response.  
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5.11 Baseline stability (freely-moving) 
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Figure 5.11.1: The average baseline recorded by the paired H2O2 sensor in-vivo over a consecutive 
period of six days in freely-moving animals. Data represented as a mean response ± SEM and n = 3. 
A decrease in sensitivity of an electrochemical sensor can often be observed following 
contact with a biological sample (Garguilo & Michael, 1994). It was necessary to 
investigate any effect the physiological environment may have on the paired H2O2 
sensor when implanted. The mean baseline current of the paired H2O2 sensor was 
examined over a consecutive period of six days and recordings were taken following an 
initial period of ca. 24 hrs following implantation. 
The mean baseline current recorded by the paired H2O2 sensor in-vivo over the stated 
successive period is shown in Figure 5.11.1. Each paired H2O2 sensor was implanted in 
the striatum of a freely-moving rat. A one-way ANOVA analysis of variance revealed 
that the baseline current showed no significant variation P > 0.05 over the stated 
duration of implantation. No significant difference P > 0.05 in sensitivity was apparent 
on the sixth day when compared to the initial day of implantation. These results support 
the stability of the H2O2 sensor design for the purpose of long-term in-vivo recording. 
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Day Mean I, (nA ± SEM) n 
1 1.04 ± 0.34 3 
2 1.66 ± 0.62 3 
3 1.47 ± 0.56 3 
4 1.83 ± 0.5 3 
5 1.82 ± 0.31 3 
6 1.77 ± 0.97 3 
 
Table 5.11.1: Summary of data shown in Figure 5.11.1. Data represented as a mean response ± 
SEM. 
Additionally the average basal H2O2 concentration in the striatum can be derived from 
the data displayed in Table 5.11.1. This value was calculated from the average in-vitro 
calibration data of the paired H2O2 sensor design. The average in-vitro sensitivity of the 
catalase-based H2O2 paired sensor is 0.47 ± 0.003 nA/µM, n = 24 (Chapter 4 Section 
4.7).  
The average baseline current response obtained from in-vivo experiments over a period 
of six days is 1.60 ± 0.30 nA, n = 3. This value corresponds to a H2O2 ECF basal 
concentration of 3.42 ± 0.27 µM. Current literature suggests that the ECF H2O2 
concentration is in the region of 25-50 µM (Hyslop et al., 1995). As previously stated a 
competing network of antioxidants are present in the brain which regulate ROS/H2O2 
levels (Rice, 2011). These antioxidants may cause the basal level of H2O2 to be much 
lower than previously expected. Electrochemical methods provide increased temporal 
and spatial resolution which may explain the disparity in the ECF basal concentration 
estimated here and that determined by Hyslop et al. (Hyslop et al., 1995). However it 
must be stated that the capacitance current of the paired H2O2 sensor will contribute to 
the overall baseline current value. Additionally, the diffusional constraints of brain 
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tissue itself may restrict mass transport of the analyte to the sensor (Cheng et al., 1979; 
Dayton et al., 1983).  
From the results presented in this chapter it is clear that mechanisms present in the 
physiological environment which remove H2O2 are robust. The evidence presented in 
this chapter would suggest that the basal ECF concentration of H2O2 is in fact much 
lower than previously reported.  
5.11.2 Blank sensor baseline stability (freely-moving) 
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Figure 5.11.2: The average baseline recorded by the Blank sensor in-vivo over a consecutive period 
of six days. Data represented as a mean response ± SEM and n = 6. 
The data shown in Figure 5.11.2 shows the mean baseline current recorded by the Blank 
sensor in-vivo over six successive days. Each Blank sensor was implanted in the striatum 
of a freely-moving rat. A one-way ANOVA analysis of variance revealed that the 
baseline current showed no significant variation P > 0.05 over the stated duration of 
implantation. The current detected by the Blank sensor remains consistent over six days. 
Any deterioration in the PPD structure which is part of this sensor design would lead to 
an increased current response as the period of implantation increases. No significant 
change (P > 0.05) in current response was detected by the Blank sensor over the stated 
duration of implantation. These results validate the stability of Blank sensor design for 
the purpose of obtaining long-term in-vivo recordings. 
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Day Mean I, (nA ± SEM) n 
1 1.51 ± 0.37 3 
2 2.11 ± 0.57 3 
3 1.89 ± 0.51 3 
4 2.28 ± 0.45 3 
5 2.35 ± 0.36 3 
6 2.44 ± 0.95 3 
 
Table 5.11.2: Summary of data shown in Figure 5.11.2. Data represented as a mean response ± 
SEM. 
 
5.11.3 Cat sensor baseline stability (freely-moving) 
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Figure 5.11.3: The average baseline recorded by the Cat sensor in-vivo over a consecutive period of 
six days. Data represented as a mean response ± SEM and n = 6. 
The data shown in Figure 5.11.3 displays the mean baseline current recorded by the 
catalase-based sensor (Cat) in-vivo over six successive days. Each Cat sensor was 
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implanted in the striatum of a freely-moving rat. A one-way ANOVA analysis of 
variance revealed that the baseline current showed no significant variation P > 0.05 over 
six days of implantation. The catalase enzyme remains stable over the specified duration 
of time in the in-vivo environment. Impairment in the function of the enzyme would lead 
to a distinct increase in current as the duration of implantation increases. No significant 
difference P > 0.05 in the response of the catalase sensor is observed over six days of 
implantation however a small increase is observed on day 5 and 6. Previous work by Hu 
et al. has demonstrated a loss in viability of an enzyme based sensor which typically 
occurs following initial exposure to brain tissue (Hu et al., 1994). The Cat sensor 
response is stable over six days of recording. The results shown in this Section validate 
the stability of Cat sensor design for the purpose of obtaining long-term in-vivo 
recordings. 
Day Mean I, (nA ± SEM) n 
1 0.47 ± 0.07 3 
2 0.46 ± 0.05 3 
3 0.42 ± 0.06 3 
4 0.45 ± 0.05 3 
5 0.53 ± 0.07 3 
6 0.67 ± 0.11 3 
 
Table 5.11.3: Summary of data shown in Figure 5.11.2. Data represented as a mean response ± 
SEM. 
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5.12 Baseline comparison (acute and freely-moving) 
A variation in the baseline level of H2O2 was observable between the acute and freely-
moving animal data. The average baseline response of the paired H2O2 sensor was 1.60 
± 0.30 nA n = 3 in freely-moving animals however the corresponding value obtained 
from the acute preparation was -0.27 ± 0.04 nA n = 3. No significant difference (P > 
0.05) between baseline levels in both experimental conditions was observed however a 
discrepancy is clearly apparent.  
In the anaesthetised animal the pre-perfusion baseline of the Cat and Blank sensor are in 
close proximity (see Section 5.10.2 and 5.10.3). This observation contrasts greatly to the 
baseline current values for the Cat and Blank sensor seen in the freely-moving animal. 
The Blank sensor baseline is consistently much higher than the Cat sensor in the freely-
moving animal (see Section 5.5.2 and 5.5.3). The lack of resolution of the Blank sensor 
baseline current over the Cat sensor baseline in the acute set-up leads to difficulty in 
obtaining an overall subtracted response.  
A limited amount of time is available to conduct an acute experiment due to the nature 
of the experimental conditions. It is possible that in the acute set-up the capacitance of 
the paired H2O2 sensor does not have sufficient time to dissipate. In order to fully 
investigate this possibility the time required to reach a steady baseline level from the 
application of potential in the acute preparation was calculated (100.67 ± 11.92 mins n = 
3). A new baseline was obtained from the freely-moving animal data following a similar 
elapsed amount of time from the application of potential (102.67 ± 3.18 n = 3). At this 
revised time point the current response of the paired H2O2 sensor in the freely-moving 
animals was 1.22 ± 0.70 n = 3. A discrepancy in baseline levels between the acute and 
freely-moving preparations was still apparent following a similar time-frame from the 
application of the potential to the working electrodes. These results suggest that the 
disparity in baseline levels in each scenario is due to a different experimental parameter 
and not due to time considerations.  
It has previously been demonstrated that neuronal activity is globally decreased during 
the use of general anaesthesia (Mueller et al., 2011). A drop in neuronal activity 
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corresponds to a decrease demand for regional cerebral blood flow and hence a matched 
reduction in oxygen levels (Li et al., 2011). The primary source of H2O2 in the brain is 
derived from the action of the enzyme superoxide dismutase (SOD) on the highly 
reactive compound superoxide which is derived from the mitochondral reduction of 
molecular O2 . The production of H2O2 is linked to increased neuronal activity due to an 
increased level of O2 consumption which generates H2O2 (Rice, 2011). This 
phenomenon may be a contributing factor in the reduction of the baseline level of H2O2 
seen here in the anesthetised animal, as the neuronal activity of the animal is supressed 
by the effect of the anaesthesia. 
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5.13 Conclusion 
The aim of this chapter was to characterise the paired catalase-based H2O2 sensor in the 
in-vivo environment. The sensitivity of the H2O2 sensor was examined when implanted 
in the striatum of the freely-moving animal by the local perfusion of various 
concentrations of H2O2 (Section 5.4). These perfusions were compared to the local 
addition of aCSF which was introduced in the same manner (Section 5.3.1). Addition of 
H2O2 to the perfusate caused no significant difference P > 0.05 to the sensor response at 
a low concentration (25 µM) in relation to perfusion of aCSF. However a significant 
difference with respect to aCSF was observed at a higher concentration of exogenously 
applied H2O2 (100 µM to 1000 µM). At each subsequent stage (100 µM to 1000 µM) 
the H2O2 sensor showed a difference in response which was proportional to an increase 
in the concentration of locally introduced H2O2 (Section 5.5). Interestingly no distinct 
increase above basal H2O2 levels was observed following introduction of H2O2 to the 
perfusate in freely-moving animals.  
A robust network of antioxidant mechanisms control the level of H2O2/ROS in the brain, 
which are responsible for the prevention of the development of oxidative stress. The  
variety of processes which maintain oxidant homeostasis in the brain has been 
exstensively reviewed (Dringen et al., 2005; Valko et al., 2007). These mechanisms 
consist of various ezymatic and non-enzymatic control mechanisms (Simonian & Coyle, 
1996) and the consequences of a disruption in the balance between antioxidants and 
ROS has been implicated in a variety of neurological diseases and dysfunctions 
(Barnham et al., 2004; Melo et al., 2011). It is therefore possible that exogenously 
applied H2O2 may be efficently controlled by the inherent mechanisms of the intact 
living brain.  
Additionally the delivery of H2O2 to the implanted catalase-based paired H2O2 sensor 
may be restricted by recovery issues associated with the MD/RD technique as discussed 
in Section 2.9. 
The selectivity of the implanted sensor in the striatum of the freely-moving animal was 
adressed by the local perfusion and systemic administration of the primary interferent 
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species present in the brain (Lowry et al., 2006). The local perfusion of AA had no 
effect on the H2O2 sensor response, no significant difference P > 0.05 was observed 
between the maximum current response and baseline levels (Section 5.8). The 
preliminary results from the systemic administration of AA on the H2O2 sensor response 
exhibited an overall decrease. The protracted gradual decrease caused by the systemic 
administration of AA should not affect the detection of H2O2. H2O2 is a highly 
permeable short-lived molecule (Bao et al., 2009) and would demonstrate more rapid 
fluctuations when compared to AA. These results indicate that the sensor is selective 
over AA in-vivo as has been demonstrated in-vitro (Section 4.8). 
Administration 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Max 
response  Return  
Pre-
perfusion 
baseline 
(pA) 
Post-
perfusion 
baseline 
(pA) 
Local AA 245.3 ± 38.4 
117.9 ± 
7.8 
10.3 ± 
3.3 mins 
29.8 ± 
2.0 mins 
1780.6 ± 
966.6 
1828.4 ± 
1105.5 
Systemic AA -170.0 4.95 6 hr 14 
mins 
14 hr 38 
mins 177.8 48.9 
 
Table 5.13.1: Summary of results obtained upon local perfusion and systemic administration of AA, 
as discussed n Section 5.8 and 5.8.1. 
The primary enzymes responsible for the degradation of H2O2 in the brain, catalase and 
glutathione peroxidase (GPx) were inhibited by the use of sodium azide (SA) and 
mercaptosuccinate (MCS) respectively. MCS and GPx have been used previously for 
the same purpose (Dringen et al., 1998; Avshalumov et al., 2005). The intention of these 
experiments (Section 5.6 and 5.7) was to inhibit the antioxidant network responsible for 
the regulation of H2O2 in an attempt to show an increase in the endogenous production 
of H2O2. The local perfusion of MCS and SA caused an increase in the paired catalase-
based H2O2 sensor response, this would indicate that the implanted sensor is responding 
to an endogenous increase in H2O2 levels and is selective to the target substrate (H2O2). 
Preliminary data presented in this chapter indicates that GPx inhibition of endogenous 
H2O2 production by use of MCS, exhibits its affect in a dose dependent manner (Section 
5.7) as has been demonstrated previously in brain preperations (Avshalumov et al., 
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2005). A higher concentration of SA was added to the perfusate with respect to MCS 
and caused a similar percentage increase in H2O2 response. Previous work has suggested 
that catalase has a higher overall activity in the brain than GPx (Avshalumov et al., 
2004). Further work is required to elucidate the role of SA (catalase inhibition) and 
MCS (GPx inhibition) on the downstream endogenous elevation of H2O2.  
Analyte 
Current 
change 
(pA) 
Baseline 
change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
perfusion 
baseline 
(pA) 
SA (10 mM) 219.8 ± 108.7 
118.4 ± 
0.8 
471.1 ± 
232.9 1.3 ±  0.2 25.5 ± 1.7 
1170.8 ± 
541.5 
MCS (1 mM) 449.9 124.6 964.4 6.2 23.5 1830.8 
 
Table 5.13.2: Summary of results obtained upon local perfusion of SA and MCS, as discussed in 
Section 5.6 and 5.7. 
The stability of the dual H2O2 sensor was assessed over a continuous period of six days 
while implanted in the striatum of a freely-moving animal (Section 5.11). No significant 
difference P > 0.05 was seen in the H2O2 sensor response for the duration of these 
recordings. These results support the feasibility of using the H2O2 sensor in the 
attainment of long-term electrochemical recordings as has been previously demonstrated 
using electrochemical sensors (Lowry et al., 1998a; Bolger et al., 2011; Finnerty et al., 
2012).  
Following the local administration of H2O2, a difference in the paired H2O2 sensor 
response was observed in the anaesthetised animal (Section 5.9) in comparison to the 
response observed in the freely-moving animal (Section 5.4). A clear increase above 
basal levels of H2O2 was observed at a higher concentration range of exogenously 
applied H2O2 (100 µM to 100 mM) in the anaesthetised animal (Section 5.10.1). The 
local administration of H2O2 in the freely-moving animal does not cause an obvious 
increase in the paired catalase-based H2O2 sensor response (Section 5.5.1). The disparity 
in response of the dual H2O2 sensor in the acute and freely-moving preperation may be 
due to a supression in neuronal activity due to anaesthesia (Mueller et al., 2011). This 
factor is fully discussed in Section 5.10. 
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The role of H2O2 as a neuromodulator may be fully understood by its real-time detection 
in the brain. The effect of this signalling molecule on inhibitory and excitatory processes 
which regulate dopamine has been thoroughly researched by Rice et al. in brain tissue 
preparations (Avshalumov et al., 2005; Rice, 2011). The real-time detection of H2O2 in 
the intact living brain presented in this chapter could provide novel information on this 
proposed neuromodulatory role.  
The highly effective anti-oxidant network present in the brain serves as a mop-up 
mechanism which removes potentially harmful reactive oxygen species such as H2O2 
(Simonian & Coyle, 1996; Valko et al., 2007). An insult to this controlled redox 
homeostasis is dealt with efficiently under normal circumstances (Droge, 2002). The 
results demonstrated in this chapter suggest that the effect of exogenously applied H2O2 
is controlled to some extent by these mop-up mechanisms in-situ. Additionally, these 
results indicate that anaesthesia has a negative effect on the normal function of the anti-
oxidant network. Preliminary findings presented in this chapter demonstrate that 
inhibition of specific peroxidase enzymes induces an elevation of endogenous H2O2.  
As previously stated a disruption in the maintenance of levels of ROS in the brain can 
lead to oxidative stress. Oxidative stress is implicated in the pathology of many 
neurological disorders such as Alzheimer’s disease, Parkinson’s disease and 
amyotrophic lateral sclerosis (Barnham et al., 2004; Melo et al., 2011). As H2O2 is 
indicative of the production of ROS (Simonian & Coyle, 1996), the real-time detection 
of H2O2 in the physiological environment may provide an understanding and more 
importantly an advancement in the therapeutic approach to a broad spectrum of 
neurodegenerative diseases. 
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6.1 Introduction 
The physiological role of nitric oxide (NO) as the endothelium derived relaxing factor 
(EDRF), involved in the process of vasodilation and regulation of blood pressure was 
discovered in the late 1980’s (Ignarro et al., 1987). Since then much interest has 
developed around the role of NO in the body. 
NO is derived from three main NO synthase enzymes (NOS). These consist of inducible 
NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) (Kiechle & 
Malinski, 1993; Bruckdorfer, 2005; Guix et al., 2005). The source of NOS in the body 
determines the specific type of NO produced. The global physiological function of NO 
has been extensively studied in processes such as the immune response (Bogdan et al., 
2000), anti-microbial activity (Fang, 2004) and penile erection (Mas et al., 2002). Of the 
three isoforms of NOS, nNOS is present in the most abundance in the brain. Neuronal 
NO has been implicated in a variety of neurological processes, specifically sleep and 
appetite regulation (Williams et al., 2002; Cavas & Navarro, 2006) synaptic plasticity, 
neurotransmission and learning and memory (Wass et al., 2006a; Wass et al., 2006b; 
Nugent et al., 2007). Hence the detection of NO in the central nervous system (CNS) 
provides an insight into a variety of vital neurological functions.  
A range of analytical techniques enable the detection of NO. However these techniques 
rely on indirect detection methods, by measuring nitrite and other markers of NO 
production using spectroscopic methods (Hetrick & Schoenfisch, 2009). The poor 
sensitivity of these techniques are not suitable for the detection of NO in-vivo, due to the 
short half-life of NO in the biological environment which is typically less than 10 
seconds (Kelm, 1999). Additionally, the concentration of NO in biological samples is 
within the pico to micromolar range (Wink & Mitchell, 1998), which requires a highly 
sensitive detection method. Also the selectivity of these spectroscopic methods are 
questionable due to interference from nitrite and nitrate from sources other than NO 
(Finnerty et al., 2012a). Electrochemical techniques provide the appropriate temporal 
and spatial resolution necessary to detect NO in the physiological environment to enable 
long-term in-vivo NO recordings. 
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The electrochemical reduction of NO has previously been shown (Meulemans, 1993; 
Maskus et al., 1996; Liu et al., 2003), however a significant amount of interference from 
oxygen is possible due to the required operating potential. The electro-oxidation of NO 
is the most suitable monitoring technique and a variety of electrode materials modified 
with permselective polymers such as Nafion®, operating between 0.6 and 1.0 V have 
been used for this purpose. They are predominantly carbon fibre (Friedemann et al., 
1996; Park et al., 1998; Heinzen & Pollack, 2002), glassy carbon (Pallini et al., 1998), 
and Pt electrodes (Park et al., 2010; Park et al., 2012).  
Our research group has demonstrated a highly sensitive, selective and stable NO sensor 
for the purpose of in-vivo NO monitoring (Brown & Lowry, 2003; Brown et al., 2009). 
This NO sensor also possesses the required operational characteristics i.e. a highly 
suitable response time and detection limit to enable the detection of NO in-vivo (Brown 
et al., 2009). Furthermore the application of this NO sensor in the physiological 
environment for the continuous real-time detection of NO in the brain has been 
extensively characterised (Finnerty et al., 2012a; Finnerty et al., 2012b). 
The NO sensor utilised here was constructed as previously described in detail by Brown 
et al. (Brown et al., 2009). A detailed procedure for the laboratory synthesis of NO; 
which was used to determine the sensitivity of the NO sensor has previously been shown 
(Brown et al., 2005). Finnerty et al. have recently published a detailed in-vivo 
characterisation of the NO sensor implanted in the striatum (Finnerty et al., 2012a). 
Additionally an extensive regional characterisation of the NO sensor was carried out in 
the striatum, prefrontal cortex (PFC) and nucleus accumbens (NA) of freely-moving 
animals (Finnerty et al., 2012b). This chapter demonstrates the in-vitro and in-vivo 
characterisation of the NO sensor with reference to this recently published work 
(Finnerty et al., 2012a; Finnerty et al., 2012b). 
At normal levels NO exhibits a neuroprotective effect, through maintaining cognitive 
function in the brain by regulating synaptic plasticity and neurotransmission (Calabrese 
et al., 2007). However, abnormally high concentrations of NO and the resulting further 
production of other reactive nitrogen species (RNS), leads to nitrosative stress in the 
CNS and exerts a damaging toxic effect (Valko et al., 2007). Nitrosative stress occurs 
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when the production of RNS surpasses the ability of the antioxidant network to suppress 
NO/RNS production. NO carries out its toxic effect in a pro-oxidant environment 
predominantly by interaction with superoxide, leading to the formation of peroxynitrite 
(Pacher et al., 2007). Nitrosative stress due to abnormal production of RNS such as NO 
has been implicated in a variety of neurodegenerative disorders such as Alzheimer’s 
disease (Pacher et al., 2007) and Parkinson’s disease (Andersen, 2004).    
The aim of this chapter is to replicate the in-vitro and in-vivo characterisation of the NO 
sensor as previously shown, in order to further illustrate the application of this sensor for 
the real-time detection of NO in animal models of neurological disease and dysfunction 
(see Chapter 7 and 8).  
6.2 Experimental 
A detailed description of the instrumentation, chemicals, solutions and software used in 
this section is given in Chapter 3. A detailed description of the manufacture of the NO 
sensor is outlined in Section 3.4. All experiments outlined in this chapter were 
performed using Constant Potential Amperometry (CPA). For all in-vitro and in-vivo 
experiments a potential of +900 mV vs. SCE and Ag wire (see Section 3.10.3) 
respectively was applied to the working electrodes. 
The number of implanted NO sensors is denoted by (n) and the number of animals 
indicated. In the case where the number of administrations included in the data exceeds 
the number of sensors/animals the value is given and denoted by (adm). Reported in-
vivo NO concentration changes are based on the average in-vitro pre-implantation 
calibration data.  
Statistical analysis was carried out using paired or unpaired t-tests. One-way ANOVA 
was used to simultaneously compare results which contained more than two seperate 
groups. These tests were performed using Graphpad Prism and gave a probability value 
(P) which indicates the level of significant or non-significant difference between groups. 
P > 0.05, denotes no significant difference. The extent of significant difference is 
divided into three parameters (P < 0.05,*), (P < 0.01,**) and (P < 0.0001,***) from the 
lowest relative level of difference (*) to the highest (***).  
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6.3 In-vitro characterisation of the NO sensor 
A detailed description of the in-vitro characterisation of the Nafion®-modified Platinum 
disc (Ptd) (5 pre-coats, 2 applications) NO sensor has been described by Brown et al. 
(Brown & Lowry, 2003; Brown et al., 2009). In the initial development of the NO 
sensor a Nafion® thermal annealing procedure of Pt microelectrodes was described that 
allowed the electrochemical detection of gaseous neurochemical species such as NO 
(Brown & Lowry, 2003). Brown & Lowry demonstrated the optimum Nafion® thermal 
annealing procedure required to enable sensitivity towards the target analyte and 
optimise interference rejection. Additional preliminary stability studies were conducted 
to demonstrate a sensor suitable for Long Term In-Vivo Electrochemistry (L.I.V.E) NO 
recordings (Brown & Lowry, 2003).   
The initial in-vitro development of the Nafion®-modified Ptd sensor was extended 
further to focus on the ability of the NO sensor design to detect NO in the in-vivo 
environment (Brown et al., 2009). In this work Brown et al. demonstrate the optimum 
applied potential for the detection of NO (+900 mV vs. SCE), the selectivity of the 
sensor over a range of interference species and the stability of the sensor design was also 
presented. The required operational characteristics of the Nafion®-modified sensor for 
the detection of NO in the physiological environment were validated and preliminary in-
vivo research presented the reliable detection of NO in the physiological environment 
(Brown et al., 2009).  
The in-vivo stability of the NO sensor following implantation has recently been 
published (Finnerty et al., 2012a) and these results are shown in Section 6.6. An 
extensive in-vivo characterisation of the Nafion®-modified NO sensor has been 
demonstrated (Finnerty et al., 2012a; Finnerty et al., 2012b) and these findings are 
discussed in Section 6.8.   
The in-vitro characterisation of the Nafion®-modified NO sensor presented in this 
chapter is a validation of the previously established sensitivity and selectivity of this 
sensor design (Brown & Lowry, 2003; Brown et al., 2009; Finnerty et al., 2012a). 
Recently published work regarding the stability of the Nafion®-modified sensor 
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determined in-vitro following implantation for a prolonged period is also presented in 
this chapter (Finnerty et al., 2012a).  
6.4 Sensitivity of the NO sensor in-vitro 
A Nafion®-modified Platinum disc (Ptd) (5 pre-coats, 2 applications) sensor was 
constructed as previously described in detail by Brown et al. (Brown et al., 2009). This 
section will outline the sensitivity of the NO sensor to the target substrate in-vitro.  
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Figure 6.4.1: (A) The current-concentration profile of NO at Nafion®-modified Ptd (5 pre-coats, 2 
applications) sensors (n = 16). (B) A typical raw data trace 0-1 µM for NO calibrations. CPA 
carried out at +900 mV vs. SCE. Arrows indicate the addition of 0.2 µM aliquots of NO. 
Figure 6.4.1 represents the response of the NO sensor with respect to the stock 
administration of NO (0 to 1 µM). The response demonstrated here is directly 
proportional to the amount of NO introduced into the electrochemical cell. Calibrating 
the NO sensor over a 0 to 1 µM NO concentration range yielded a sensitivity of 1.53 ± 
0.02 nA/µM, n = 16. No significant difference (P > 0.05) was observed between the NO 
sensitivity of the Nafion®-modified Ptd sensor reported here in comparison to that 
previously reported by Finnerty et al. (Finnerty et al., 2012a). 
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Table 6.4.1: Data obtained from the calibration shown in Figure 4.6.1(A), n = 16. R2 = 0.9994. Data 
is represented as a Mean ± standard error of the mean (SEM). Background values subtracted. 
Mean background current = 0.13 ± 0.02 nA. 
 
6.4.2 Limit of detection of the NO sensor in-vitro 
The limit of detection (LOD) of the NO sensor was calculated from in-vitro data. The 
LOD is defined as the smallest concentration of analyte detectable by a given sensor. 
The LOD value corresponds to three times the standard deviation of the background 
current and was calculated as 2.73 ± 0.34 nM, n = 12 for the NO sensor. The LOD of the 
Nafion®-modified NO senor is consistent with previous findings for the same sensor 
design (Brown et al., 2009). The ECF concentration of NO is expected to be within the 
pico to micromolar range (Shibuki, 1990; Wink & Mitchell, 1998). In an in-vivo 
environment the LOD of our sensor is sufficient to detect the expected neuronal 
concentration.  
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6.4.3 Response time of the NO sensor in-vitro 
The response time of a sensor is defined as the time required to change from 10% to 
90% of the maximum response. The in-vitro response of the NO sensor over time is 
shown below in Figure 6.4.3.  
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Figure 6.4.3: The average NO response at the Nafion®-modified Ptd (5 pre-coats, 2 applications) 
sensor design (n = 7) for addition of 1 µM NO. Data shown as a percentage with 100% 
representative of the maximum NO sensitivity, SEM is denoted by the dashed line. The entire 
response is plotted vs. seconds (A) and the immediate response (B). Arrows indicate the addition of 
1 µM NO. 
Following the introduction of 1 µM NO into the cell a gradual increase in the sensor 
response was observed. The response time of the NO sensor was calculated as 12.21 ± 
1.83 secs, n = 7. The solution was stirred immediately following the injection for 
approximately 3 seconds as outlined in Figure 6.3.3 (B). The increase in response 
observed here due to the introduction of NO outlasted the period of agitation of the bulk 
solution. The response time of the Nafion®-modified NO sensor is consistent with 
previous findings (Brown et al., 2009).The response time of this NO sensor design is 
sufficient to determine NO which has a short lifetime in tissue (Kiechle & Malinski, 
1993; Kelm, 1999). Additionally, it has previously been demonstrated that the response 
time of the NO sensor improves when tested under physiological temperature conditions 
of 37◦C (Brown et al., 2009).   
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6.5 Selectivity of the NO sensor in-vitro 
The most abundantly present interference species in the brain is ascorbic acid (AA), 
which has a reported concentration of ca. 500 µM in the ECF (Miele & Fillenz, 1996). 
However other potential sources of interference are possible from a wide range of 
species. These interferents can be detected at similar potentials to NO.  
A detailed in-vitro selectivity characterisation of the NO sensor has been demonstrated 
by Brown et al. (Brown et al., 2009). In this work presented by Brown et al. the current 
arising from the NO sensor by introduction of a wide range of chemical species was 
examined. The effect of uric acid (UA), serotonin (5-HT), DOPAC, 5-HIAA, dopamine 
(DA), glutathione, homovanillic acid (HVA), nitrite (NO2-) and hydrogen peroxide 
(H2O2) on the NO sensor response was tested. The expected ECF concentration of each 
analyte was utilised in this examination. The selectivity of the NO sensor over these 
interference species was established in these investigations (Brown et al., 2009).  
The sensitivity of the NO sensor was also maintained in the presence of AA (500 µM), 
DA (0.05 µM) and O2 (50 µM) (Brown et al., 2009). As the interference rejection 
properties of the NO sensor had previously been examined a subsequent AA calibration 
was sufficient to elucidate the selectivity of the NO sensor. 
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6.5.1 AA Selectivity of the NO sensor 
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Figure 6.5.1: (A) The current-concentration profile of AA at Nafion®-modified Ptd (5 pre-coats, 2 
applications) sensors (n = 16). (B) A typical raw data trace 0-1000 µM for AA calibrations. CPA 
carried out at +900 mV vs. SCE. Arrows indicate the addition of 200 µM aliquots of AA. 
AA, µM Mean I, nA S.E.M 
0 
200 
400 
600 
800 
1000 
0 
-0.07 
-0.05 
-0.04 
-0.02 
0.005 
0 
0.03 
0.04 
0.05 
0.06 
0.08 
 
Table 6.5.1: Data obtained from the calibration shown in Figure 6.4.1(A). Data is represented as a 
Mean ± SEM. Background values subtracted. Mean background current = 0.30 ± 0.03 nA. 
Figure 6.5.1(A) above shows the current values recorded by the NO sensor in response 
to the addition of AA (0-1000 µM). As can be seen in Figure 6.5.1(A) the average NO 
sensor response exhibits an initial gradual drift below baseline levels, denoted by the 
dashed line. The current remains in close proximity to basal levels, up to a concentration 
of 1000 µM. No significant difference (P > 0.05) was observed between baseline levels 
and the maximum response of the NO sensor due to addition of AA. Figure 6.5.1(B) 
demonstrates the typical response of the NO sensor to AA and the proximity of the 
response to baseline levels is apparent. The selectivity over AA of the NO sensor is 
clearly evident. It is clear that the AA response of the NO sensor design is negligible 
with a calculated sensitivity of 0.03 ± 0.04 pA/µM, n = 16. This response is diminutive 
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when compared to the response observed at an unmodified sensor as demonstrated in the 
next Section (6.5.2). 
6.5.2 AA Ptd 
This section examines the response observed at an unmodified Ptd electrode calibrated at 
900 mV vs. SCE following the addition of aliquots of AA in the concentration range of 
0-1000 µM. The purpose of this experiment is to act as a control against which the AA 
response of the Nafion®-modified NO sensor may be measured. 
0 200 400 600 800 1000
0
10
20
30
 [AA], µM
I, 
n
A
0 5 10 15 20 25 30
0
10
20
30
40
50
Time, min
I/A
A
, 
n
A
A
B
 
Figure 6.5.2: (A) The current-concentration profile of AA at an unmodified Ptd electrode (n = 20). 
(B) A typical raw data trace 0-1000 µM for AA calibrations. CPA carried out at +900 mV vs. SCE. 
Arrows indicate the addition of 200 µM aliquots of AA. 
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Table 6.5.2: Data obtained from the calibration shown in Figure 6.4.2(A), n = 20. R2 = 0.9977. Data 
is represented as a Mean ± standard error of the mean (SEM). Background values subtracted. 
Mean background current = 0.23 ± 0.05 nA. 
Table 6.5.2 displays data representing the AA response of the unmodified Ptd electrode. 
The response to AA is proportional to the concentration of AA added to the 
electrochemical cell with a calculated sensitivity of 28.6 ± 0.04 pA/µM, n = 20.  
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6.5.3 AA response comparison 
This section compares the AA response of the Ptd electrode to the Nafion®-modified Ptd 
NO sensor. It is clear from Figure 6.5.3 below that the Nafion® thermal annealing 
procedure as previously demonstrated (Brown et al., 2009), has greatly reduced the AA 
response observed at an unmodified Ptd electrode. 
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Figure 6.5.3: Comparison between AA responses of Ptd and the NO sensor. Average response 
represented as a slope value (pA/µM) mean response ± SEM and (P < 0.0001, ***). 
A significant difference (P < 0.0001, ***) in AA response was seen with the Nafion®-
modified Ptd NO sensor when compared to an unmodified electrode (Ptd). The AA 
response of the Pd electrode was 28.6 ± 0.04 pA/µM, n = 20 and a sensitivity to AA of 
0.03 ± 0.04 pA/µM, n = 16 was obtained with the NO sensor. It is clear that the 
modification of the bare electrode has effectively eliminated the detection of AA at the 
active surface of the electrode. It is paramount that the modification of the working 
electrode in order to reject interference from AA does not hinder the detection of NO 
and this is demonstrated in the next Section (6.6).  
6.6 In-Vitro Sensitivity and Selectivity of the NO sensor summary 
The in-vitro sensitivity to NO and the AA rejection characteristics of the NO sensor 
have been demonstrated in Sections (6.4 and 6.5) respectively. This section compares 
the sensitivity of the Nafion®-modified sensor to these two analytes (NO and AA).  
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Figure 6.6.1: Comparison between sensitivities of the Nafion®-modified Ptd (5 pre-coats, 2 
applications) sensor to NO and AA. Average response represented as a slope value (nA/µM) mean 
response ± SEM and (P < 0.0001, ***). 
The in-vitro NO sensitivity (1.53 ± 0.02 nA/µM, n = 16) was significantly different (P < 
0.0001, ***) to the recorded in-vitro AA response (0.03 ± 0.04 pA/µM, n = 16) of the 
NO sensor. These results substantiate the suitability of the Nafion®-modified NO
 
sensor 
for the detection of NO in the in-vivo environment.  
 
6.7 Post in-vivo stability 
The NO sensor was implanted into the brain of Wistar rats over an extended period, 
subsequently the sensors were removed and re-calibrated. The sensors sensitivity 
towards NO and selectivity over AA was examined following implantation. The 
calibration procedures are outlined in Section 3.7.4 and 3.7.3 respectively. The in-vitro 
characteristics of a sensor may differ from that observed in-vivo. The influence of the in-
vivo environment on the properties of a sensor is due in part to how the sensor may be 
altered by the various constituents of brain tissue. When in contact with a biological 
sample a drop in sensitivity of the sensor may occur due to fouling of the sensor by 
proteins and other biomolecules present within the tissue (Garguilo & Michael, 1994; 
Hu et al., 1994). The natural defence mechanism of the body to the presence of a foreign 
object can also inhibit the sensitivity of an implanted sensor (Wisniewski et al., 2000). 
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The effect of the environment may be reflected by variations in the sensors 
characteristics. The aim of this section is to examine the stability of the NO sensor 
following exposure to the physiological environment.  
The following section is a discussion of the post in-vivo stability results of the NO 
sensor; which we have recently published (Finnerty et al., 2012a).  
6.7.1 Post in-vivo NO sensitivity  
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Figure 6.7.1: (A) The current-concentration profile of NO at Nafion®-modified Ptd (5 pre-coats, 2 
applications) sensors; pre in-vivo (■) and post in-vivo (▲) (n = 7). (B) A typical raw data trace 0-1 
µM for post in-vivo NO calibrations. CPA carried out at +900 mV vs. SCE. Arrows indicate the 
addition of 0.2 µM aliquots of NO. 
Figure 6.7.1 demonstrates the average NO sensitivity of the Nafion®-modified Ptd (5 
pre-coats, 2 applications) sensors prior to and following implantation. The sensors 
represented here were implanted over a period of 11 to 23 days. The pre in-vivo NO 
sensitivity of these sensors which was determined from in-vitro calibration data was 
1.30 ± 0.01 nA/µM, n = 7. These sensors were removed following cessation of in-vivo 
experiments and the post in-vivo sensitivity to NO of these sensors was determined as 
0.62 ± 0.03 nA/µM, n = 7. This value is significantly different (P < 0.0001,***) when 
compared to the pre-implantation sensitivity of the same sensors. 
A drop in sensitivity of approximately 48 % was apparent following calibration with 
NO. This value is consistent with other reports which have demonstrated a 20 to 50 % 
loss in sensitivity of sensors following exposure to biological samples (Garguilo & 
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Michael, 1994; Hu et al., 1994). The loss in sensitivity recorded here is also comparable 
to previous in-vitro bio-compatibility determinations by Brown et al. of the same sensor 
design (Brown et al., 2009). In this work a 38 % loss in sensitivity was recorded due to 
exposure to lipid and protein, however the loss observed was seen within an initial 24 hr 
period and no significant difference was apparent subsequently (Brown et al., 2009).  
On further inspection of the raw data trace in Figure 6.7.1 (B) an increase in response is 
observed following each addition of NO. A decline in response is observed following 
each injection and this contrasts greatly when compared to the response seen with the 
average in-vitro NO calibration data prior to implantation (see Figure 6.4.1 (B)). It is 
possible that the adhesion of proteins and lipids to the surface of each sensor creates a 
diffusional barrier which limits the movement of NO added to the bulk solution to the 
active surface of each sensor. The process of stirring following addition of NO creates 
forced convection of the analyte to the active surface of the sensor. This is a possible 
explaination for the initial increase and subsequent decline in response observed with 
the post in-vivo calibration which is not apparent with these sensors prior to 
implantation.  
Additionally the process of ex-plantation can cause damage to the modified sensor 
which may negatively affect the characteristics of the working electrode. However 
during in-vivo experiments the Nafion®-modified active surface of the NO sensor 
remains intact which is proven by the sensor’s response towards systemically introduced 
ascorbate while implanted (Finnerty et al., 2012a). Also the mean baseline current of the 
Nafion®-modified Ptd NO sensor is largely unaffected in-vivo over a chronic period of 
continuous recording (Finnerty et al., 2012a).  
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NO, µM Mean I, nA SEM 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
0 
0.24 
0.52 
0.78 
1.04 
1.28 
0 
0.02 
0.05 
0.07 
0.08 
0.10 
 
Table 6.7.1: Pre-implantation NO data shown in Figure 4.6.1(A), (■); n = 7. R2 = 0.9996. Data is 
represented as a Mean ± standard error of the mean (SEM). Background values subtracted. Mean 
background current = 0.12 ± 0.02 nA. 
NO, µM Mean I, nA SEM 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
0 
0.05 
0.20 
0.35 
0.48 
0.59 
0 
0.01 
0.05 
0.11 
0.15 
0.18 
 
Table 6.7.2: Post-implantation NO data shown in Figure 4.6.1(A), (▲); n = 7. R2 = 0.9889. Data is 
represented as a Mean ± standard error of the mean (SEM). Background values subtracted. Mean 
background current = 0.26 ± 0.06 nA. 
 
NO sensor  NO
 
sensitivity (nA/µM) R2 n 
Pre in-vivo sensitivity 1.30 ± 0.01 0.9996 7 
Post in-vivo sensitivity 0.62 ± 0.03 0.9889 7 
 
Table 6.7.3: Comparison between sensitivities of NO sensors prior to and following implantation for 
11 to 23 days 
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6.7.2 Post in-vivo AA selectivity 
Pre Post-0.2
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Figure 6.7.2: Comparison between pre in-vivo and post in-vivo AA sensitivities of the NO sensor. 
Average response represented as a slope value (pA/µM) mean response ± SEM and (P < 0.0001, 
***). 
Figure 6.7.2 represents the AA response of the NO
 
sensor prior to and following an 
implantation period of 11 to 23 days. The pre in-vivo AA sensitivity of these sensors 
which was determined from in-vitro calibration data was -0.05 ± 0.02 pA/µM, n = 7. 
The post in-vivo sensitivity of these sensors to AA which was determined from in-vitro 
data was 1.39 ± 0.04 pA/µM, n = 7. This value is significantly different (P < 
0.0001,***) when compared to the pre-implantation AA response of the same sensors. 
A clear increase in AA sensitivity of the NO
 
sensor following implantation is apparent. 
However, when the post in-vivo AA response of the sensor is compared to an 
unmodified Ptd a significant difference (P < 0.01,**) is observed. This supports the 
stability of the modified Pt active surface of the NO sensor, a disruption to the surface 
would lead to a larger exposed surface area of Pt and hence a higher sensitivity to AA as 
seen in Figure 6.5.2.  
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6.8 In-vivo characterisation of the NO sensor 
The in-vitro characterisation of the NO sensor has been discussed (Section 6.4 to 6.6). 
The results displayed in the remainder of this chapter demonstrate the viability of the 
NO sensor performance in the physiological environment. Our research group has 
previously conducted a detailed in-vivo characterisation of the Nafion®-modified NO 
sensor which was carried out in the striatum of freely-moving Wistar rats (Finnerty et 
al., 2012a). An extensive regional characterisation of the NO sensor has also been 
conducted in the striatum, nucleus accumbens (NA) and prefrontal cortex (P.F.C) 
(Finnerty et al., 2012b). 
As demonstrated by Finnerty et al. the implanted Nafion®-modified Ptd sensor 
demonstrates significant changes from baseline following the local and systemic 
administration of known inducers and inhibitors of NO production (Finnerty et al., 
2012a; Finnerty et al., 2012b). Additionally, the NO sensor displayed no significant 
response following the systemic administration of sodium ascorbate which demonstrates 
the selectivity of the NO sensor over AA which is discussed in Section 6.8.4. 
The remainder of this chapter will demonstrate the NO sensor response to the systemic 
administration of saline and the relevant substances which induce and inhibit NO 
production. The results in this section demonstrate the sensitivity, selectivity and 
stability of the NO sensor implanted in the nucleus accumbens (NA) of freely-moving 
male Wistar rats.  
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6.8.1 Systemic administration of saline (i.p.) 
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Figure 6.8.1: A typical example of a 1mL injection of saline (i.p.) detected by the NO sensor 
implanted in the NA of a freely-moving Wistar rat. Inset: Immediate response following injection 
(secs). The arrow indicates the point of administration. 
All systemic administrations shown in this chapter were carried out by intraperitoneal 
injection (i.p.) in 1 mL of saline. As a control experiment saline (see Section 3.3.3.2) 
was administered (i.p.) (see Section 3.11.1) and the effect on the NO signal was 
measured (see Figure 6.8.1). Upon the injection of saline a brief fluctuation in NO is 
observable which is due to the physical manipulation of the subject as can be seen in 
Figure 6.8.2 (inset). The animal must be positioned on its back to facilitate an i.p. 
injection (see Section 3.11.1) which requires more physical movement than a 
subcutaneous injection (s.c.). A disparity in the NO signal due to the extent of 
movement can be observed with an s.c injection (see Section 7.3.1). However, the NO 
response with each administration (s.c. and i.p.) is minimal and short-lived. A small 
increase was found following the i.p. injection of saline in this case, which was 12.3 ± 
3.9 pA (n = 9) following 2.5 ± 0.3 mins (n = 9) and a return to pre-injection baseline 
levels was seen 7.5 ± 0.2 mins (n = 9) subsequently. The recorded change in current 
corresponds to a concentration change of 7.8 ± 2.5 nM NO (n = 9). However, this NO 
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concentration change is short lived. The aim of the experiments shown in this section is 
to demonstrate the NO response which is attributable to the injection itself which is 
minor. No significant difference (P > 0.05) was observed between pre and post-injection 
baseline levels. No lasting effect on the NO response of the Nafion®-modified NO 
sensor was observed following this injection. The data presented in this section is 
consistent with previous findings of the effect of systemic administration of saline on 
the response of this NO sensor design monitored in the NA (Finnerty et al., 2012b).  
Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
Saline 
12.3 ± 
3.9 
3.2 ± 
1.0 
7.8 ± 
2.5 
2.5 ± 
0.3 
7.5 ± 
0.2 
378.6 ± 
137.8 
389.6 ± 
142.7 
 
Table 6.8.1: Summary of results shown in Section 6.8.1. Data obtained from 9 sensors implanted in 
the NA of 3 Wistar rats.  
6.8.2 Systemic administration of L-arginine 
The amino acid L-arginine is the precursor to NO production in the body (Kiechle & 
Malinski, 1993; Guix et al., 2005). The reaction of molecular oxygen with L-arginine in 
the presence of nitric oxide synthase and other co-factors produces NO and L-citrulline 
in equimolar quantities. L-citrulline can then be converted back to L-arginine as part of 
the normal nitrogen metabolism of the body (Bruckdorfer, 2005). This section 
demonstrates the effect of systemic administration of the substrate for NO production 
(L-arginine) on the NO sensor response while implanted in the NA of freely-moving 
rats.  
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Figure 6.8.2: A typical example of an L-arginine (300 mg/kg) injection (i.p.) monitored in the NA of 
a freely-moving Wistar rat. The arrow indicates the point of administration. 
Following the injection of L-arginine (300 mg/kg) (see Section 3.3.2.2) a clear increase 
in NO above baseline levels denoted by the dashed line was apparent as can be seen in 
Figure 6.8.2. A significant change in current above baseline levels (59.4 ± 10.2 pA, P < 
0.05,*), (n = 4, 6ad) was observed which corresponds to a concentration change of 37.6 
± 6.4 nM (n = 4, 6ad). The maximum increase was recorded 82.6 ± 10.2 mins (n = 4, 
6ad) following the administration. A return to a baseline level was observed 159.4 ± 
12.7 mins (n = 4, 6ad) subsequently. A drift below baseline can be seen in Figure 6.8.2 
however no significant difference (P > 0.05) was observed between pre and post-
injection baseline levels. 
Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
L-arginine 
59.4 ± 
10.2 
16.6 ± 
2.8 
37.6 ± 
6.4 
82.6 ± 
10.2 
159.4 
± 12.7 
358.3 ± 
115.7 
390.4 ± 
110.3 
 
Table 6.8.2: Summary of results shown in Section 6.8.2. Data obtained from 4 sensors implanted in 
the NA of 3 Wistar rats. Average data from 6 administrations. 
The data presented in this section is consistent with previous findings of the effect of 
systemic injection of L-arginine on the response of the NO sensor implanted in the NA 
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(Finnerty et al., 2012b). Furthermore this data further supports work demonstrated by 
our research group on the effect of local and systemic administration of L-arginine on 
the response of this NO sensor design (Brown et al., 2009; Finnerty et al., 2012a). It is 
evident that the NO sensor is responding to an increase in endogenous levels of NO. 
Additionally the data outlined in this section validates finding by other research groups 
who have reported an increase in NO due to the administration of L-arginine (Heinzen & 
Pollack, 2002; Mas et al., 2002).  
6.8.2.1 Systemic administration of L-arginine vs. saline 
Saline L-Arginine
0
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Figure 6.8.2.1: Comparison between systemic (i.p.) saline (1ml) and L-arginine (300 mg/kg in 1mL 
saline) administration. Data represented as meant current change from baseline. P < 0.0001,***. 
The effect of saline administration (see Section 6.8.1) may be used as a control against 
which the systemic injection of L-arginine (300 mg/kg) may be compared. It is clear 
from Figure 6.8.2.1 that the effect of L-arginine administration (n = 4, 6ad) on the NO 
sensor response is significantly different (P < 0.0001,***) from the control experiment. 
These results demonstrate that following L-arginine administration the NO sensor 
responds to an endogenous elevation of NO and that the observed response is not 
attributable to injection stress. 
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6.8.3 Systemic administration of L-NAME 
In this section the effect of L-NAME, a known inhibitor of NO production on NO levels 
monitored in the NA is investigated. L-NAME is a non-selective NO inhibitor and it 
carries out its action by competing with L-arginine for its binding site on the NOS 
enzyme (Alderton et al., 2001; Salerno et al., 2002). Therefore the systemic 
administration of L-NAME results in a decreased production of NO, thereby causing a 
reduction in the NO sensor response.  
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Figure 6.8.3: A typical example of an L-NAME (30 mg/kg) injection (i.p.) monitored in the NA of a 
freely-moving Wistar rat. The arrow indicates the point of administration. 
Figure 6.8.3 demonstrates the effect of systemic L-NAME (30 mg/kg) administration on 
the NO sensor response monitored in the NA. Following systemic administration of L-
NAME a clear decrease in NO levels below baseline levels (dashed line) was evident. A 
significant current decrease below baseline levels (-23.2 ± 2.7 pA, P < 0.0001,***), (n = 
7, 5ad) was observed which corresponds to a concentration change of -15.2 ± 1.8 nM (n 
= 7, 5ad). The maximum decrease was recorded 72.6 ± 19.6 mins (n = 7, 5ad) following 
the administration. A return to a baseline level was observed 176.0 ± 12.6 mins (n = 7, 
5ad) following the injection. No significant difference (P > 0.05) was observed between 
pre and post-injection baseline levels. 
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Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
L-NAME 
-23.2 ± 
2.7 
-7.6 ± 
0.9 
-15.2 
± 1.8 
72.6 ± 
19.6 
176.0 
± 12.6 
304.4 ± 
32.2 
318.5 ± 
23.3 
 
Table 6.8.3: Summary of results shown in Section 6.8.2. Data obtained from 7 sensors implanted in 
the NA of 2 Wistar rats. Average data from 5 administrations. 
The results presented in this section are consistent with previously published work on 
the effect of systemic injection of L-NAME on the response of the NO sensor implanted 
in the NA (Finnerty et al., 2012a; Finnerty et al., 2012b). It is clear from the data 
presented here that inhibition of endogenous NO production is represented by a decrease 
in NO sensor response.   
6.8.3.1 Systemic administration of L-NAME vs. saline 
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Figure 6.8.3.1: Comparison between systemic (i.p.) saline (1ml) and L-NAME (30 mg/kg in 1mL 
saline) administration. Data represented as meant current change from baseline. P < 0.0001,***. 
In Figure 6.8.3.1 the systemic administration of L-NAME (30 mg/kg) on NO levels 
detected by the NO sensor implanted in the NA is compared against the corresponding 
saline response (see Section 6.8.1). It is evident that the effect of L-NAME 
administration (n = 7, 5ad) on the NO sensor response is significantly different (P < 
0.0001,***) from systemic saline administration. These results demonstrate that 
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following L-NAME administration the NO sensor responds to an endogenous reduction 
in NO production. The observed response is not attributable to injection stress but to the 
NOS inhibitory effect of L-NAME. 
6.8.4 Systemic administration of sodium ascorbate  
Ascorbic acid is the primary interference species in the brain, with an estimated 
concentration of between 100 and 500 µM in the ECF (Miele & Fillenz, 1996). Sodium 
ascorbate was utilised as an interference test in-vivo since AA, even with pH adjustment, 
causes significant discomfort to the animal. Ascorbate can be easily detected using 
voltametric methods in-vivo due to the high concentration of this molecule and relative 
ease of oxidation (O'Neill et al., 1998; Lowry et al., 2006). Therefore it is necessary to 
verify the selectivity of the NO sensor against this possible interferent. In order to 
determine whether the presence of this interferent would affect the NO sensor response 
sodium ascorbate was systemically administered and the current was monitored. 
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Figure 6.8.4: A typical example of a (2 g/kg) sodium ascorbate injection (i.p.) monitored in the NA 
of a freely-moving Wistar rat. The arrow indicates the point of administration. 
Figure 6.8.4 demonstrates the effect of systemic ascorbate administration on the NO 
sensor response. Previous investigations utilising a carbon paste sensor to monitor 
ascorbate have demonstrated a maximal effect due to systemic ascorbate administration 
within 60 minutes (Lowry et al., 1996; Finnerty et al., 2012b). It is quite clear from 
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Figure 6.8.4 that the current response of the NO sensor remains close to basal levels for 
the initial 60 min period. A slight deviation from baseline levels was observed however 
no significant difference (P > 0.05) was observed between the maximum current 
response (-23.2 ± 13.9 pA, n = 8, 5ad) and pre-injection baseline levels (342.3 ± 93.6 
pA, n = 8, 5ad) in these experiments. The current remained in close proximity to 
baseline levels for the duration of the recording period (Figure 6.8.4). The minimal 
response of the NO sensor due to the introduction of ascorbate demonstrates the 
integrity of the Nafion®-modified surface of the NO sensor design. These findings 
further demonstrate the selectivity of the NO sensor over AA as has previously been 
successfully demonstrated in-vivo (Finnerty et al., 2012a; Finnerty et al., 2012b).  
Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
Sodium 
ascorbate 
-23.2 ± 
13.9 
-6.8 ± 
23.7 
-14.7 ± 
8.8 
118.3 ± 
10.1 
267.8 
± 16.5 
342.3 ± 
93.6 
343.3 ± 
96.1 
 
Table 6.8.4: Summary of results shown in Section 6.8.4. Data obtained from 8 sensors implanted in 
the NA of 3 Wistar rats. Average data includes 5 administrations. 
6.8.4.1 Systemic administration of Sodium ascorbate vs. saline 
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Figure 6.8.4.1: Comparison between systemic (i.p.) saline (1ml) and sodium ascorbate (2 g/kg in 
1mL saline) administration. Data represented as meant current change from baseline.  
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Figure 6.8.4.1 compares the effect of systemic administration of sodium ascorbate 
against the administration of saline. No significant difference (P = 0.0653) was observed 
between the control experiments conducted using saline (see Section 6.8.1) and the 
response of the NO sensor following injection of ascorbate. These results re-establish 
that the NO sensor is selective over AA in-vivo and stable in the physiological 
environment. A disruption to the Nafion®-modified Pt active surface of the sensor would 
lead to an increased surface area of exposed Pt and an increase in AA detection which is 
clearly absent (see Figures 6.8.4 and 6.8.4.1). 
6.8.5 Baseline stability of the NO sensor 
The mean in-vivo baseline current of the NO sensor was examined over a consecutive 
period of 14 days of implantation. A decrease in sensitivity of an electrochemical sensor 
can often be observed following contact with a biological sample due to fouling of the 
sensor by proteins and other biomolecules present within the tissue (Garguilo & 
Michael, 1994). The normal reaction of the body to the presence of a foreign object may 
also negatively affect the sensitivity of an implanted sensor (Wisniewski et al., 2000).  
It has previously been demonstrated that the baseline current value of the implanted NO 
sensor remains consistent for a consecutive period of 8 days (Finnerty et al., 2012a). 
These findings indicate that the NO sensor is stable over a prolonged period in the in-
vivo environment. Any disruption to the modified active surface of the NO sensor 
should lead to an increase in baseline current values as the period of implantation 
progresses. It was necessary to investigate any effect the physiological environment may 
have on the stability of the NO sensor while implanted. The data presented in this 
section is taken from NO sensors implanted in the NA.  
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Figure 6.8.5.1: Baseline stability of the NO sensor implanted in the NA for a consecutive period of 
14 days (n = 2-6, 2-5 animals).  
The data shown in Figure 6.8.5.2 demonstrates the mean baseline current recorded by 
the NO sensor in-vivo over fourteen consecutive days. The baseline value was calculated 
from the same time point for each day of implantation and recordings were taken 
following an initial period of ca. 24 hrs following implantation. The data represented 
here is from NO sensors implanted in the NA of freely-moving rats. A one-way 
ANOVA analysis of variance revealed that the baseline current showed no significant 
variation P > 0.05 over the stated duration of implantation. The current detected by the 
NO sensor remains consistent over fourteen days. Any deterioration in the Nafion®-
modified active surface which is part of this sensor design would lead to an increased 
current response as the duration of implantation progresses. No significant change (P > 
0.05) was observed in current response detected by the NO sensor over the stated 
duration of implantation. These results verify the stability of the NO sensor for the 
purpose of obtaining L.I.V.E recordings. 
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Day 
Mean I, 
(pA ± SEM) n Day 
Mean I, 
(pA ± SEM) n 
1 293.8 ± 28.3 6 8 249.6 ± 41.4 4 
2 304.5 ± 21.2 6 9 265.9 ± 37.8 4 
3 285.2 ± 18 6 10 263.7 ± 39.8 4 
4 280.3 ± 20.3 5 11 265.8 ± 45.9 3 
5 279.3 ± 34.7 5 12 260.6 ± 49.8 3 
6 264.5 ± 32.4 4 13 270.8 ± 44.4 3 
7 241.6 ± 37.5 4 14 301.4 ± 29.7 2 
 
Table 6.8.5.1: Summary of the data provided in Figure 6.8.5.1. Day 1-3: (n = 6, 5 animals), Day 4-5: 
(n = 5, 5 animals), Day 6-10: (n = 4, 4 animals), Day 11-13: (n = 3, 3 animals) and Day 14 (n = 2, 2 
animals).  
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6.9 Conclusion 
The primary aim of this chapter was to verify the in-vitro and in-vivo characterisation of 
the NO sensor as previously demonstrated by our research group (Brown & Lowry, 
2003; Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 2012b).  
The in-vitro NO sensitivity was established (see Section 6.4) and reported as 1.53 ± 0.02 
nA/µM, n = 16. No significant difference (P > 0.05) was observed between the NO 
sensitivity of the NO sensor design presented here in comparison to that previously 
demonstrated by Finnerty et al (Finnerty et al., 2012b). The sensitivity of the NO sensor 
is highly suitable for the detection of NO in-vivo, as NO has a short half-life in 
biological tissues (Kelm, 1999). Additionally the concentration of NO in biological 
samples is within the pico-micromolar range (Wink & Mitchell, 1998).  
The NO sensor must exhibit a fast response time and low limit of detection (LOD) in 
order to detect physiological NO, due to the afore mentioned low concentration and 
short lifetime of NO in-vivo. The operational characteristics of the NO sensor, i.e. the 
response time (see Section 6.4.3) and LOD (see Section 6.4.2) were calculated as 12.21 
± 1.83 secs, (n = 7) and 2.73 ± 0.34 nM, (n = 12) respectively. The response time and 
LOD of the NO sensor reported in this chapter are consistent with previous reports of 
the operational characteristics of the NO sensor (Brown et al., 2009) and are efficient for 
the detection of NO in-vivo.  
The in-vitro selectivity of the NO sensor against AA, the primary interferent species in 
the brain in relation to NO detection was validated (see Section 6.5) and reported as 0.03 
± 0.04 pA/µM, n = 16. No significant difference (P > 0.05) was observed between 
baseline levels and the maximum response of the NO sensor due to addition of AA (see 
Section 6.5). The selectivity characteristics of the NO sensor reported here are consistent 
with previous findings (Brown et al., 2009), where it was determined that AA had no 
effect on the NO sensor response in-vitro. Additionally Brown et al. have previously 
described the excellent rejection characteristics of the NO sensor, the sensor was tested 
over a wide range of potential interferent species (see Section 6.5) and the unaffected 
response of the NO sensor was shown. The sensitivity of the NO sensor was also 
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preserved in the presence of AA (500 µM), DA (0.05 µM) and O2 (50 µM) (Brown et 
al., 2009).  
An examination of NO sensor characteristics following implantation was discussed in 
Section 6.7. It was determined that the post in-vivo sensitivity of the NO sensor was 
approximately 48 % less than the pre-implantation sensitivity of the same sensors. 
Details of the post-implantation sensitivity of the NO sensor have recently been 
published (Finnerty et al., 2012a). The AA selectivity characteristics of the NO sensor 
following implantation were described in Section 6.7.2. An increased response to AA 
following implantation of the NO sensor was observed which was significantly different 
(P < 0.0001,***) to the pre in-vivo response of the same sensors. However, the Nafion®-
modified active surface of the NO sensor remains intact when implanted as proven by 
the sensor response to systemically introduced ascorbate in-vivo as shown in Section 
6.8.4.   
The in-vitro characterisation of the NO sensor was discussed in Section 6.4 to Section 
6.7. The next step was to establish the sensitivity, selectivity and stability of the NO 
sensor in the in-vivo environment. As a control experiment the effect of systemic 
administration of saline on the implanted NO sensor was examined in Section 6.8.1. The 
in-vivo functionality of the NO sensor was then confirmed while implanted in the 
nucleus accumbens (NA) of the freely-moving animal (see Sections 6.8.2 and 6.8.3). 
The precursor to NO production in the body (L-arginine) was systemically administered 
and NO levels in the NA were monitored (see Section 6.8.2). A significant increase (P < 
0.0001,***) in the NO sensor response was observed following the administration of L-
arginine with respect to the injection of saline (see Section 6.8.2.1).  
Additionally the effect of the non-selective NOS inhibitor (L-NAME) on the response of 
the NO sensor was determined in the NA (see Section 6.8.3). A significant decrease in 
the NO sensor response was observed following the administration of L-NAME with 
respect to the corresponding saline response (see Section 6.8.3.1).  
To verify the selectivity of the NO sensor over AA in the physiological environment 
sodium ascorbate was administered systemically (see Section 6.8.4). No significant 
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difference (P > 0.05) was observed between the maximum current response and pre-
injection baseline levels of the NO sensor following the injection of ascorbate. The main 
results from the in-vivo characterisation of the NO sensor in the NA, as previously 
determined by Finnerty et al. are summarised in Table 6.9.1 (Finnerty et al., 2012b). 
Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
P 
Saline 
12.3 ± 
3.9 
3.2 ± 
1.0 
7.8 ± 
2.5 2.5 ± 0.3 
7.5 ± 
0.2 
378.6 ± 
137.8 
389.6 ± 
142.7 n/a 
L-Arginine 
59.4 ± 
10.2 
16.6 ± 
2.8 
37.6 ± 
6.4 
82.6 ± 
10.2 
159.4 
± 12.7 
358.3 ± 
115.7 
390.4 ± 
110.3 ↑,*** 
L-NAME 
-23.2 ± 
2.7 
-7.6 ± 
0.9 
-15.2 ± 
1.8 
72.6 ± 
19.6 
176.0 
± 12.6 
304.4 ± 
32.2 
318.5 ± 
23.3 ↓,*** 
Sodium 
ascorbate 
-23.2 ± 
13.9 
-6.8 ± 
23.7 
-14.7 ± 
8.8 
118.3 ± 
10.1 
267.8 
± 16.5 
342.3 ± 
93.6 
343.3 ± 
96.1 > 0.05 
 
Table 6.9.1.: Summary of in-vivo NO sensor results from systemic administrations discussed in 
Section 6.8. Where (P) represents the outcome of an unpaired t-test of the maximum response 
following each administration vs. saline response. Where (↑) denotes an increase and (↓) denotes a 
decrease in NO monitored in the NA. 
The sensitivity of the NO sensor in the NA of the freely-moving animal was established 
as summarised in Table 6.9.1. No significant difference (P > 0.05) was observed 
between the maximum current response following each administration (saline, L-
arginine, L-NAME and sodium ascorbate) when compared to the corresponding in-vivo 
results previously shown by Finnerty et al. in the NA (Finnerty et al., 2012b). 
Additionally, the maximum response time and subsequent time required to return to a 
baseline level following the administration of saline, L-arginine and L-NAME showed 
no significant difference (P > 0.05) to that previously presented by Finnerty et 
al.(Finnerty et al., 2012b).  
The baseline stability of the NO sensor while implanted in the NA for a consecutive 
period of 14 days was shown in Section 6.8.5. Previous investigations have 
demonstrated the stability of the NO sensor implanted in the brain for a continuous 
period of 8 days (Finnerty et al., 2012a). No significant variation P > 0.05 was observed 
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in the baseline current of the NO sensor over the stated duration of implantation (see 
Section 6.8.5). These results further verify the stability of the NO sensor for the purpose 
of obtaining long-term in-vivo recordings. 
In summary the in-vitro and in-vivo characterisation of the NO sensor was verified. The 
application of this NO sensor for the real-time detection of NO in animal models of 
neurological disease and dysfunction is presented in Chapter 7 and Chapter 8.  
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7.1 Introduction 
The in-vitro and in-vivo characterisation of the Nafion®-modified Platinum disc (Ptd) (5 
pre-coats, 2 applications) nitric oxide (NO) sensor has been established as discussed in 
Chapter 6. The purpose of this chapter is to utilise the NO sensor in detecting changes in 
NO levels in the brain of freely-moving rats following systemic administration of 
Propionic acid (PPA).  
PPA is endogenous to the body and exists as an intermediate of normal cellular 
metabolism and is a product of bacterial metabolism in the human gut (Al-Lahham et 
al., 2010). MacFabe et al. have demonstrated that PPA may be used in rats to mimic the 
behavioural changes and neuroinflammatory responses which are associated with autism 
spectrum disorders (ASDs) (MacFabe et al., 2008; Shultz et al., 2009).  
ASDs consist of related neurodevelopmental disorders which are characterised by a 
varying degree of social impairment, difficulties with communication, repetitive 
behaviours and restricted interests (Rapin & Tuchman, 2008). These symptoms may be 
debilitating in certain individuals depending on the severity of the condition. However 
the characteristics of ASDs can display positive attributes in some individuals such as 
enhanced memory, heightened skills in areas such as mathematics and a superior ability 
to concentrate (Walsh et al., 2011). To date the relationship between the brain and the 
behavioural characteristics which are symptomatic of ASDs are not fully understood. 
The pathogenesis of ASDs has a strong genetic basis, however the exact cause of ASDs 
is not entirely explained by genetic factors (Folstein & Rosen-Sheidley, 2001). A variety 
of environmental agents have been indicated in the development of autism such as 
prenatal exposure to infection (Meyer et al., 2011), ethanol and valproic acid (Arndt et 
al., 2005).  
Current research indicates that the development of ASDs is the result of contributing 
factors. Gastrointestinal (GI) disturbances have been strongly associated with ASDs, 
specifically due to an abnormal composition of enteric microbiota in autistic individuals 
(Parracho et al., 2005; de Theije et al., 2011). Evidence has been shown that treatment 
of these GI abnormalities in ASDs patients with antibiotics has resulted primarily in 
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alleviating local symptoms and additionally in a short-term improvement of cognitive 
skills (Sandler et al., 2000). Research and anecdotal evidence has been reported that the 
symptoms of ASDs may be exacerbated by the ingestion of wheat and dairy food 
products (Jyonouchi et al., 2002).These combined reports indicate that a gut derived 
factor may contribute to the pathogenesis of ASDs. Among other short-chain fatty acids 
PPA is produced by oppurtunistic enteric bacteria such as clostridial species in the gut 
and elevated levels of these bacteria have been found in ASDs individuals (Finegold et 
al., 2002). PPA is also commonly found in wheat and dairy food products (Brock & 
Buckel, 2004). A dysfunction in normal short-chain fatty acid metabolism can result in 
access of PPA to the bloodstream. PPA can readily cross the blood-brain barrier by 
passive or active means and gain access to the central nervous system (Conn et al., 
1983). PPA and other short-chain fatty acids have been shown to negatively affect 
processes such as lipid metabolism (Hara et al., 1999), immune function (Le Poul et al., 
2003) and neurotransmitter release (DeCastro et al., 2005) all of which have been 
implicated in the etiology of ASDs.  
Increased oxidative stress in ASDs may contribute to development of the disorder. A 
variety of underlying contributing factors combined with oxidative stress have been 
proposed as a causative factor in ASDs (Chauhan & Chauhan, 2006). Reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) production is regulated by a robust 
anti-oxidant network. A disruption in normal ROS (e.g. H2O2) and RNS (e.g. NO) 
homeostasis leads to oxidative/nitrosative stress and consequently mitochondrial 
dysfunction, inflammation and cell injury (Valko et al., 2007). Several studies have 
shown a decrease in anti-oxidant enzyme activity in ASDs including catalase (Zoroglu 
et al., 2004), and superoxide dismutase (Yorbik et al., 2002) in the blood. Elevated 
levels of oxidative stress markers have also been measured in ASDs brain tissue 
preparations (Chauhan et al., 2012; Rose et al., 2012). Haematological studies 
undertaken by Sogut et al. have demonstrated that a decreased level of anti-oxidant 
activity and an elevated level of NO is found in individuals with ASDs (Sogut et al., 
2003). NO has been shown to exert neuroprotective effects at normal concentrations, 
however NO can become neurotoxic at high concentrations (Calabrese et al., 2007). 
Evidence has been shown that treatment with PPA has resulted in a reduction in anti-
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oxidant enzyme levels and increased oxidative stress markers in brain homogenates of 
rats (El-Ansary et al., 2012). Additionally chronic administration with ascorbic acid 
prevents behavioural alterations associated with the administration of PPA in rats 
(Pettenuzzo et al., 2002). Recent work conducted by MacFabe et al. has demonstrated 
that intracerebroventricular infusions of PPA produced behavioural, biochemical, 
electrophysiological and pathological effects in rats consistent with that found in ASDs 
(MacFabe et al., 2007; MacFabe et al., 2008; MacFabe et al., 2011).  
The novel investigations discussed in this chapter present the real-time detection of NO 
in the nucleus accumbens (NA) and dorsal hippocampus (DH) of male Wistar rats in 
response to the systemic administration of PPA. The NA and DH are part of the limbic 
system which plays a role in emotional and social cognitive processing. It has been 
postulated that the social and behavioural impairments which manifest in ASDs may 
reflect a dysfunction in the limbic system (MacFabe et al., 2008). The NA has been 
shown to play a role in processes such as reward emotion and addiction (Saulskaya & 
Fofonova, 2006; Saul'skaya et al., 2008). Functional magnetic resonance imaging has 
indicated that a general reward dysfunction is implicated in ASDs (Dichter et al., 2012; 
Kohls et al., 2012). The hippocampus is strongly associated with learning and memory 
and abnormalities in this brain region have been indicated in ASDs individuals (Goh & 
Peterson, 2012). NO has been shown to play an important role in synaptic plasticity 
(Garthwaite, 2008) and plays a vital role in learning and memory (Wass et al., 2006a; 
Wass et al., 2006b; Nugent et al., 2007). The main aim of this chapter is to demonstrate 
the effect of PPA on NO levels in the central nervous system (CNS) of freely-moving 
animals.  
 
 
 
 
 
Chapter 7: ASDs and NO 
 
288 
 
7.2 Experimental 
A detailed description of the instrumentation, chemicals, solutions and software used 
during these experiments is given in Chapter 3. A detailed description of the 
manufacture of the NO sensor is outlined in Section 3.4. The surgical protocol followed 
for the implantation of NO sensors is provided in Section 3.10.2. All experiments 
outlined in this chapter were performed using Constant Potential Amperometry (CPA). 
A potential of +900 mV vs. Ag wire (see Section 3.10.3) was applied to the working 
electrodes for all in-vivo experiments. For systemic administration a stock solution of 
PPA was prepared by dissolving 0.5 g of sodium propionate in 1 mL saline which was 
subsequently injected at 1 mL/kg (500 mg/kg) twice daily at 12.00 hrs and 15.00 hrs.  
The number of implanted NO sensors is denoted by (n) and the number of animals 
utilised is provided. In the case where the number of administrations included in the data 
exceeds the number of sensors/animals the value is given and denoted by (adm). NO 
sensors were implanted in two different regions of the brain, the dorsal hippocampus 
(DH) and the nucleus accumbens (NA).  
Reported in-vivo NO concentration changes are based on the average in-vitro pre-
implantation calibration data. Area under the curve (AUC) analysis was utilised to 
determine the overall NO response following administration of PPA. The net AUC 
value is represented in this chapter i.e. the average AUC value was calculated for peaks 
below and above baseline levels. AUC provides an integrated measurement of a 
measurable effect or phenomenon. AUC determines the overall change in NO before 
returning to a baseline level which is relative to the effect of PPA administration.  
Statistical analysis was carried out using paired or unpaired t-tests. These tests were 
performed using Graphpad Prism and gave a probability value (P) which indicates the 
level of significant or non-significant difference between groups. P > 0.05, denotes no 
significant difference. The extent of significant difference is divided into three 
parameters (P < 0.05,*), (P < 0.01,**) and (P < 0.0001,***) from the lowest relative 
level of difference (*) to the highest (***).  
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7.3 Systemic control experiments (s.c.) 
The data displayed in this section was obtained from freely-moving rats. This section 
outlines the control experiments conducted in freely-moving animals. The effect of the 
systemic administration of saline on the NO sensor response is described within. The 
systemic administration of various physiologically relevant substances on the NO sensor 
response may be compared against the control experiments shown in this section.  
7.3.1 Systemic (s.c.) saline administration (NA) 
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Figure 7.3.1 A typical example of a 1mL/kg s.c. injection of saline detected by the NO sensor 
implanted in the nucleus accumbens (NA) of a freely-moving Wistar rat. Inset: Immediate response 
following injection (secs). The arrow indicates the point of administration. 
All systemic administrations shown in this chapter were carried out in 1 mL/kg of saline 
by subcutaneous injection (s.c.). As a control experiment saline (Section 3.3.3.2) was 
administered subcutaneously (s.c.) (Section 3.11.2) and the effect on the NO signal was 
measured. Upon the administration of saline a brief fluctuation in NO is observed which 
is due to the physical manipulation of the subject as can be seen in Figure 7.3.1 (inset). 
A small increase was found subsequently of 10.5 ± 1.9 pA (n = 6, 10ad) after 3.0 ± 0.3 
mins (n = 6, 10ad) and a return to pre-injection baseline levels was seen 7.4 ± 0.4 mins 
(n = 6, 10ad) following the injection. The recorded change in current corresponds to a 
concentration change of 6.9 ± 1.2 nM NO (n = 6, 10ad). However this NO concentration 
Chapter 7: ASDs and NO 
 
290 
 
change is short lived. The aim of the experiments shown in this section is to demonstrate 
the NO response which is attributable to the injection itself is minimal. No significant 
difference (P > 0.05) was observed between pre and post-injection baseline levels. No 
lasting effect on the response of the NO sensor was observed following the systemic 
administration of saline. The data presented in this section is consistent with previous 
findings of the effect of systemic administration of saline on the response of this sensor 
design monitored in the NA (Finnerty et al., 2012).  
Analyte 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
Saline 
10.5 ± 
1.9 
1.9 ± 
0.3 
7.0 ±  
1.0 
3.0 ± 
0.3 
7.4 ± 
0.4 
550.7 ± 
104.3 
554.6 ± 
104.8 
 
Table 7.3.1: Summary of results shown in Section 7.3.1. Data obtained from 6 sensors implanted in 
the nucleus accumbens of 3 Wistar rats. Average data includes 10 administrations. 
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7.4 Propionic acid (PPA) administration dose response 
The preliminary results in this section demonstrate the response of the NO sensor 
implanted in the nucleus accumbens (NA) following the systemic administration of 
PPA. A dose response study was conducted and the NO response attributable to the 
administration of 1 µM/g, 2 µM/g and 4 µM/g PPA was examined. 
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Figure 7.4.1 The effect of each dose of systemically administered PPA on the NO sensor response 
monitored in the Nucleus Accumbens (NA) of freely-moving Wistar rats. An example of each dose is 
represented as follows (A) 1 µM/g, (B) 2 µM/g and (C) 4 µM/g. Arrows indicates the point of 
administration. 
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Figure 7.4.2 Dose response comparison of PPA systemic administration vs. saline on the NO sensor 
response implanted in the nucleus accumbens (NA) of a freely-moving Wistar rat. Data represented 
as the maximum current response ± SEM (pA) above baseline. 
The data represented in Figure 7.4.2 demonstrates the maximum current response of the 
NO sensor implanted in the nucleus accumbens (NA) of freely-moving animals 
following the systemic administration of PPA. A clear increase above baseline levels of 
NO was observed following the administration of each dose of PPA (1 µM/g, 2 µM/g 
and 4 µM/g). The 1 µM/g dose of PPA resulted in a recorded maximal current increase 
of 29.67 ± 6.03 pA (n = 3). The systemic administration of a higher dose of PPA (2 
µM/g) resulted in a similar increase of 28.80 ± 2.91 pA (n = 3) which was not 
significantly different (P > 0.05) to the lower dose (1 µM/g). The highest dose of PPA 
administered resulted in the highest observed current change of 69.15 ± 9.85 pA (n = 2) 
and was significantly different (P < 0.05,*) from the NO response recorded following 
injection of the lowest dose of PPA (1 µM/g). With each dose a significant difference (P 
< 0.05) in the current response was observed compared to the NO response seen upon 
administration of saline recorded in the NA (Section 7.3.2). The results are summarised 
in Table 7.4.1. Similar maximum response times were observed with the 1 µM/g, 2 
µM/g and 4 µM/g dose of PPA and the time required to return to a baseline level 
following the injection was similar in each case. However the NO response recorded 
following the administration of 4 µM/g PPA is much more attenuated when compared to 
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the lower doses (Figure 7.4.1). It is possible that PPA exerts its effects on the NO 
response in a dose independent manner. However it must be stated at this point that the 
experiments shown in this section are preliminary. Further work is required to elucidate 
the effect of different systemically administered doses of PPA on the NO sensor 
response. The increase in NO levels due to administration of 4 µM/g PPA may be due to 
an accumulation of PPA as the previous lower doses (1 µM/g and 2 µM/g) had been 
administered to the same animal. Future work may involve the extension of the time 
allowed between the injection of each dose of PPA in order to fully examine the long-
term effect of each systemically administered dose. PPA has been shown to accumulate 
within cells and induce intracellular acidification (Shultz et al., 2008). The pilot study 
demonstrated in this section indicates that the systemic administration of PPA induces 
the production of NO in the NA. In order to elucidate the possible accumulative effect of 
PPA on NO levels, PPA was administered to the subject at a different dose (500 mg/kg), 
more frequently and over an extended period and these results are outlined in the next 
Section (Section 7.5).  
PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
1 
µM/g 
29.7 ± 
6.0 
9.2 ±  
3.0 
19.4 ± 
3.9 
111.0 ± 
35.0 
271.0± 
112.0 
359.5 ± 
70.4 
355.3 ± 
58.2 3 
2 
µM/g 
28.8 ± 
2.9 
8.2 ±  
1.8 
18.8 ± 
1.9 
284.7 ± 
8.3 
436.3 ± 
54.7 
383.0 ± 
65.9 
373.7 ± 
64.8 3 
4 
µM/g 
69.2 ± 
9.8 
20.8 ± 
3.8 
45.3 ± 
6.4 270 375 
334.5 ± 
14.4 
392.2 ± 
4.0 2 
 
Table 7.4.1: Summary of results shown in Section 7.4. With n = the number of sensors 
implanted in 2 animals (1 µM/g), 2 animals (2 µM/g) and 1 animal (4 µM/g). 
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7.5 Chronic Propionic acid (PPA) administration (NA) 
This section outlines the effect of chronic repetitive administration of PPA on NO levels 
in the NA of freely-moving animals. Each animal was administered PPA (500 mg/kg) 
twice daily (see Section 3.3.2.2) for a continuous period of 12 days and the 
corresponding changes in NO levels on each day were monitored by the NO sensor.  
 
7.5.1 24 hr Control NO data (NA) 
The results in this section demonstrate the response detected by the NO sensor for a 
continuous period of 24 hrs while implanted in the nucleus accumbens (NA). The 
administration of saline has no lasting effect on the NO sensor response as has been 
demonstrated in Section 7.3.2. The results shown in this section act as a control against 
which the NO response due to the long term administration of PPA, recorded in the NA 
for a period of 24 hrs may be compared.  
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Figure 7.5.1 The recorded NO response in the NA over a continuous period of 24 hrs. Data 
represented as a percentage current change ± SEM. SEM represented by dashed line (black). 
Figure 7.5.1 represents the NO levels recorded in the NA over a continuous period of 24 
hrs for an average of 8 days (n = 3, 2 animals). The data represents the long-term NO 
response recorded in the NA. It is clear that the NO response remains close to baseline 
levels for the duration of the recording period. The dark phase of the light cycle is 
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represented by the hatched box in Figure 7.5.1. A slight drift below baseline levels of 
NO which is denoted by the dashed line is apparent within the dark phase of the light 
cycle and a return to a stable baseline level of NO can be seen subsequently. In order to 
examine the overall change in NO over a 24 hr period for an average of 8 days AUC 
analysis was performed which gave a response of -22.4 ± 9.7 pA/hr (n = 3).  
Recordings were taken after an initial period of ca. 24 hrs following the application of 
potential to the working electrodes. Therefore the contribution of the capacitance current 
to the overall NO sensor response represented in Figure 7.5.1 is greatly reduced. 
Additionally the baseline stability of the NO sensor is maintained while implanted in the 
NA for a consecutive period of 14 days (see Section 6.8.5). However it is possible that 
some remaining capacitance may contribute to the overall NO response presented in 
Figure 7.5.1. Therefore the small variation in NO response recorded over the 24 hr 
period demonstrated in Figure 7.5.1 is likely attributable to a combination of residual 
capacitance (signal drift) and contributions to the NO response from the circadian 
rhythms of the animal.  
The role of NO in the maintenance of the sleep-wake cycle has been extensively 
reviewed (Gautier-Sauvigne et al., 2005; Cespuglio et al., 2012). The influence of NOS 
inhibitors and inducers on the sleep-wake cycle in rats has been demonstrated by 
Gautier-Sauvigne et al. (Gautier-Sauvigne et al., 2005). Nycthemeral variations i.e. 
changes pertaining to the duration of a day (24 hrs), in NO levels have been 
demonstrated by Cespuglio et al. using voltametric methods in freely-moving rats. A 
variation in the level of NO was determined between episodes of waking and sleep in 
the animal within a 24 hr period by this research group. Additionally regional deviations 
were determined where opposite nycthemeral changes in NO within the light and dark 
phase were detected (Cespuglio et al., 2012). These combined findings may contribute 
to the small variations in the long-term NO response recorded in the NA (Figure 7.5.1). 
However the overall contribution of previously determined sleep/wake effects and 
possible residual capacitance on the level of NO over a 24 hr period are effectively 
eliminated from the overall signal attributable to administration of PPA (see Section 
7.5.2) by the control data presented in this section.   
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7.5.2 Chronic PPA administration (NA) day 1-6 
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Figure 7.5.2 The average NO response recorded in the NA over a continuous period of 24 hrs 
following systemic administration of PPA. (A) 1 day of PPA treatment (B) 2 days, (C) 3 days, (D) 4 
days, (E) 5 days and (F) 6 days. Data represented as a percentage change ± SEM. Arrows indicate 
the injection of PPA.  
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This section presents NO levels in the nucleus accumbens (NA) monitored by the NO 
sensor following the administration (s.c.) of PPA (Section 3.3.2.2) for an initial period 
of 1 to 6 days. PPA was administered twice daily, the first injection was given at 12.00 
hrs and the second injection was administered at 15.00 hrs as indicated by the arrows 
shown in Figure 7.5.2. The NO response was monitored for a continuous period of 24 
hrs. The results demonstrated in this chapter represent the novel detection of NO in the 
freely-moving animal following treatment with PPA. It was deemed necessary to 
investigate the long-term effect of PPA over 24 hrs on the level of NO in the NA as the 
effect of PPA on NO levels in the brain of freely-moving animals has not previously 
been demonstrated.   
AUC analysis was utilised in determining the overall effect of PPA on the NO current 
response. The NO response in the NA remained close to baseline levels upon the initial 
exposure to PPA on day 1 as can be seen in Figure 7.5.2(A). The maximum NO 
response was achieved within 9.1 ± 2.0 hrs, n = 4 and a return to pre-injection basal 
levels was observed 14.3 ± 2.1 hrs, n = 4 subsequently. The pre-injection (318.1 ± 33 
pA, n = 4) and post-injection baseline values (313.5 ± 38.4 pA, n = 4) were not 
significantly different (P > 0.05). Day 1 of the PPA administration protocol resulted in 
an AUC value of -12.2 ± 14.0 pA/hr, this value was not significantly different (P > 0.05) 
to the control experiments outlined in Section 7.5.1.  
The AUC determined for day 2 of the PPA administration protocol was -13.7 ± 8.7 
pA/hr (n = 5). This value was not significantly different (P > 0.05) to the control 
experiments outlined in Section 7.5.1. No significant difference was observed between 
the pre and post-injection basal levels on day 2 and the results are summarised in Table 
7.5.2. No significant difference (P > 0.05) was observed between the maximum 
response time and the time required to return to a baseline level on day 2 with respect to 
day 1.  
As can be seen in Figure 7.5.2(C) an increase above baseline levels of NO occurred on 
day 3 of PPA treatment which gave an AUC value of 5.3 ± 5.3 pA/hr (n = 4). The AUC 
value determined for day 3 was not significantly different (P > 0.05) to the 
corresponding AUC value calculated for day 0 (see Section 7.5.1). No significant 
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difference (P > 0.05) was observed between the baseline level recorded prior to 
administration of PPA (278.3 ± 20.4 pA, n = 4) and the subsequent return to baseline 
levels (281.5 ± 22.1 pA, n = 4) on day 3. The time required to achieve a maximum NO 
current response on day 3 (5.4 ± 0.1 hrs, n = 4) was less than that seen on day 1 (9.1 ± 
2.0 hrs, n = 4) and day 2 (6.4 ± 0.7 hrs, n = 5). However the maximum response time 
recorded on day 3 was not significantly different P > 0.05 when compared to day 1 and 
similarly the time required to return to a baseline level was not significantly different (P 
> 0.05).  
The AUC determined for days 4 and 5 of PPA treatment was -16.7 ± 11.8 pA/hr (n = 4) 
and -11.1 ± 12.2 (n = 4) respectively. No significant difference P > 0.05 was observed 
on day 4 and 5 of PPA administration when compared to the NO response determined 
by AUC on day 0. The pre and post-injection baseline levels recorded on day 4 and 5 
were not significantly different (P > 0.05) and the results are summarised in Table 7.5.2. 
No significant difference (P > 0.05) was observed between the maximum response time 
and subsequent return to baseline levels on day 4 and 5 when compared to day 1.  
A similar trend was observed on day 6 of the PPA administration protocol. AUC 
analysis revealed a response of -5.8 ± 8.0 pA/hr (n = 4) on day 6. When compared to the 
AUC value determined on day 0 no significant difference (P > 0.05) was observed on 
day 6. The pre and post-injection baseline levels recorded on day 6 revealed no 
significant difference (P > 0.05). A summary of these results is provided in Table 7.5.2. 
The maximum response time and the time required to reach a subsequent baseline level 
on day 6 did not significantly differ, P > 0.05, from day 1 of PPA administration. 
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Figure 7.5.2.1 Comparison between control NO response recorded in the NA and the response 
following systemic administration of PPA. Control data (day 0) and day 1-7 of PPA administration. 
Data represented as Mean AUC ± SEM (pA/hr). 
Figure 7.5.2.1 represents the average NO response recorded on day 1 to 6 of PPA 
treatment determined by AUC analysis. The control NO response calculated by AUC 
(Section 7.5.1) is represented by day 0. The NO response recorded on day 1 to day 6 of 
the PPA treatment protocol is not significantly different (P > 0.05) on each day when 
compared to the NO response determined for day 0. An increase in NO levels in the NA 
has occurred due to the systemic administration of PPA. However no significant 
difference (P > 0.05) in NO response was determined by AUC analysis on each day 
between day 1 and 6 of the PPA administration protocol when compared to day 0. It was 
necessary to extend the administration of PPA to fully examine the effect of PPA 
administration on the NO response. Day 7 to day 12 of the systemic administration of 
PPA is shown in the next Section (7.5.3). 
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PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
Day 
0 
n/a n/a n/a n/a n/a -22.4 ± 9.7 n/a n/a 3 
Day 
1 
17.6 ± 
32.6 
5.5 ± 
10.2 
11.1 ± 
20.6 
9.1 ± 
2.0 
14.3 ± 
2.1 
-12.2 ± 
14.0 
318.1 ± 
33.0 
313.5 ± 
38.4 4 
Day 
2 
-23.1 ± 
16.6 
-7.5 ± 
5.4 
-14.6 
± 10.5 
6.4 ± 
0.7 
14.6 ± 
0.6 
-13.7 ± 
8.7 
306.9 ± 
25.8 
284.8 ± 
23.4 5 
Day 
3 
24.3 ± 
3.6 
8.7 ± 
1.3 
15.4 ± 
2.3 
5.4 ± 
0.1 
12.3 ± 
0.8 
5.3 ± 
5.3 
278.3 ± 
20.4 
281.5 ± 
22.1 4 
Day 
4 
-7.0 ± 
45.3 
-2.4 ± 
15.7 
-4.4 ± 
28.7 
10.1 ± 
2.0 
15.4 ± 
1.9 
-16.7 ± 
11.8 
287.7 ± 
24.4 
280.5 ± 
34.4 4 
Day 
5 
-2.1 ± 
31.4 
-0.7 ± 
11.2 
-1.3 ± 
19.8 
7.3 ± 
1.2 
14.3 ± 
0.9 
-11.1 ± 
12.2 
279.3 ± 
34.7 
268.8 ± 
36.9 4 
Day 
6 
60.2 ± 
43.8 
22.0 ± 
16.0 
38.1 ± 
27.7 
7.1 ± 
1.6 
15.5 ± 
0.5 
-5.8 ± 
8.0 
274.1 ± 
26.9 
256.3 ± 
31.5 5 
 
Table 7.5.2 Summary of the NO data recorded between day 1 and 6 of chronic PPA administration 
(NA). With n = the number of sensors implanted in 2 animals (day 0), 4 animals (day 1-5) and 5 
animals (day 6).  
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7.5.3 Chronic PPA administration (NA) day 7-12 
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Figure 7.5.3 The average NO response recorded in the NA over a continuous period of 24 hrs 
following systemic administration of PPA. (A) 7 days of PPA treatment (B) 8 days, (C) 9 days, (D) 
10 days, (E) 11 days and (F) 12 days. Data represented as a percentage change ± SEM. Arrows 
indicate the injection of PPA.  
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The results demonstrated in this section examine the extension of the PPA 
administration protocol discussed in Section 7.5.2 (1 to 6 days). This section represents 
NO levels monitored in the NA by the NO sensor following the administration (s.c.) of 
PPA (Section 3.3.2.2) for a subsequent period of 7 to 12 days. PPA was administered 
twice daily, the first injection was given at 12.00 hrs and the second injection was 
administered at 15.00 hrs as indicated by the arrows shown in Figure 7.5.3.  
Figure 7.5.3(A) demonstrates the average NO response recorded following 7 days of 
systemic PPA administration. An increase in NO was observed following the 
administration of PPA. AUC analysis revealed a significant difference (P < 0.05,*) 
between the overall NO response on day 7 (24.1 ± 7.4 pA/hr, n = 3) when compared to 
day 0. The pre-injection (225.4 ± 47.8 pA, n = 3) and post-injection baseline values 
(238.1 ± 51.5 pA, n = 3) on day 7 did not significantly differ (P > 0.05). As had been 
observed on day 2 to day 6 of PPA treatment the maximum response time and the time 
required to achieve a subsequent baseline level on day 7 did not significantly differ (P > 
0.05) from day 1 of PPA administration. 
Figure 7.5.3(B) illustrates the NO response recorded by the NO sensor implanted in the 
NA following the systemic administration of PPA for a total of 8 days. A clear increase 
in NO above baseline levels was observed, the calculated AUC analysis of the NO 
response on day 8 was 23.4 ± 7.5 pA/hr, n = 5. A significant difference (P < 0.01,**) 
was observed between the AUC of day 8 and day 0. The maximum NO response was 
achieved within 5.2 ± 0.7 hrs, n = 5 and a return to pre-injection basal levels occurred 
17.6 ± 0.8 hrs, n = 5 subsequently. No significant difference P > 0.05 was observed 
between the baseline level recorded prior to administration of PPA (384.9 ± 152.8 pA, n 
= 5) and the subsequent return to baseline levels (406.1 ± 152.1 pA, n = 5) on day 8.  
Day 9 of the PPA administration protocol resulted in an increase in NO above baseline 
levels and the AUC of this response was 20.2 ± 4.8 pA/hr (n = 5). The response on day 
9 was significantly different (P < 0.01,**) from the NO response determined by AUC 
on day 0. No significant difference was observed between the pre and post-injection 
basal levels of NO on day 9 and the results are summarised in Table 7.5.3. The 
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maximum response time and the time required to return to a baseline was not 
significantly different P > 0.05 on day 9 with respect to day 1.  
The AUC determined for day 10 of the PPA administration protocol was 29.7 ± 11.1 
pA/hr (n = 3). A similar trend was observed to that seen on day 8 and 9. An increase in 
NO response was observed with respect to day 0 and this response was significantly 
different (P < 0.05,*). No significant difference (P > 0.05) was observed between the 
baseline level recorded prior to administration of PPA (278.6 ± 26.5 pA, n = 3) and the 
subsequent return to baseline levels (300.3 ± 24.9 pA, n = 3) on day 10. The maximum 
response time and the baseline return time period was not significantly different (P > 
0.05) from day 1.  
The calculated AUC for day 11 of the PPA administration protocol was 25.8 ± 1.6 pA/hr 
(n = 2). A similar trend was observed on day 11 when compared to that seen from day 7 
to 10. An increase in NO response was observed with respect to day 0, however in this 
case the response was not significantly different (P > 0.05). The statistical abnormality 
determined on day 11 is likely due to a discrepancy in the number of sensors examined 
in the data (n = 2) (see Table 7.6.2). Future work may include the repetition of the PPA 
administration protocol for a period of 11 days in order to fully examine this possibility. 
However an overall increase was observed on day 11 in relation to day 0. No significant 
difference P > 0.05 was observed between the NO baseline level recorded prior to 
administration of PPA (278.6 ± 26.5 pA, n = 2) and the subsequent return to baseline 
levels (271.7 ± 8.6 pA, n = 2) on day 11. The maximum response time and the time 
required to return to baseline was not significantly different P > 0.05 from day 1.  
Figure 7.5.3(F) demonstrates the average NO response recorded in the NA following 12 
days of systemic PPA administration. A clear attenuated increase in NO was observed 
following the administration of PPA. As seen previously a significant difference (P < 
0.01,**) in response was observed on day 12 (30.7 ± 9.9 pA/hr, n = 4) when compared 
to the AUC determined on day 0. The pre-injection (258.1 ± 35.3 pA, n = 4) and post-
injection baseline values (276.5 ± 36.0 pA, n = 4) on day 12 were not significantly 
different P > 0.05. As had been observed on day 2 to day 11 of PPA treatment, the 
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maximum response time and the time required to achieve a subsequent baseline level on 
day 12 did not significantly differ P > 0.05 from day 1 of PPA administration. 
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Figure 7.5.3.1 Comparison between control NO response recorded in the NA and the response 
following systemic administration of PPA. Control data (day 0) and day 8-14 of PPA 
administration. Data represented as Mean AUC ± SEM (pA/hr) with (P < 0.05,*) and (P < 0.01,**). 
Figure 7.5.3.1 demonstrates the average NO response monitored in the NA on day 7 to 
12 of systemic PPA administration determined by AUC analysis. The control NO 
response calculated by AUC (Section 7.5.1) is displayed and denoted by day 0. It is 
clear that the NO response recorded on day 7 to day 12 of the PPA treatment protocol is 
significantly different (P < 0.05) on each day with the exception of day 11 when 
compared to the NO response recorded on day 0. A discussion of the effect of each day 
of PPA treatment (day 1 to 12) monitored in the NA by the Nafion®-modified NO 
sensor is discussed in the next Section (7.5.4).  
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PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
Day 
0 
n/a n/a n/a n/a n/a -22.4 ± 9.7 n/a n/a 3 
Day 
7 
52.3 ± 
18.2 
23.2 ± 
8.1 
33.1 ± 
11.5 
7.0 ± 
0.5 
17.0 ± 
0.5 
24.1 ± 
7.4 
225.4 ± 
47.8 
238.1 ± 
51.5 3 
Day 
8 
61.4 ± 
20.2 
16.0 ± 
5.2 
38.9 ± 
12.8 
5.2 ± 
0.7 
17.6 ± 
0.8 
23.4 ± 
7.5 
384.9 ± 
152.8 
406.1 ± 
152.1 5 
Day 
9 
50.5 ± 
7.7 
12.6 ± 
2.0 
50.2 ± 
7.9 
5.3 ± 
0.9 
16.3 ± 
0.9 
20.2 ± 
4.8 
459 ± 
168.3 
289.4 ± 
19.0 5 
Day 
10 
92.7 ± 
29.1 
33.3 ± 
10.4 
58.6 ± 
18.4 
7.0 ± 
2.8 
15.3 ± 
1.2 
29.7 ± 
11.1 
278.6 ± 
26.5 
300.3 ± 
24.9 3 
Day 
11 
104.2 ± 
24.9 
38.0 
±9.1 
65.9 ± 
15.7 
6.5 ± 
1.5 
15.8 ± 
0.7 
25.8 ± 
1.6 
274.4 ± 
12.5 
271.7 ± 
8.6 2 
Day 
12 
86.1 ± 
19.9 
22.3 ± 
3.7 
59.4 ± 
9.7 
7.0 ± 
0.7 
16.4 ± 
0.6 
30.7 ± 
9.9 
258.1 ± 
35.3 
276.5 ± 
36 4 
 
Table 7.6.2 Summary of the NO data recorded between day 7 to 12 of chronic PPA administration 
(NA). With n = the number of sensors implanted in 2 animals (day 0), 3 animals (day 7), 4 animals 
(day 8-9), 3 animals (day 10), 2 animals (day 11) and 4 animals (day 12).   
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7.5.4 AUC comparison chronic PPA administration (NA) day 1-12 
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Figure 7.5.4 Comparison between the NO responses recorded in the NA on day 0 and day 1-12 of 
PPA administration. Data represented as Mean AUC ± SEM (pA/hr). With (P < 0.05,*) and (P < 
0.01,**).  
Figure 7.5.4 represents the overall NO response before returning to baseline (AUC) 
recorded in the NA on day 0 (Section 7.5.1) against the AUC values obtained on day 1 
to 14 of the PPA administration protocol. It is clear that an increase in NO response 
occurs as the experimental protocol proceeds from day 7 through to day 12 and the level 
of exposure to PPA is increased. It can be deduced that the observed increases in NO 
due to the administration of PPA are incurred by an accumulative effect of the presence 
of PPA. The more prolonged the exposure time to PPA the more attenuated and 
maximal the NO response in the NA becomes. The results presented in this section are 
summarised in Table 7.5.4. 
No significant difference P > 0.05 was observed between the maximum response time 
and the time required to return to baseline on each day of PPA treatment when 
compared to day 1. No significant difference P > 0.05 was observed between the pre and 
post-injection basal levels of NO on each day of PPA treatment (day 1 to 12).  
A significant difference (P < 0.05) in NO response was determined by AUC analysis on 
day 8 and 9 following the administration of PPA when compared to day 1 of PPA 
treatment. Similarly a significant difference (P < 0.05) was observed between the AUC 
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value determined on day 12 when compared to day 1. With (day 8, P = 0.0484), (day 9, 
P = 0.0472) and (day 12, P = 0.0464) when compared to the AUC value calculated for 
day 1 of PPA treatment. 
Day 0 1 2 3 4 5 6 
AUC 
(pA/hr) 
-22.4 ± 
9.7 
-12.2 ± 
14.0 
-13.7 ± 
8.7 
5.3 ± 
5.3 
-16.7 ± 
11.8 
-11.1 ± 
12.2 
-5.8 ± 
8.0 
P n/a 0.5677 0.5655 0.0984 0.7402 0.5164 0.2750 
n 3 4 5 4 4 4 5 
 
Day 0 7 8 9 10 11 12 
AUC 
(pA/hr) 
-22.4 ± 
9.7 
24.1 ± 
7.4 
23.4 ± 
7.5 
20.2 ± 
4.8 
29.7 ± 
11.1 
25.8 ± 
1.6 
30.7 ± 
9.9 
P n/a 0.0262 0.0077 0.0093 0.0175 0.0518 0.0074 
n 3 3 5 5 3 2 4 
 
Table 7.5.4 Comparison of the NO data (NA), Data represented as AUC ± SEM (pA/hr), recorded 
on day 0 against day 1-12 of chronic PPA administration. 
From the results presented in this section, it is clear that the systemic administration of 
PPA, which has previously been used in the development of an animal model of autism, 
leads to an increased production of NO in the NA. The PPA induced elevation of NO 
levels is particularly evident towards the end of the experimental procedure i.e. day 7-12 
(see Figure 7.5.4). The evidence of a PPA induced increase in NO presented here is 
further supported by the previous detection of increased oxidative stress markers in 
brain homogenates of PPA treated rats (MacFabe et al., 2008; El-Ansary et al., 2012). 
Increased oxidative stress has been implicated in the development of autism as reviewed 
by Chauhan and Chauhan (Chauhan & Chauhan, 2006). A disruption in anti-oxidant 
enzyme levels in autism has been demonstrated, specifically by a reduction in catalase 
and superoxide dismutase (SOD) in erythrocytes of autistic individuals (Yorbik et al., 
2002; Zoroglu et al., 2004). Additionally the impairment of glutathione redox 
homeostasis which maintains the primary anti-oxidant defence systems in the CNS has 
been demonstrated in post mortem ASDs brain preparations (Chauhan et al., 2012).  
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An elevated level of NO has previously been demonstrated in blood samples of autistic 
persons (Sogut et al., 2003). Indirect markers of elevated NO production i.e. nitrite and 
nitrate have been demonstrated in the plasma of autistic individuals (Zoroglu et al., 
2003; Sweeten et al., 2004). Additionally an elevation of oxidative stress markers has 
been presented in PPA treated rat brain tissue preparations (MacFabe et al., 2008; El-
Ansary et al., 2012). It is well established that a disruption to the robust anti-oxidant 
network leads to an increased production of oxidative (e.g. H2O2) and nitrosative stress 
markers (e.g. NO) (Andersen, 2004; Valko et al., 2007). The downstream effects of an 
abnormally high concentration of NO in the CNS is the formation of peroxynitrite which 
is highly neurotoxic (Calabrese et al., 2007). These combined reports indicate that 
oxidative/nitrosative stress is highly implicated in the pathophysiology of ASDs.  
7.6 Chronic Propionic acid (PPA) administration (DH) 
The results displayed in this section outline the effect of chronic repetitive 
administration of PPA on NO levels in the dorsal hippocampus (DH) of freely-moving 
animals. Each animal was administered PPA twice daily (Section 3.3.2.2) for a 
continuous period of 12 days and the corresponding changes in NO levels on each day 
were monitored by the NO sensor. The first injection of PPA was given at 12.00 hrs and 
the second injection was administered at 15.00 hrs. 
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7.6.1 24 hr Control NO data (DH) 
The results in this section demonstrate the response of the NO sensor implanted in the 
DH for a continuous period of 24 hrs. The administration of saline has no lasting effect 
on the NO sensor response as can be seen in Section 7.3.1. The results shown in this 
section act as a control against which the NO response due to the long term 
administration of PPA recorded in the DH may be compared.  
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Figure 7.6.1 The recorded NO response in the DH over a continuous period of 24 hrs. Data 
represented by a mean response ± SEM (pA). SEM represented by dashed line (black). 
Figure 7.6.1 presents the NO levels recorded in the DH over a continuous period of 24 
hrs for an average of 8 days (n = 2, 2 animals). It can be seen that the level of NO 
remains close to baseline levels for the duration of the recording period. A small drift 
below baseline levels of NO which is denoted by the dashed line was apparent. The 
AUC determined for the overall change in NO in the DH over a 24 hr period was -23.6 
± 10.5 pA/hr (n = 2) and this value is not significantly different (P > 0.05) when 
compared to the NO response obtained in the NA on day 0.   
The variation in NO levels between different brain regions following the administration 
of known inducers and inhibitors of NO production has previously been demonstrated 
(see Section 7.7). A relative lack of information is available on the comparison between 
long-term changes in NO in different brain regions in the absence of pharmacological 
treatment. However a time-dependent variation in the level of NO monitored in the 
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hippocampus has previously been demonstrated using electrochemical recordings 
(Heinzen & Pollack, 2002).  This research group demonstrated changes of NO over a 
chronic recording period in saline treated rats which they attribute to the circadian 
rhythms of the animal (Heinzen & Pollack, 2002).  
A strong correlation was observed in these experiments between changes in baseline 
levels of NO monitored over a 24 hr recording period in the DH when compared to the 
corresponding NO levels in the NA. The time-dependent minor variation in NO which is 
mirrored closely in both regions over the recorded time frame which suggests a 
contribution to the signal from a circadian variation in the level of NO.  
As previously discussed (see Section 7.5.1) capacitance contributions to the overall NO 
signal as presented in Figure 7.6.1 are greatly reduced as recordings were taken 
following an initial period of ca. 24 hrs following implantation. Additionally the 
baseline stability of the NO sensor is maintained while implanted for a consecutive 
period of 14 days (see Section 6.8.5). As seen in the NA the small variation in the NO 
response recorded over 24 hrs in the DH is likely mainly attributed to the circadian 
rhythms of the animal, which is supported by research previously conducted by 
Cespuglio et al. as discussed in Section 7.5.1 (Cespuglio et al., 2012).  
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7.6.2 Chronic PPA administration (DH) day 1-6 
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Figure 7.5.2 The average NO response recorded in the DH over a continuous period of 24 hrs 
following systemic administration of PPA. (A) 1 day of PPA treatment (B) 2 days, (C) 3 days, (D) 4 
days, (E) 5 days and (F) 6 days. Data represented as a percentage change ± SEM. Arrows indicate 
the injection of PPA.  
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The NO response recorded in the DH remained close to baseline levels on the initial day 
of PPA treatment (day 1) as can be seen in Figure 7.6.2(A). The maximum NO response 
was achieved within 16.9 ± 1.5 hrs, n = 5 and a subsequent decline in NO levels was 
observed which reached a baseline level 21.8 ± 0.5 hrs, n = 5 following the initial 
injection. The pre (455.1 ± 104.2 pA, n = 5) and post-injection baseline values (428.4 ± 
114.7 pA, n = 5) showed no significant difference (P > 0.05). Day 1 of PPA treatment 
resulted in an AUC value of -25.4 ± 6.0 pA/hr (n = 4) and this value was not 
significantly different (P > 0.05) to the control experiments outlined in Section 7.6.1.   
The AUC determined for day 2 of the PPA administration protocol was -12.8 ± 11.7 
pA/hr (n = 5) and this response was not significantly different P > 0.05 from the NO 
response determined by AUC on day 0. No significant difference was observed between 
the pre and post injection basal levels on day 2 and the results are summarised in Table 
7.6.2. A significant difference (P < 0.05) was observed between the maximum response 
time and the time required to return to a baseline level on day 2 when compared to day 
1.  
The NO response on day 3 of the PPA administration protocol is represented in Figure 
7.6.2(C). AUC analysis revealed a response of 15.2 ± 7.5 pA/hr (n = 4) on day 3. When 
compared to the AUC value determined on day 0 no significant difference (P > 0.05) 
was observed. The pre and post-injection baseline levels recorded on day 3 revealed no 
significant difference P > 0.05, a summary of these results is provided in Table 7.6.2. 
The maximum response time and the time required to achieve a subsequent baseline 
level on day 3 were significantly different (P < 0.05) from day 1 of PPA administration. 
The AUC determined for day 4 and 5 of PPA treatment was 13.5 ± 15.8 pA/hr (n = 4) 
and -35.5 ± 18.2 (n = 6) respectively. No significant difference P > 0.05 was observed 
on day 4 and 5 of PPA administration when compared to the NO response determined 
by AUC on day 0 (Section 7.6.1). The pre and post-injection baseline levels recorded on 
day 4 and 5 were not significantly different P > 0.05 and the results are summarised in 
Table 7.6.2. A significant difference (P < 0.05) was observed between the maximum 
response time and subsequent return to baseline levels on day 4 when compared to day 
1. The maximum response time and the time required to achieve a subsequent baseline 
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level on day 5 did not significantly differ P > 0.05 when compare to day 1 of PPA 
administration. 
AUC analysis revealed a response of -11.7 ± 7.9 pA/hr (n = 6) on day 6. When 
compared to the AUC value determined on day 0 no significant difference (P > 0.05) 
was observed on day 6. The pre and post-injection baseline levels recorded on day 6 
revealed no significant difference P > 0.05 and a summary of these results is provided in 
Table 7.6.2. The maximum response time and the time required to achieve a subsequent 
baseline level on day 6 did not significantly differ P > 0.05 from day 1 of PPA 
administration. 
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Figure 7.6.2.1 Comparison between control NO response recorded in the DH and the response 
following systemic administration of PPA. Control data (day 0) and day 1-6 of PPA administration. 
Data represented as Mean AUC ± SEM (pA/hr).  
Figure 7.6.2.1 represents the average NO response recorded in the DH on day 1 to 6 of 
PPA treatment which was determined by AUC analysis. The control NO response 
calculated by AUC (Section 7.6.1) is represented by day 0. The NO response recorded 
on day 1 to day 6 of the PPA treatment protocol is not significantly different P > 0.05 on 
each day when compared to the NO response recorded on day 0. It is clear that the 
systemic administration of PPA has caused an increase in NO levels in the DH on day 3 
and day 4 of PPA administration. However no significant difference P > 0.05 in NO 
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response was determined by AUC analysis on day 3 and 4 of the PPA administration 
protocol when compared to day 0. It was necessary to extend the administration of PPA 
to fully examine the effect of PPA administration on the NO response. Day 7 to day 12 
of systemic administration of PPA is shown in the next Section (7.6.3). 
PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
Day 
0 
n/a n/a n/a n/a n/a -23.6 ± 10.5 n/a n/a 2 
Day 
1 
-74.7 ± 
13.0 
-16.4 ± 
2.9 
-47.3 
± 8.3 
16.9 ± 
1.5 
21.8 ± 
0.5 
-25.4 ± 
6.0 
455.1 ± 
104.2 
428.4 ± 
114.7 5 
Day 
2 
-20.4 ± 
25.0 
-4.0 ± 
4.9 
-12.9 
± 15.8 
7.0 ± 
1.3 
15.0 ± 
1.7 
-12.8 ± 
11.7 
515.7 ± 
124.5 
492.2 ± 
131.0 5 
Day 
3 
-18.6 ± 
30.0 
-3.7 ± 
6.0 
-11.8 
± 19 
6.3 ± 
0.5 
14.2 ± 
1.4 
15.2 ± 
7.5 
499.6 ± 
132.7 
414.3 ± 
116.8 4 
Day 
4 
54.1 ± 
15.6 
12.6 ± 
3.6 
34.2 ± 
9.9 
4.8 ± 
0.8 
13.5 ± 
0.9 
13.5 ± 
15.8 
428.7 ± 
121.8 
429.0 ± 
109.2 4 
Day 
5 
-111.3 
± 27.4 
-17.7 ± 
4.4 
-70.5 
± 17.4 
15.9 ± 
2.1 
20.1 ± 
0.9 
-35.5 ± 
18.2 
629.6 ± 
228.5 
542.4 ± 
218.9 6 
Day 
6 
-83.8 ± 
52.9 
-16.2 ± 
10.2 
-53.0 
± 33.5 
14.8 ± 
2.7 
19.8 ± 
0.8 
-11.7 ± 
7.9 
516.8 ± 
191.3 
488.3 ± 
184.9 6 
 
Table 7.6.2 Summary of the NO data recorded between day 1 and 6 of chronic PPA administration 
(DH). With n = the number of sensors implanted in 2 animals (day 0), 3 animals (day 1), 4 animals 
(day 2-3), 3 animals (day 4), 4 animals (day 5) and 5 animals (day 6).  
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7.6.3 Chronic PPA administration (DH) day 7-12 
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Figure 7.6.3 The average NO response recorded in the DH over a continuous period of 24 hrs 
following systemic administration of PPA. (A) 7 days of PPA treatment (B) 8 days, (C) 9 days, (D) 
10 days, (E) 11 days and (F) 12 days. Data represented as a percentage change ± SEM. Arrows 
indicate the injection of PPA.  
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The results demonstrated in this section examine the extension of the PPA 
administration protocol discussed in Section 7.6.2 (1 to 6 days). This section represents 
NO levels monitored in the DH by the NO sensor following the administration (s.c.) of 
PPA (Section 3.3.2.2) for a subsequent period of 7 to 12 days. PPA was administered 
twice daily, the first injection was given at 12.00 hrs and the second injection was 
administered at 15.00 hrs as indicated by the arrows shown in Figure 7.6.3.  
Figure 7.5.3(A) demonstrates the average NO response recorded following 7 days of 
systemic PPA administration. An increase in NO can be seen following the 
administration of PPA. AUC analysis revealed a significant difference (P < 0.05,*) 
between the overall NO response on day 7 (19.0 ± 4.5 pA/hr, n = 3) when compared to 
day 0. The pre-injection (323.0 ± 62.9 pA, n = 3) and post-injection baseline values 
(334.3 ± 57.9 pA, n = 3) on day 7 did not significantly differ P > 0.05. The maximum 
response time and the time required to achieve a subsequent baseline level on day 7 did 
not significantly differ P > 0.05 from day 1 of PPA administration. 
Figure 7.6.3(B) illustrates the NO response recorded by the Nafion®-modified NO 
sensor implanted in the NA following the systemic administration of PPA for a total of 8 
days. An increase in NO above baseline levels can be seen. The AUC analysis of the NO 
response on day 8 was 11.1 ± 3.9 pA/hr, n = 4. A significant difference (P < 0.05,*) was 
observed when the AUC on day 8 was compared to day 0. The maximum NO response 
was achieved within 5.75 ± 0.6 hrs, n = 4 and a return to pre-injection basal levels was 
observed 18.0 ± 2.1 hrs, n = 4 subsequently. No significant difference (P > 0.05) was 
observed between the baseline level recorded prior to administration of PPA (560.1 ± 
303.8 pA, n = 4) and the subsequent return to baseline levels (568.0 ± 300.4 pA, n = 4) 
on day 8.  
The AUC determined for day 9 of the PPA administration protocol was 8.7 ± 3.6 pA/hr 
(n = 4), this response did not significantly differ P > 0.05 from the NO response 
determined by AUC on day 0. However a relative increase in NO is apparent. No 
significant difference was observed between the pre and post injection basal levels on 
day 9 and the results are summarised below in Table 7.6.3. A significantly different (P < 
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0.05) maximum response time and return to baseline level was observed on day 9 with 
respect to day 1.  
The AUC determined for day 10 and 11 of PPA treatment was 11.2 ± 5.9 pA/hr (n = 3) 
and 10.6 ± 1.9 (n = 4) respectively. When compared to the AUC value determined on 
day 0 no significant difference (P > 0.05) was observed on day 10 however a relative 
increase in NO is apparent. A significant difference (P < 0.05,*) was observed between 
the AUC determined on day 11 and day 0. The pre and post-injection baseline levels 
recorded on day 10 and 11 revealed no significant difference P > 0.05, a summary of 
these results is provided in Table 7.6.3. The maximum response time and the time 
required to achieve a subsequent baseline level on day 10 and 11 were significantly 
different P < 0.05 from day 1 of PPA administration. 
As can be seen in Figure 7.5.3(F) a clear increase above baseline levels of NO occurred 
on day 12 of PPA treatment which gave an AUC value of 34.4 ± 7.2 pA/hr (n = 3). The 
AUC value determined for day 12 is significantly different (P < 0.05,*) to that recorded 
on day 0. Although a continuation of the increase in NO is observed at the end of the 
recording period in Figure 7.5.3(F), the pre-injection (301.1 ± 32.2, n = 3) and post-
injection baseline values (322.2 ± 23.7 pA, n = 3) did not significantly differ (P > 0.05).  
Additionally a significantly different (P < 0.05,*) maximum response time and return to 
baseline level was observed on day 12 with respect to day 1.  
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Figure 7.6.3.1 Comparison between control NO response recorded in the DH and the response 
following systemic administration of PPA. Control data (day 0) and day 7-12 of PPA 
administration. Data represented as Mean AUC ± SEM (pA/hr) with (P < 0.05,*).  
Figure 7.6.3.1 demonstrates the average NO response recorded on day 7 to 12 due to the 
systemic administration of PPA determined by AUC analysis. The control NO response 
calculated by AUC (Section 7.6.1) is displayed and denoted by day 0. The NO response 
recorded on day 7, 8, 11 and 12 of the PPA treatment protocol is significantly different 
(P < 0.05) on each day when compared to the NO response recorded on day 0. No 
significant difference was determined on day 9 and 10 in comparison to day 0; however 
a relative increase in NO is apparent. A discussion of the effect of each day of PPA 
treatment (day 1 to 12) on the response of the NO sensor implanted in the DH is 
discussed in the next Section (7.6.4).  
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PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
Day 
0 
n/a n/a n/a n/a n/a -23.6 ± 10.5 n/a n/a 2 
Day 
7 
52.8 ± 
14.2 
16.4 ± 
4.4 
33.4 ± 
9.0 
8.8 ± 
3.9 
18.0 ± 
2.1 
19.0 ± 
4.5 
323.0 ± 
62.9 
334.3 ± 
57.9 3 
Day 
8 
35.2 ± 
30.6 
6.3 ± 
5.5 
22.3 ± 
19.4 
5.75 ± 
0.6 
17.13 
± 0.9 
11.1 ± 
3.9 
560.1 ± 
303.8 
568.0 ± 
300.4 4 
Day 
9 
34.4 ± 
8.6 
11.7 ± 
2.9 
21.8 ± 
5.4 
7.4 ± 
0.8 
16.5 ± 
0.6 
8.7 ± 
3.6 
294.5 ± 
32.2 
299.3 ± 
28.1 4 
Day 
10 
37.9 ± 
9.4 
13.1 ± 
3.2 
24.0 ± 
6.0 
6.0 ± 
1.0 
15.5 ± 
2.5 
11.2 ± 
5.9 
289.5 ± 
45.4 
300.4 ± 
45.1 3 
Day 
11 
34.6 ± 
5.2 
10.9 ± 
1.6 
21.9 ± 
3.3 
3.9 ± 
0.2 
17.3 ± 
0.9 
10.6 ± 
1.9 
316.3 ± 
33.0 
321.8 ± 
30.9 4 
Day 
12 
73.7 ± 
17.9 
24.5 ± 
5.9 
46.6 ± 
11.3 
7.7 ± 
2.2 
19.2 ± 
0.7 
34.4 ± 
7.2 
301.1 ± 
32.2 
322.2 ± 
23.7 3 
 
Table 7.6.3 Summary of the NO data recorded between day 7 and 12 of chronic PPA administration 
(DH). With n = the number of sensors implanted in 2 animals (day 0), 3 animals (day 7), 4 animals 
(day 8), 3 animals (day 9-11) and 2 animals (day 12).   
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7.6.4 AUC comparison chronic PPA administration (DH) day 1-14 
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Figure 7.6.4 Comparison between the NO responses recorded in the DH on day 0 and day 1-12 of 
PPA administration. Data represented as Mean AUC ± SEM (pA/hr) and (P < 0.05,*).  
Figure 7.6.4 represents the overall NO response recorded in the DH (AUC) on day 0 
against the AUC values obtained on day 1 to 12 of the PPA administration protocol. It 
can be seen that an overall increase in NO response above baseline levels occurs on day 
3 and 4 of systemic PPA administration. Generally as the exposure time to PPA is 
increased the NO response in the DH becomes more maximal. As discussed in Section 
7.6.3 day 7, 8, 11 and 12 of PPA treatment results in an NO response which is 
significantly different P < 0.05 to the control experiments outlined in Section 7.6.1. 
Therefore the presence of systemically introduced PPA causes an increase in the level of 
NO in the DH.  
As observed in the NA it can be seen that an increase in NO response occurs as the 
experimental protocol proceeds from day 7 through to day 12 and the level of exposure 
to PPA is increased. It can be determined that the observed increase in NO due to the 
administration of PPA is incurred by an accumulative effect of the presence of PPA. The 
more prolonged the exposure time to PPA the more attenuated and maximal the NO 
response in the DH becomes. However the magnitude of the increase in NO is lower in 
the DH in comparison to the NA and this observation is discussed in Section 7.6.4. The 
results presented in this section are summarised in Table 7.6.4. 
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No significant difference P > 0.05 was observed between the pre and post-injection 
basal levels of NO on each day of PPA treatment (day 1 to 12). A significant difference 
P < 0.05 was observed between the maximum response time and the time required to 
return to baseline on day 2-4 and day 8-12 of PPA treatment when compared to day 1. 
Generally a decrease in the maximum response time and the subsequent time required to 
achieve a stable baseline was observed where a relative increase in NO was determined 
by AUC analysis in relation to day 0.  
A significant difference (P < 0.05) in NO response was determined by AUC analysis on 
day 3, 7, 8, 9, 10 and 11 following the administration of PPA when compared to day 1 
of PPA treatment. Similarly a significant difference (P < 0.05) was observed between 
the AUC value determined on day 12 when compared to day 1. With (day 3, P = 
0.0079), (day 7, P = 0.0027), (day 8, P = 0.0023), (day 9, P = 0.0028), (day 10, P = 
0.0082), (day 11, P = 0.0013) and (day 12, P = 0.0014) when compared to the AUC 
value calculated for day 1 of PPA treatment. 
Day 0 1 2 3 4 5 6 
AUC 
(pA/hr) 
-23.6 ± 
10.5 
-25.4 ± 
6.0 
-12.8 ± 
11.7 
15.2 ± 
7.5 
13.5 ± 
15.8 
-35.5 ± 
18.2 
-11.7 ± 
7.9 
P n/a 0.9100 0.5177 0.0621 0.0737 0.5539 0.4120 
n 2 5 5 4 4 6 6 
 
Day 0 7 8 9 10 11 12 
AUC 
(pA/hr) 
-23.6 ± 
10.5 
19.0 ± 
4.5 
11.1 ± 
3.9 
8.7 ± 
3.6 
11.2 ± 
5.9 
10.6 ± 
1.9 
34.4 ± 
7.2 
P n/a 0.0414 0.0484 0.0622 0.0860 0.0493 0.0110 
n 2 3 4 4 3 4 3 
 
Table 7.6.4 Comparison of the NO data (DH) AUC ± SEM (pA/hr) recorded on day 1 of PPA 
treatment against day 1-12 of chronic PPA administration 
A similar effect was observed with the NO response monitored in the DH following the 
chronic systemic administration of PPA in comparison to the response recorded in the 
NA. The administration of PPA for a continuous period of 12 days leads to an increased 
production of NO in the DH. The PPA induced elevation of NO levels is particularly 
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noticeable towards the end of the experimental procedure i.e. day 7-12 (see Figure 
7.6.4). PPA has been utilised previously in the development of an animal model of 
autism as previously discussed (MacFabe et al., 2008; MacFabe et al., 2011). The 
detection of elevated NO levels presented in this section is further supported by the 
detection of increased oxidative stress markers measured in PPA treated rodent brain 
tissue preparations (El-Ansary et al., 2012).  
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7.7 Regional comparison (Chronic PPA administration) DH and NA 
This section demonstrates a comparative analysis of the effect of chronic repetitive 
administration of PPA for 12 days on NO levels in the NA and DH of freely-moving 
animals. Each animal was administered PPA twice daily (Section 3.3.2.2) for a 
continuous period of 12 days and the corresponding changes in NO levels on each day 
were monitored by the NO sensor. The AUC of the NO response calculated on each day 
of PPA administration in the NA and the DH is compared in this section.  
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Figure 7.7.1 Comparison between the NO responses recorded in the NA and the DH following 
systemic administration of PPA. Data includes day 0-6 of PPA administration. Data represented as 
Mean AUC ± SEM (pA/hr).  
A similar trend was observed in the NA and the DH on day 1-6 of the PPA 
administration protocol. No significant difference (P > 0.05) in NO response, which was 
determined by AUC analysis, was observed between day 1-6 inclusively in comparison 
to the corresponding value determined for day 0 in both regions. Additionally no 
significant difference (P > 0.05) was observed between both regions on day 0-6 of PPA 
administration as shown in Table 7.7.1.  
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Day 0 1 2 3 4 5 6 
NA, AUC 
(pA/hr) 
-22.4 ± 
9.7 
-12.2 ± 
14.0 
-13.7 ± 
8.7 
5.3 ±  
5.3 
-16.7 ± 
11.8 
-11.1 ± 
12.2 
-5.8 ± 
8.0 
DH, AUC 
(pA/hr) 
-23.6 ± 
10.5 
-25.4 ± 
6.0 
-12.8 ± 
11.7 
15.2 ± 
7.5 
13.5 ± 
15.8 
-35.5 ± 
18.2 
-11.7 ± 
7.9 
P 0.4187 0.1841 0.3326 0.2386 0.2295 0.1507 0.0616 
NA (n) 3 4 5 4 4 4 5 
DH (n) 2 3 4 4 3 4 3 
 
Table 7.7.1 Comparison between NO levels monitored in NA and DH. Data represented as AUC ± 
SEM (pA/hr), recorded on day 0-6 of chronic PPA administration. 
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Figure 7.7.2 Comparison between the NO responses recorded in the NA and the DH following 
systemic administration of PPA. Data includes day 7-12 of PPA administration. Data represented as 
Mean AUC ± SEM (pA/hr).  
A disparity was observed between NO levels recorded in the NA and the DH on day 7-
12 of the PPA administration protocol. In both regions a relative increase in NO was 
determined by AUC analysis between day 7-12 and day 0 (see Section 7.5.4 and 7.6.4). 
However a relatively higher NO response was determined in the NA in comparison to 
the DH on day 7-12 of the PPA administration as shown in Figure 7.7.2. A significantly 
higher (P < 0.05) PPA induced NO response was observed in the NA on day 7, 9 and 11 
when compared to the corresponding values obtained from sensors implanted in the DH.  
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Day 7 8 9 10 11 12 
NA, AUC 
(pA/hr) 
24.1 ± 
7.4 
23.4 ± 
7.5 
20.2 ± 
4.8 
29.7 ± 
11.1 
25.8 ± 
1.6 
30.7 ± 
9.9 
DH, AUC 
(pA/hr) 
19.0 ± 
4.5 
11.1 ± 
3.9 
8.7 ± 
3.6 
11.2 ± 
5.9 
10.6 ± 
1.9 
34.4 ± 
7.2 
P 0.0445 0.3878 0.0349 0.1586 0.0036 0.0992 
NA (n) 3 5 5 3 2 4 
DH (n) 3 4 4 3 4 3 
 
Table 7.7.2 Comparison between NO levels monitored in NA and DH. Data represented as AUC ± 
SEM (pA/hr), recorded on day 7-12 of chronic PPA administration. 
It is difficult to draw direct comparisons between NO levels in different regions of the 
CNS as previously discussed by Finnerty et al. (Finnerty et al., 2012). NO is derived 
from three main NO synthase enzymes (NOS), these consist of inducible NOS (iNOS), 
endothelial NOS (eNOS) and neuronal NOS (nNOS) (Kiechle & Malinski, 1993; 
Bruckdorfer, 2005; Guix et al., 2005).  The distribution of nNOS within the CNS is 
abundant, the activity and inhibition of nNOS by interaction with a variety of proteins 
may contribute to a disparity in the level of NO in different brain regions (Garthwaite, 
2008).  
The previous detection of indirect markers of NO production (i.e. nitrite and nitrate) 
obtained by microdialysis has revealed a regional difference in L-arginine induced NO 
production in the hippocampus and striatum (Hara et al., 2004). Interestingly Hara et al. 
reported no significant change in markers of NO production in the striatum following 
the systemic administration of L-arginine. These findings contradict that published by 
other researchers who utilised similar detection methods to measure L-arginine induced 
NO production in the cerebellum (Yamada & Nabeshima, 1997). Additionally the 
detection of cGMP, an indirect marker of NO production, was found to be unchanged 
following the administration of the NOS inhibitors L-NAME and L-NARG in the 
prefrontal cortex (Laitinen et al., 1994; Pepicelli et al., 2004). This contrasts with other 
reports of an L-NAME induced inhibition of NO production in the hippocampus and 
cerebellum determined via cGMP detection and retrodialysis administration (Fedele & 
Raiteri, 1999). These combined reports may reflect an underlying disparity in the extent 
of exogenously altered NO production between different brain regions. This may lead to 
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conflicting experimental results depending on the sensitivity of the NO detection 
method utilised and the region investigated. These combined afore mentioned findings 
rely on indirect detection methods which lack the specificity and improved time 
resolution of direct electrochemical NO recordings demonstrated by our research group 
(Finnerty et al., 2012). The NO precursor L-Arginine and NOS inhibitor L-NAME 
produce regional differences in the respective elevation and inhibition of NO in the 
striatum, prefrontal cortex and NA (Finnerty et al., 2012). These previously determined 
regional differences may explain the disparity between PPA induced NO production in 
the NA and DH. 
The activity of the constitutive isoforms of NOS in the CNS i.e. nNOS and eNOS on the 
level of NO in different regions of the brain must be considered. The expression of 
iNOS is rarely present at tonic levels in the brain and is normally produced in 
pathological conditions in response to an inflammatory insult (Guix et al., 2005). It is 
well established that the expression of iNOS is a hallmark of neurodegenerative 
disorders such as Parkinson’s and Alzheimer’s disease (Calabrese et al., 2007). 
Specifically in a pro-oxidant environment NO produced from either nNOS or iNOS can 
interact with superoxide and lead to the production of peroxynitrite which can damage 
cells (Calabrese et al., 2007). The expression of iNOS has been implicated in the 
development of autism however the exact mechanism of NO production in autistic 
individuals is yet to be elucidated (Chauhan & Chauhan, 2006).   
However a general similarity is observed in the DH and NA on day 7-12 of chronic PPA 
administration. An increase in NO production was determined in both regions following 
repeated injections of PPA. Increased susceptibility to oxidative stress may contribute to 
the development of autism (Chauhan & Chauhan, 2006). The global elevated NO 
production induced by the systemic administration of PPA may be derived from a 
disruption in normal redox homeostasis which would result in nitrosative stress and 
hence an increase in NO (Valko et al., 2007).  
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7.8 Behavioural observations  
MacFabe et al. have previously demonstrated a detailed description of the behavioural 
abnormalities induced in freely-moving rats by repeated intracerebroventricular (ICV) 
administrations of PPA (MacFabe et al., 2007). In research conducted by Shultz et al. an 
impairment in the social behaviour of the animal has been demonstrated following ICV 
treatment with PPA (Shultz et al., 2008). The chronic systemic administration (s.c.) of 
PPA has been shown to cause cognitive deficits in rats (Pettenuzzo et al., 2002) and a 
conditioned place avoidance (Ossenkopp et al., 2012). Repetitive systemic 
administration of PPA has also been demonstrated to reduce social interaction, increase 
anxiety-like behaviour and hypoactivity in rats (Shams et al., 2009). Additionally the 
development of increased locomotor activity and repetitive dystonic or neurological 
movement disorders due to exposure to PPA has been demonstrated (MacFabe et al., 
2007; MacFabe et al., 2008).  
The reported behavioural outcomes due to repetitive administration of PPA consist of 
four main behavioural abnormalities including retropulsion, a snake-like posture, 
repetitive turning and limb dystonia (MacFabe et al., 2007). The main characteristics of 
ASDs include social impairment, difficulties with communication, repetitive behaviours 
and restricted interests (Rapin & Tuchman, 2008). The social impairment and the 
repetitive and restricted behavioural characteristics of PPA treated rodents are consistent 
with the expectations for an animal model of autism (MacFabe et al., 2011).  
As seen previously in PPA treated rats abnormal behavioural characteristics were noted 
in the subjects utilised in these sets of experiments. As previously observed with 
systemic administrations of PPA, the subjects remained healthy for the duration of the 
PPA administration protocol outlined here (Pettenuzzo et al., 2002). In the absence of 
detailed behavioural testing the most noticeable change in behaviour of the subjects 
utilised in this study occurred towards the end of the experimental protocol. The 
behaviour of the animal was consistently normal during the initial 5 days of PPA 
administration. 
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Upon the extension of the level of PPA administration (day 6-12), the animal manifested 
a propensity to turn repeatedly in a 360 degree manner in the housing bowl and postural 
abnormalities were observed. The observed PPA induced behavioural changes mirror 
the behavioural abnormalities previously demonstrated by MacFabe et al. in PPA treated 
rats (MacFabe et al., 2007). In the study outlined in this chapter the observed abnormal 
behavioural traits of the PPA treated animal were particularly noticeable following 8 
days of systemic administration and were exacerbated towards the end of the 
experimental procedure. Additionally the behavioural changes incurred by the 
administration of PPA were prominent within a few hours of the injection itself.  The 
effect of PPA on the behavioural traits of the animal has previously been shown to exert 
a maximal effect within 30 mins following ICV infusion (MacFabe et al., 2007). The 
discrepancy in the time required to induce a behavioural change seen in the subjects 
used in these experiments may be explained by the route of PPA administration i.e. s.c. 
Interestingly the observed behavioural abnormalities in the subjects utilised in this 
chapter were more prominent where an increase in NO was recorded. In the absence of a 
detailed behavioural analysis of the subjects presented in this chapter, it is difficult to 
draw accurate correlations between the recorded changes in NO and the observed 
abnormal behaviours caused by the systemic administration of PPA. However, in 
general the manifestation of the behavioural abnormalities observed towards the end of 
the experimental protocol in this study were consistent with an increased production of 
NO.  
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7.9 Conclusion 
The primary aim of this chapter was to demonstrate the novel detection of NO in an 
animal model of autism. The in-vitro and in-vivo characterisation of the NO sensor 
utilised in this chapter was verified with respect to previous work conducted by our 
research group in Chapter 6. The PPA induced animal model of autism described in this 
chapter has previously been extensively researched by MacFabe et al. (MacFabe et al., 
2007; MacFabe et al., 2008; MacFabe et al., 2011).  
As a control experiment the effect of systemic administration of saline (s.c.) on the 
implanted NO sensor was examined in Section 7.3.2. No lasting effect on the NO sensor 
response was observed following the systemic administration of saline. These results are 
consistent with previous findings of the effect of systemic administration of saline on 
the response of this NO sensor design (Finnerty et al., 2012).  
An initial pilot study was conducted as presented in Section 7.4. The relative short-term 
effect of PPA administration on the level of NO in the NA was examined. A significant 
increase (P < 0.05) in NO response was determined following the administration of 
each dose of PPA (1 µM/g, 2 µM/g and 4 µM/g) with respect to the administration of 
saline. A summary of the results presented in Section 7.4 is shown in Table 7.8.1.   
PPA 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change 
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
1 
µM/g 
29.7 ± 
6.0 
9.2 ±  
3.0 
19.4 ± 
3.9 
111.0 ± 
35.0 
271.0± 
112.0 
359.5 ± 
70.4 
355.3 ± 
58.2 3 
2 
µM/g 
28.8 ± 
2.9 
8.2 ±  
1.8 
18.8 ± 
1.9 
284.7 ± 
8.3 
436.3 ± 
54.7 
383.0 ± 
65.9 
373.7 ± 
64.8 3 
4 
µM/g 
69.2 ± 
9.8 
20.8 ± 
3.8 
45.3 ± 
6.4 270 375 
334.5 ± 
14.4 
392.2 ± 
4.0 2 
  
Table 7.4.1: Summary of results shown in Section 7.4. 
Previous demonstrations of a PPA induced animal model of autism involved the long-
term systemic administration of PPA (500mg/kg) (Shams et al., 2009). It was deemed 
necessary to investigate the long-term effect of PPA over 24 hrs on the level of NO in 
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the NA and DH. The effect of repetitive chronic PPA administration on NO levels in the 
intact living brain of freely-moving animals has not previously been demonstrated. As a 
control experiment the response of the NO sensor implanted in the NA for a continuous 
period of 24 hrs was examined in Section 7.5.1. A small variation in the NO response 
was observed over the 24 hr period which is likely attributable to the circadian rhythms 
of the animal (Heinzen & Pollack, 2002; Cespuglio et al., 2012). 
Additionally the corresponding level of NO in the DH was examined over a continuous 
period of 24 hrs (see Section 7.6.1). No significant difference (P > 0.05) was observed 
between the 24 hr control data response, determined by AUC analysis, in the NA and 
the DH. However minor differences were observed in the recorded NO signal in both 
regions (see Figure 7.5.1 and 7.6.1). These small changes in NO over the specified time 
period may be attributed to the circadian rhythms of the animal as discussed in Section 
7.5.1. However, the overall contribution of natural processes on the level of NO are 
effectively eliminated from the overall signal attributable to administration of PPA by 
the control data presented in Section 7.5.1 and 7.6.1. 
NO levels in the NA and DH monitored by the NO sensor following the systemic 
administration of PPA for an initial period of 1 to 6 days are presented in Sections 7.5.2 
and 7.6.2 respectively. A similar trend was observed in the NA and the DH on day 1-6 
of the PPA administration protocol. No significant difference (P > 0.05) in NO 
response, determined by AUC analysis, was observed between day 1-6 inclusively in 
comparison to the corresponding value determined for the 24 hr control data in both 
regions. A robust network of antioxidant mechanisms regulate the level of RNS such as 
NO in the CNS (Calabrese et al., 2007). These mechanisms are responsible for the 
prevention of the development of nitrosative stress and consequently maintain cognitive 
function. The variety of processes which maintain this vital balance in the brain has 
been extensively reviewed (Droge, 2002; Valko et al., 2007). It is therefore plausible 
that the initial exposure to PPA (day 1-6) is dealt with effectively by these control 
mechanisms. 
The effect of the extension of the PPA administration protocol (day 7-12) on the level of 
NO monitored in the NA and DH is represented in Section 7.5.3 and 7.6.3 respectively. 
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A general trend emerged in the NO response recorded in both regions following the 
systemic administration of PPA after 7 days of repetitive PPA administration. An 
increase in NO was detected in both regions from day 7-12 inclusively when compared 
to the corresponding control data. The results are summarised in Section 7.5.4 and 7.6.4. 
The consistent over production of NO due to the development of oxidative/nitrosative 
stress has previously been implicated in the development of autism (Chauhan & 
Chauhan, 2006). Elevated levels of NO and indirect markers of NO production have 
been demonstrated in biological samples of autistic individuals (Sogut et al., 2003; 
Sweeten et al., 2004). Additionally increased oxidative stress markers have been 
detected in post-mortem autistic brain preparations (Chauhan et al., 2012; Rose et al., 
2012). Also increased oxidative stress markers have been determined in brain 
preparations of a PPA induced animal model of autism (MacFabe et al., 2007; MacFabe 
et al., 2008).  
The exact neuropharmacological role of PPA in the induced elevation of NO in the brain 
has yet to be fully elucidated. Previous ex-vivo brain preparation studies have indicated 
that PPA acts through a glutamatergic pathway. Specifically the incubation of brain slice 
preparations with PPA has been shown to stimulate the phosphorylation of cytoskeletal 
proteins. The use of specific N-methyl-D-aspartate (NMDA) receptor agonists has been 
shown to mimic the stated effect following brain slice exposure to PPA (de Mattos-
Dutra et al., 2000). Additionally PPA has previously been shown to promote 
intracellular calcium (Ca2+) release (Nakao et al., 1992). It is known that activation of 
NMDA receptors which are abundantly present in the NA (Monaghan & Cotman, 1985), 
by glutamate or by other agonists result in an influx of Ca2+ and leads to depolarisation 
of the cell. The constitutive forms of NOS (eNOS and nNOS) are activated by Ca2+ 
followed by binding with calmodulin which leads directly to the production of NO 
(Alderton et al., 2001; Saulskaya & Fofonova, 2006).    
As previously stated the exact mechanism of NO production in the animal model of 
autism presented here remains to be elucidated. The role of iNOS in the expression of 
NO has been demonstrated in neurodegenerative disease states such as Parkinson’s and 
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Alzheimer’s disease (Calabrese et al., 2007). Additionally the expression of iNOS has 
been implicated in the development of autism (Chauhan & Chauhan, 2006).  
PPA itself is not cytotoxic as determined by a lack of apoptotic cell death or loss in 
brain tissue analysis of PPA treated rats (MacFabe et al., 2007). Neuropathological 
investigations of PPA treated rat brain tissue and post mortem autistic brain preparations 
have indicated the presence of activated microglia and astrocytes (Vargas et al., 2005; 
MacFabe et al., 2011). Cytokines produced by this process lead to an inflammatory 
process which is known to activate iNOS and hence elicit an increase in NO (Guix et al., 
2005). Also the time required for iNOS expression and a subsequent production of NO 
due to an inflicted inflammatory response may be extended (Guix et al., 2005). 
Specifically iNOS induced NO production by astrocytes and macrophages challenged 
with inflammatory cytokines may take up to three days to elicit a response (Ding & 
Merrill, 1997). This process may be a possible explanation for the observed time delay 
i.e. 7 days for the clear increase in NO production presented following continuous 
systemic administration of PPA.  
The behavioural abnormalities found in the animal model of autism presented in this 
chapter are discussed in Section 7.8. The administration of the primary anti-oxidant 
species in the brain, ascorbic acid, in conjunction with PPA results in suppression of the 
cognitive deficits observed following PPA administration (Pettenuzzo et al., 2002). 
Future work may involve the pre-administration or combined administration of ascorbic 
acid or other antioxidants in an effort to elucidate the proposed nitrosative stress 
mediation of autism. Additional research may involve the use of specific NOS inhibitors 
(Alderton et al., 2001), to elucidate the exact mechanism of NO production in the PPA 
animal model of autism. This proposed research may further support the proposed role 
of oxidative/nitrosative stress in the etiology of ASDs. Current research and the results 
presented in this chapter indicate that oxidative/nitrosative stress is a major contributing 
factor in the etiology of ASDs.  
The further detection of NO in an animal model of autism may lead to a better 
understanding of the etiology of ASDs and hence the development of potential 
therapeutic strategies.  
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8.1 Introduction 
Parkinson’s disease (PD) is a severe progressive neurodegenerative movement disorder. 
The neuropathological feature of PD is dopamine (DA) cell degeneration in an area of 
the midbrain known as the substantia nigra pars compacta (SNc) which leads to an 
insufficient availability of striatal DA (Olanow & Tatton, 1999; Schapira & Jenner, 
2011). Dopaminergic neurons project from the SNc and terminate in the striatum where 
they maintain the normal physiological level of DA. The role of this dopaminergic 
nigrostriatal system in the maintenance of striatal DA and the subsequent control of 
voluntary movement has previously been described by Obeso et al. (Obeso et al., 2008).  
Neuropathological investigations of PD have routinely demonstrated the presence of 
intracytoplasmic inclusions known as ‘Lewy bodies’ that are composed of several 
proteins including α-synuclein and parkin (Olanow & Tatton, 1999; Lotharius & 
Brundin, 2002; Schapira & Jenner, 2011). The protein α-synuclein has been 
hypothesised to play a role in the normal physiological intracellular storage of DA 
within the presynaptic terminal (Lotharius & Brundin, 2002). Additionally α-synuclein 
has also been postulated to play a role in synaptic plasticity (Clayton & George, 1998). 
Various familial forms of PD exist which have been linked to genetic mutations in 
specific proteins including α-synuclein and parkin (Olanow & Tatton, 1999; Lotharius 
& Brundin, 2002; Schapira & Jenner, 2011). However familial forms of PD are 
relatively uncommon and count for less than 10 % of all PD cases (Maguire-Zeiss et al., 
2005). 
Sporadic idiopathic PD is the predominant form of the neurodegenerative disease, it is 
largely associated with advancing age and has been linked to certain environmental 
factors including exposure to pesticides, herbicides and toxins (Olanow & Tatton, 1999; 
Schapira & Jenner, 2011). The role of various toxins including rotenone, paraquat (PQ) 
and MPTP in the development of PD has previously been examined and utilised to study 
PD in animal models (Beal, 2001; McCormack et al., 2005; McCormack et al., 2006).  
The degeneration of dopaminergic cells in the SNc which is a pathological hallmark of 
PD has been attributed to oxidative stress specifically as a result of DA metabolism 
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(Lotharius & Brundin, 2002; Andersen, 2004; Chinta & Andersen, 2008). DA may be 
metabolised enzymatically or auto-oxidised to form hydrogen peroxide (H2O2). The 
metabolism of DA leads to the formation of the primary reactive oxygen species (ROS) 
superoxide (O·), DA-quinone species and hydroxy radicals. The over production of 
ROS and subsequent production of reactive nitrogen species (RNS) leads to 
oxidative/nitrosative stress which leads to damage to cell structures, DNA, lipids and 
proteins (Valko et al., 2007). A detailed description of DA metabolism related oxidative 
stress and the postulated role of this pathway in the degeneration of dopaminergic cells 
in the SNc is discussed in detail in Section 1.7. 
The herbicide paraquat (PQ) otherwise known as methyl viologen dichloride hydrate is 
an environmental toxin which has previously been linked to the development of PD in 
humans (Tanner et al., 2011). PQ is structurally similar to the parkinsonism inducing 
toxin MPP+ (Dinis-Oliveira et al., 2006; Bove & Perier, 2012). The repeated systemic 
administration of PQ has previously been utilised to develop an animal model of PD 
(McCormack et al., 2005; McCormack et al., 2006).  
The ability of PQ to cross the blood brain barrier (BBB) has previously been questioned, 
PQ is a charged hydrophilic molecule which is unlikely to cross the BBB by passive 
means (Di Monte, 2003). Additionally non-human primate studies have indicated that 
the BBB impedes the access of PQ to the brain (Bartlett et al., 2009). However PQ has 
been shown to reach the brain in rodents following systemic administration in a dose 
dependent manner (Corasaniti et al., 1998; Shimizu et al., 2001; McCormack & Di 
Monte, 2003). The systemic co-administration of simple amino acids (e.g. L-valine and 
L-phenylalanine) in addition to PQ has previously been shown to reduce the access of 
PQ to the brain in a rodent model (Shimizu et al., 2001; McCormack & Di Monte, 
2003). Therefore PQ may gain access to the CNS via the BBB neutral amino acid 
transporter supporting the role of active transport of PQ across the BBB (Shimizu et al., 
2001; McCormack & Di Monte, 2003).  
Systemic PQ administration has been shown to selectively induce neurodegeneration of 
dopaminergic cells in the SNc of rodents primarily via oxidative stress (McCormack et 
al., 2005; McCormack et al., 2006). It has been postulated that PQ may be transported 
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directly into dopaminergic neurons by the dopamine transporter (DAT). The local co-
administration of GBR-12909, a selective DAT inhibitor, reduced paraquat uptake into 
the striatal tissue of rats (Shimizu et al., 2003a). This process may explain PQ mediated 
specific dopaminergic neurodegeneration as demonstrated by other research groups 
(McCormack et al., 2005; McCormack et al., 2006). Alternatively Richardson et al. 
have excluded the role of DAT in the active uptake of PQ. This research group has 
suggested that the loss of dopaminergic neurons following systemic administration of 
PQ is attributable to the unique susceptibility of the DA neurons to PQ mediated 
oxidative stress (Richardson et al., 2005).  
As previously stated the loss of striatal DA and the presence of ‘Lewy bodies’ are the 
major characteristics of the pathology of PD. Shimizu et al. have previously 
demonstrated that repeated subcutaneous injections of PQ to rodents resulted in a 
significant decrease in DA and its metabolites in the striatum (Shimizu et al., 2003a). 
Additionally systemic PQ administration has been shown to induce the up-regulation of 
α-synuclein the major constituent of ‘Lewy bodies’ (Manning-Bog et al., 2002). The 
systemic administration of PQ has been shown to cause a decrease in locomotor activity 
in rodents due to a proposed decline in striatal dopamine nerve terminal density (Brooks 
et al., 1999). 
Intracellular PQ may lead to oxidative stress through indirect mitochondrial dysfunction 
(MTdys) via redox cycling and by direct MTdys via inhibition of Complex I of the 
mitochondrial ETC known as NADH-ubiquinone oxioreductase. The exact mechanism 
of PQ induced MTdys has been disputed (Richardson et al., 2005; Miller, 2007; Cory-
Slechta et al., 2008; LoPachin & Gavin, 2008). Direct PQ mediated mitochondrial 
(Complex I) inhibition has been indicated by several research groups (Castello et al., 
2007; Cocheme & Murphy, 2008; Czerniczyniec et al., 2011). Equally indirect MTdys 
due to the cytosolic redox cycling of PQ has been postulated as a causative factor in PQ 
mediated oxidative stress (Bonneh-Barkay et al., 2005a; Bonneh-Barkay et al., 2005b; 
McCormack et al., 2006; Berry et al., 2010). However both direct and indirect MTdys 
initiated by PQ leads to the development of oxidative/nitrosative stress and the 
subsequent deleterious process of neuronal cell damage (Lin & Beal, 2006).   
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Under normal physiological conditions Complex I of the mitochondrial ETC accepts 
electrons from NADH (Uversky, 2004). However, when PQ is present PQ preferentially 
accepts these electrons and leads to Complex I inhibition, the production of (O· and 
subsequent MTdys (Dinis-Oliveira et al., 2006; Cocheme & Murphy, 2008).  
The process of cytosolic redox cycling of PQ is facilitated by intracellular enzymes 
(cellular diaphorases) such as NADPH oxidase, NADPH-cytochrome c reductase and 
nitric oxide synthase (NOS) (Day et al., 1999; Dinis-Oliveira et al., 2006; Purisai et al., 
2007). This pathway leads to the production of O·  and hence the development of 
oxidative/nitrosative stress. PQ may be reduced in the cytosol to form a PQ monocation 
free radical (PQ•+) by cellular diaphorases (e.g. NOS), which are enzymes that transfer 
electrons from NADPH to small molecules such as PQ (Day et al., 1999). PQ•+ is 
rapidly re-oxidised in the presence of molecular oxygen thereby generating O· and 
reformed PQ which initiates the processes which lead to oxidative/nitrosative stress and 
subsequently indirect MTdys (Day et al., 1999; Dinis-Oliveira et al., 2006; Bove & 
Perier, 2012).   
It has previously been demonstrated that dose dependent PQ treatment stimulates 
transient striatal glutamate release (Shimizu et al., 2003a). It is known that activation of 
N-methyl-D-aspartate (NMDA) receptors which are abundantly present in the NA 
(Monaghan & Cotman, 1985), by glutamate or by other agonists results in an influx of 
Ca2+ and leads to depolarisation of the cell. The constitutive forms of NOS (eNOS and 
nNOS) are activated by Ca2+ followed by binding with calmodulin which leads directly 
to the production of NO (Alderton et al., 2001; Saulskaya & Fofonova, 2006).  
The PQ evoked release of NO may diffuse to dopaminergic terminals leading to MTdys 
mediated by reactive nitrogen species (RNS) and consequently the overproduction of 
dopamine (Shimizu et al., 2003a; Dinis-Oliveira et al., 2006). The non-selective NOS 
inhibitor L-NAME has previously been shown to block PQ mediated dopamine overflow 
in-vivo (Shimizu et al., 2003b). In a pro-oxidant environment NO can interact directly 
with O· and lead to the formation of the main secondary highly toxic reactive 
nitrogen species (RNS) peroxynitrite ONOO(Ramalingam & Kim, 2012). NOS itself 
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may act as a diaphorase in conjunction with PQ and ‘uncoupling’ of the NOS enzyme 
may lead to the preferential formation of O·over NO (Day et al., 1999; Margolis et al., 
2000). It is unclear whether L-NAME exerts a protective effect via inhibition of NOS 
mediated NO production or by inhibition of O·  formation from NOS ‘uncoupling’ 
(Dinis-Oliveira et al., 2006; Moran et al., 2010). As previously discussed the redox 
cycling of PQ is known to result in the production of O·which is the main source of 
H2O2 production in the brain. An increase in striatal H2O2 determined by a fluorescent 
method has been shown by Czerniczyniec et al. following the systemic administration of 
PQ (Czerniczyniec et al., 2011).  
The characteristics of PQ, MPP+ and rotenone as Complex I inhibitors and oxidative 
stressors have enabled the successful replication of certain aspects of the 
pathophysiology of PD in animal models (Beal, 2001; McCormack et al., 2005; 
McCormack et al., 2006). A variety of reports indicate that changes in NO and H2O2 
occur in the neuronal environment following systemic injections of PQ as determined by 
indirect methods of analysis. The main aim of this chapter is to demonstrate the novel 
direct in-vivo electrochemical detection of NO and H2O2 following the systemic 
administration of PQ in order to examine PQ mediated oxidative/nitrosative stress.  
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8.2 Experimental 
The instrumentation, chemicals, solutions and software used in this section are described 
in detail in Chapter 3. Details of the manufacture of the working electrodes are outlined 
in Section 3.4. All experiments outlined in this chapter were performed using Constant 
Potential Amperometry (CPA). A potential of +700 mV and +900 mV vs. Ag wire (see 
Section 3.10.3) was applied to the working electrodes for the detection of H2O2 and NO 
respectively for all in-vivo experiments. The number of implanted NO sensors is 
denoted by (n) and the number of animals indicated. NO sensors were implanted ipsi-
laterally (same side). The number of implanted dual catalase-based H2O2 sensors is 
denoted by (n) i.e. a Blank and a Cat sensor in the same number of animals. The Blank 
and Cat sensor were implanted ipsi-laterally to each other and contra-laterally to NO 
sensors. All sensors (NO/H2O2) were implanted in the nucleus accumbens (NA). 
For systemic administration of PQ varying doses including 5, 10, 20 and 30 mg/kg were 
prepared in normal saline and injected in a volume of 2 mL/kg. Each injection of PQ 
was given at 12.00 hrs followed by a 72 hr recording period.  
Reported in-vivo NO concentration changes are based on the average in-vitro pre-
implantation calibration data. Area under the curve (AUC) analysis was utilised to 
determine the overall NO response following administration of PQ. The net AUC value 
is represented in this chapter i.e. the average AUC value was calculated for peaks below 
and above baseline levels. AUC provides an integrated measurement of a measurable 
effect or phenomenon. AUC determines the overall change in NO before returning to a 
baseline level which is relative to the effect of PQ administration.  
Statistical analysis was carried out using paired or unpaired t-tests. These tests were 
performed using Graphpad Prism and gave a probability value (P) which indicates the 
level of significant or non-significant difference between groups. P > 0.05, denotes no 
significant difference. The extent of significant difference is divided into three 
parameters (P < 0.05,*), (P < 0.01,**) and (P < 0.0001,***) from the lowest relative 
level of difference (*) to the highest (***). 
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8.3 Systemic control experiments  
All systemic administrations shown in this chapter were carried out in 2 mL/kg of saline 
by subcutaneous injection (s.c.). The effect of systemically administered saline on the 
NO sensor and paired H2O2 sensor response has previously been demonstrated in 
Section 7.3.1 and 5.3.2 respectively. For the purpose of clarity the response of each 
sensor design NO/H2O2 following the systemic administration of saline is presented in 
Figure 8.3.1.   
8.3.1 Systemic (s.c.) saline administration 
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Figure 8.3.1 Typical example of an s.c. injection of saline detected by the NO and H2O2 sensor. Top 
panel: NO sensor (A) and H2O2 sensor (B), response monitored in the brain of a freely-moving 
Wistar rat following injection of saline. Bottom panel: Immediate response following injection 
(secs); NO sensor (C) and H2O2 sensor (D). The arrow indicates the point of administration. 
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Saline 
Current 
change 
(pA) 
Change 
(%) 
Conc. 
change  
(nM) 
Max 
response 
(mins) 
Return 
(mins) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
NO 10.5 ± 1.9 
1.9 ±  
0.3 
7.0 ±  
1.0 
3.0 ±  
0.3 
7.4 ±  
0.4 
550.7 ± 
104.3 
554.6 ± 
104.8 
H2O2        155.3 ± 
123.9 
1.0 ±  
4.4 
69.3 ± 
55.3 
7.9 ±  
0.9 
12.7 ± 
0.4 
842.6 ± 
749.9 
1390.2 ± 
699.9 
 
Table 8.3.1: Summary of NO/H2O2 data monitored in freely-moving animals obtained on injection 
of saline. NO Data obtained from 6 sensors; average data includes 10 administrations. H2O2 Data 
obtained from 3 paired H2O2 sensors. All data obtained from sensors implanted in the brain of 6 
Wistar rats. 
As a control experiment saline (Section 3.3.3.2) was administered subcutaneously (s.c.) 
(Section 3.11.2) and the effect on the NO/H2O2 signal was measured. The NO response 
following the injection of saline has previously been shown in Section 7.3.1 and the 
corresponding H2O2 response is discussed in Section 5.3.2. Briefly, in each case no 
significant difference (P > 0.05) was observed between the pre and post-injection 
baseline levels of NO/H2O2. A short lived change in NO/H2O2 concentration was 
measured following the injection of saline. However, no lasting effect on the NO or 
paired H2O2 sensor response was observed and no significant difference (P > 0.05) was 
observed between the maximum percentage change and the baseline level recorded by 
the NO and H2O2 sensor following the injection of saline.  
 
 
 
 
 
 
   Chapter 8: PD, NO and H2O2 
 
347 
 
8.4. Chronic Paraquat (PQ) dose response (NA)  
The results presented in this section demonstrate the long term effect of paraquat (PQ) 
administration on the level of NO monitored in the NA. The response of the NO sensor 
was examined following the systemic injection of a low dose of PQ (5 mg/kg) and a 
relatively high dose of PQ (30 mg/kg) for a period of 72 hrs. The long-term response of 
the NO sensor over 72 hrs in the absence of treatment is also presented in this section. 
Additionally the preliminary simultaneous detection of H2O2 and NO in the same animal 
following each administered dose of PQ (5 and 30 mg/kg) is shown.  
8.4.1 Control NO data (NA) 
The results presented in this section demonstrate the response detected by the NO sensor 
for a continuous period of 72 hrs while implanted in the NA. The administration of 
saline has no lasting effect on the NO/H2O2 sensor response as has been demonstrated in 
Section 8.3.1. The results presented in this section act as a control against which the NO 
response due to the administration of PQ, recorded in the NA for a period of 72 hrs may 
be compared.  
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Figure 8.4.1 The average NO response in the NA over a continuous period of 72 hrs. Data 
represented as a percentage current change ± SEM. SEM represented by dashed line (black). 
Figure 8.4.1 represents the NO levels recorded in the NA over a continuous period of 72 
hrs (n = 10, 3 animals). It is clear that the NO response remains close to baseline levels 
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for the duration of the recording period. A slight deviation from baseline levels of NO, 
which is denoted by the dashed line, can be seen, however a return to stable baseline 
levels of NO can be seen subsequently. In order to examine the overall change in NO 
over a 72 hr period AUC analysis was performed which gave a response of -96.2 ± 92.9 
pA/hr (n = 10).  
The NO recordings presented in Figure 8.4.1 were taken after an initial period of ca. 24 
hrs following the application of the potential to the working electrodes. Therefore the 
contribution of the capacitance current to the overall NO sensor response represented in 
Figure 8.4.1 is greatly reduced. The minor variation in NO levels recorded over a 
continuous period of 72 hrs is likely attributable to the circadian rhythms of the animal 
which is supported by work conducted by other research groups.  
Heinzen & Pollack have previously demonstrated a time dependent variation in the level 
of NO in saline treated animals. This research group recorded brain NO over an 
extended time period via electrochemical methods and found time dependent 
fluctuations; which they attributed to a circadian variation in the production of NO 
(Heinzen & Pollack, 2002). Additionally, Cespuglio et al. have previously demonstrated 
circadian dependent changes in the level of NO, as determined by long-term 
electrochemical recordings in freely-moving animals (Cespuglio et al., 2012). However 
the overall contribution of sleep-wake effects or possible residual capacitance to the NO 
response following the administration of PQ may be compared to the control data 
presented in Figure 8.4.1.  
8.4.2 PQ dose response (NO) 
The aim of this section is to investigate the effect of the systemic administration of 
paraquat (PQ) on the NO sensor response while implanted in the NA of freely-moving 
animals. A dose response study was conducted and the long-term NO response 
attributable to the administration of a low dose of PQ (5 mg/kg) and a relatively high 
dose of PQ (30 mg/kg) was examined.  
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Figure 8.4.2.1 The average NO response recorded in the NA following the systemic administration 
of PQ (5 mg/kg) (A) Initial 3 hr average NO response recorded following injection (5 mg/kg PQ) (B) 
The average NO response recorded over a continuous period of 72 hrs following injection (5 mg/kg 
PQ). Data represented as a percentage change ± SEM. SEM represented by dashed line (black). 
Arrow indicates the injection of PQ. 
Figure 8.4.2.1 represents the average NO response (n = 9, 3 animals) recorded in the NA 
following the administration of a low dose of PQ (5 mg/kg). The animals included in the 
data presented in Figure 8.4.2.1 were not previously exposed to PQ. Figure 8.4.2.1 (A) 
demonstrates the average NO response monitored for a period of 3 hrs immediately 
following the systemic administration of PQ (5 mg/kg). It is clear that the NO response 
remains close to baseline levels for the duration of this initial recording period (3 hrs), it 
was therefore necessary to examine the NO response over an extended time-frame 
following PQ exposure and this extended NO response (72 hrs) can be seen in Figure 
8.4.2.1 (B).  
Shimizu et al. and Hara et al. have previously demonstrated a lasting increase in indirect 
markers of NO production following PQ exposure as determined by a microdialysis 
method (Hara et al., 2001; Shimizu et al., 2003a). The effect of systemic PQ 
administration on the direct electrochemical detection of NO levels in the brain of 
freely-moving animals has not previously been reported. Therefore it was deemed 
necessary to investigate the long-term influence (72 hrs) of PQ administration on the 
level of NO monitored in the NA. It is apparent that a slight deviation in the average NO 
response above and below baseline levels occurred for a period of 72 hrs following the 
systemic administration of PQ (5 mg/kg) as can be seen in Figure 8.4.2.1 (B).  
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In this case it was not possible to definitively measure a maximum NO current response 
following the injection of 5 mg/kg PQ due to conflicting NO responses mediated by 
administration of this low dose of toxin (5 mg/kg) as presented in Figure 8.4.2.1. AUC 
analysis was utilised to determine the overall effect of 5 mg/kg PQ on the NO current 
response monitored in the NA. The systemic administration of 5 mg/kg PQ resulted in 
an AUC value of -15.0 ± 36.7 pA/hr (n = 9) and this value was not significantly 
different (P > 0.05) to the control experiments outlined in Section 8.4.1. The pre-
injection (458.1 ± 66.6 pA, n = 9) and post-injection baseline values (429.3 ± 57.0 pA, n 
= 9) were not significantly different (P > 0.05).  
It is evident from Figure 8.4.2.1 that a deviation from basal levels of NO does occur 
following the administration of 5 mg/kg PQ. Although no significant difference (P > 
0.05) was observed between the NO response following administration of this low dose 
of PQ and the corresponding control data, the variation in the average NO response as 
represented by the dashed line (black) is clear in Figure 8.4.2.1 and is due to inter-
animal variability. Conflicting deviations above and below baseline levels of NO were 
observed between the different animals utilised in this study following the 
administration of this low dose of PQ (5 mg/kg) as presented in Figure 8.4.2.2.   
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Figure 8.4.2.2 Typical examples of the NO response recorded in the NA of independent animals 
over a continuous period of 72 hrs following systemic administration of PQ (5 mg/kg). (A) Animal 1 
(B) Animal 2 and (C) Animal 3. 
It is clear from Figure 8.4.2.2 that the systemic administration of 5 mg/kg PQ leads to an 
increase in NO response in Animal 1 (A) and a contrasting decrease in Animal 2 (B) and 
Animal 3 (C). This discrepancy may reflect the susceptibility of a given animal to the 
influence of PQ as an oxidative stressor. The development of PD has been postulated to 
be partially as a consequence of an underlying weakened energy metabolism (Wellstead 
& Cloutier, 2011). This pre-condition may be a considerable influence on the 
subsequent susceptibility of neurons to progressive degeneration which is a pathological 
characteristic of PD.  
In relation to the studies presented in this section this factor may lead to a variation in 
the vulnerability of a given animal to the subsequent PQ mediated development of 
oxidative/nitrosative stress. Additionally, this process may partly replicate the variable 
underlying susceptibility of individuals to the development of PD due to advancing age 
and exposure to various environmental toxins (Lotharius & Brundin, 2002; Tanner et 
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al., 2011; Wirdefeldt et al., 2011). Therefore these results further support the use of PQ 
to develop a suitable animal model of PD. The effect of the low administered dose of 
PQ (5 mg/kg) utilised in these sets of experiments, may be efficiently regulated by the 
robust antioxidant network which maintains redox homeostasis in the intact living brain. 
The effect of a higher administered dose of PQ (30 mg/kg) on the level of NO in the NA 
is shown in Figure 8.4.2.2.    
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Figure 8.4.2.3 The average NO response recorded in the NA over a continuous period of 72 hrs 
following systemic administration of PQ (30 mg/kg). Data represented as a percentage change ± 
SEM. SEM represented by dashed line (black). Arrow indicates the injection of PQ. 
Figure 8.4.2.3 represents the average NO response (n = 13, 5 animals) recorded in the 
NA following the administration of a relatively higher dose of PQ (30 mg/kg). The 
animals included in the data presented in Figure 8.4.2.3 were naive to previous PQ 
exposure. Following the systemic administration of PQ (30 mg/kg) a clear decrease in 
NO levels below baseline levels (dashed line) was evident as can be seen in Figure 
8.4.3.  
AUC analysis was utilised to determine the overall effect of 30 mg/kg PQ systemic 
administration on the NO current response monitored in the NA. It was possible to 
determine a maximum current change following the administration of 30 mg/kg PQ due 
to the recorded reproducible distinct decrease in NO. The maximum NO response was 
achieved within 47.1 ± 2.1 hrs (n = 13) following the injection and a return to a stable 
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baseline level was observed 62.5 ± 1.0 hrs (n = 13) subsequently. The pre-injection 
(482.9 ± 62.6 pA, n = 13) and post-injection baseline values (423.5 ± 44.0 pA, n = 13) 
were not significantly different (P > 0.05). However, it is clear from Figure 8.4.3 that 
the level of NO fails to completely return to pre-injection baseline levels for the duration 
of the recording period.  
The systemic administration of 30 mg/kg PQ resulted in an AUC value of -193.9 ± 43.4 
pA/hr (n = 9). This value was not significantly different (P > 0.05) to the control 
experiments outlined in Section 8.4.1. However a significant difference (P < 0.01,**) 
was observed between the AUC value calculated for the 30 mg/kg and 5 mg/kg PQ NO 
response. No significant difference (P > 0.05) was observed between the maximum 
response time and subsequent return to baseline levels following the administration of 5 
mg/kg PQ and the relatively higher administered dose (30 mg/kg PQ). It is clear that PQ 
exhibits its effect on NO levels in the neuronal environment in a dose dependent 
manner. It has previously been demonstrated by Corasaniti et al. that the systemic 
administration of a moderate and high dose of PQ in rats (20 mg/kg and 100 mg/kg) 
leads to induced tremors, rearing and occasional wet-dog shakes. Whereas a relatively 
low dose of PQ failed to replicate these behavioural abnormalities (Corasaniti et al., 
1998).  
Following systemic administration of 30 mg/kg PQ a pronounced attenuated decrease in 
NO levels below baseline levels (dashed line) was apparent for a continuous period of 
72 hrs as can be seen in Figure 8.4.3. This response contrasts greatly to that seen 
following the systemic administration of a relatively low dose of PQ, i.e. 5 mg/kg (see 
Figure 8.4.2). The highly reproducible marked decrease in NO levels following the 
systemic administration of 30 mg/kg PQ may be explained by the diaphorase activity of 
the NOS enzyme. NOS is an example of a cellular diaphorase which are a class of 
enzymes that can transfer electrons from NADPH to small molecules such as PQ (Day 
et al., 1999; Dinis-Oliveira et al., 2006). 
It has previously been demonstrated that NOS can preferentially produce O·upon 
exposure to PQ by a process known as ‘uncoupling’ of the NOS enzyme (Day et al., 
1999; Margolis et al., 2000). NOS may transfer electrons to PQ at the reductase domain 
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of the enzyme which leads to the increased production of O·at the expense of NO from 
NOS (Margolis et al., 2000). Day et al. have previously demonstrated a PQ related 
decrease in indirect markers of NO production from NOS in-vitro and a corresponding 
increase in NOS mediated O·production markers (Day et al., 1999). Additionally, 
NOS ‘uncoupling’ was more pronounced upon increasing the concentration of PQ (Day 
et al., 1999). Margolis et al. have also demonstrated the proportional concentration 
dependent PQ induced preferential production of O·over NO from NOS in-vitro 
(Margolis et al., 2000). The ‘uncoupling’ of NOS would explain the highly reproducible 
distinct depletion in NO levels following the systemic administration of 30 mg/kg PQ as 
presented in Figure 8.4.3. 
PQ 
Current 
change 
(pA) 
Change                        
(%) 
Conc. 
change 
(nM) 
Max 
response 
(hrs) 
Return 
(hrs) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
5 
mg/kg n/a n/a n/a n/a n/a 
-15.0 
± 36.7 
458.1 ± 
66.6 
429.3 ± 
57.0 9 
30 
mg/kg 
-349.9 
± 80.2 
-22.7 
± 5.2 
-229.0 
± 52.5 
47.1 ± 
2.1 
62.5 ± 
1.0 
-193.9 
± 43.4 
482.9 ± 
62.6 
423.5 ± 
44.0 13 
 
Table 8.4.1: Summary of the NO data recorded following PQ administration. With n = the number 
of sensors implanted in the NA of 3 animals (5 mg/kg) and 5 animals (30 mg/kg).  
8.4.3 Preliminary PQ dose response (NO and H2O2) 
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Figure 8.4.4 The dual NO (■; blue) and H2O2 (▲; green) response recorded in the NA over a 
continuous period of 72 hrs. Following the systemic administration of (A) PQ (5 mg/kg) and (B) PQ 
(30 mg/kg). Data represented as a percentage change ± SEM. Arrow indicates the injection of PQ. 
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The results presented in this section demonstrate the preliminary simultaneous long-term 
detection of H2O2 and NO in the same animal following the administration of PQ. The 
animals included in the data presented in Figure 8.4.4 were naive to previous PQ 
exposure. Figure 8.4.4(A) demonstrates the dual NO and H2O2 response in the NA 
following the systemic injection of a low dose of PQ (5 mg/kg). A slight deviation in 
baseline levels of NO was observed following this injection and a large attenuated 
increase in H2O2 can be seen following the administration of 5 mg/kg PQ. It is possible 
that this relatively low dose of PQ is not sufficient to induce ‘uncoupling’ of the NOS 
enzyme as discussed in Section 8.4.2. Therefore the level of NO remains largely 
unaffected following the administration of this dose of PQ. It has previously been 
demonstrated that the redox cycling of PQ produces O·(Dinis-Oliveira et al., 2006; 
Bove & Perier, 2012). As O·is the main source of H2O2 production in the neuronal 
environment (see Section 2.10.2). The redox cycling of PQ may explain the large 
increase in H2O2 response following the injection of PQ. An increased in-vitro 
mitochondrial production of H2O2 has previously been shown following exposure to PQ 
as determined by flourometric methods in-vitro (Cocheme & Murphy, 2008).  
The preliminary simultaneous detection of NO and H2O2 in the NA following the 
systemic administration of a moderate dose of PQ (30 mg/kg) is presented in Figure 
8.4.4(B). As previously demonstrated in Section 8.4.2 a protracted distinct decrease in 
NO below baseline levels was observed following the administration of 30 mg/kg PQ 
which may be attributed to the diaphorase activity of the NOS enzyme as discussed in 
Section 8.4.2. The large decrease in H2O2 levels may reflect the formation of •OH from 
H2O2 in a pro-oxidant environment (see Section 2.10.2). It must be stated at this point 
that the experiments outlined in this section are preliminary, however, the future 
simultaneous detection of H2O2/NO in a paraquat model of PD may provide an insight 
into the independent role of oxidative/nitrosative stress in the process of PQ mediated 
dopaminergic neurodegeneration which is characteristic of PD.  
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8.5 PQ additive dose response (NO) 
This section demonstrates the effect of an additive dose sequence of PQ administration 
on the NO sensor response implanted in the NA. The aim of this section is to investigate 
the effect of systemic pre-administration of PQ (10 mg/kg) followed by the 
administration of a higher dose of PQ (20 mg/kg) 72 hrs subsequently, on the NO sensor 
response while implanted in the brain of freely-moving animals.  
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Figure 8.5.1 The average NO response recorded in the NA over a continuous period of 72 hrs 
following systemic administration of PQ (20 mg/kg) with pre-administration of PQ (10 mg/kg). Data 
represented as a percentage change ± SEM. SEM represented by dashed line (black). Arrow 
indicates the injection of PQ (20 mg/kg). 
This section investigates the effect of systemic pre-administration of PQ (10 mg/kg) 
followed by the systemic injection of a higher dose of PQ (20 mg/kg) on the NO 
response (n = 2, 2 animals) monitored in the NA. Following systemic administration of 
PQ (20 mg/kg) a clear increase above basal levels of NO (dashed line) was apparent as 
can be seen in Figure 8.5.1. The calculated AUC value for the administration of PQ (20 
mg/kg) following pre-treatment with a lower dose of PQ (10 mg/kg) was 58.6 ± 27.6 
pA/hr (n = 2). The maximum NO response was achieved within 34.5 ± 4.5 hrs (n = 2) 
and a return to pre-injection basal levels was observed 61.5 ± 1.5 hrs (n = 2) 
subsequently. The pre-injection (392.0 ± 41.7 pA, n = 2) and post-injection baseline 
values (409.3 ± 59.5 pA, n = 2) were not significantly different (P > 0.05).  
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The AUC value calculated from this additive dose response was not significantly 
different (P > 0.05) to the AUC value determined for the control experiments outlined in 
Section 8.4.1. However, an increase above baseline levels of NO was observed 
following the additive PQ dose response (see Figure 8.5.1). Following on from this pilot 
study the effect of the repetitive administration of a moderate dose of PQ (30 mg/kg) on 
NO levels in the NA was examined as shown in Section 8.6.  
Shimizu et al. have previously demonstrated that the local administration of PQ results 
in a transient release of glutamate in the striatum (Shimizu et al., 2003a). Additionally, 
this research group has shown a concentration dependent elevated level of indirect 
markers of striatal NO production following the local addition of PQ (Shimizu et al., 
2003a). It is known that activation of NMDA receptors which are abundantly present in 
the NA (Monaghan & Cotman, 1985), by glutamate or by other agonists results in an 
intracellular influx of Ca2+ and initiates the process of excitotoxicity (Garthwaite, 2008).  
This glutamate mediated Ca2+ influx may then activate the constitutive forms of NOS 
(eNOS and nNOS) and lead to the production of NO (Alderton et al., 2001; Saulskaya & 
Fofonova, 2006). It is plausible in this case that the diaphorase activity of NOS as 
previously discussed is overcome by the PQ stimulated glutamatergic production of NO 
thereby leading to an increase in NO. This process would explain the substantial 
increase in NO levels following the administration of 20 mg/kg with the pre-treatment 
of a lower dose of PQ (10 mg/kg). The subsequent fall in NO levels may be attributed to 
the known interaction between NO and O·in a pro-oxidant environment induced in 
this case by PQ which leads to the production of the highly toxic RNS peroxynitrite 
ONOO (Calabrese et al., 2007; Ramalingam & Kim, 2012).  
In order to further examine the PQ stimulated production of NO as seen in Figure 8.5.1 a 
moderate dose of PQ (30 mg/kg) was administered to the animal repetitively in a 
sequential manner and the results are presented in Section 8.6.  
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8.6 PQ repetitive dose response (NO) 
This section examines the effect of the repeated administration of a moderate dose of PQ 
(30 mg/kg) on the NO sensor response monitored in the NA. Three systemic 
administrations of PQ (30 mg/kg) were administered to each animal and were 
interspersed with a 72 hr recording period. The animals included in the data presented in 
Figure 8.5.1 were naive to PQ exposure prior to initiation of these experiments. It has 
previously been demonstrated that the repeated systemic administration of a moderate 
dose of PQ is necessary to replicate the characteristics of PD in an animal model; 
including dopaminergic cell degeneration and the production of increased markers of 
oxidative/nitrosative stress (McCormack et al., 2005; McCormack et al., 2006).  
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Figure 8.6.1 The average NO response recorded in the NA over a continuous period of 72 hrs 
following the systemic administration of PQ (30 mg/kg) (A) 1st injection (B) 2nd injection and (C) 3rd 
(D) Overlay of all 3 injections of PQ (30 mg/kg). Data represented as a percentage change ± SEM. 
Arrow indicates the injection of PQ (30 mg/kg). 
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Figure 8.6.1(A) demonstrates the NO response monitored in the NA following the initial 
systemic administration of a moderate dose of PQ (30 mg/kg). As previously seen in 
Section 8.4.2 this moderate dose of PQ is sufficient to induce a prolonged decrease in 
NO levels for a continuous period of 72 hrs. The maximum NO response (-339.0 ± 71.2 
pA, n = 10) was achieved within 47.1 ± 4.1 hrs (n = 10) and a return to pre-injection 
basal levels was observed 65.7 ± 1.0 hrs (n = 10) subsequently. The pre-injection 
(1370.4 ± 269 pA, n = 10) and post-injection baseline values (1043.9 ± 202.5 pA, n = 
10) were not significantly different (P > 0.05). However it is clear from Figure 8.5.1 that 
the NO response does not fully return to pre-injection baseline NO levels following the 
injection of this initial dose of PQ (30 mg/kg).  
The systemic administration of this initial moderate dose of toxin (30 mg/kg PQ) 
resulted in an AUC value of -236.8 ± 55.2 pA/hr (n = 10). As previously discussed this 
marked decrease in NO levels detected following the initial administration of PQ (30 
mg/kg) may be explained by the diaphorase activity of the NOS enzyme. PQ exposure 
results in ‘uncoupling’ of the NOS enzyme in a dose dependent manner (Day et al., 
1999; Margolis et al., 2000; Moran et al., 2010). Therefore, following the initial 
exposure to PQ (30 mg/kg) as demonstrated in Figure 8.6.1(A) O·may be 
preferentially produced by the NOS enzyme at the expense of the production of NO 
leading to a decrease in NO monitored by the sensor implanted in the NA.  
Following the second administration of PQ (30 mg/kg) as presented in 8.6.1(B) the NO 
levels initially remain close to pre-injection baseline levels. A maximum increase in NO 
levels (134.5 ± 117.2 pA, n = 10) was then observed 51.0 ± 4.2 hrs (n = 10) following 
this injection which corresponds to a 12.7 ± 11.1 %, n = 10 change. The AUC value 
determined for this administration of PQ was -29.0 ± 51.8 pA/hr (n =10). No significant 
difference (P > 0.05) was observed between this AUC response and the corresponding 
value obtained from the control data presented in Figure 8.4.1. However, a significant 
difference (P < 0.05,*) was observed between the AUC value determined between the 
initial administration of PQ (30 mg/kg) and that following the second administration of 
PQ (30 mg/kg). It can be seen in Figure 8.6.1(B) that a delayed increase in the level of 
brain NO occurs following the second administration of 30 mg/kg PQ. It is possible that 
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this second injection (30 mg/kg PQ) leads to a stimulated glutamate efflux and a 
subsequent increase in the level of NO above baseline levels due to an influx of 
intracellular Ca2+ which may cause an increase in brain NO as previously discussed in 
Section 8.4.3 (Alderton et al., 2001; Shimizu et al., 2003a).  
The second administration of PQ was not sufficient to lead to an uncontrolled 
production of NO however. The level of NO returns towards pre-injection baseline 
levels prior to the third injection of 30 mg/kg PQ. This may reflect the ability of the 
opposing anti-oxidant network to dampen the production of ROS/RNS (see Section 
2.10). The subsequent decline in NO levels following the transient increase in NO as 
seen in Figure 8.6.1(B) may also be explained by the interaction between NO and O·in 
a pro-oxidant environment which leads to the formation of the highly toxic nitrogen 
species ONOO (Calabrese et al., 2007; Ramalingam & Kim, 2012). It has been 
postulated that NO produced from the action of PQ may diffuse to dopaminergic nerve 
terminals where it can exhibit deleterious effects primarily by the formation of the 
highly toxic RNS, ONOO and subsequently lead to dopamine release (Shimizu et al., 
2003a; Moran et al., 2010). 
Following the administration of the third moderate dose of PQ (30 mg/kg) as shown in 
Figure 8.6.1(C), an elevated production of NO can be seen which is substantially larger 
than that observed following the initial and secondary dose of systemic PQ 
administration (30 mg/kg). A prolonged attenuated increase in the level of NO was 
recorded which remained above baseline levels for the duration of the recording period. 
The AUC value determined for this third administration of PQ (30 mg/kg) was 237.6 ± 
74.8 pA/hr (n = 10). The maximum NO current response (894.6 ± 253.6 pA, n = 10) 
following the administration of the third dose of PQ was achieved within 53.7 ± 4.3 hrs 
(n = 10) and a return to pre-injection basal levels was observed 62.4 ± 2.5 hrs (n = 10) 
following this administration. The pre-injection (988.6 ±136.6 pA, n = 10) and post-
injection baseline values (1648.5 ± 307.4 pA, n = 10) were not significantly different (P 
> 0.05), however it is clear from Figure 8.6.1(C) that the NO response fails to return 
completely to pre-injection baseline levels. It is possible that the proposed glutamatergic 
pathway of NO production due to repetitive moderate PQ administration suppresses the 
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diaphorase activity of the NOS enzyme and the opposing anti-oxidant network which 
leads to an unrecoverable elevation of brain NO levels (Shimizu et al., 2003a; Dinis-
Oliveira et al., 2006; Moran et al., 2010). No significant difference (P > 0.05) was 
observed between the maximum response time and subsequent return to baseline levels 
following the administration of each systemically administered dose of 30 mg/kg PQ. A 
summary of the main results discussed in this section is provided for in Table 8.6.1. 
PQ   
(30 
mg/kg) 
Current 
change 
(pA) 
Change                        
(%) 
Conc. 
change 
(nM) 
Max 
response 
(hrs) 
Return 
(hrs) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
1st -339.0 
± 71.2 
-19.2 ± 
4.0 
-221.8 
± 46.6 
47.1 ± 
4.1 
65.7 ± 
1.0 
-236.8 
± 55.2 
1370.4 
± 269 
1043.9 
± 202.5 
2nd 134.5 ± 117.2 
12.7 ± 
11.1 
88.0  ± 
76.7 
51.0 ± 
4.2 
65.1 ± 
1.1 
-29.0 ± 
51.8 
1059.6 
± 208.9 
1091.9 
± 162.7 
3rd 894.6 ± 253.6 
90.5 ± 
25.6 
588.5 ± 
166.8 
53.7 ± 
4.3 
62.4 ± 
2.5 
237.6 
± 74.8 
988.6 
±136.6 
1648.5 
± 307.4 
 
Table 8.6.1: Summary of the NO data recorded following the repetitive administration of 30 mg/kg 
PQ. With n = 10 sensors implanted in the NA of 3 animals in each case.  
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8.7 Preliminary PQ ascending dose response (NO and H2O2) 
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Figure 8.7.1 The dual NO (■; blue) and H2O2 (▲; green) response recorded in the NA over a 
continuous period of 336 hrs. Following the systemic administration of (A) PQ (5 mg/kg), (B) PQ 
(10 mg/kg), (C) PQ (20 mg/kg) and (D) PQ (30mg/kg). Data represented as a percentage change ± 
SEM. Arrow indicates the injection of PQ. 
This section demonstrates the preliminary simultaneous detection of NO and H2O2 
following the repetitive systemic administration of paraquat (PQ) in a sequential manner 
of ascending doses. A PQ induced animal model of PD has previously been successfully 
demonstrated by McCormack et al. following the repetitive systemic administration of a 
moderate dose of PQ (McCormack et al., 2005; McCormack et al., 2006). The purpose 
of this section is to investigate the effect of an ascending administered level of PQ on 
the preliminary simultaneous measurement of NO and H2O2 in the freely-moving 
animal.  
An initial low dose of PQ was injected (s.c.) as represented in Figure 8.7.1(A). This dose 
of PQ was sufficient to initiate a marked increase in the production of H2O2 in the NA. 
Following the administration of this initial dose of PQ the level of PQ administered was 
increased sequentially from 10 mg/kg (Figure 8.7.1(B)) to 20 mg/kg Figure 8.7.1(C) and 
finally 30 mg/kg Figure 8.7.1(D) with an allowed intervening period of 72 hrs in each 
case and a subsequent 120 hr recording period following cessation of the ascending PQ 
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dose response. The initial substantial elevation of H2O2 may be explained by the redox 
cycling of PQ which is known to produce O· , the main source of H2O2 in the neuronal 
environment (see Section 2.10.2). As the level of H2O2 remains elevated the NO 
response remains close to PQ naive pre-injection baseline levels. It has previously been 
demonstrated in Section 8.4.2 that a relatively low dose of PQ is not sufficient to induce 
an overall substantial change in the level of NO.  
As the ascending dose response progresses a deviation above pre-injection baseline 
levels of NO can be seen following the administration of 10 and 20 mg/kg PQ which 
increases after the injection of 30 mg/kg PQ. A corresponding decrease in the level of 
H2O2 was observed following the fourth and final injection (30 mg/kg PQ). The opposite 
correlation between NO and H2O2 levels seen towards the end of the ascending PQ dose 
response may be explained by the interaction between O· and NO which leads to 
ONOO production (Calabrese et al., 2007; Ramalingam & Kim, 2012). This process 
may lead to an insufficient availability of O· which is required for the formation of 
H2O2 (see Section 2.10). It is important to state at this point that these results are 
preliminary, however, they do suggest a potential role for the simultaneous detection of 
NO and H2O2 in a PQ mediated animal model of PD in order to further knowledge 
surrounding the role of oxidative/nitrosative stress in the development of PD.  
8.7 Behavioural observations 
Brooks et al. have previously demonstrated the development of a neurobehavioral 
syndrome in freely-moving rodents following the repeated systemic administration of a 
moderate dose of PQ (Brooks et al., 1999). This behavioural syndrome was primarily 
characterised by a PQ induced reduction in locomotor activity which the authors 
attribute to PQ mediated dopaminergic cell degeneration (Brooks et al., 1999). 
Additionally, Hara et al. have reported the appearance of shaking behaviour known as 
wet dog shakes (WDS) in a dose dependent manner in rodents following the systemic 
administration of PQ. Furthermore the appearance of WDS was ameliorated by the pre-
administration of NOS inhibitors which suggests that NO may be involved in the 
development of this PQ related behavioural characteristic (Hara et al., 2001). However 
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the correlation between WDS and NO production could not be substantiated by this 
research group, the authors suggest that this finding may be due to the insufficient 
sensitivity of the microdialysis NO detection method utilised (Hara et al., 2001).  
It has previously been demonstrated by Corasaniti et al. that the systemic administration 
of a moderate and high dose of PQ in rats (20 mg/kg and 100 mg/kg) leads to induced 
tremors, rearing, salivation and occasional WDS. It was found that a relatively low dose 
of PQ (5 mg/kg) was not sufficient to produce these same behavioural abnormalities 
(Corasaniti et al., 1998). The abnormal motor characteristics previously reported in PQ 
treated rodents demonstrated by several research groups supports the use of PQ in an 
animal model of PD. 
As seen previously in PQ treated rodents abnormal behavioural characteristics were 
noted in the subjects utilised in these sets of experiments including temporary tremors 
and a reduction in general movement. In the absence of detailed behavioural testing the 
most noticeable change in behaviour of the subjects utilised in this study occurred 
following the administration of a relatively high dose of PQ (30 mg/kg). The injection of 
a low dose of PQ (5 mg/kg) did not elicit any gross behavioural changes in all animals 
utilised in this study as noted previously by Corasaniti et al. (Corasaniti et al., 1998). 
The administration of 30 mg/kg PQ elicited occasional shaking behaviour, piloerection 
and transient tremors in the subjects and the repetitive administration of this dose of PQ 
(30 mg/kg) was sufficient to increase this abnormal motor behaviour. Additionally the 
PQ mediated change in behavioural characteristics were prominent within a few hours 
of the injection itself.  
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8.8 PQ mediated toxicity in-vivo 
 
Figure 8.8.1 Proposed neurochemical pathway of PQ mediated toxicity in-vivo.  
(Schematic courtesy of Dr. Niall Finnerty). 
 
Figure 8.8.1 demonstrates the proposed mechanism of PQ mediated neuronal toxicity as 
studied in this chapter. It has previously been proposed that the redox cycling properties 
of PQ facilitates direct MTdys via inhibition of Complex I of the ETC leading to the 
production of superoxide O· (Castello et al., 2007; Cocheme & Murphy, 2008; 
Czerniczyniec et al., 2011). Additionally redox cycling of PQ may be mediated by 
cellular diaphorases which are enzymes that transfer electrons from NADPH to small 
molecules such as PQ (Day et al., 1999; Purisai et al., 2007; Berry et al., 2010). NOS is 
an example of a cellular diaphorase (Day et al., 1999). PQ may be reduced in the cytosol 
in this manner to form a PQ monocation free radical (PQ•+). Subsequently PQ•+ is 
rapidly re-oxidised in the presence of molecular oxygen leading to the production of 
O·  and reformed PQ which initiates the processes which lead to oxidative/nitrosative 
stress (see Figure 8.8.1[1]) (Dinis-Oliveira et al., 2006; Berry et al., 2010).  
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It has previously been demonstrated that NOS can preferentially produce O·upon 
exposure to PQ and is termed ‘uncoupling’ of the NOS enzyme (Day et al., 1999; 
Margolis et al., 2000). NOS may transfer electrons to PQ at the reductase domain of the 
enzyme resulting in the increased production of O·at the expense of NO from NOS 
(Margolis et al., 2000). The proposed ‘uncoupling’ of the NOS enzyme due to PQ 
exposure and the resulting decrease in brain NO levels is supported by the response 
detected by the NO sensor implanted in the NA following the administration of 30 
mg/kg PQ (see Section 8.4.2 and Figure 8.6.1(A)). The production of O·leads to the 
formation of the secondary reactive oxygen species (ROS), H2O2, which is primarily 
facilitated by the superoxide dismutase enzyme (SOD) (see Section 2.10). It has 
previously been demonstrated via indirect detection methods that the systemic injection 
of PQ leads to the production of H2O2 in-vitro and in ex-vivo brain preparations 
(Cocheme & Murphy, 2008; Czerniczyniec et al., 2011). The preliminary detection of 
elevated H2O2 levels following the administration of a relatively low dose of PQ (5 
mg/kg) is demonstrated in Section 8.4.3.  
The interaction between NO and O·in a PQ mediated pro-oxidant environment leads 
to the production of the highly toxic RNS; ONOO as represented in Figure 8.8.1[3] (see 
Section 2.10.3). The proposed glutamatergic pathway of NO production due to PQ 
exposure is represented in Figure 8.8.1[2]. As previously discussed the systemic 
administration of PQ has been shown to lead to a transient increase in brain glutamate 
levels (Shimizu et al., 2003a). Glutamate mediated activation of non-NMDA receptors 
leads to the hyperactivation of NMDA receptor channels and subsequently an 
intracellular influx of Ca2+ (Shimizu et al., 2003a; Garthwaite, 2008; Moran et al., 
2010). This glutamate mediated Ca2+ influx may then activate the constitutive forms of 
NOS (eNOS and nNOS) and lead to the production of NO (Alderton et al., 2001; 
Saulskaya & Fofonova, 2006). It has previously been postulated that NO produced from 
this PQ induced glutamatergic pathway diffuses to dopaminergic terminals and leads to 
MTdys primarily via interaction between NO and O·  and the subsequent formation of 
the highly toxic species ONOO (Shimizu et al., 2003a; Moran et al., 2010) This process 
may explain the degeneration of dopaminergic neurons following the systemic 
   Chapter 8: PD, NO and H2O2 
 
367 
 
administration of PQ as previously demonstrated by McCormack et al. in a rodent 
model (McCormack et al., 2005; McCormack et al., 2006). In addition the prolonged 
attenuated production of NO recorded in the NA following the repetitive administration 
of PQ may support this hypothesis (see Figure 8.6.1(A)). Additionally PQ mediated 
production of •OH from H2O2 (see Section 2.10.2) among other ROS/RNS due to PQ 
exposure as represented in Figure 8.8.1, may lead to damage to cell structures, DNA and 
lipids (Valko et al., 2007).  
It has previously been demonstrated that the systemic administration of PQ leads to the 
up-regulation of the α-synuclein protein which is the main constituent of the PD related 
intracytoplasmic inclusions commonly known as ‘Lewy bodies’ (Manning-Bog et al., 
2002). It has been postulated that the development of oxidative/nitrosative stress may 
contribute to α-synuclein accumulation by altering the protein itself or by the 
interruption of processes involved in protein degradation (Ostrerova-Golts et al., 2000; 
Butterfield & Kanski, 2001).  
The combined results presented in this chapter suggest that the administration of a 
relatively low dose of PQ leads to the induction of the diaphorase activity of the NOS 
enzyme and a decrease in brain NO due to the preferential production of  O·  (see 
Figure 8.8.1[1]). Further exposure to PQ may lead to a transient increase in brain NO 
mediated by the proposed glutamatergic pathway (Figure 8.8.1[2]) which is recoverable 
due to a decline in NO facilitated by the production of ONOO (see Figure 8.8.1[3]). 
Above a certain threshold of PQ exposure glutamate mediated production overcomes 
these processes and leads to an unrecoverable elevation of NO levels amongst other 
ROS/RNS species.  
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8.9 Conclusion 
The primary aim of this chapter was to demonstrate the novel detection of NO in a 
paraquat (PQ) induced animal model of Parkinson’s disease (PD). Additionally, the 
preliminary simultaneous detection of NO and H2O2 in the brain of freely-moving 
animals following the systemic administration of PQ was demonstrated in this chapter. 
The systemic administration of PQ has previously been demonstrated to elicit 
dopaminergic cell degeneration, the increased production of brain oxidative/nitrosative 
stress markers, behavioural motor abnormalities and the up-regulation of α-synuclein in 
rodents (Corasaniti et al., 1998; Hara et al., 2001; Manning-Bog et al., 2002; Shimizu et 
al., 2003a; McCormack et al., 2005; Dinis-Oliveira et al., 2006; McCormack et al., 
2006). All of these afore mentioned characteristics are successfully displayed following 
PQ exposure in rodents and are consistent with the main pathophysiological 
consequences of PD development in humans (Olanow & Tatton, 1999; Lotharius & 
Brundin, 2002; Schapira & Jenner, 2011).  
As a control experiment the effect of the systemic administration of saline (s.c.) on the 
implanted NO and H2O2 sensors was examined in Section 7.3.2. No lasting effect on the 
NO sensor response was observed following the systemic administration of saline. 
These results are consistent with previous findings of the effect of systemic 
administration of saline on the response of this NO sensor design (Finnerty et al., 2012). 
Additionally no lasting effect on the H2O2 response can be seen following the systemic 
administration of saline (see Section 8.3).  
As an additional control experiment the response of the NO sensor implanted in the NA 
for a continuous period of 72 hrs was examined in Section 8.4.1. The NO response 
remained close to baseline levels for the duration of the recording period. A slight 
deviation from baseline levels of NO was apparent, which is likely attributable to the 
previously reported circadian variation in the level of brain NO recorded over an 
extended time-frame (Heinzen & Pollack, 2002; Cespuglio et al., 2012). However a 
return to a stable baseline level of NO was observed within the recording period (see 
Figure 8.4.1). 
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A PQ dose response study was conducted in Section 8.4.2 and the long-term NO 
response attributable to the administration of a low dose of PQ (5 mg/kg) and a 
relatively high dose of PQ (30 mg/kg) was examined. Following the administration of a 
relatively low dose of PQ (5 mg/kg) the recorded level of brain NO remained close to 
pre-injection baseline levels for a continuous period of 72 hrs. However individual 
conflicting minor deviations above and below baseline levels of NO were noted 
following the administration of this low dose of PQ (5 mg/kg) due to inter-animal 
variability. This response may reflect the susceptibility of a given animal to the 
influence of PQ as an oxidative stressor. The previously hypothesised influence of an 
underlying weakened energy metabolism to the development of PD, mediated by 
oxidative/nitrosative stress, gives credence to the variation in the recorded NO response 
between animals following the administration of this low dose of PQ (Wellstead & 
Cloutier, 2011). 
The systemic administration of 30 mg/kg PQ elicited a contrasting NO response in 
comparison to the administration of a relatively lower dose of the toxin (5 mg/kg). 
Following the systemic administration of PQ (30 mg/kg) a clear decrease in NO levels 
below pre-injection baseline levels was evident (see Figure 8.4.3). This marked 
reproducible decrease in brain NO may be explained by the diaphorase activity of the 
NO producing enzyme nitric oxide synthase (NOS). It has previously been demonstrated 
that NOS as a cellular diaphorase can preferentially produce O·over NO upon 
exposure to PQ and is termed ‘uncoupling’ of the NOS enzyme (Day et al., 1999; 
Margolis et al., 2000). NOS may transfer electrons to PQ at the reductase domain of the 
enzyme resulting in the increased production of O·at the expense of NO from NOS 
(Margolis et al., 2000). The previously determined ‘uncoupling’ of the NOS enzyme 
provides an explanation for the decrease in NO observed following the initial exposure 
to a moderate level of PQ (30 mg/kg). A summary of the main PQ dose response NO 
results is displayed in Table 8.9.1.  
In addition, the preliminary simultaneous detection of changes in H2O2 and NO by the 
paired catalase-based H2O2 sensor and the previously characterised NO sensor following 
the administration of a low (5 mg/kg) and moderate dose (30 mg/kg) of PQ was 
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examined in Section 8.4.3. It has previously been demonstrated that the redox cycling of 
PQ results in the production of O·(Dinis-Oliveira et al., 2006; Bove & Perier, 
2012). O·is the primary source of H2O2 production in the neuronal environment 
(Ramalingam & Kim, 2012). An increase in H2O2 was detected following the 
administration of 5 mg/kg PQ possibly due to the redox cycling properties of PQ. 
Additionally an attenuated decrease in H2O2 levels was recorded following the 
administration of a moderate dose of PQ (30 mg/kg) which may be attributable to the 
formation of •OH from H2O2 in a pro-oxidant environment (see Section 2.10.2). 
PQ 
Current 
change 
(pA) 
Change                        
(%) 
Conc. 
change 
(nM) 
Max 
response 
(hrs) 
Return 
(hrs) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
n 
5 
mg/kg n/a n/a n/a n/a n/a 
-15.0 
± 36.7 
458.1 ± 
66.6 
429.3 ± 
57.0 9 
30 
mg/kg 
-349.9 
± 80.2 
-22.7 
± 5.2 
-229.0 
± 52.5 
47.1 ± 
2.1 
62.5 ± 
1.0 
-193.9 
± 43.4 
482.9 ± 
62.6 
423.5 ± 
44.0 13 
 
Table 8.9.1: Summary of NO results shown in Section 8.4.2 
Following on from the initial PQ exposure dose response the effect of an additive 
sequential dose of PQ on the implanted NO sensor was examined in Section 8.5. It has 
previously been demonstrated by McCormack et al. that the repetitive administration of 
a moderate dose of PQ is required to induce an increased production of nitrotyrosine-
containing proteins in ex-vivo brain preparations, which is an indication of 
oxidative/nitrosative stress (McCormack et al., 2005). An increase in NO above baseline 
levels was determined following the injection of 20 mg/kg PQ with pre-administration 
of 10 mg/kg PQ. This pilot study demonstrates that repetitive exposure to PQ is a 
necessary requirement in the development of PQ mediated NO production in the 
neuronal environment.  
The increase in NO recorded following the administration of a sequential additive dose 
of PQ may occur via a glutamatergic pathway. It has previously been demonstrated that 
the local administration of PQ results in a transient release of glutamate in the striatum 
(Shimizu et al., 2003a). Glutamate mediated activation of non-NMDA receptors leads to 
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the hyperactivation of NMDA receptor channels and subsequently an intracellular influx 
of Ca2+ (Shimizu et al., 2003a; Garthwaite, 2008; Moran et al., 2010). This glutamate 
mediated Ca2+ influx may then activate brain NOS and lead directly to the production of 
NO (Alderton et al., 2001; Saulskaya & Fofonova, 2006).  
The effect of the repeated systemic administration of PQ (30 mg/kg) on the level of NO 
monitored in the NA is presented in Section 8.6. The initial administration of 30 mg/kg 
PQ leads to an attenuated decrease in NO levels below baseline levels (see Figure 
8.6.1(A)). As previously discussed this marked decrease in brain NO induced by the 
initial exposure to a moderate dose of PQ (30 mg/kg) may be explained by the 
diaphorase activity of the NOS enzyme which leads to the preferential production of 
O·over NO from NOS (Day et al., 1999; Margolis et al., 2000).  
Following the second administration of PQ (30 mg/kg) the initial NO response 
monitored in the NA remains close to pre-injection baseline levels followed by a 
delayed increase in brain NO (see Figure 8.6.1(B)). The increase in NO detected 
following this injection may be explained by a glutamate mediated production of NO as 
previously discussed. The subsequent return of elevated NO to pre-injection baseline 
levels may be explained by the interaction between NO and PQ mediated  O·  
production which is known to lead to the formation of ONOO which would result in a 
decline in brain NO production.   
The systemic administration of the third dose of 30 mg/kg PQ leads to an elevated 
attenuated production of brain NO (see Figure 8.6.1(C)). This finding suggests that 
beyond a certain level of PQ exposure an unrecoverable elevation of brain NO occurs. It 
has been postulated that NO produced from the action of PQ may diffuse to 
dopaminergic nerve terminals where it can exert deleterious effects primarily by the 
formation of the highly toxic RNS, ONOO (Shimizu et al., 2003a; Moran et al., 2010). 
This process may lead to progressive dopaminergic cell degeneration which is 
characteristic of the pathology of PD. The overall proposed mechanism of PQ induced 
neuronal toxicity is discussed in detail in Section 8.8. A summary of the results 
presented in Section 8.6 is shown in Table 8.9.2.  
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PQ   
(30 
mg/kg) 
Current 
change 
(pA) 
Change                        
(%) 
Conc. 
change 
(nM) 
Max 
response 
(hrs) 
Return 
(hrs) 
AUC 
(pA/hr) 
Pre-
injection 
baseline 
(pA) 
Post-
injection 
baseline 
(pA) 
1st -339.0 
± 71.2 
-19.2 ± 
4.0 
-221.8 
± 46.6 
47.1 ± 
4.1 
65.7 ± 
1.0 
-236.8 
± 55.2 
1370.4 
± 269 
1043.9 
± 202.5 
2nd 134.5 ± 117.2 
12.7 ± 
11.1 
88.0  ± 
76.7 
51.0 ± 
4.2 
65.1 ± 
1.1 
-29.0 ± 
51.8 
1059.6 
± 208.9 
1091.9 
± 162.7 
3rd 894.6 ± 253.6 
90.5 ± 
25.6 
588.5 ± 
166.8 
53.7 ± 
4.3 
62.4 ± 
2.5 
237.6 
± 74.8 
988.6 
±136.6 
1648.5 
± 307.4 
 
Table 8.9.2: Summary of NO results shown in Section 8.6. 
The preliminary simultaneous detection of NO and H2O2 following the repetitive 
systemic administration of paraquat (PQ) in a sequential manner of ascending doses is 
presented in Section 8.7. An initial substantial elevation of H2O2 was recorded following 
the administration of a low dose of PQ (5 mg/kg). This increase in brain H2O2 may be 
explained by the redox cycling of PQ in the neuronal environment which is known to 
lead to the production of  O· and sequential H2O2 formation (see Section 2.10.2) 
(Dinis-Oliveira et al., 2006; Bove & Perier, 2012). The corresponding level of NO 
remained close to baseline levels upon the initial exposure to PQ (see Figure 8.7.1).  
An opposite correlation was observed between NO and H2O2 levels towards the end of 
the ascending PQ dose response. This observation may be explained by the interaction 
between O· and NO which leads to ONOO production (Calabrese et al., 2007; 
Ramalingam & Kim, 2012). The NO mediated formation of ONOO may lead to an 
insufficient availability of O·  which is required for the formation of H2O2 (see Section 
2.10). The dual detection of NO and H2O2 presented in Section 8.7 is preliminary 
however and the future detection of theses species in the neuronal environment 
following the administration of PQ may facilitate an examination of the role of 
oxidative/nitrosative stress in PQ mediated neurotoxicity.  
The behavioural changes induced in rodents by PQ exposure are discussed in Section 
8.7. The main behavioural abnormalities observed in this study included a general 
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reduction in movement, occasional shaking behaviour and transient tremors. These 
behavioural traits were more noticeable at higher doses of administered PQ (30 mg/kg) 
and following repeated exposure. In the absence of detailed behavioural testing it is 
difficult to correlate changes in NO with PQ elicited behavioural abnormalities. Future 
work may focus on a possible link between these PQ mediated behavioural responses 
and changes in brain NO as previously examined (Hara et al., 2001). 
The further real-time detection of NO, along with other RNS and ROS, including H2O2, 
in a PQ induced animal model of PD may provide previously undetermined information 
surrounding the etiology and pathophysiology of PD. An understanding of the role of 
oxidative/nitrosative stress in the initiation and development of PD may hopefully lead 
to the development of novel PD therapeutic strategies. 
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The detection of chemical changes in the extracellular fluid (ECF) of the brain using 
Long Term In-Vivo Electrochemistry (L.I.V.E) provides an insight into the processes 
which underlie cognitive function. In addition information regarding the 
pathophysiology of a variety of neurodegenerative diseases and disorders may be 
yielded by this technique. The fundamental basis of L.I.V.E is the implantation of an 
electrochemical sensor into the brain, the application of a suitable potential and the 
subsequent detection of a faradaic current which is proportional to the concentration of 
the target species.  
Monitoring neurochemicals using L.I.V.E in the ECF is complicated by a variety of 
technical obstacles. A range of neurotransmitters (NTs) in the ECF are not electroactive 
and many species oxidise at similar potentials. Additionally, brain tissue consists of 
lipids and proteins which may affect the properties of the sensor in-vivo (Garguilo & 
Michael, 1994). The reaction of the body to the presence of a foreign object can also 
negatively affect the characteristics of a sensor (Wisniewski et al., 2000). Mass transport 
of the analyte to an electrochemical sensor may also be restricted by the brain tissue 
itself (Cheng et al., 1979; Dayton et al., 1983). 
In recent years various strategies have been utilised in order to improve the sensitivity, 
selectivity and stability of implanted electrochemical sensors. The incorporation of a 
biological recognition unit, usually an enzyme into the design of the sensor facilitates 
the detection of non-electroactive species (Hu et al., 1994; Lowry et al., 1994; Garguilo 
& Michael, 1996; Ryan et al., 1997). The application of a suitable potential and the 
modification of the electrode surface with various permselective membranes has 
improved the selectivity and stability of the L.I.V.E technique (McAteer & O'Neill, 
1996; Lowry et al., 1998; Brown et al., 2009). The primary aim of this thesis is to 
authoritatively establish the detection of hydrogen peroxide (H2O2) and nitric oxide 
(NO) in the in-vitro environment and to demonstrate the detection of these species in the 
ECF of the brain.  
An extensive in-vitro and in-vivo characterisation of a highly suitable electrochemical 
sensor for the purpose of the chronic real-time detection of NO has previously been 
demonstrated by our research group (Finnerty et al., 2012a; Finnerty et al., 2012b). The 
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initial in-vitro characterisation of the paired catalase-based H2O2 sensor utilised in this 
body of work has previously been reported (O'Brien et al., 2007). A validation of the 
previous in-vitro and in-vivo characterisation of the NO sensor with the inclusion of new 
in-vitro stability attributes is presented in this thesis. Novel in-vitro characteristics of the 
paired catalase-based H2O2 sensor are also demonstrated in this thesis. The previously 
unreported in-vivo characterisation of the paired H2O2 sensor in the anaesthetised and 
freely-moving animal is also presented.  
Following on from this work the novel detection of NO in an animal model of autism 
spectrum disorders (ASDs) is shown. Additionally, the dual detection of NO and H2O2 
in an animal model of Parkinson’s disease (PD) is presented. In both instances the 
specific focus is on the role of oxidative/nitrosative stress in the pathophysiology of 
these conditions. The aim of this novel contribution to the field of neurochemistry is the 
further advancement of knowledge surrounding the etiology and progression of ASDs 
and PD which may yield new therapeutic advancements. 
Chapter 4 demonstrates the replication of the catalase-based dual H2O2 sensor design to 
establish the sensitivity, selectivity and stability of the H2O2 sensor in the in-vitro 
environment. Novel selectivity and stability parameters of the dual H2O2 sensor design 
are also presented in Chapter 4. Specifically the long-term stability (28 days) of the 
sensor is addressed following exposure to lipids, proteins and ex-vivo brain tissue.  
As shown in Chapter 4 the detection of H2O2 in the in-vitro environment is not impaired 
in the presence of other electroactive species including dopamine (DA) and ascorbic 
acid (AA). Aqueous and substrate in-vitro media conditions were changed to artificial 
cerebrospinal fluid (aCSF) in order to mimic in-vivo characterisation parameters. The 
oxidation of H2O2 at platinum electrodes (Ptd) was not significantly different under 
either of these conditions. The operational characteristics of the paired H2O2 sensor are 
also demonstrated. The catalase-based paired H2O2 sensor possesses the required 
response time and limit of detection for the purpose of in-vivo H2O2 monitoring. H2O2 is 
a highly permeable short-lived molecule which may be particularly prevalent in the in-
vivo environment (Maier & Chan, 2002; Bao et al., 2009).  
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The characterisation of the H2O2 sensor in the in-vivo environment is demonstrated in 
Chapter 5. The paired H2O2 sensor was implanted into the brain of anaesthetised and 
freely-moving Wistar rats. The effect of local and systemic administration of known 
inducers and inhibitors of H2O2 on the performance of the dual H2O2 sensor response 
was investigated. 
Following the local administration of H2O2 (100 µM to 1000 µM) in the freely-moving 
animal a significant difference was observed with respect to the perfusion of aCSF. 
However no distinct increase above basal levels of endogenous H2O2 was observed 
following introduction of H2O2 to the perfusate. It is plausible that exogenously applied 
H2O2 may be efficiently controlled by the inherent mechanisms of the intact living brain. 
A variety of enzymatic/non-enzymatic processes regulate the production of reactive 
oxygen species (ROS) such as H2O2 in order to prevent the development of oxidative 
stress and subsequent deleterious processes (Barnham et al., 2004; Valko et al., 2007; 
Melo et al., 2011; Ramalingam & Kim, 2012). It is therefore possible that exogenously 
applied H2O2 is capably dealt with by the extensive antioxidant network. This 
observation is further supported by the recorded response of the H2O2 sensor following 
the local administration of H2O2 in the anaesthetised animal.  
The effect of the local administration of H2O2 on the paired sensor response was 
relatively more pronounced in the anaesthetised animal. A clear increase above basal 
levels of H2O2 was observed at a higher concentration range of exogenously applied 
H2O2 (100 µM to 100 mM). It is possible that the robust network of antioxidant 
mechanisms which regulate the level of H2O2/ROS in the brain cannot function 
normally due to the effect of anaesthesia; consequently an increase was recorded by the 
implanted H2O2 sensor following the local administration of H2O2 (100 µM to 100 mM) 
in the acute experimental set-up.  
Additionally, a lower baseline level of H2O2 was recorded in the acute preparation, 
where anaesthesia is constantly administered to the animal, in comparison to the freely-
moving regime. Suppressed neuronal activity corresponds to a decrease demand for 
regional cerebral blood flow and hence a matched reduction in oxygen levels (Li et al., 
2011). Neuronal H2O2 is primarily derived through the action of the enzyme superoxide 
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dismutase (SOD) on superoxide O· which is derived from the mitochondrial 
reduction of molecular O2. The endogenous production of H2O2 is linked to increased 
neuronal activity due to an increased level of O2 consumption which generates H2O2 
(Rice, 2011). Therefore, a drop in neuronal activity due to anaesthesia may explain a 
reduction in H2O2 baseline levels. 
The next step in the in-vivo characterisation of the H2O2 sensor was to inhibit the 
antioxidant network responsible for the regulation of H2O2 in an attempt to show an 
increase in the endogenous production of H2O2. The primary enzymes responsible for 
the degradation of H2O2 in the brain are catalase and glutathione peroxidase (GPx) 
which are inhibited by sodium azide (SA) and mercaptosuccinate (MCS) respectively. 
The local perfusion of MCS and SA caused an increase in the paired catalase-based 
H2O2 sensor response, this preliminary data would indicate that the implanted sensor is 
responding to an endogenous increase in H2O2 levels and is therefore selective towards 
H2O2. Additionally, the in-vivo selectivity of the paired H2O2 sensor over locally 
introduced AA was demonstrated and the preliminary selectivity of the sensor over 
systemically administered AA was shown.   
Chapter 6 demonstrates the in-vitro and in-vivo characterisation of the NO sensor as 
previously shown; in order to further illustrate the application of this sensor for the real-
time detection of NO in animal models of neurological disease and dysfunction. The 
sensitivity and selectivity of the NO sensor in the in-vitro environment were in 
agreement with previously published demonstrations (Finnerty et al., 2012a; Finnerty et 
al., 2012b). Additionally, the operational characteristics of the sensor including the 
response time and the limit of detection were consistent with previous reports (Brown et 
al., 2009). The required in-vitro characteristics of the NO sensor were established, 
which are needed to detect NO in the physiological environment, due to the relatively 
low concentration and short half-life of the target species in-vivo (Kiechle & Malinski, 
1993; Wink & Mitchell, 1998; Kelm, 1999).  
An examination of NO sensor characteristics following implantation was presented in 
Chapter 6 as has been published recently (Finnerty et al., 2012a). It was determined that 
the post in-vivo sensitivity of the NO sensor was approximately 48 % less than the pre-
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implantation sensitivity of the same sensors. The AA selectivity characteristics of the 
NO sensor following implantation were also described. An increased response to AA 
following implantation of the NO sensor was observed. However, the Nafion®-modified 
active surface of the NO sensor remains intact while implanted as proven by the sensor 
response to systemically administered ascorbate in-vivo as shown in Chapter 6. An 
explanation for the altered in-vitro NO sensitivity and AA selectivity of the NO sensor 
following implantation may be that the process of ex-plantation causes damage to the 
active surface of the sensor.  
The sensitivity, selectivity and stability of the NO sensor while implanted in the nucleus 
accumbens (NA) of the freely-moving animal was validated in Chapter 6. The response 
of the implanted NO sensor to systemically administered saline was established and no 
lasting effect on the NO response of the Nafion®-modified NO sensor was observed 
following this injection. The precursor to NO production in the body (L-arginine) was 
systemically administered and NO levels in the NA were monitored. A significant 
increase in the NO sensor response was observed following the administration of L-
arginine with respect to the injection of saline. The effect of the non-selective nitric 
oxide synthase (NOS) inhibitor (L-NAME) on the response of the NO sensor was 
determined in the NA. A significant decrease in the NO sensor response was observed 
following the administration of L-NAME with respect to the corresponding saline 
response.  
The in-vivo selectivity of the NO sensor over ascorbate, the primary interference species 
present in the brain was examined. No significant difference was observed between the 
maximum current response and pre-injection baseline levels of the NO sensor following 
the injection of ascorbate. These results further support the proficient sensitivity, 
selectivity and stability of the NO sensor in the in-vivo environment as previously 
demonstrated (Finnerty et al., 2012a; Finnerty et al., 2012b). 
The in-vivo characterisation results recorded by the NO sensor as presented in this thesis 
are consistent with recently published data. No significant difference (P > 0.05) was 
observed between the maximum current response following each administration (saline, 
L-arginine, L-NAME and sodium ascorbate) when compared to the corresponding in-
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vivo results previously shown by Finnerty et al. in the NA of freely-moving animals 
(Finnerty et al., 2012b). Additionally the baseline stability of the NO sensor while 
implanted in the NA for a consecutive period of 14 days was shown in Chapter 6. 
Previous investigations have demonstrated the stability of the NO sensor implanted in 
the brain for a consecutive period of 8 days (Finnerty et al., 2012a). No significant 
variation was observed in the baseline current of the NO sensor over this extended 
duration of implantation (14 days). These results further verify the stability of the NO 
sensor for the purpose of obtaining long-term in-vivo recordings. 
Chapter 7 demonstrates the novel electrochemical detection of NO in an animal model 
of autism. The previously characterised NO sensor was implanted in the NA and dorsal 
hippocampus (DH) of freely-moving animals. The long-term detection of NO was 
recorded by the sensor prior to and following the chronic systemic administration of 
Propionic acid (PPA). MacFabe et al. have previously demonstrated that PPA may be 
used in rats to mimic the behavioural changes and neuroinflammatory responses which 
are associated with autism spectrum disorders (ASDs) (MacFabe et al., 2007; MacFabe 
et al., 2008; MacFabe et al., 2011).  
As a control experiment the level of NO in the NA and DH was examined over a 
continuous period of 24 hrs in the absence of treatment. A small variation in the NO 
response was observed over the 24 hr period which is likely attributable to the circadian 
rhythms of the animal (see Section 7.5.1 and 7.6.1).  Also no significant difference was 
observed between the 24 hr control data response recorded in the NA and the DH as 
determined by area under the curve (AUC) analysis. Time dependent changes in the 
level of NO recorded over a 24 hr period have previously been demonstrated by 
Cespuglio et al. using voltametric methods in freely-moving rats (Cespuglio et al., 
2012). The time-dependent minor variation in NO over 24 hrs as presented in Chapter 7, 
which is mirrored closely in both regions suggests a contribution to the signal from a 
diurnal variation in the level of NO. The overall contribution of natural processes and 
possible residual capacitance of the sensor to the recorded level of NO are effectively 
eliminated from the overall signal attributable to administration of PPA by this control 
data. 
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An initial pilot study determined the relative short-term effect of PPA administration on 
the level of NO in the NA. A significant increase in NO response was determined 
following the administration of each dose of PPA (1 µM/g, 2 µM/g and 4 µM/g) with 
respect to the administration of saline. Previous demonstrations of a PPA induced 
animal model of autism involved the long-term systemic administration of PPA 
(500mg/Kg) (Shams et al., 2009). Following on from the pilot study presented in 
Chapter 7 the PPA administration protocol was extended and the dose of PPA 
administered was changed (500 mg/kg). Each animal was administered PPA (500 
mg/Kg) twice daily for a continuous period of 12 days and the corresponding changes in 
NO levels in the NA and DH on each day were monitored by the NO sensor. 
A similar trend was observed in the NA and the DH on Day 1-6 of the PPA 
administration protocol. No significant difference in NO response, as determined by 
AUC analysis, was observed between Day 1-6 inclusively in comparison to the 
corresponding value determined for the 24 hr control data in both regions.  
A robust network of antioxidant mechanisms regulate the level of reactive nitrogen 
species (RNS) such as NO in the CNS (Calabrese et al., 2007; Valko et al., 2007). The 
antioxidant network is responsible for the prevention of the development of 
oxidative/nitrosative stress and exists to maintain normal cognitive function. It is 
therefore plausible that the initial exposure to PPA (Day 1-6) is dealt with effectively by 
these robust control mechanisms inherent to the intact living brain and suppresses the 
over production of NO. Therefore no significant difference in NO response was 
recorded in both regions on Day 1-6 of the PPA administration protocol in comparison 
to the corresponding control data.  
Following the extension of the PPA administration protocol (Day 7-12) a general trend 
emerged in the NO response recorded in the NA and the DH. Following 7 days of 
chronic PPA administration, an increase in NO was detected in both regions from Day 
7-12 inclusively when compared to the corresponding control data.  
The unregulated overproduction of NO due to the development of oxidative/nitrosative 
stress has previously been implicated in the development of autism (Chauhan & 
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Chauhan, 2006). An increase in the level of NO and indirect markers of NO production 
have been demonstrated in biological samples of autistic individuals (Sogut et al., 2003; 
Sweeten et al., 2004). Additionally, increased oxidative stress markers have been 
detected in pathological studies of autistic brain preparations (Chauhan et al., 2012; 
Rose et al., 2012). Also, increased oxidative stress markers have been determined in 
brain preparations of a PPA induced animal model of autism (MacFabe et al., 2007; 
MacFabe et al., 2008). The recorded elevation of NO levels in the animal model of 
autism presented in Chapter 7 would support this research. Neuropathological 
investigations of ASDs brain preparations have indicated the presence of activated 
microglia and astrocytes (Vargas et al., 2005). Cytokines produced by this process lead 
to an inflammatory process which is known to activate iNOS and hence induce an 
increase in NO (Guix et al., 2005). The observed PPA induced increase in NO levels 
may be attributable to iNOS or alternatively is derived from the constitutive forms of 
NOS (eNOS and nNOS).  
Previous studies conducted with ex-vivo brain preparations have indicated that PPA may 
act through a glutamatergic pathway. This research demonstrates that the incubation of 
brain slice preparations with PPA has been shown to stimulate the phosphorylation of 
cytoskeletal proteins. The use of specific N-methyl-D-aspartate (NMDA) receptor 
agonists has been shown to mimic the stated effect following brain slice exposure to 
PPA (de Mattos-Dutra et al., 2000). PPA has also previously been shown to promote 
intracellular calcium (Ca2+) release (Nakao et al., 1992). It is known that activation of 
NMDA receptors, abundantly present in the NA (Monaghan & Cotman, 1985), by 
glutamate or by other agonists results in an influx of Ca2+ and leads to depolarisation of 
the cell. eNOS and nNOS are activated by Ca2+ followed by binding with calmodulin 
which leads directly to the production of NO (Alderton et al., 2001; Saulskaya & 
Fofonova, 2006).    
However, the exact neuropharmacological role of PPA in the induced elevation of NO in 
the brain as presented in Chapter 7 has yet to be fully elucidated. Future work may 
involve the use of specific NOS inhibitors (Alderton et al., 2001), to elucidate the exact 
mechanism of NO production in the PPA animal model of autism presented in Chapter 
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7. The further detection of NO in an animal model of autism with a specific focus on the 
role of nitrosative stress may lead to a better understanding of the etiology and 
pathophysiology of ASDs. This research may lead to the development of novel potential 
therapeutic strategies for incidences of severe impairment by debilitating restricted and 
repetitive traits seen in certain ASDs cases.  
Chapter 8 demonstrates the novel electrochemical detection of brain NO in a paraquat 
(PQ) induced animal model of Parkinson’s disease (PD). Additionally the preliminary 
simultaneous detection of NO and H2O2 in the same animal following the systemic 
administration of PQ is presented in Chapter 8. NO was monitored in the NA using the 
previously extensively characterised NO sensor (Finnerty et al., 2012a; Finnerty et al., 
2012b) and the level of H2O2 in the NA was recorded using the catalase-based H2O2 
sensor (see Chapter 4 and 5). The role of various toxins including rotenone, PQ and 
MPTP in the development of PD has previously been examined and utilised to study PD 
in animal models (Beal, 2001; McCormack et al., 2005; McCormack et al., 2006).  
The structural similarity of PQ to the parkinsonism inducing toxin MPP+ (Davis et al., 
1979; Langston et al., 1983; Dinis-Oliveira et al., 2006; Bove & Perier, 2012) has led to 
the development of an animal model of PD by the repeated systemic administration of 
PQ in rodents (McCormack et al., 2005; McCormack et al., 2006). Systemically 
administered PQ has been shown to cross the blood brain barrier (BBB) in rodents via a 
neutral amino acid transporter (Corasaniti et al., 1998; Shimizu et al., 2001; 
McCormack & Di Monte, 2003) and subsequently leads to dopaminergic cell 
degeneration, behavioural motor abnormalities and the up-regulation of α-synuclein 
which is the major constituent of ‘Lewy bodies’ which are cytoplasmic inclusions 
commonly found in pathological studies of PD (Brooks et al., 1999; Manning-Bog et 
al., 2002; McCormack et al., 2005).  
It has been postulated that the degeneration of dopaminergic cells which is a 
pathological hallmark of PD is mediated by oxidative/nitrosative stress specifically as a 
result of DA metabolism (Lotharius & Brundin, 2002; Andersen, 2004; Chinta & 
Andersen, 2008). The main focus of Chapter 8 is the detection of NO as a marker of 
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nitrosative stress and the preliminary detection of H2O2 as an indication of the 
development of oxidative stress in a PQ induced animal model of PD.  
As long-term changes in NO were examined in Chapter 8 following the systemic 
administration of PQ, a control experiment was conducted, where the level of NO in the 
NA was monitored over a continuous period of 70 hrs in the absence of treatment. 
Minor deviations in the baseline level of NO were apparent over the recorded time 
period which are largely attributable to a circadian variation in the level of NO as 
previously demonstrated (Heinzen & Pollack, 2002; Cespuglio et al., 2012).  
The neurotoxic effect of PQ is primarily mediated by the redox cycling properties of this 
molecule (see Section 8.8) which leads to direct and indirect mitochondrial dysfunction 
(MTdys) and the deleterious consequences of oxidative/nitrosative stress. A PQ dose 
response study was conducted in Chapter 8 and the long-term NO response attributable 
to the administration of a low dose of PQ (5 mg/kg) and a relatively high dose of PQ (30 
mg/kg) was examined. The recorded NO response monitored in the NA following the 
administration of 5 mg/kg PQ displayed inter-animal variability. Conflicting NO 
responses above and below baseline levels of NO were observed between animals 
following this administration (5 mg/kg PQ). The discrepancy observed between the 
animals utilised in this study (5 mg/kg PQ) may reflect an underlying susceptibility to 
oxidative/nitrosative stress mediated by PQ. It is postulated that this variable NO 
response is consistent with a previously hypothesised underlying weakened energy 
metabolism and vulnerability to oxidative/nitrosative stress processes leading to the 
development of PD (Wellstead & Cloutier, 2011).  
The systemic administration of 30 mg/kg PQ elicited a contrasting NO response in 
comparison to the administration of a relatively lower dose of the toxin (5 mg/kg). 
Following the systemic administration of PQ (30 mg/kg) a clear decrease in NO levels 
below pre-injection baseline levels was evident. This decrease in NO may be attributed 
to the diaphorase activity of the NO producing enzyme NOS. It has previously been 
demonstrated that NOS may act as a cellular diaphorase in that it may donate electrons 
to PQ and lead to ‘uncoupling’ of NOS which results in the preferential formation of 
O·over NO from NOS (Day et al., 1999; Margolis et al., 2000).  
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The preliminary detection of an increased level of H2O2 in the NA was demonstrated 
following the administration of 5 mg/kg PQ. This can be attributed to the formation of 
the primary source of H2O2 production; O·due to PQ redox cycling in the neuronal 
environment (see Section 8.8). Additionally, a preliminary decrease in H2O2 was 
recorded following the administration of a relatively higher dose of PQ (30 mg/kg) 
which may be due to the formation of •OH from H2O2 in a PQ mediated pro-oxidant 
environment (see Section 2.10.2). The preliminary simultaneous detection of H2O2 and 
NO following an extended sequential additive administration of PQ is demonstrated in 
Section 8.7. Following a relatively low exposure to PQ, a substantial increase in H2O2 
was recorded in the NA and the corresponding NO levels remained close to baseline 
levels. Following increased exposure to PQ an opposite correlation was observed 
between NO and H2O2 levels which may be explained by the interaction between O·  
and NO which leads to ONOO production (Calabrese et al., 2007; Ramalingam & Kim, 
2012). This process may lead to an insufficient availability of O· which is required for 
the formation of H2O2 and a corresponding decrease in NO levels (see Section 2.10). 
However, future work is required to ascertain changes in neuronal H2O2 levels following 
the administration of PQ. 
The additive (see Section 8.5) and repetitive (see Section 8.6) systemic administration of 
PQ (30 mg/kg) resulted in an increase in brain NO above baseline levels. It is postulated 
that the PQ mediated increase in NO levels is facilitated by a glutamatergic pathway. It 
has previously been demonstrated that PQ exposure in rodents leads to a transient 
increase in glutamate levels in the neuronal environment (Shimizu et al., 2003). 
Glutamate mediated activation of non-NMDA receptors leads to the hyperactivation of 
NMDA receptor channels and subsequently an intracellular influx of Ca2+ (Shimizu et 
al., 2003; Garthwaite, 2008; Moran et al., 2010). This glutamate mediated Ca2+ influx 
may then activate brain NOS and lead directly to the production of NO (Alderton et al., 
2001; Saulskaya & Fofonova, 2006). Additionally, this proposed glutamatergic pathway 
of NO production may exceed the proposed ‘uncoupling’ of the NOS enzyme and the 
opposing anti-oxidant network at high levels of PQ exposure. This process may lead to 
an unrecoverable elevation of brain NO levels as demonstrated in Section 8.6 following 
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the repetitive administration of PQ (30 mg/kg). A detailed description of this 
glutamatergic NO producing pathway is provided for in Section 8.8.  
The further real-time detection of NO amongst other RNS and reactive oxygen species 
(ROS) including H2O2 in a PQ induced animal model of PD may provide previously 
undetermined information surrounding the etiology and pathophysiology of PD. An 
understanding of the role of oxidative/nitrosative stress in the initiation and development 
of PD may hopefully lead to the development of novel PD therapeutic strategies.  
Progression of this body of work may include the further detection of H2O2 in-vivo 
combined with NO as a method of simultaneous oxidative/nitrosative stress detection in 
a PQ induced animal model of PD amongst other neurodegenerative diseases and 
dysfunctions. As NO and H2O2 are relatively stable RNS/ROS species in the neuronal 
environment they present suitable markers for the detection of neurodegenerative 
disease initiation and progression mediated by oxidative/nitrosative stress (Maier & 
Chan, 2002; Valko et al., 2007; Rice, 2011). The real-time electrochemical detection of 
NO and H2O2 in-vivo provides an advantageous distinction over currently available 
analytical techniques. It facilitates the temporal analysis of the initiation and progression 
of oxidative/nitrosative stress, which has been implicated in the pathophysiology of a 
variety of neurodegenerative diseases and dysfunctions and its role is currently not fully 
understood (Andersen, 2004; Barnham et al., 2004; Chauhan & Chauhan, 2006; Obeso 
et al., 2010; Melo et al., 2011; Walsh et al., 2011).    
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Try again. Fail again.  
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